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ABSTRACT 
In recent years, HIV-1 integrase (IN) has emerged as an attractive target for the treatment 
of human immunodeficiency virus type 1 (HIV-1), the causative pathogen of acquired immuno-
deficiency syndrome (AIDS). Several classes of IN inhibitors are known but many of these 
compounds are toxic, do not show antiviral activity or display decreased potency. Therefore, new 
classes of potent IN inhibitors are desperately needed. The b-diketo (b-DK) class of compounds 
has emerged as one of the most successful classes of IN inhibitors. Although several b-DK 
inhibitors with potent antiviral activity are known, compounds containing b-DK motifs have 
limitations in drug development. The overall objective of this dissertation was to design and 
synthesize a novel series of IN inhibitors that retain the favorable characteristics of the b-DK 
scaffolds but are devoid of the “undruggable” properties. The design of the target molecules was 
established from crystal structure-based correlation and structure-activity relationship studies, 
which led to scaffolds containing three specific functional groups. Each molecule was designed 
to contain the core functional motif (a,b-diketoamide), optimal aryl groups (3-benzylphenyl or 
substituted 3-benzylphenyl) and a terminal group (proton donor or acceptor or amphoteric 
functional groups) in a planar or near planar configuration. Several oxalamate containing 
compounds were successfully designed and synthesized; and many of these synthetic analogs 
were sent to be screened for inhibitory activity against HIV-1 IN. The synthetic analogs 
described herein may elicit alluring antiviral activity, serve as potential lead molecules for future 
optimizations and ultimately elucidate mechanistic insight into HIV-1 IN inhibition. 
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I. INTRODUCTION 
  
Human immunodeficiency virus type-1 (HIV-1) is a lentivirus that infects CD4 (cluster of 
differentiation 4) positive (CD4+) T-lymphocytes (T-cells) and macrophages of the human 
immune system. Infection with the HIV-1 virus results in the progressive deterioration and 
impairment of the host immune system, leading to an ‘immune deficiency’. A person infected 
with HIV-1 is easily susceptible to infections, most of which are rare among healthy people. 
Infections associated with an immunodeficiency are known as ‘opportunistic infections’ (OIs), 
because they take advantage of the weakened immune system.
5
  HIV-1 is a slow disease that  
continues to cause progressive damage to the immune system from the time of infection to the 
manifestation of severe immunologic damage by OIs, neoplasms, wasting, or low CD4+ cell 
count that will eventually lead to acquired immunodeficiency syndrome (AIDS).
6
 
 
1.1. HIV-1 AND AIDS BACKGROUND 
1.1.1. History 
The simian version, simian immunodeficiency virus (SIV), of human immunodeficiency 
virus type 1 (HIV-1) was conceivably transferred from its natural host, the chimpanzee, to man 
in the early to middle years of the 20
th
 century in the west central African countries of Cameroon 
and Gambia.
7
 The spread of HIV-1 was initially slow and limited, but due to rapid urbanization 
in the post-colonial era, the disease rapidly spread worldwide appearing in at-risk individuals in 
most regions by the mid-to-late 1970s.
8
  
2 
 HIV-1 infection was not recognized in medical publications until the clinical syndrome of 
advanced immune deficiency, later termed AIDS, was reported in the early 1980s.
8
  Unusual 
cases of infection and illness among young, previously healthy individuals began to appear in 
large cities in the United States (U.S.) in 1981. Kaposi's Sarcoma (KS) was a rare form of 
relatively benign cancer that tended to occur in elderly people. In March 1981 at least eight cases 
of a more aggressive form of KS had transpired amid young homosexual men in New York.
9
 On 
June 5, 1981, the first acquired immunodeficiency syndrome (AIDS) cases were reported by the 
Centers for Disease Control and Prevention (CDC): five cases of Pneumocystis carinii (now P. 
jiroveci) pneumonia (PCP) among previously healthy homosexual men in Los Angeles. The 
accompanying editorial suggested that the illness might be related to the men’s sexual 
behavior.
10
  Later in 1981, more cases of PCP and KS among homosexual men in New York and 
California were seen.
11, 12
 When the CDC reported the new outbreak they called it “gay-related 
immune deficiency” (GRID) or “gay cancer”, stigmatizing the gay community as carriers of this 
deadly disease.
13 However by December 1981, cases started appearing in heterosexuals, injecting 
drug users (IDUs) and people who received blood transfusions, also the first case of AIDS was 
reported in the United Kingdom (UK), proving the syndrome knew no boundaries.
14, 15
 The 
disease continued to spread across the U.S. and by July 1982, a total of 452 cases from across the 
U.S. had been reported to the CDC.
16
 By 1983 it was becoming increasingly clear that the 
disease was not limited to spreading across the U.S. Cases were also being reported in Europe, 
Uganda, Australia, Canada, Latin America and Japan.
17 It took eighteen months from the first 
report to identify the primary risk factors for AIDS; guidelines for prevention of occupational, 
drug-related and sexual transmission of the illness were issued by the CDC in March 1983.
18
 It 
was later that year, that Luc Montangier and Francoise Barre-Sinoussi isolated the suspected 
3 
retrovirus
19
 which was later confirmed to be the causative agent of AIDS by Robert Gallo in 
1984.
20, 21
 This virus was ultimately termed ‘human immunodeficiency virus’ (HIV).22 
 
1.1.2. Transmission 
The transmission of HIV-1 from an infected person to an uninfected person occurs when 
an infected person’s bodily fluids, mainly semen, vaginal fluids, blood or breast milk enters an 
uninfected person’s body.23-25 The most common routes of transmission are unprotected sexual 
intercourse, injection drug use (IDU), and from infected mother to infant.
26
 Blood transfusions 
and organ transplants were initially a way that HIV-1 was spread, but now due to careful tests 
and screening the risk is extremely low.
27
 
The first phase of HIV-1 infection is the asymptomatic incubation period. Most people 
that become infected with HIV-1 do not know that they have become infected because they do 
not feel ill immediately after infection.
5
 However, some people at the time of seroconversion 
(development of antibodies to HIV-1; 1-6 weeks after HIV-1 infection) develop acute retroviral 
syndrome characterized by fever, malaise, generalized lymphadenopathy, pharyngitis, diarrhea, 
and rash.
28
 An acute infection is often unrecognized because the complex of symptoms is easily 
confused with other illnesses and diseases (e.g., influenza or infectious mononucleosis).
29
 In 
acute primary infection, plasma HIV-1 RNA (ribonucleic acid) concentrations can be very high, 
making secondary transmission a high risk if an infected individual continues to engage in 
behavior that could transmit HIV-1 to an uninfected person. After the symptoms of primary 
infection resolve, the infected person enters the second phase of HIV-1, the asymptomatic latent 
phase.
8
 An infected person displays no symptoms and this stage can persist for several years 
(average eight to ten years), although rapid progression is usually common. During this stage, 
4 
HIV-1 is actively replicating and will continue to weaken the immune system. The symptomatic 
disease phase (one to three years) often emerges as the peripheral CD4+ cell count falls below 
350 cells per µL and many people become susceptible to infections and begin to experience 
HIV-1 disease related symptoms. The last stage of infection is the progression of HIV-1 to AIDS 
when the immune-system’s ability to fight infection on its own is lost. A diagnosis of AIDS is 
given when a patient CD4+ count falls below 200 cells per µL and individuals experience 
multiple OIs (pneumonia, neurological diseases and cancers). The CDC classification system is 
used to determine the severity and progression of HIV-1 and AIDS infection and disease (Table 
1.1). This classification system is based on specific conditions that a patient has developed 
(Table 1.2).
30, 31
 
The clinical staging and case definition for resource-constrained settings were developed 
by the World Health Organization (WHO) in 1990 and revised in 2007. 
32
 Staging is based on 
clinical findings that guide diagnosis, evaluation, and management of HIV-1 and AIDS and it 
does not require a CD4+ cell count. In many countries this staging will help to determine the 
eligibility for antiretroviral therapy (ART), particularly in locations where CD4+ testing is not 
available. Clinical stages, defined by clinical conditions, are categorized as 1 through 4, 
progressing from primary HIV-1 infection to advanced HIV-1 and AIDS (Table 1.3).
32
 
 
CD4+ Cell Counts Clinical Categories 
 A 
Asymptomatic, 
Acute HIV-1 or 
PGL* 
B 
Symptomatic 
Conditions, not A or 
C 
C 
AIDS-Indicator 
Conditions 
> 500 cells/µL A1 B1 C1 
200-499 cells/µL A2 B2 C2 
<200 cells/µL A3 B3 C3 
*PGL= persistent generalized lymphadenopathy; Patients in categories A3, B3, C1-C3 are considered to have  
 AIDS 
Table 1.1 CDC Classification System for HIV-1 Infection
30, 31
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Category B Symptomatic Condition Examples Category C AIDS Indicator Conditions 
Symptomatic condition as are attributed to HIV 
infection or indicate a defect in cell-mediated 
immunity and/or  
They are considered to have a clinical management that 
is complicated by HIV infection 
Bacterial angiomatosis 
Oropharyngeal candidiasis (thrush) 
Vulvovaginal candidiasis, persistent/resistant 
Pelvic inflammatory disease (PID) 
Cervial dysplasia/ cervical carcinoma 
Hairy leukoplakia, oral 
Herpes zoster (shingles) > 2 episodes 
Idiopathic thrombocytopenic purpura (low platelet count) 
Fever (>38.5°C) or diarrhea >1 month 
Peripheral neuropathy 
Bacterial Pneumonia (> 2 episodes in 12 months)  
Candidiasis of bronchi, trachea, or lungs 
Candidiasis, esophageal 
Cervical carcinoma, invasive 
Coccidioidomycosis (fungal disease) 
Cryptococcosis, extrapulmonary (fungal disease) 
Cryptosporidiosis, chronic intestinal >1 month 
(parasitic disease) 
Cytomegalovirus disease (other than liver, spleen, or 
nodes) 
Encephalopathy, HIV-1 related 
Herpes simplex: chronic ulcers (>1 month), or 
bronchitis, pneumonitis, or esophagitis 
Kaposi sarcoma  
Mycobacterium tuberculosis 
Salmonella septicemia, recurrent (nontyphoid) 
Wasting syndrome caused by HIV (involuntary 
weight loss >10% of baseline body weight) 
Table 1.2 Selected Examples of Clinical Categories B and C Conditions
30, 31
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Table 1.3  WHO Clinical Staging of HIV-1/AIDS
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Stage Symptoms 
Primary HIV-1 Infection Asymptomatic, Acute retroviral syndrome 
Clinical Stage 1 Asymptomatic, Persistent generalized lymphadenopathy (PGL) 
Clinical Stage 2 
 
Weight loss (<10 % measured body weight) 
Recurrent respiratory infections 
Herpes zoster 
Angular cheilitis (lesions)  
Recurrent oral ulceration 
Seborrheric dermatitis (inflammation) 
Fungal nail infection 
Clinical Stage 3 
Some persons with clinical stage 
3 have AIDS 
Severe weight loss (>10 % measured body weight)  
Chronic diarrhea >1 month 
Persistent fever >1 month 
Oral candidiasis  
Oral hairy leukoplakia 
Pulmonary tuberculosis 
Severe bacterial infections (pneumonia, bone or joint infection, meningitis) 
Anemia (hemoglobin <8 g/dL) 
Neutropenia (neutrophils <500 cells/µL) 
Chronic thrombocytopenia (platelets <50, 000 cells/µL) 
Clinical Stage 4 
Includes 22 opportunistic 
infections or cancers related to 
HIV-1. All persons with clinical 
stage 4 have AIDS. 
HIV wasting syndrome (>10 % measured body weight)  
Pneumocystis pneumonia 
Recurrent severe bacterial pneumonia 
Chronic Herpes simplex infection 
Esophageal candidiasis 
Extrapulmonary tuberculosis 
Kaposi sarcoma  
Cytomegalovirus infection (retinitis or infection of other organs) 
Candidiasis of bronchi, trachea, esophagus or lungs 
Lymphoma (cerebral or B-cell non-Hodgkin) 
Salmonella septicemia, recurrent (nontyphoid) 
Cervical carcinoma, invasive 
Symptomatic HIV-associated nephropathy 
Symptomatic HIV-associated cardiomyopathy 
6 
1.1.3. Statistics 
Human immunodeficiency virus type 1 (HIV-1) is the etiological agent that causes AIDS. As of 
2009, it is estimated that worldwide there are 33.3 million people living with HIV-1, with 22.5 
million (68 % of the global total) in Sub-Saharan Africa (Figure 1.1).
33
 The  CDC has estimated 
that more than 1.1 million adults and adolescents were living with HIV infection in the U.S. at 
the end of 2006, the most recent year for which national prevalence estimates are available.
26
 
There is no cure for HIV-1 or AIDS and since the discovery of AIDS in 1981, it has led to the 
deaths of more than 30 million people.
33
 HIV-1 is arguably the most intensely studied virus in 
the history of biomedical research. Despite the wealth of knowledge, however, HIV-1 infection 
remains a pandemic today and elusive in terms of a ‘cure’.34 
 
Figure 1.1 Adults and Children Estimated to be Living with HIV-1, 2009
33
 
(Permission to reprint ID:87551 WHO, permissions@who.int; 02-20-2012) 
 
1.1.4. Current Trends Worldwide 
 HIV-1 has become one of the most challenging and serious health concerns worldwide. 
When the first cases of HIV-1 and AIDS were reported in 1981, no one could have predicted 
7 
how the epidemic would spread around the world and how many millions of lives it would 
ultimately affect. Even though HIV-1 and AIDS cases have been reported in all regions of the 
world, about 95% of people living with HIV-1 and AIDS reside in low- and middle-income 
countries, where most new HIV-1 infections and AIDS-related deaths occur.
33, 35
 The major route 
of transmission worldwide is heterosexual sex, although risk factors vary within and across 
populations.
36
 In several regions of the world, men who have sex with men (MSM), IDUs, and 
sex workers account for substantial proportions of infections.
33
 
 The most affected regions of the world are sub-Saharan Africa, Asia, Latin America and 
the Caribbean, Eastern Europe and Central Asia (Table 1.4).
33, 35, 36
  Sub-Saharan Africa, the 
most severely affected region in the world, has two-thirds (68%, 22.5 million) of people living 
with HIV-1 but only about 12% of the world’s population.37, 38 At the end of 2009, there were 
nine countries with more than 10% of adults are estimated to be HIV-positive.
33
 Most children 
with HIV-1 live in this region (91%).
39
 About 1.7 million people are estimated to be living with 
HIV-1 in Latin America and the Caribbean combined, including 112,000 newly infected in 
2010.
35
 The Caribbean itself, with an adult HIV-1 prevalence rate of nearly 1%, is the second 
most affected region in the world after sub-Saharan Africa.
37
 Nearly 5 million people are living 
with HIV-1/AIDS across South/Southeast Asia and East Asia. While most national epidemics 
appear to have stabilized, HIV-1 prevalence is increasing in Bangladesh, Pakistan, and the 
Philippines.
37
 An estimated 1.5 million people are living with HIV-1 in Eastern Europe and 
Central Asia, an increase of 250% since 2001.
35, 37
 The major transmission route for this 
epidemic is primarily caused by injecting drug use, although heterosexual transmission also 
plays an important role.
35
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Region Total No. (%) Living 
with HIV end of 2010 
Newly Infected in 2010 Adult Prevalence Rate 
2010 
Global Total 34 million (100%) 2.7 million 0.8% 
Sub-Saharan Africa 22.9 million (67%) 1.9 million 5.0% 
South/Southeast Asia 4.0 million (12%) 270,000 0.3% 
Eastern Europe/Central Asia 1.5 million (4%) 160,000 0.9% 
Latin America 1.5 million (4%) 100,000 0.4% 
North America 1.3 million (4%) 58,000 0.6% 
Western/Central Europe 840,000 (2%) 30,000 0.2% 
East Asia 790,000 (2%) 88,000 0.1% 
Middle East/North Africa 470,000 (1%) 59,000 0.2% 
Caribbean 200,000 (0.6%) 12,000 0.9% 
Oceania 54,000 (0.2%) 3,300 0.3% 
Table 1.4 HIV-1 Prevalence and Incidence by Region
35
 
 
In the early years of the AIDS epidemic, it was quickly recognized that HIV-1 was 
having a severe impact on MSM. Currently, it is estimated that MSM accounts for between 5-
10% of all HIV-1 infections worldwide.
40
 Interestingly, more people have become infected with 
HIV-1 through male to male sex than through any other transmission route in many developed 
countries, such as U.S., Canada, Australia, New Zealand and many areas of Western Europe.
41
 In 
many countries however, MSM are less observable. Sex between men is stigmatized, officially 
denied and criminalized in various parts of the world.
41
 There are several factors that distort the 
statistics, in some countries the social identity of MSM is not acknowledged by the government 
and therefore they are simply counted as the general population. Also, it is not always possible to 
tell how a man initially became infected with HIV-1 especially if he is having sex with both men 
and women.
41
 Many MSM often hide their same-sex relations from their families and friends to 
avoid persecution. Many have wives, or have sex with women, and this means that they may 
easily transmit HIV-1 to their female partners if they become infected. MSM is not an isolated 
problem but one that is potentially linked to countries’ wider HIV-1 epidemics.42, 43 
Women comprise an increasing proportion of people living with HIV-1 and AIDS. 
Globally, HIV-1/AIDS is the leading cause of death among women of reproductive age.
44
  More 
9 
than half of the population of people living with HIV-1 globally is women, from whom the most 
usual route of infection is heterosexual intercourse.
45
 This trend is occurring in most regions of 
the world, and is particularly pronounced in sub-Saharan Africa, where women represent 59% of 
all adults living with HIV-1 and AIDS.
33
 In sub-Saharan Africa, more women than men are 
living with HIV, and young women aged 15-24 are about eight times more likely to be HIV-1 
positive.
45
 Gender inequalities in social and economic status and limited access to prevention and 
care services increase women’s vulnerability to HIV-1.35 Sexual violence also increases a 
women’s risk to contract HIV-1 and women, especially young women, are biologically more 
susceptible to HIV-1 infection than men. 
 
1.1.5. Current Trends in the United States 
Homosexual, bisexual and other men of all races who have sex with men continue to be 
the risk group most severely affected by HIV-1 in the U.S. (Figure 1.2).
46
 MSM represent 
approximately 2% of the U.S. population,
47
 yet are the population most severely affected by 
HIV-1, and are the only risk group in which new HIV-1 infections have been increasing steadily 
since the early 1990s.
48
 In 2006, more than half (53%) of all new HIV-1 infections in the U.S. 
were MSM. Additionally, MSM with a history of injection drug use (MSM-IDU) accounted for 
an additional 4% of new infections.
48
 Since the beginning of the U.S. epidemic, MSM have 
consistently represented the largest percentage of persons diagnosed with AIDS and persons with 
an AIDS diagnosis who have died.
48
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Figure 1.2 Estimated New HIV-1 Infections in the U.S., 2009.
49
 
 (Reprinted with Permission from CDC) 
In the U.S., African Americans face the most severe burden of HIV-1 of all racial or 
ethnic groups (Table 1.5). Despite representing 14% of the US population in 2009, African 
Americans accounted for 44% of all new HIV-1 infections that year (Figure 1.2).
50
 For both 
African American men and women, having unprotected sex with a man is the leading cause of 
HIV-1 infection, with injecting drug use being the second most likely infection route. Key 
factors such as high levels of poverty, limited access to healthcare, and stigma surrounding MSM 
shape the epidemic among African Americans.
4
 
Hispanics/Latinos are also disproportionately affected by the HIV-1 and AIDS epidemic 
in America (Table 1.5). It is estimated that 1 in every 52 Hispanics/Latinos will be diagnosed 
with HIV-1 in their lifetime.
51
 Interestingly, the risk for men and women differs widely; 1 in 36 
Hispanic/Latino men will be diagnosed with HIV in their lifetime compared to 1 in 106 
Hispanic/Latino women.
52
 Language barriers, cultural factors, low access to healthcare and 
migration patterns have been identified as barriers to HIV-1 prevention and treatment within the 
Hispanic/Latino community.
52
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Table 1.5 Percentage of AIDS in U.S. among Various Ethnic Groups
2
 Compared to Percentage of        
Population Each Ethnic Group Represents
3, 4
 
 
  Geographic differences are a significant feature of the epidemic in the U.S. The epidemic 
was once concentrated primarily in the homosexual populations on the East and West coasts. 
However, in recent years HIV-1 has also become increasingly prevalent within African 
American and Hispanic/Latino communities in many Southern states as well as certain urban 
areas in the North-east and West-coast.
4
 The map in Figure 1.3 shows the states with the number 
of people living with AIDS in 2009, relative to the population of each state. HIV-1 and AIDS 
remains mostly an urban disease, with the majority of individuals diagnosed with AIDS in 2009 
residing in areas with more than 500,000 people. Areas hardest hit (by ranking of AIDS cases per 
100,000 people) include Miami and Jacksonville, Florida; Baton Rouge, Louisiana; New York 
City, New York; and Washington, D.C.
53
 Ten states account for 71% of AIDS diagnosis reported 
since the beginning of the AIDS epidemic. Nine of these states also rank in the top ten for new 
diagnosis in 2009 (Table 1.6).
54
 As the epidemic has developed, it has become evident that the 
quality of prevention and treatment services than an individual receives is influenced by their 
socio-economic group and where they live. Poor urban communities are particularly affected by 
HIV-1 and AIDS in the US, which can be attributed to a number of factors including inadequate 
disease reporting, poverty, absence of adequate healthcare and lack of comprehensive sex 
education in schools.
55
 
Race Estimated % of new AIDS diagnosis in 2009 % of US population in 2008
White 27 65
African American/Black 47.9 12
Hispanic/Latino 21.2 15
Asian 1.2 4
American Indian/Alaska Native <1 <1
Native Hawaiian/Other Pacific Islander <1 <1
Multiple Races 2 2
12 
 
Figure 1.3 Estimated Numbers of AIDS Diagnoses, All Ages, 2009
56
 
(Permission to reprint Kaiser Family Foundation, 03-02-12) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.6 Top Ten States by Cumulative AIDS Diagnosis and by AIDS Diagnosis Rate Per 100,000
2
   
(Requested permission to reprint Kaiser Family Foundation, 03-02-12) 
New infections due to injection drug use has declined significantly over time and 
accounted for 9% of new infections in 2009.
53, 57
 Throughout the epidemic, prevention efforts 
among IDUs has been controversial. For 21 years, programs where users exchange their needles 
for clean ones (needle exchange programs) were not permitted any federal funding, even though 
in some areas in the US these programs have been shown to reduce the rate of transmission.
58, 59
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The ban on federal funding for needle exchange programs was lifted in 2009, however, at the end 
of 2011, in a controversial action by Congress, the ban was later reinstated.
60
 
 
1.1.6. HIV-1 Structure and Genome 
 HIV-1 is spherical in shape and has a diameter of 1/10,000 of a millimeter. The outer coat 
of the virus (the viral envelope) is composed of two layers of fatty acids, taken from the 
membrane of a human cell when a newly formed virus particle buds from the cell. Embedded 
within the viral envelope are proteins from the host cell, as well as about 72 copies of the 
complex protein envelope glycoprotein (Env). Env consists of a cap made of three molecules 
called glycoprotein 120 (gp120), and a stem consisting of three molecules gp41 that anchor the 
structure into the viral envelope. HIV-1 has three structural genes (gag, pol and Env) and six 
regulatory genes (tat (transcriptional activator), rev (regulator of viral gene expression), nef 
(negative effector), vif (viral infectivity factor), vpr (viral protein R), and vpu (viral protein U)) 
that contain information needed to produce proteins that control the ability for HIV-1 to infect a 
cell, produce new copies of virus, or cause disease (Figure 1.4). The ends of each strand of HIV-
1 RNA contain an RNA sequence called the long terminal repeat (LTR). Regions in the LTR act 
as switches to control production of new viruses and can be triggered by proteins from either 
HIV-1 or the host cell.
61
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1.2. HIV-1 VIRAL LIFE CYCLE 
HIV-1 is a retrovirus (“slow virus”), which means it has genes composed of RNA 
molecules. Like all viruses, HIV-1 replicates inside host cells. It is considered a retrovirus 
because it uses an enzyme, reverse transcriptase (RT), to convert RNA into DNA, which can 
then be incorporated into the host cell’s genome. 62  The replication cycle of HIV-1 is a complex 
multistep process that depends on both viral and host cell factors (Figure 1.5). The HIV-1 
replication cycle has two distinct phases. During an early pre-integration stage, the virus infects 
the cell, RT takes place and the proviral genome is transported into the nucleus and integrated 
into the host cell genome. In the subsequent post-integration stage, the integrated provirus 
expresses genes, and virus assembly and maturation takes place.
63
 
Figure 1.4. HIV-1 Genome: An overview of the organization of the ~9-kilobase genome of the HIV provirus and 
summary of its nine genes encoding 15 proteins. (Reprinted with permission from NPG: License 2863790720427) 
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Figure 1.5 Schematic Representation of the HIV-1 Replication Cycle
64
 
(Reprinted with permission from Elsevier license: 2857380636210) 
 
 
1.2.1. Viral Entry Binding and Fusion 
The life cycle of HIV-1 begins with adsorption of virions to the host cell (Figure 6), the 
viral envelope (Env) gp120 interacts nonspecifically with heparan sulfate, a sulfated 
polysaccharide widely expressed on animal cells and involved in virus cell binding of array of 
enveloped viruses.
65-67
 This first interaction enables the virus to initially make contact with the 
host cell.
68
 While attachment of HIV-1 to the cell surface can result for interactions with many 
surface molecules,
69, 70
 specific binding of the gp120 subunit to CD4 is the first required step for 
viral infection.
71
 CD4 is an integral membrane glycoprotein, belonging to the immunoglobulin 
gene superfamily, which is expressed mainly on the surface of T cells and cells of the 
macrophage/monocyte lineage.
72
 CD4 binding alone is not sufficient for virus infection as it does 
not trigger the conformational changes needed for membrane fusion. For this to occur, the viral 
Env gp120 must interact with its coreceptor, CXCR4 (chemokine receptor 4) for  T-cell line 
16 
tropic (T-tropic) or X4 HIV-1 strains or CCR5 (C-C chemokine receptor 5) for macrophagetropic 
(M-tropic) of R5 HIV-1 strains.
71
  R5 virus strains typically infect macrophages and primary T 
cells, and are the virus type most commonly transmitted between individuals. The X4 virus 
strains tend to evolve years after infection in a subset of individuals as a consequence to mutation 
in Env, and infect primary T cells and transformed T cell lines.
73, 74
  While the viral glycoprotein 
gp120 is responsible for viral interaction with the CD4 receptor and CCR5 or CXCR4 
coreceptor, the viral glycoprotein gp41 (which has remained noncovalently attached to gp120 
after their precursor glycoprotein gp160 has been cleaved by cellular proteases to yield the 
gp120/gp41 heterodimer ) is responsible for the fusion of viral envelope with the cell 
membrane.
72
  The interaction of gp120 with CCR5 or CXCR4 coreceptor triggers a series of 
conformational changes in the gp120-gp41 complex that ultimately led to the formation of a 
‘trimer-of-hairpins’ structure in gp41. The ‘trimer-of-hairpins’ is a bundle of six α-helices: three 
α–helices formed by the amino-terminal regions. The fusion-peptide region, located at the 
extreme amino terminus, will insert into the cellular membrane, while the carboxy-terminal 
region remains anchored in the viral envelope, thus, bringing the two membranes together.
75
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Figure 1.6 Schematic description of early events occurring after HIV infection of a susceptible target cell including interactions 
between gp120, CD4 and chemokine receptors (CCR5 or CXCR4) leading to gp41 mediated fusion followed by virion uncoating, 
reverse transcription of the RNA genome, nuclear import of the viral preintegration complex (PIC), and integration of the double-
stranded viral complementary DNA strain (cDNA) into the host chromosome thus establishing the provirus.76 
 (Reprinted with permission from NPG: License 2863790346117) 
 
1.2.2. Reverse Transcription 
 Once fusion delivers the viral core into the cytoplasm of the host cell, viral uncoating 
takes place. The viral core is composed of a capsid (CA) protein shell that encapsulates the 
single-stranded, dimeric viral RNA genome in complex with the viral nucleocapsid (NC) protein 
and the viral enzymes RT and integrase (IN) (Figure 1.6).
77, 78
Although the viral uncoating 
process if poorly understood, it likely involves the phosphorylation of matrix (MA) mediated by 
a mitogen activation protein (MAP) kinase
79
  and additional actions of cyclophilin A,
80
 and the 
viral negative factor (nef)
81
 and viral infectivity factor (vif) proteins.
82
 Successful uncoating 
generates the viral reverse transcription complex, which contains the diploid viral RNA genome, 
tRNA
Lys 
(transfer RNA) primer, RT, IN, MA, NC, viral protein R (vpr) and various host 
proteins; the reverse-transcription complex is thus liberated from the plasma membrane.
83
 Next, 
18 
the complex docks with actin microfilaments and this interaction, which is mediated by the 
phosphorylated MA, is required for efficient viral DNA synthesis.
84
 HIV-1 now uses the enzyme 
RT to make a DNA copy of the RNA genome. Normal transcription in nature occurs when the 
DNA genome is transcribed into messenger RNA (mRNA) which is translated into protein. In 
HIV-1 RT, RNA is reverse-transcribed into DNA.
68
 To convert viral RNA to pregenomic 
proviral DNA, three successive enzymatic reactions, all ensured by the p66 subunit of the 
p66/p51 RT heterodimer, are required. RT has three enzymatic activities: (i) it has RNA-
dependent DNA polymerase activity that transcribes the viral (+) RNA strand to a (-) viral 
complementary DNA strain (cDNA); (ii) it has ribonuclease activity that degrades the (+) RNA 
strand during the synthesis of cDNA; and (iii) it has DNA-dependent DNA polymerase activity 
that copies the (-) cDNA strand into a (+) DNA strand to form a double-stranded DNA 
intermediate that enters the infected host cell's nucleus.
68, 72
  
 
1.2.3. Integration 
Approximately 40-100 IN molecules are packaged within an HIV-1 particle.
85
 The 
principal role of IN is to catalyze the insertion of the proviral DNA (cDNA) into the genome of 
infected host cells. Integration is essential for viral replication because efficient transcription of 
the viral genome and production of viral proteins require that the proviral DNA is fully 
integrated into the cellular genome (Figure 1.7).
72
 Following RT, the proviral DNA is primed for 
integration by integrase-mediated 3’-processing, which correlates to an endonucleolytic cleavage 
of the 3’ ends of the proviral DNA, thus generating CA-3’-hydroxyl ends. Following 3’-
processing, IN remains bound to the proviral DNA as a multimeric complex that bridges both 
ends of viral DNA within intracellular particles termed preintegration complexes (PICs).
72
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Isolated PICs contain both viral and cellular proteins in addition to the IN-DNA complexes. The 
viral proteins RT, MA, NC and vpr can contribute to the transport of PICs through the nuclear 
envelope.
86
 The cellular proteins packaged with the PICs, interactor 1 (Ini1),
87
 lens epithelium-
derived growth factor (LEDGF or p75),
88
 embryonic ectoderm-development protein,
89
 and heat-
shock protein 60 (HSP60),
90
 can bind to IN and stimulate its enzymatic activities.
91
 Once in the 
nucleus, IN catalyzes the insertion of the proviral DNA into the host cell chromosome. This 
‘stand transfer’ reaction consists of the ligation of the viral 3’-OH DNA ends (generated from 3’-
processing) to the 5’-DNA phosphate of the host chromosome.  Completion of integration can 
only take place after trimming of the last two nucleotides at the proviral DNA 5’-ends and 
extension (gap filling) from the 3’-OH end of the genomic DNA.86  
The HIV-1 provirus can integrate into many different chromosomal locations in the cell 
and most infected cells harbor more than one provirus.
76
 Integration can lead to either latent or 
transcriptionally active forms of infection, 
92
 which is determined by genetic factors of the viral 
strain, the type of cell infected, and the production of specific host cell proteins.
68
 The majority 
of the proviral DNA is integrated into the chromosomes of activated CD4+ T cells. These 
generally comprise between 93% and 95% of infected cells and are productively infected, not 
latently infected. However, a small percentage of HIV-infected memory CD4+ T cells persist in 
a resting state because of a latent provirus. These, along with infected monocytes, macrophages, 
and dendritic cells, provide stable reservoirs of HIV-1 capable of escaping host defenses and 
Antiretroviral (ARV) chemotherapy.
68
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Figure 1.7 The Two IN Catalytic Reactions (3’-Processing and Strand Transfer). The figure shows the viral DNA recombination 
attachment (att) sites. 3’-processing takes place in the cytoplasm following reverse transcription (Figure 1.) It is a water-mediated 
endonucleolytic cleavage (green arrow in a and BOX 1, figure part a) of the viral DNA immediately 3’ from the conserved CA 
dinucleotide (BOX 1, figure part a.). 3’-processing generates reactive 3’-hydroxyls at both ends of the viral DNA (red circles (b); 
other 3’-hydroxyl ends and 5’-phosphate ends are shown as red and green dots, respectively.) IN multimers (not shown) remain 
bound to the ends of viral DNA as the PICs translocate to the nucleus. The second reaction (c to d) catalyzed by IN is strand 
transfer (3’-end joining), which inserts both viral DNA ends into a host-cell chromosome (acceptor DNA in blue). Strand transfer 
is coordinated in such a way that each of the two 3’-hydroxyl viral DNA ends (red circles) attacks a DNA phosphodiester bond 
on each strand of the host DNA acceptor with a five-base-pair stagger across the DNA major groove (d). Strand transfer leaves a 
five-base, single-stranded gap at each junction between the integrated viral DNA, and a two-base flap at the 5’-ends of the viral 
DNA (d and e). Gap filling and release of the unpaired 5’-ends of the viral DNA (arrows in e) are carried out in coordination with 
cellular repair enzymes.86  (Reprinted with permission from NPG: License 2862620377001) 
 
1.2.4. Transcription 
 The vast majority of CD4+ T cells, which are productively infected, immediately begin to 
produce new viruses. In the case of resting memory CD4+ T cells, before replication can occur, 
the HIV-1 provirus must become activated. This activation is accomplished by such means as 
antigenic stimulation of the infected CD4+ T cells or their activation by factors such as 
cytokines, endotoxins and superantigens.
68
 
 Once integrated, the HIV-1 proviral genome is subject to transcriptional regulation by 
the host cell, as well as its own transcriptional control mechanism.
63, 93
 In the host genome, the 5’ 
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long-terminal repeat (LTR) functions like other 
eukaryotic transcriptional units. It contains 
downstream and upstream promoter elements, 
which include the initiator (Inr), TATA-box (T) 
and three Specificity Protein 1 (Sp1) sites.
94
 These 
regions help position the RNA polymerase II 
(RNAPII) at the site of initiation of transcription 
and assemble the preinitiation complex. In the 
HIV-1 promoter, RNAPII activity is quickly 
stalled after initiation of transcription (Figure 1.8, 
Panel A). There are two cellular complexes, DRB 
sensitivity-inducing factor (DSIF) and negative 
elongation factor (NELF), that function together to 
block the elongation from occurring (Figure 1.8, 
Panel B).
95, 96
 Although binding of DSIF and 
NELF to RNAPII shortly after initiating RNA 
synthesis leads to inhibition of elongation, this step is regulated by the phosphorylation of 
carboxy-terminal domain (CTD) of the largest subunit of RNAPII. Importantly, in the nuclear 
extract, DSIF and NELF tightly bind to hypophosphorylated RNAPII, but not to the 
hyperphosphorylated form, suggesting that phosphorylation of CTD caused dissociation of these 
negative factors from RNAPII.
97
  The repression caused by DSIF and NELF is counteracted in 
HIV-1 transcription by trans-activator of transcription (tat), an 81-101-amino acid peptide 
(Figure 1.8, Panel C). In the absence of tat, HIV-1 transcription is highly inefficient because the 
Figure 1.8 Stimulation of Transcriptional 
Elongation by HIV-1 Tat (Reprinted with 
permission from NPG: License) 
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assembled RNAPII complex cannot elongate efficiently on the viral template. 
98
 First, tat forms a 
complex with the positive transcription elongation factor b (P-TEFb), which is composed of 
cyclin T1 and cyclin-dependent protein kinase 9 (CDK9).The complex of Tat with P-TEFb, 
which is composed of cyclin T1 and CDK9, then binds to the TAR (Tat response) element, 
thereby positioning CDK9 to phosphorylate the cellular RNA polymerase and this ensuring 
transcription elongation.
97
 The tat protein is acetylated on lysine resides within its TAR-RNA-
binding arginine rich motif by transcriptional coactivators/acetyltransferases, p300/CBP (CREB-
binding protein), and PCAF (p300/CREB-binding protein-associated factor) which help to 
activate the HIV-1 promoter (Figure 1.8, Panel D).
99
 Other phosphorylation and acetylation 
events accompany and may at least partially account for the activation of the HIV-1 transcription 
process.
72
 
The integrated proviral DNA is transcribed to generate full-length progeny viral RNA 
and a number of spliced mRNA transcripts that are translated into the cytoplasm.
100
 
Transcription and translation, performed by cellular machinery, results in the synthesis of several 
major structural proteins: (i) the Gag polyprotein precursor, which is composed of four domains-
MA, CA, NC and p6-and two spacer peptides, SP1 and SP2, (ii) the Gag-Pol polyprotein 
precursor, which is produced via a 1-ribosomal frameshift during gag translation and encodes the 
viral enzymes PR, RT and IN, and (iii) the Env glycoprotein precursor, gp160, which is cleaved 
into the gp120 and gp41 subunits by a host protease during trafficking through Golgi 
apparatus.
100
 These protein components, together with full-length viral genomic RNA, are each 
transported to the site of virus particle assembly at the plasma membrane.
77
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1.2.5. Assembly, Budding and Maturing 
 After the transcription of the viral genome, more than a dozen HIV-specific transcripts 
are generated. Assembly is directed by Gag, which coordinates the incorporation of each of the 
viral components, together with a number of host cell factors, into the assembling particle.
77
  
All of the components of the virion are ultimately assembled at the plasma membrane of the host 
cell where budding occurs. Prior to budding the Env polyprotein (gp160) goes through the 
endoplasmic reticulum and is transported to the Golgi complex where it is cleaved by a protease 
and processed into the two HIV envelope glycoproteins gp41 and gp120. These envelope 
glycoproteins are transported to the plasma membrane of the host cell where gp41 anchors the 
gp120 to the membrane of the infected cell.
68
  The Gag (p55) and Gag-Pol (p160) also interact 
with the inner surface of the plasma membrane along with HIV genomic RNA as the forming 
virion begins to bud from the host cell. Following budding from the plasma membrane, the viral 
protease cleaves the Gag and Gag-Pol precursors into their respective protein domains. Gag and 
Gog-Pol cleavage leads to virion maturation, a reassembly event that produces mature particles 
containing the condensed, conical core.
77, 78
 In addition to the structural proteins listed above, 
HIV-1 encodes two regulatory gene products (tat and rev (regulation of viral gene expression)) 
and several accessory proteins: viral infectivity factor (vif), viral protein U (vpu), negative factor 
(nef), and viral protein R (vpr).
100
 The various structural components then assemble to produce a 
mature HIV-1 virion which is now able to infect another cell. 
 
1.3. CURRENT THERAPY 
 To date, there are 25 ARV drugs approved for the treatment of HIV-1 infection and 
AIDS. These drugs can be divided into six different mechanistic classes that target distinct steps 
24 
in the HIV-1 replication cycle (Figure 1.9): eight nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTIs),
101
 nine protease inhibitors (PIs),
102
 five non-nucleoside reverse transcriptase 
inhibitors (NNRTIs),
103
 one integrase inhibitor,
104
 and two entry inhibitors.
105
 There are two 
drugs that have been developed as entry inhibitors. 
Enfuvirtide (T-20) is a fusion inhibitor that blocks 
viral fusion by targeting glycoprotein 41 (gp41) and 
maraviroc is an inhibitor of chemokine receptor 
CCR5, making it the only approved ARV drug that 
targets a host cell factor.
105
 The remaining four 
mechanistic classes target each of the viral enzymes: 
RT, PR and IN.  
 
1.3.1. Nucleotide/Nucleoside Reverse Transcriptase 
Inhibitors (NRTIs) 
In 1986, there were 5,833 AIDS cases in the 
U.S. and the 1-year mortality was 51%-which 
translated to the public as ‘certain death’.34 In 1987,  
four years after the identification of HIV,
19
 3’-
azidothymidine (AZT, zidovudine),  a nucleoside 
HIV-1 reverse transcriptase inhibitor (NRTI), was the 
first ARV drug approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of AIDS. 
Over the course of over 25 years that followed after this 
Figure 1.9 The HIV-1 Replication 
Cycle and Drug Targets 
(Reprinted with permission from NPG) 
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seminal discovery, seven nucleosides and one nucleotide have been approved by the FDA for the 
treatment of HIV infection (Figure 1.10).   
 
Figure 1.10 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)  
 
A total of thirteen NRTI drug products are available for clinical application: eight 
individual NRTIs, four fixed-dose combinations of two or three NRTIs, and one complete fixed-
dose regimen containing two NRTIs and one non-nucleoside RT inhibitor (Table 1.7).
101
 NRTIs 
target the HIV-1 RT, which offers two target sites for inhibitors: the catalytic substrate 
(deoxynucleoside triphosphate) binding site, and an allosteric site, which is distinct from (yet 
closely located to) the substrate binding site.
106, 107
 NRTIs are analogues of endogenous 2’-
deoxynucleosides and nucleotides (Figure 1.11). They are inactive in their parent forms and are 
first metabolized inside cells and then converted to their active 5’-triphosphate forms, which 
compete with the natural deoxynucleoside triphosphate (dNTP) substrates for HIV-1 RT and 
inhibit DNA polymerization.
108-110
 In addition, after the drugs are incorporated into a growing 
viral DNA, they serve as chain-terminators of viral reverse transcripts owing to lack of a 3’-
26 
hydroxy group (present in natural dNTPs) necessary for further DNA synthesis.
110
 The NRTIs 
act early in the viral replication cycle by inhibiting a critical step of proviral DNA synthesis prior 
to integration into the host cell genome.   
 
Figure 1.11 Structure of Natural Deoxynucleoside Triphosphates (dNTP) 
 
NRTIs are the backbone of current combination ART. The standard of care for HIV-1 patients is 
highly active antiretroviral therapy (HAART), which consists of three or more HIV-1 drugs. The 
common use of combinations of NRTIs has led to the clinical development of the fixed-dose 
combination pills (Table 1.7).
101
 The success of NRTIs in HIV-1 therapy is due, at least in part, 
to the unique pharmacology and intracellular persistence. The intracellular retention of the active 
triphosphorylated NRTI metabolites allows for constant viral inhibition. Based on the Adult and 
Adolescent Antiretroviral Treatment Guidelines updated by the Department of Health and 
Human Services (DHHS) in October 2011, the two preferred NRTIs for the first-line regimens 
are TDF and FTC.
111
 
While the unique pharmacology of NRTIs has helped them become a cornerstone of 
successful HAART treatment, the effectiveness of NRTIs can be limited by drug-drug 
interactions, emergence of drug resistance, and adverse side-effects of ART.
101
 NRTIs are 
metabolized by complex and often overlapping pathways shared with the endogenous dNTPs 
27 
they compete with for activity, resulting in the potential for intra-class pharmacokinetic and 
pharmacodynamics drug interactions.
112
 The error-prone reverse transcription due to lack of a 
proofreading function of RT
113
 multiplied by the sheer number of replication cycles occurring in 
an infected individual facilitate the selection of drug resistant mutant strains of HIV-1.
114
 A 
major toxicity that has been recognized for more than a decade is NRTI-related mitochondrial 
toxicity, which manifests as serious side effects such as hepatic failure and lactic acidosis.
115
 
 
Table 1.7 Clinically Approved Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
101
 
 
 
1.3.2. Protease Inhibitors (PIs) 
The discovery of HIV-1 protease inhibitors (PIs) in 1995 was a pivotal moment in the 
development of ARV therapy because the PIs made possible the dual class therapy a reality. 
Currently, there are nine PIs approved by the FDA for clinical use and most of them are 
prescribed with a concomitant low dose of ritonavir as a boosting agent (Table 1.8). 
HIV-1 PR, an aspartyl protease, plays a crucial role in the viral life cycle and is essential for the 
generation of mature infectious virus particles. PR generates mature infectious virus particles 
through the cleavage of the viral Gag and Gag-Pol precursor proteins.
116
 The Gag precursor 
protein codes for all the structural viral proteins, MA, CA and NC, the p6 protein and the two 
Trade Name Generic Name NRTI Base Manufacturer Approval Date
Retrovir AZT, ZDV, azidothymidine, zidovudine Pyrimidine GlaxoSmithKline 19-Mar-87
Videx ddI, didanosine, dideoxyinosine Purine Bristol Myers-Squibb 9-Oct-91
Hivid  (Discontinued in 2006) ddC, zalcitabine, dideoxycytidine Pyrimidine Hoffman-La Roche 19-Jun-92
Zerit d4T, stavudine Pyrimidine Bristol Myers-Squibb 24-Jun-94
Epivir 3TC, lamivudine Pyrimidine GlaxoSmithKline 17-Nov-95
Combivir zidovudine + lamivudine GlaxoSmithKline 27-Sep-97
Ziagen ABC, abacavir sulfate Purine GlaxoSmithKline 17-Dec-98
Videx EC ddI EC, enteric coated didanosine Purine Bristol Myers-Squibb 31-Oct-00
Trizivir abacavir + zidovudine + lamivudine GlaxoSmithKline 14-Nov-00
Viread (Supplied as a Prodrug, Nucleotide NRTI) TDF, tenofovir disoproxil fumarate Purine Gilead Sciences 26-Oct-01
Emtriva FTC, emtricitabine Pyrimidine Gilead Sciences 2-Jul-03
Truvada tenofovir disoproxil fumarate + emtricitabine Gilead Sciences 2-Aug-04
Epzicom (or Kivexa) abacavair + lamivudine GlaxoSmithKline 2-Aug-04
28 
spacer proteins p2 (SP1) and p1 (SP2).
117
 PIs have been designed to bind the viral PR with high 
affinity but tend to occupy more space than the natural substrates. HIV-1 PIs prevent cleavage of 
gag and gag-Pol precursors in acutely and chronically infected cells, arresting maturation and 
thereby blocking the infectivity of nascent virions.
118, 119
 
Table 1.8 Clinically Approved Protease Inhibitors (PIs)
102 
 All of the FDA approved PIs, with the exception of tipranavir, are competitive 
peptidomimetic inhibitors, mimicking the natural substrate of viral PR (Figure 1.13).
102
 The 
peptidomimetic inhibitors contain a hydroxyethylene core, which prohibits cleavage of the PI by 
the HIV-1 protease.
120-127
 Instead of a peptidomimetic hydroxyethylene core, tipranavir contains 
a dihydropyrone ring as a central scaffold.
128
 
Many of the first-generation PIs (saquinavir, indinavir, ritonavir and nelfinavir) suffered 
from low bioavailability and high protein binding, high pill burden (3-4 times per day dosing), 
the development of resistance and wide spectrum of side effects and toxicities.
102
 Since one of 
the major initial problems with the PIs was poor bioavailability the second-generation drugs 
were developed in attempt to address this issue by reducing the molecular weight of the inhibitor 
and increasing the solubility.
129
 In 1999, these attempts led to a smaller more bioavailable 
inhibitor, amprenavir. However, even though amprenavir was more bioavailable compared to the 
previous PIs it was not very soluble or potent and formulation led to a high pill burden. In 2003, 
Trade Name Generic Name Manufacturer Approval Date
Invirase SQV, saquinavir mesylate Hoffman-La Roche 6-Dec-95
Norvir RTV, ritonavir Abbott Laboratories 1-Mar-96
Crixivan IDV, indinavir Merck 13-Mar-96
Viracept NFV, nelfinavir mesylate Agouron Pharmaceuticals 14-Mar-97
Fortovase SQV, saquinavir Hoffman-La Roche 7-Nov-97
Agenerase (Discontinued in 2007) APV, amprenavir GlaxoSmithKline 15-Apr-99
Kaletra LPV/RTV, lopinavir + ritonavir Abbott Laboratories 15-Sep-00
Reyataz ATV, atazanavir sulfate Bristol-Myers Squibb 20-Jun-03
Lexiva (Prodrug of amprenavir) FOS-APV, Fosamprenavir Calcium GlaxoSmithKline 20-Oct-03
Aptivus TPV, tipranavir Boehringer Ingelheim 22-Jun-05
Prezista darunavir Tibotec 23-Jun-06
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GSK introduced a phosphate prodrug fosamprenavir with improved solubility and a reduced pill 
burden.
130
 
Another concerning issue that were revealed with PIs had was the development of a 
resistance profile. Lopinavir was developed with an alternative scaffold to try and overcome this 
problem. The isopropylthiazolyl group of ritonavir was removed and then a conformational 
constraint in the resulting urea by incorporation of a six-member ring was used in the scaffold. 
Although lopinavir was more potent than ritonavir and less affected by the mutation commonly 
found in ritonavir-resistant viruses, it suffered from poor bioavailability in humans.
126
 A 
landmark breakthrough in the field of PIs was discovered with lopinavir. Since it is mainly 
metabolized by CYP3A4 it was discovered that dosing with ritonavir (CYP3A4 inhibitor) 
increased the bioavailability. This led to the development of a fixed-dose combination of the two, 
marketed as Kalertra. Lopinavir was the first boosted PI that compared head-to-head with an 
NNRTI as initial therapy.
102
 Currently, Kaletra and atazanavir have the major share in the PI 
market. Atazanavir has good bioavailability and antiviral activity and 
a unique resistance profile, which sensitizes the virus to all other 
PIs.
129
  
After the screening of a compound library, warfarin (Figure 1.12) was discovered as a 
lead molecule and researchers realized that this pyrone derivative 
was a good start for nonpeptidic and low molecular weight analogs.
129
 After extensive structure-
activity relationship studies, tipranavir was discovered and approved in 2005. Tipranavir is 
effective against resistant mutants and has a good bioavailability profile but unfortunately suffers 
from significant incidences of side effects. Tipranavir is a strong CYP450 inducer, inducing its 
own metabolism and requiring double the usual boosting dose of ritonavir (200 mg), resulting in 
Figure 1.12 Warfarin 
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multiple drug-drug interactions.
131
 These problems are so great the use of tipranavir is largely 
restricted to deep salvage regimens.
129
  
 With the sole exception of tipranavir, the evolution of commercial PIs can be described in 
as incremental structural changes in the initially described leads that led to greater potency, 
increased activity against mutants, and in some cases improved bioavailability. The common 
practice of using ritonavir to boost blood levels and trough levels exemplifies the struggle to 
identify PIs with good bioavailability.
129
 
 
Figure 1.13 Protease Inhibitors (PIs)(hydroxyethylene core/ dihydropyrone ring highlighted in blue) 
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1.3.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
 Shortly after the approval of the first PI, non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) quickly followed (Figure 1.14). NNRTIs inhibit RT by binding in a reversible and 
non-competitive manner to the enzyme in 
a hydrophobic pocket located close to the 
catalytic site. The interaction of the 
compounds with RT induces 
conformational changes that impact the 
catalytic activities of the enzyme.
132
 
Unlike the NRTIs, NNRTIs are active as 
such, and do not need metabolized intracellularly 
to become active.
103
  NNRTIs are highly specific for HIV-1 and are not active against other 
retroviruses. 
The first generation of NNRTIs were approved in 1996 (nevirapine, NVP), 1997 
(delavirdine, DLV), 1998 (efavirenz, EFV). Two NNRTIs, NVP and EFV are currently 
cornerstones of first line HAART, whereas DLV is rarely used today.
103
 NVP is the drug of 
choice in developing countries and due to its reduced teratogenesis and pediatric toxicity it is 
also widely used in pregnant women and young children.
133
 NNRTIs are generally characterized 
by a low genetic barrier to the development of resistance: they need to be combined with at least 
two other fully active non-NNRTI ARV drugs, and resistance to one of them precludes 
subsequent use of other first generation NNRTIs. They are generally well-tolerated and safe; 
however, hepatotoxicity and severe hash are associated with NVP
134
 and central nervous system 
(CNS) side effects are associated with EFV that are sometimes difficult to overcome.
135
 An 
Figure 1.14 Non-Nucleotide Reverse 
Transcriptase Inhibitors (NNRTIs) 
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important consideration with the first generation NNRTIs is that they are metabolized by 
CYP450 and although the isoenzymes involved vary for each compound, there is a potential for 
drug-drug interactions with drugs that are also metabolized via the CYP450 pathway.  
The success of the first-generation class of compounds prompted research for the discovery and 
development of the next generation of NNRTIs that would have a better resistance profile, in 
order to offer treatment experienced patients the option to benefit from the convenience and good 
safety profile of the NNRTI class of compounds. Etravirine was the first of the second generation 
class of compounds to be approved by the FDA. Etravirine and rilpivirine belong to the family of 
di-aryl-pyrimidine (DAPY) compounds and are reported to be clinically effective in HIV-1 
strains that are resistant to other NNRTIs. They have a higher genetic barrier to resistance than 
the first generation NNRTI compounds.
133
   
Table 1.9 Clinically Approved Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs) 
 
1.3.4. Highly Active Antiretroviral Therapy (HAART) 
The combination of several classes of  multiple classes of compounds, referred to as 
Highly Active Antiretroviral Therapy (HAART) or, more recently, as combined Antiretroviral 
Therapy (cART), reduces the viral load by sufficiently slowing the rate of viral replication, thus 
by restoring the immune system by increasing circulating levels of CD4+ T cells.
133
 As a result, 
HAART  has changed the prognosis for patients with HIV-1 infection from that of high 
morbidity and rapid mortality to, for many at least, a chronic, manageable, but still complicated 
Trade Name Generic Name Manufacturer Approval Date
Viramune (Immediate Release) NVP, nevirapine Boehringer Ingelheim 21-Jun-96
Rescriptor DLV, delavirdine Pfizer 4-Apr-97
Sustiva EFV, efavirenz Bristol-Myers Squibb 17-Sep-98
Intelence etravirine Tibotec Therapeutics 18-Jan-08
Viramune XR (Extended Release) NVP, nevirapine Boehringer Ingelheim 25-Mar-11
Edurant rilpivirine Tibotec Therapeutics 20-May-11
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disease.
136
 The key components of HAART are the RT inhibitors (NRTI or NNRTI) and PI, 
which target different stages of the viral replication cycle. The combination therapy optimizes 
the ARV effect of each drug and avoids genetic resistance.
133
 There are several HAART 
strategies, which vary with the status of infection and/or patient characteristics, and are 
frequently updated. According to the current guidelines, initial regimens should be composed of 
two NRTIs with either a NNRTI or boosted PI.
137
  
Over the past decade HAART has gradually evolved from drug regimens with more than 20 pills 
daily (i.e., stavudine plus lamivudine plus indinavir) in 1996 to 3 pills daily (i.e., zidovudine 
(Combivir
®
) twice daily and efavirenz once daily) in 2003 to 2 pills daily (i.e., 
emtricitabine/tenofovir disoproxil fumarate (Truvada
®
) and efavirenz) in 2004 and finally to one 
pill daily in 2006 (Atripla) and in 2011 (Complera
®
) (Table 1.10).
138
 
Table 1.10 Multi-Class HIV-1 Combination Drugs 
1.3.5. Fusion inhibitors 
Viral entry is a particularly attractive target for drug intervention since it involves the 
exposure of highly conserved domains in Env and depends on the cell surface receptors that can 
be targets for orally available small molecule inhibitors.
71
 Enfuvirtide (Fuzeon
®
, DP-178, 
pentafuside, or T-20) is the first ARV fusion inhibitor approved for the treatment of HIV-1 
infected patients.  This new family of ARVs was eagerly awaited by the growing number of 
patients carrying drug-resistant viruses to RT and PR inhibitors.
139
 Since the early 1990s it has 
been known that peptides synthesized on the basis of the amino acid sequence of heptad repeat 1 
(HR1) and heptad repeat 2 (HR2) of gp41 may show antiviral properties against HIV-1.
140-142
 In 
1993, the in vivo potency of a peptide, D-178, which was synthesized on the basis of the amino 
Trade Name Generic Name Manufacturer Approval Date
Atripla efavirenz + emtricitabine + tenofovir disoproxil fumarate Bristol-Myers Squibb & Gilead Sciences 12-Jul-06
Complera emtricitabine + rilpivirine + tenofovir disoproxil fumarate Gilead Sciences 10-Aug-11
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acid sequence of HR2, was demonstrated.
139
 This molecule, enfuvirtide, is a synthetic peptide of 
36 amino acids, which mimics the HR2 region of gp41 (Figure 1.15).
143, 144
 It is homologous to 
the heptad repeat HR2 region of gp41 glycoprotein and, while T-20 will itself engage in a coiled-
coil interaction with the heptad HR2 region of gp41, it prevents the six-helical bundle formation 
required to initiate the fusion process.
72
 Enfuvirtide, the only HIV-1 drug injected 
subcutaneously, is generally used in combination with HAART regimens for the treatment of 
patients suffering failure to prior therapies. Although enfuvirtide is active in patients whose virus 
is resistant to other classes of ARVs, as in the case of all other ARVs, continued exposure, 
especially if the virus is not completely suppressed, can lead to emergence of viral resistance to 
enfuvirtide. It is by far the most complex ARV ever manufactured at such a large scale, which 
provides both production and economic challenges.
145
 
Table 1.11 Clinically Approved HIV-1 Fusion Inhibitor 
Figure 1.15  Linear schematic of the HIV gp41. Four regions of functional importance are depicted: fusion peptide (FP), heptad repeat 1 (HR1), 
the cysteineresidues (cc) that form disulphide bridges, heptad repeat 2 (HR2) and the transmembrane region (tm). The amino acid sequences of 
the HR1 and HR2 regionsare shown in detail. Amino acids involved in the interaction between HR1 and HR2 are shown in bold, including those 
thought to be involved in resistance to enfuvirtide. The 36 amino acid region in HR2 corresponding to enfuvirtide indicated by a bold arrow.146 
(Reprinted with permission from Oxford Journals: License) 
Trade Name Generic Name Manufacturer Approval Date
Fuzeon T-20, enfuvirtide Hoffmann-La Roche & Trimeris 13-Mar-03
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1.3.6. Chemokine Receptor Antagonists 
The coincidental use of CXCR4 and CCR5 by HIV-1 as coreceptors to enter cells has 
prompted the search for CXCR4 and CCR5 antagonists (Figure 1.16), through blockade of the 
corresponding receptor, might be able to inhibit HIV entry into the cells.
72
  
The most characterized of the CXCR4 antagonists is AMD3100 (JM3100, mozobil™). It was 
originally discovered as an anti-HIV agent with 
strong inhibitory effect on the replication of X4 HIV-
1 strains
147
 and was later found to inhibit X4 HIV-1 
replication as a selective antagonist of CXCR4
148
 then 
found to specifically mobilize hematopoietic stem 
CD34+ cells from bone marrow into the 
bloodstream. 
Although several CCR5 antagonists have been evaluated in clinical trials only maraviroc 
has been approved for clinical use in the treatment of HIV-1 infected patients (Table 1.12).
149
 
Maraviroc binds to CCR5, thereby blocking the HIV-1 protein gp120 from associating with the 
receptor and HIV-1 is unable to enter the host cell.
150
  Since HIV-1 can also use other 
coreceptors, such as CXCR4, and HIV-1 tropism test such as a trofile assay must be performed 
to determine if the drug will be effective.
151
 Maraviroc has an extremely safe and tolerability 
profile, however, the long-term safety of blocking CCR5 is not fully understood.
152
 Despite 
being approved in 2007, the optimal use of maraviroc has yet to be defined in HIV-1 therapy.  
Unfortunately, one limitation to the clinical use of maraviroc is that it is only effective against 
CCR5-using R5 HIV-1 strains. From dual (CCR5 and CXCR4)-tropic or mixed HIV-1 
populations that use both CCR5 and CXCR4 (which are commonly used among highly treatment 
Figure 1.16 CXCR4 and CCR5 Antagonists 
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experienced patients), maraviroc may select for the outgrowth of pure CXCR4-tropic X4 
strains.
153
 In addition, R5 HIV-1 strains may develop resistance to maraviroc while still utilizing 
the inhibitor-bound receptor for entry.
154
 Evidently, to cope with dual-tropic or mixed X4/R5 
HIV-1 populations, a combination of CXCR4inhibitors with CCR5 inhibitors will be needed.
72
 
Table 1.12 Clinically Approved CCR5 Antagonist 
 
1.3.7. Integrase Inhibitors 
 Among the furthest advanced IN inhibitors in clinical development are raltegravir 
(Isentress®, MK-0518) and elvitegravir (GS-9137) (Figure 1.17). Raltegravir was approved by 
the FDA in 2007 and elvitegravir’s approval is 
currently pending (Table 1.13).
72
 Both 
compounds inhibit the strand transfer reaction 
in the integration process and were validated as 
genuine HIV-1 IN inhibitors is cell culture 
assays.
155
 When added onto an optimized 
background regimen, raltegravir, offered better viral suppression than placebo over a 24-week 
treatment period.
156
 Undoubtedly, the IN inhibitors may be welcomed (following NRTIs, 
NNRTIS, PIs, and virus entry inhibitors) as the next new class of anti-HIV drugs. However, just 
like all other classes of HIV-1 inhibitors, IN inhibitors should be carefully monitored for the 
emergence of drug-resistant virus strains.
72
 
 
 
Trade Name Generic Name Manufacturer Approval Date Mechanism of Action 
Selzentry maraviroc Pfizer 6-Aug-07 Non-competitive Inhibitor
Trade Name Generic Name Manufacturer Approval Date
Isentress raltegravir Merck 12-Oct-07
Figure 1.17 HIV-1 Integrase Inhibitors 
Table 1.13 Clinically Approved HIV-1 Integrase Inhibitor 
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1.3.8. Vaccines 
There is currently little prospect of an effective vaccine for HIV-1 on the horizon. An 
HIV-1 and AIDS vaccine does not yet exist, but efforts to develop a vaccine against HIV-1, have 
been underway for many years. Since 1987, more than 30 vaccine candidates have been tested.
157
 
The development of an HIV-1 vaccine faces formidable scientific challenges related to high 
genetic variability in the virus, the lack of immune correlates of protection, lack of animal 
models and logistical problems associated with the conduct of multiple clinical trials.
158
 
 
1.4. ANTIRETROVIRAL DRUGS AND LABORATORY MONITORING 
 Antiretroviral drugs development was substantially accelerated by the development of 
accurate, reproducible, and inexpensive laboratory tests. These laboratory tests are used today to 
help individuals decide when to start ARV and continue to monitor the success of their anti-HIV 
therapy. 
 
1.4.1. CD4 Testing 
 The average CD4 T cell count of an uninfected adult is typically more than 500 cells per 
µL, Most OIs occur as the CD4 T cell counts fall below 200 cells per µL. Recent guidelines  
suggest the threshold of 350 cells per µL as a strong indicator for starting ARV.
137
  Once 
treatment begins CD4 T cells typically increase rapidly for the first 3 months of treatment and 
then slowly increase by roughly 50-75 cells per µL per year, with rates declining CD4 T cell 
count reaches normal.
159
 The biological and assay variability of the peripheral CD4 cell count is 
high, making it difficult to rely on one measurement.
72
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1.4.2. Quantitative Viral Load Testing 
 Quantitative viral load, or concentrations of plasma HIV-1 RNA, is measured with PCR 
or related methods. Chronic established HIV-1 infection is often associated with a stable set 
point, which varies widely among individual patients. The viral set point is associated with the 
rate of CD4 T cell decline and the risk of AIDS and death.
160, 161
 Viral load is measured before 
ARV therapy begins, but its primary value is monitoring treatment response or failure. The 
immediate goal of therapy is to reduce HIV-1 replication threshold below which the virus does 
not evolve and drug resistance does not emerge.
8
 
1.4.3. Drug Resistance Testing 
Antiretroviral drug-resistance mutations will almost inevitably emerge if HIV-1 is 
allowed to replicate in the presence of ARV drug concentrations insufficient to exert complete 
suppression. The common resistance mutations for all drugs have been well characterized and 
their detection with reproducible commercial assays is straightforward, as long as the plasma 
viral load is at least 500-1000 copies per mL.
162
  
 
1.4.4. Chemokine Receptor Tropism and HLA-B* Testing 
 HIV-1 enters the preferred target cells by binding to one of both of the chemokine 
receptors CXCR4 and CCR5. Nearly all patients with primary HIV-1 infection harbor a virus 
that binds to CCR5 (R5 virus). For unclear reasons, as the disease progresses overtime, many 
individuals develop a virus that also binds to CXCR4 (X4 virus).
163
 Since one therapeutic drug 
specifically targets CCR5, testing is needed to define which tropism of the virus (CCR5 or 
CXCR4) is present.
137
 The only validated tropism assay is an expensive phenotypic test that 
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takes 2-4 weeks and is only completed in a few specialized laboratories.
164
 In view of these 
limitations, genotypic tropism assays are being developed and might gain widespread use.
72
 
 
1.5. COMPLICATIONS OF CURRENT ANTIRETROVIRAL THERAPIES 
Considering the low fidelity of HIV-1 RT coupled with the high replication of the virus, 
it is not surprising that even triple-class HAART therapy eventually fails in the majority of 
patients and is typically associated with the emergence of drug resistance. The success of 
HAART relies on a concerted multipoint attack that shuts down HIV replication so effectively 
that it reduces the likelihood that drug-resistant viral mutants will emerge. But if a patient 
doesn’t follow the demanding regimen and concentrations of anti-HIV drugs in the blood taper 
off gradually, pressure on the virus is reduced, giving resistant strains a chance to emerge and 
crowd out “wild-type” virus.165 Patients therefore need to be treated with sequential HAART 
regimens progressively, using up the diminishing pool of active drugs that are left available.
145
  
The combination of toxicity, “pill fatigue” and frequent changes in drug regimens has created the 
perfect conditions for the worst of all limitations: drug resistance.  
 The cost for most combination regimens approaches $12,000 yearly. Despite the expense, 
ART is generally seen as cost effective, at least compared with other therapeutic strategies 
generally used.
166
 In many resource-rich regions, treatment is often subsidized by public funding. 
There is a concern, however, in these countries, full and continuous access to ART could be 
threatened by a weak economy. Long waiting lists for access to publically supported treatment 
programs exist in many states within the US, and the lists seem to be getting longer. 
72
  
The impact of the newly developed compounds incorporated in the HAART regimen remains to 
be seen. However, the fact that HIV-1 is now a chronic illness implies that therapies are 
40 
administered for life; therefore, their selection should be based not only on their efficacy but also 
on their toxicological profile.
133
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II. HIV-1 INTEGRASE INHIBITOR DEVELOPMENT 
 
Extensive reviews of HIV-1 integrase (IN) inhibitor design, development and mechanism 
of action have been previously published (Table 2.1). For the sake of brevity, a summary of 
significant contributions and discoveries that outline and provide a historical perspective as to 
the progression of the field of HIV-1 IN inhibition will be discussed. 
 
2.1. HIV-1 INTEGRASE: A TARGET FOR DRUG DISCOVERY 
HIV-1 integrase (IN) was initially considered to be a difficult and “undruggable” target 
for antiretroviral (ARV) drug discovery and design. In comparison to HIV reverse transcriptase 
(RT) and protease (PR) inhibitors, where lead compounds were abundant in chemical 
repositories of major pharmaceutical companies, there were no authentic leads for IN inhibitors. 
The first decade of development in the field of HIV-1 IN inhibitor design was slow. The early 
lead IN inhibitors were not selective and in most cases were either inactive in blocking viral 
replication or too cytotoxic for further development.  
 
 
Table 2.1 Review Articles Detailing HIV-1 Integrase Inhibitors (1992-2011) 
 
 
Title Reference
Design and Discovery of HIV-1 integrase inhibitors Drug Discovery Today  1997, 2, (11), 487-498.
HIV-1 integrase as a target for antiviral drugs Antiviral chemistry & chemotherapy 1997, 8, 463-483.
Retroviral integrase inhibitors year 2000: update and perspectives Antiviral Research  2000, 47, (3), 139-148.
HIV-1 integrase inhibitors: past, present, and future Advances in Pharmacology 2000,49, 147-165.
Patented small molecule inhibitors of HIV-1 integrase: a ten year saga Expert Opinion on Therapeutic Patents 2002, 12, (5), 709-724.
Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update Current Pharmaceutical Design  2003, 9, (22), 1789.
Integrase inhibitors to treat HIV/AIDS Nature Reviews Drug Discovery  2005, 4, (3), 236-248.
HIV-1 integrase inhibitors: 2003-2004 update Medicinal Research Reviews  2006, 26, (3), 271-309.
HIV-1 integrase inhibitors: 2005-2006 update Medicinal Research Reviews  2008, 28, (1), 118-154.
HIV-1 IN inhibitors: 2010 update and perspectives Current Topics in Medicinal Chemistry  2009, 9, (11), 1016-1037.
HIV-1 integrase inhibitors: 2007-2008 update  Medicinal Research Reviews  2010, 30, (6), 890-954.
HIV-1 integrase mechanism and inhibitor design Mechanism and Inhibitor Design. 1 ed.; Wiley: 2011; p 528
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2.1.1. Challenges of HIV-1 IN as a Target 
The long process of HIV-1 IN inhibitor discovery and development can be attributed to 
the complexity of the IN and the integration reaction itself. Many copies of IN (50-100 copies) 
enter the cell with the infecting virus and only two integration events are required to produce the 
functional provirus.
167
 Unlike RT, where several thousand enzymatic turnovers by RT are needed 
to complete the synthesis of viral RNA, providing numerous opportunities for NRTIs and 
NNRTIs to block RT, the relatively small number of events needed to complete integration 
potentially makes IN difficult to inhibit. Secondly, the absence of the crystal structure of the full 
length HIV-1 IN with viral or host DNA and its inhibitors has been an significant obstacle to the 
rational design of specific IN inhibitors.
168
 Other challenges also include a shallow surface 
substrate binding site located on the surface of IN
169, 170
 and its formation of a multimeric 
complex in preintegration complexes.
171
 Finally, there were several initial technological 
complications that researchers encountered in respect to designing inhibitors of IN. Many of the 
early IN inhibitors were neither confirmed as antiviral nor specific inhibitors. Integrase can use 
either Mn
2+
 or Mg
2+
 as a metal cofactor to catalyze integration. It has always been a challenge to 
obtain good activity in the presence of Mg
2+
 and, therefore, most of the early inhibitors were 
reported using Mn
2+
 as cofactor.
168
 It is now commonly acknowledged that Mg
2+
 is probably the 
biological cofactor of IN.
86, 172
 Many of the early inhibitors screened in Mn
2+
 assays may have 
been responsible for a large number of false positives.  
Collectively, the challenges were so significant that many in the field questioned the 
rationality of IN as a “druggable” target. Several recent studies predicting druggability still 
characterize the binding site of HIV-1 IN as not druggable. 
1, 169, 170
 In 2007, Cheng et al. used a 
model-based approach based on basic biophysical principles to predict the druggability of several 
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targets using the crystal structure of the target protein binding site.
1
 They calculated values of the 
maximal affinity achievable by a drug-like molecule and correlated these values with expected 
drug-discovery outcomes. The group validated their theoretical data with experimental results 
against two targets using high-throughput screening of a diverse compound collection. They 
calculated druggability for a set of 27 protein target binding sites and remarkably HIV-1 IN was 
determined to be the most challenging and fundamentally “undruggable” target (Figure 2.1).1 
 
2.1.2. HIV-1 IN as a Valid and Attractive Target 
With the long-term commitment of researchers dedicating time and resources to HIV-1 
IN research, although once considered an invalid target, IN is now considered to be one of the 
promising new targets in preclinical and early clinical trials. HIV-1 IN enzyme is an attractive 
target for anti-HIV therapy for several reasons. First, IN specifically catalyzes the integration of 
proviral DNA into the host cell genome, which is an early and crucial step in the HIV-1 
retroviral life cycle, and represents a point of no return.
173, 174
 Upon inhibition of IN, the viral 
DNA is converted into circular DNA unable to be integrated into the host genome.
175
 Moreover, 
a key component of the catalytic core of HIV IN is the highly conserved DDE motif which is 
composed of three amino acids: D64, D116 and E152.
86
 A mutation in any of these conserved 
residues reduces the ability of the virus to replicate. Second, inhibitors of IN appear to be 
particularly promising since, unlike PR and RT, this enzyme does not have direct human 
homologs.
176
  Therefore drug selectively targeting IN are expected to show low toxicity in the 
host. Third, reactions carried out by IN are unique, and sensitive assays exist for testing IN 
enzymatic activity in vitro.
177
 In addition, crystal and nuclear magnetic resonance (NMR) 
structures are available for use in rational structure-based drug design.
172, 178
 Lastly, combination 
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therapy with IN inhibitors and drugs directed against PR and RT was shown to be synergistic in 
several tested models.
179
 
It is inconceivable to imagine that HIV-1 IN inhibitors were once considered an 
unattainable option for HIV-1 therapy.  The continuous research in the IN field is responsible for 
the approval of the first marketed HIV-1 IN inhibitor and several other inhibitors emerging out 
of late stage clinical development. The 20 year journey from hypothetical concept to a proof-of-
concept treatment option was not easy. The path was heavily laden with adversity and skepticism 
but dedication to the field led to a realistic and “druggable” target.  
 
Figure 2.1 Calculated Druggability. Calculated druggability for a set of 27 
target binding sites. Known druggable protein targets are shown on the left 
vertical, whereas known difficult targets (prodrug and “undruggable”) are 
shown in the right verticals. Difficult and druggable target binding sites 
are effectively separated by the gray bar. The predicted druggability is the 
MAPpod score calculated from the protein-ligand site structure. HMG-CoA, 
3-hydroxy-3-methylglutaryl-CoA; EGFR, epidermal growth factor 
receptor kinase; CDK, cyclin-dependent kinase 2; PDE, 
phosphodiesterase; COX, cyclooxygenase; HIV RT, HIV reverse 
transcriptase; PBP2x, penicillin binding protein 2x; IMPDH, inosine 
monophosphate dehydrogenase; ACE-1, angiotensin-converting enzyme 1; 
ICE1, interleukin-1β-converting enzyme 1; PTP1b, phosphotyrosine 
phosphatase 1B.
1 
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2.2. THE EARLY YEARS OF DEVELOPMENT 
Concisely, prior to 1992, inhibition of HIV-1 had been considered as a treatment 
approach, but no specific IN inhibitor had been identified yet. Important biochemical studies on 
HIV-1 life cycle conducted during this period were fundamental for future IN inhibitor 
discovery.
180-182
  Topoisomerase inhibitors and DNA-binding drugs were among the first drugs 
to be screened against IN (Figure 2.2).
183
 However, the approach of using the DNA-binding 
drugs involved unfavorable risks and toxicity, and therefore, this route was quickly abandoned. 
Interestingly, topoisomerase II inhibitors, doxorubicin  and mitoxantrone, inhibited HIV-1 IN 
catalytic activities but a topoisomerase I inhibitor, camptothecin, did not (Figure 2.2).
183
 From 
these initial studies it was apparent that a common feature of the topoisomerase II inhibitors is 
the 5,8-dihydroxynapthtalene-1,4-dione (Figure 2.2). This was the first piece of evidence that 
compounds containing a keto-enol functionality (previously known to chelate divalent metal) 
inhibited HIV-1 IN activities. 
 
 
 
Figure 2.2 Select Examples of DNA Binders and Topoisomerase 
Inhibitors 
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2.2.1. The Development of an In Vitro Screening Assay 
  During the period of 1992-1996, NRTIs, NNRTIs and PIs were already undergoing 
clinical testing or in an advanced phase of preclinical development and the discovery of IN 
inhibitors was just beginning.
184
 These years would eventually lay the foundation for modern 
small molecule IN inhibitor discovery. A crucial step in the advancement of HIV-1 IN inhibitors 
was in 1992 with the development of  an in vitro screening assay to identify inhibitors of IN.
185
 
This assay was based on labeled short oligonucleotide duplexes mimicking U5 and U3 viral 
DNA ends. These could act as mimics of both donor (e.g., viral) and target (e.g., cellular) DNA. 
Together with these methods used for producing purified recombinant retroviral integrases, this 
assay allowed to elucidate the first insights and several details regarding structure, catalytic 
activities and inhibitors of IN.  
 
2.2.2. Hydroxylated Aromatics and Catechol-Containing 
Inhibitors 
In the mid-1990s several classes of IN inhibitors 
began to emerge and it became clear that a majority of 
compounds contained one or more catechol moieties were active against purified IN. Although 
the reported inhibitors are from unrelated structures, several of these compounds possessed 
multiple aromatic rings, with poly(arylhydroxylation), frequently in the 1,2-catechol 
arrangement. In many cases the aryl units of these compounds were separated by a variety of 
aromatic or aliphatic central linkers (Figure 2.3). By systemic screening using purified IN-based 
assays, several hydroxylated aromatic compounds (Figure 2.4) have been identified which 
include flavones and flavonoids,
186, 187
 bis-catechols,
188
  caffeic acid phenethyl ester (CAPE), 
189
 
 
 
Figure 2.3 General Structure of  
Catechol Containing Inhibitors 
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curcumin,
186
   arctigenins,
190
 tyrphostins,
191
 styrylquinolines (SQLs) and chicoric acid and its 
derivatives.
192, 193
 Although catechols as a group exhibit favorable inhibitory profiles in cell-free 
integrase assays, often these compounds have failed to have antiviral activity due to the dose-
limiting toxicities in in vitro assays. Many polyhydroxylated aromatics showed considerable 
cytotoxicity, which obscures their potential antiviral activity.
194
 One potential in vivo limitation 
is the cellular oxidation of the catechol to semiquinones or orthoquinones results in reactive 
intermediates that tend to cross-link to various cellular-targets.
195
  
 
2.2.3. Non-Catechol-Containing Aromatic Inhibitors 
Several classes of compounds lacking hydroxyl groups were developed in attempt to 
improve the toxicity and lack of antiviral activity of the catechol-containing compounds. These 
 
 
Figure 2.4 Select Examples of Polyhydroxylated Aromatic IN inhibitors 
 
48 
compounds were tested in an effort to distinguish between mechanism of cytotoxicity and IN 
inhibition. In support of this endeavor, computer-assisted molecular modeling has been 
employed to identify potential inhibitors from among 206,876 open compounds contained within 
the National Cancer Institute (NCI) Drug Information System (DIS) database.
196
  
An interesting detour in attempts to improve the profile and lack of antiviral activity of 
the catechol containing compounds led to the discovery of hydrazides (Figure 2.5). The N, N’- 
bis-salicylhydrazine (H1) generated fresh enthusiasm, albeit short lived, in synthetic exploration 
of its analogues.
197, 198
 These hydrazide compounds are potent IN inhibitors, however, they do 
not show selectivity for 3’-P or ST. These compounds have been reported to inhibit IN through 
metal chelation but were only effective in assays using Mn
2+ 
and not
 
Mg
2+ 
cofactors and lacked 
antiviral efficacy in HIV-1 infected cells.
199, 200
 
The search for IN inhibitors that are superior to hydroxylated aromatics led to the 
discovery of several sulfones. Unfortunately, highly potent and selective inhibitors did not 
emerge from early structure-activity relationship studies of several screened sulfone analogues. 
 
Figure 2.5 Select Examples of Hydrazide-Based Inhibitors of IN 
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However, the search continued with other variations of sulfones such as sulfonates, sulfonamides 
and sulfides (Figure 2.6).
194
 Among these, the mercaptobenzenesulfonamides and benzothiazines 
were shown to be promising for further optimization. In contrast to previously reported 
catechols, several of the sulfone analogues inhibited HIV-1 replication at a concentration below 
their cytotoxic concentrations. Futhermore, studies indicated that disulfones target an early-stage 
HIV-1 replication event as well as a later step in virus replication, with IN as a possible target.
201
  
Although, several compounds were found to inhibit IN function at low µM concentrations this 
endeavor was unsuccessful in yielding a selective bona fide lead. 
 
2.2.4. An Assay to Identify Strand Transfer Inhibitors of HIV-1 IN 
Much of the earlier IN inhibition work led to the identification of compounds that interfered with 
the assembly and processing activities of IN in biochemical assays but did not show antiviral 
activity in cells.
202
  In 1994, Merck researchers developed a novel rapid assay for the DNA 
strand–transfer activity of HIV-1 IN. This biochemical assay was able to separate the final strand 
transfer step from the earlier assembly and processing steps allowing high-throughput screening 
of compound libraries.
175, 203
 This was achieved by allowing isolated IN enzyme to form an in 
 
 
Figure 2.6 Select Examples of Sulfone-Based Inhibitors of IN  
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vitro IN-DNA-metal complex, also known as the preintegrase complex (PIC).
204-206
  This assay 
allowed compounds to inhibit PIC-catalyzed strand transfer to a labeled “target” piece of DNA to 
be evaluated and ultimately evaluated for their ability to act exclusively as strand transfer 
inhibitors.
207, 208
   
After about a decade of searching for a bona fide lead IN inhibitor it was apparent that 
there was an overwhelming sense of frustration among researchers. It had become apparent that 
the identification of a clinical candidate was noticeable more difficult than for other antiretroviral 
drug classes. In 1996, IN inhibitor research was overshadowed by the enthusiasm of the 
scientific community for the initial success of highly active antiretroviral treatment (HAART). 
The potential of HAART was initially overestimated due to the calculations forecasting the 
prolonged periods of HAART might lead to HIV eradication; therefore it was inevitable that 
main interest in drug companies was NRTIs, NNTIs and PIs.  Merck was one of the few large 
pharmaceutical companies continuing huge efforts in IN research. 
209
 Despite the decay of 
interest in IN inhibitors, the assays optimized in the previous years allowed the screening of large 
numbers of molecules.
209
 
 
2.3. The β-DIKETO ACID CLASS OF INHIBITORS  
The β- diketo acid (DKA) class of compounds represents one of the most promising 
classes of IN inhibitors and opened up a new frontier of IN antiviral drug discovery. A previous 
large-scale random screening of over 250,000 compounds yielded potent inhibitors, and the most 
active compounds proved to be 4-aryl-2,4-diketobutanoic acids, containing a distinct DKA 
functionality that was capable of coordinating metal ions in the active site of IN.
175
 The DKA or 
keto-enol acid family of inhibitors were the first IN inhibitors reported with selectivity for the 
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Figure 2.7 First Lead DKA IN Inhibitors with Selectivity for ST 
 
strand transfer step of the integration reaction (STI),
86
 high specificity for IN, and antiviral 
activity that could be related to IN inhibition.
175
  During the time that the DKAs were first 
recognized, the hopes for HIV-1 eradication through HAART were definitively abandoned. Side 
effects became a serious problem affecting a large number of people. Thus, the interest in IN 
inhibitors in the scientific community was recharged.  
 The first small molecules (MW <500 Da) independently identified as potential HIV-1 IN STIs 
were L-731,988 (2.1) and L-708,906 (2.2) from Merck Research Laboratories, 
175, 210
 and 1-(5-
chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone (5-CITEP, 2.3) from Shionogi & 
Co. Ltd.
211
  It was immediately clear that both the Merck and Shionogi compounds could be 
functionally classified together as DKAs.  
The DKAs from Merck (L-731,988 and L-708,906) were shown to selectively and 
potently inhibit both IN catalyzed ST and HIV-1 replication in vitro. Further studies of  2.1 and 
2.2 showed that these compounds had no effect on viral entry, reverse transcription, PIC 
assembly, or 3’ processing.175 Additionally, upon serial passage of the HIV virus in cell culture 
in the presence of the two inhibitors, mutations that confer resistance to inhibition arose in the 
integrase active-site region (T66I/S153Y for L-731,988 , T661/M154I for L-708,906). These 
mutations are very near to the active-site amino acid residues D64 and E152, two of the three 
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amino acids critical for catalysis.
175, 212
 This data was evidence that 2.1 and 2.2 were preventing 
integration by binding at the catalytic site. 
The selectivity of these DKA containing compounds for ST inhibition over 3’P was 
greatly increased compared to previously reported IN inhibitors.  For example, 5-CITEP 
presented and IC50 value of 35 µM for 3’P and 0.65 µM for ST.
211, 213
 Compound 5-CITEP (2.3) 
is a DKA bioisostere where the carboxylic acid group is replaced with its well-known isostere 
the tetrazole group. 
214
 The compound 5-CITEP was a breakthrough in the field of IN inhibitor 
research because it was co-crystallized with the catalytic core domain (CCD).
211
  The electron 
density map clearly revealed the inhibitor bound in the center of the active site of the enzyme, 
lying between the three catalytic acidic residues D64, D166 and E152, suggesting that this 
binding mode might mimic interactions with the DNA substrate.
211
 Of note, 5-CITEP was found 
to assume a planar conformation within the active site (Figure 2.8, panel A).
211
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Figure 2.8. 5-CITEP Complexed with Crystal Structure. Panels A, B and C are derived from the crystal structure of the IN core domain 
complexed with 5-CITEP.211, 215 The catalytic amino acids are shown in red, the magnesium ion is colored in magenta and the four coordinating 
water molecules are yellow. A: 5-CITEP interactions within the HIV-1 IN active site. Amino acids with direct interactions with 5-CITEP.211 are 
highlighted in green. The view angle is the same in panel C. B: Crystal structure of the IN core domain dimer.216 Alpha helices targeted by 
peptide inhibitors are colored and labeled. Helices 1 (cyan) and 5 (magenta) from the dimerization interface between two IN monomers. Helix 4 
(green) is proximal to the active site and includes the catalytic amino acid E152. The three catalytic residues, D64, D116, and E152 are shown in 
red. C and D: Illustration of the amino acids that are mutated in the DKA resistant viruses. The side chains of the amino acids conferring 
resistance to DKA are highlighted in gold. Panel C is a view of the same orientation as in panel A. In panel D, the IN is rotated horizontally 90°. 
 
The DKA derivatives mediate their antiviral activity through metal chelation.
213, 217, 218
 It 
has been postulated that the integration mechanism involves two divalent metals (magnesium) in 
the catalytic site of the enzyme. The first magnesium atom, as observed in the different crystal 
structures, is coordinated by the two catalytic residues D64 and D116 (Figure 2.8) and the 
second would be coordinated either by D116 and E152.
213, 217, 218
 
Extensive SAR of the DKA series of compounds would eventually lead to some most 
successful classes of IN inhibitors. The DKA integrase inhibitors 2.1-2.3 display a template of 
two carbonyl groups flanking a central enol moiety.
175, 210, 212
 The DKA moiety was quickly 
recognized as important for activity, but it offered several liabilities as a drug candidate. The 
dicarbonyl portion was found to react reversibly with glutathione and the DKA was observed to 
54 
 
Figure 2.9 Instability of DKA in Aqueous Base  
 
be unstable in the presence of aqueous base. Under these conditions the inactive methyl ketone 
was observed to form, as the result of loss of oxalate (Figure 2.9).
219
 The terminal carboxyl 
group appears to act as a Lewis base rather than a Lewis acid, as has been confirmed by 
replacement by heterocyclic aromatic rings that have Lewis basic but not Lewis acid character 
(Figure 2.10).
220
  
The discovery of compounds  L-731,988 (2.1), L-708,906 (2.2) and 5-CITEP(2.3) 
represented a turning point in the IN inhibitor development because of their potent antiviral 
activity and well-characterized selectivity targeting integrase in HIV-infected cells.
175
 From 
these initial series of DKAs several DKA derivatives advanced to clinical trials and ultimately 
the field of IN drug discovery started to gain momentum. 
 
2.3.1. HIV-1 Integrase Inhibitors Enter Clinical Trials  
 The first IN inhibitor to enter clinical trials was S-1360 (2.10), a diaryl diketone 
derivative of 5-CITEP, developed by Shionogi & Co. Ltd in partnership with GlaxoSmithKline 
(GSK) (Figure 2.11).
221, 222
 S-1360  proved that IN is indeed a “druggable” target, and results 
 
Figure 2.10 Replacement of DKA with Diaryl Diketones 
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Figure 2.11 Examples of Clinically Tested DKA IN inhibitors 
 
with this drug in phase I clinical trials was very encouraging. Unfortunately, S-1360 failed phase 
II clinical trials due to lack of efficacy and pharmacokinetic problems.
222
 It turned out that the 
DKA portion of the molecule, important for IN inhibition, was also a good substrate for aldo-
keto reductase.
223
Although S-1360 did not proceed successfully through clinical trials it served 
as a good lead for structural optimization studies to identify more potent IN inhibitors.  
Further optimization of the DKA series of compounds led to another class of IN inhibitors, the 
napthyridine carboxamides (2.11) and (2.12) by Merck. In this series of compounds the 
carboxylate group was replaced with an appropriate heterocycle, which contained a lone pair 
donor atom such as an 8-hydroxy-1, 6-napthyridine linked to a benzoyl substituent (Figure 2.11). 
Representative compounds from this class, L-870, 810 (2.11) and L-870-812 (2.12) show potent 
inhibition of the ST reaction with good antiviral potency.
224, 225
  Most importantly these 
compounds provided the first proof-of-concept that IN inhibitors could prevent viral replication 
in vivo.
226
 Unfortunately, following preliminary success in L-870, 810 (2.11) short-term 
monotherapy in both naïve and treatment experienced HIV-1 infected patients, the clinical 
development of this drug was terminated due to an observed long-term dosing toxicity in the 
liver and kidneys of dogs.
227
 Additionally, L-870, 810 (2.11) exhibits a high affinity for serum 
protein binding, which may result in a lower effective plasma drug concentration.  Although L-
870, 812 (2.12) was one of the most extensively studied compounds of this series, the clinical 
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status has not been made public. Considering the structural similarity to L-870, 810 (2.11) it is 
assumed to display the same in vivo characteristics. 
 
2.4. HIV-1 IN INHIBITORS: FROM CLINCAL TRIALS TO MARKET 
 
2.4.1. Raltegravir 
 In October 2007, raltegravir (Isentress®, RAL, also known as MK-0518, 2.20) was the 
first U. S. Food and Drug Administration (FDA) approved IN inhibitor to be used in combination 
with other ARV agents for the treatment of HIV-1 in treatment-experiences adults.
228
 Raltegravir 
is the result of a long-term commitment by Merck Research Laboratories, West Point USA, and 
Istituto Ricerca Biologia Molecolare (IRBM) Italy in the development of IN inhibitors.
229
  The 
medicinal chemistry behind the discovery of RAL by Merck Research Laboratories Rome 
(known as IRBM) relies on the understanding of the similarities of the mechanism of action of 
HIV-1 IN and another polynucleotidyl transferase, the NS5b RNA-dependent RNA polymerase 
of hepatitis C virus (HC V).
230
  HIV-1 IN and HCV share the common feature of using two Mg
2+ 
ions in the active site as a key constituent of the catalytic mechanism.  The two enzymes catalyze 
two different types of reactions, however, the amino acids within the catalytic site and the 
geometry of the catalytic metals are conserved. This observation was the basis of the integrated 
drug discovery program, where compounds designed as inhibitors for one viral target using the 
catalytic machinery, were screened across enzymes belonging to the same superfamily from 
other viruses.
231
 
The research group working on hepatitis C virus polymerase discovered a simple DKA 
(2.13) and meconic acid (2.14) derivative as inhibitors of active site HCV NS5b RNA-
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Figure 2.12 Discovery of Dihydroxypyrimidine Carboxamide (2.17) as an 
HIV-1 IN Inhibitor 
 
 
polymerase by random 
screeening.
232, 233
 Both 
classes (2.13) and 
(2.14) were liable to 
problems such as 
chemical instability, 
irreversible covalent 
binding to protein, and poor stability in plasma. The constraint of the six member ring was an 
attractive template and  a third class, dihydroxypyrimidine carboxylic acids (2.15) and N-alkyl 
hydroxypyrimidinone carboxylic acids (2.16), were designed to have more drug-like properties 
and maintain the correct geometry to bind the Mg
2+
 ions in the active site of HCV 
polymerase.
232
. The mechanism of action of inhibition is likely due to the interaction with metals 
in the active site, resulting in a functional impairment by chelation of the critical metal 
cofactors.
217
  Unfortunately, most of these inhibitors showed a suboptimal activity in the HCV 
cell assay resulting from compounds containing a free carboxylic acid.
234
 Several carboxylic acid 
isostere derivatives, including amides (2.17), were synthesized to circumvent this problem.  The 
dihydroxypyrimidine carboxamide that evolved from DKA in the HCV polymerase program
232
 
was a potent, reversible and selective HIV-1 INSTI while being completely inactive on the HCV 
polymerase.
231
  
RAL was a result of continuous efforts to optimize these inhibitors, addressing pharmacokinetic, 
metabolic and antiviral activity issues presented by previously reported DKA inhibitors. RAL is 
an orally administrated (400 mg twice daily), well-tolerated, highly potent, and with an excellent 
pharmacokinetic profile.
228
 In July 2009, RAL was also approved by the FDA for use in first-line 
58 
antiretroviral (ARV) therapy and is undergoing Phase III studies in ARV treatment-naïve 
subjects including investigation of once daily dosing.
104
  
 
2.4.2. Elvitegravir 
A second compound, elvitegravir (EVG, GS-9137 also known as JTK-303, 2.19) is the 
next most advanced IN inhibitor in clinical development. EVG is a quinolone carboxylic acid 
derivative originally discovered by Japan Tobacco, Inc. that was subsequently licensed to Gilead 
Sciences for development outside of Japan. The 4-quinoline-3-glyoxlic acid scaffold was based 
on the idea that IN inhibitors with this scaffold maintain the co-planarity of DKA functional 
groups. Interestingly, the original developed scaffold (2.18) did not show activity, however, its 
precursor 4-quinoline-3-carboxylic acid (2.19) had IN inhibitory activity. This eventually led to 
the discovery of EVG. It is a potent, boosted, once-daily HIV-1 IN inhibitor with ARV activity 
against wild-type and drug-resistant strains on HIV-1. EVG is not yet approved by the FDA 
however; it is currently in Phase III clinical trials.
235
 Unlike, RAL, EVG is primarily metabolized 
by cytochrome P450 3A4 isozyme and significant increases (boosts) in plasma exposure have 
been achieved by co-administering it with CYP3A4 inhibitors (e.g., ritonavir or cobicistat).
236
 
Boosting also results in a prolonged elimination half-life to ~9.5 hours, allowing once daily 
administration of a low 150 mg dose.
236
 Structural modeling studies indicate that the efficient 
 
 
Figure 2.13 Discovery of 4-quinolone-3-carboxylic acid as an IN inhibitor 
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binding of EVG to IN results from the β–ketone and carboxylic acid functional groups that have 
coplanar conformation similar to DKA derivatives.
235
 RAL and EVG share the same mechanism 
of inhibitory action against IN.
228, 237
  
 
2.4.3. GSK-364735 
Several studies to develop follow-on analogs of S-1360, the two groups involved jointly 
discovered a novel lead napthyridinone-based inhibitor, GSK-364735 (2.21). This compound 
contains hydrophobic fluorobenzyl substituent flexibly linked to a chelatable quinolone 
region.
238
 GSK-364735 exhibited ST inhibition comparable to RAL and EVG and demonstrated 
satisfactory results in a phase I clinical trial, 
239, 240
 but its clinical development was halted in a 
phase II clinical trial because of an unfavorable long-term safety profile. 
 
2.4.4. Dolutegravir (S/GSK1349572) 
The collaborative effort between Shionogi and GSK has advanced a Tricyclic hydroxy-
pyridone carboxamide, S/GSK1349572 (2.22), into Phase IIb clinical trials. S/GSK1349572 is 
considered a second-generation HIV-1 IN inhibitor with demonstrates pharmacokinetic 
properties in humans consistent with once-daily unboosted dosing. Resistance data suggests that 
this compound may have an improved resistance profile on RAL and EVG selected mutations, 
which offers a potential therapeutic opportunity for patients suffering from RAL resistance.  
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Compound Structural 
Class 
IN 
inhibition 
profile 
Anti-HIV 
activity 
Pharmacokinetic 
Profile 
Status 
 
Pyrimidione 
carboxamide 
IC50 
a
= 2-7 
nM 
CIC95 
b= 19 nM 
(10% FBS) 
CIC95= 33 nM 
(50 % NHS) 
Rat: Fabsolute= 62% 
T1/2= <1 h 
Cl= 46 mL/min/kg 
Dog: Fabsolute= 62% 
T1/2= <1 h 
Cl= 46 mL/min/kg 
Human: Fabsolute= 32% 
T1/2 (i.v.)= 1.4 h 
 
Market 
 
4-Quinolone-3-
carboxylic acid 
IC50= 7 nM EC50 
c= 0.7 nM  
EC90 
d= 1.7 nM 
(serum-
adjusted)  
 
Rat: Fabsolute= 34% 
T1/2= 2.3 h 
Cl= 8.3 mL/min/kg 
Dog: Fabsolute= 29.6% 
T1/2= 5.2 h 
Cl= 17 mL/min/kg 
 
Phase 
III 
 
1, 6-
Naphthyridinone 
carboxamide 
IC50= 8 nM EC50 = 1.2 nM  
EC90 = 42 nM 
(serum- 
adjusted)  
 
Rat: Fabsolute= 42% 
T1/2= 1.5 h 
Cl= 3.2 mL/min/kg 
Dog: Fabsolute= 12% 
T1/2= 1.6 h 
Cl= 8.6 mL/min/kg 
Rhesus: Fabsolute= 32% 
T1/2= 3.9 h 
Cl= 2 mL/min/kg 
 
Halted 
Phase II  
 
Tricyclic 
hydroxy-
pyridone 
carboxamide 
IC50= 2.7 
nM 
EC50 = 0.51 
nM  
EC90 = 2 nM 
 
Human: Frelative= 70% 
T1/2= 15 h 
Phase 
IIb 
 a
IC50—Concentration of compound that results in 50% inhibition of in vitro integrase assay 
 b
CIC95—Concentration of compound that results in 95% inhibition of the spread of HIV-1 infection in cell culture 
 c
EC50—Concentration of compound that results in 50% inhibition of in vivo viral replication 
 d
EC90—Concentration of compound that results in 90% inhibition of in vivo viral replication 
Table 2.2 IN inhibitors in Clinic and Clinical Development
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2.5. PERSPECTIVE 
Despite the clear successes of selective strand transfer IN inhibitors, the need for second-
generation and new classes of inhibitors remains. Emergence of resistance leading to the 
treatment failure has already been reported for RAL and EVG.
229, 241
  Consistent with selective 
targeting of IN by RAL and EVG, resistance pathways have been described in relationship with 
point mutations of IN residues surrounding the IN catalytic core site.
215
 Three main resistance 
pathways involving the primary mutations Q148R/H/K, N155H and Y143R/C,
241-243
 are 
61 
responsible for virological failure.
244-248
 These pathways seem to be associated with secondary 
mutations that appear to rescue the viral fitness of those primary mutants for example G140S is 
observed together with Q148H, or G140A with Q148R.
244, 248
 Several studies have shown the 
presence of significant genotypic and phenotypic cross-resistance between RAL and EVG, 
including mutations E92Q, Q148R/K/H, and N155H, suggesting that a common mechanism is 
involved in a resistance and potential cross-resistance of both IN inhibitors.
249
 It is clear from the 
emergence of resistance from RAL and EVG in the clinic that second-generation HIV-1 IN 
inhibitors are needed.  
After 20 years (Figure 2.14) IN is now a validated target for the development of anti-HIV 
therapies. However, our knowledge about its structure and function is still lacking. After the 
DKA series of compounds were discovered as STIs of IN and assay methods were refined, a 
plethora of compounds were revealed. These efforts have produced one marketed IN inhibitor 
(RAL) and several in late-stage clinical development, which validates IN as an effective target 
for the treatment of HIV/AIDS. Several companies, academic institutions and agencies continue 
to pursue novel scaffolds and inhibitors of HIV-1 IN.  
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Figure 2.14 Timeline of IN Inhibitor Milestones  
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III. DESIGN AND SYNTHETIC APPROACHES TOWARDS THE DEVELOPMENT 
OF NOVEL HIV-1 INTEGRASE INHIBITORS 
 
Despite the lack of valid structural information, several IN inhibitors have been 
discovered using in vitro assays specific to IN. The clinical success of selective ST inhibitors 
such as marketed raltegravir and the drug candidate elvitegravir, DKA-derived compounds, has 
validated IN as a rational ARV target. However, the exact mechanism of action of the DKA class 
of IN inhibitors has not yet been completely elucidated.
250, 251
 Insights derived from studies in the 
field indicate several proposed mechanism of actions of IN inhibition by the DKA class of 
compounds. Several questions concerning the interactions of IN inhibitors with IN have 
remained unanswered
86, 184
 and include: the docking site, possible interactions with metal ion(s) 
and viral DNA, the amino acids involved in IN binding, the role of drug resistance mutations, 
and the conformations assumed by the inhibitors in complex with the enzyme.
252
 Clarification of 
these issues is critical, given the strict requirement of IN for insertion of proviral DNA into the 
host cell genome, leading to retroviral latency and persistence during therapy.
253
 
 
3.1. HIV-1 IN STRUCTURE AND FUNCTION 
HIV-1 IN enzyme belongs to the DNA processing polynucleotide transferase 
superfamily, enzymes that cleave and join DNA by trans-esterfication and is the key viral 
enzyme for catalyzing DNA integration.
104
 HIV-1 IN is a 32 KDa enzyme that contains 288 
amino acids, divided into three structural and functional domains. The three functional domains 
consist of the N-terminal domain (NTD), the catalytic core domain (CCD) and the C-terminal 
64 
domain (CTD).
211, 254, 255
 Each IN monomer associates with another IN monomer to form a 
homo-dimer and these have been proposed to further associate into functional tetrameric or 
higher order IN complexes.
254, 255
  
 
Figure 3.1 Structural Domains of HIV-1 Integrase
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Reprinted with permission from Elsevier 2866750655927 
Each of the three IN functional domains contains recognizable functional motifs (Figure 
3.1). The NTD is composed of residues 1-50 and contains two histidine residues (His12 and 
His16) and two cysteine residues (Cys40 and Cys43), all of which are conserved and form a 
HHCC zinc finger motif that chelates one zinc atom per IN monomer.
256, 257
 The NTD is 
essential for higher order multimer formation, a process which requires zinc. The zinc atom acts 
to stabilize the fold of the NTD and is necessary for the activity of IN.
258
  The CCD is composed 
of residues 51-212 and contains three conserved negatively charged amino acids (residues Asp64 
(D), Asp116 (D) and Glu152 (E), DDE motif). Mutation of any one of these three residues is 
sufficient to inactivate IN. These key catalytic residues are involved in coordinating divalent 
metal ions (Mg
2+
 or Mn
2+
) for catalysis of the chemical steps of DNA integration (Figure 3.2).
259
 
The crystal structure of the CCD shows that it consists of 5 β-sheets and six α-helices that are 
linked by flexible loops.
211, 260, 261
 The CCD is essential for two key steps of the integration 
reaction, 3’ processing (3’-P) of the viral DNA and the strand transfer (ST) reaction, in which it 
cleaves the phosphodiester bond of the host genomic DNA and subsequently joins the 3’-
processed viral DNA ends to the host genomic DNA (Figure 3.3.). The CCD forms a dimer in 
solution and is a dimer in the functional IN enzyme.
211, 260, 261
 The CTD is composed of residues 
65 
213-288 and has some structural homology 
with SH3 DNA binding domains and binds 
DNA nonspecifically.
262
 The CTD is less 
conserved than the other two domains and 
has positively charged regions on its surface 
that are capable of binding DNA 
nonspecifically.
255
  Coordinated action 
between the three domains is, however, 
necessary for the 3’-P and ST reactions to be 
catalyzed efficiently.  Even though all three 
domains are required for full catalytic 
activity, site-directed mutagenesis studies 
have shown that the CCD is sufficient to 
promote a reverse integration in vitro, disintegration, indicating that this region contains the 
enzymatic catalytic center.
263, 264
 The structures of the individual domains of IN have been 
determined but there still are no structures of the full-length protein and importantly, no 
structures with DNA substrate bound.
265
  
The DNA product formed after RT is a double-stranded linear DNA with LTR sequences 
at each end. This molecule is the substrate for integration and is acted upon in several 
biochemical and temporally discrete steps, before being co-linearly integrated in a host cell’s 
chromosome. As soon as RT synthesizes double-stranded DNA, IN multimers will bind to DNA. 
IN will exert its catalytic activity when it recognizes an intact LTR end.
266
 In the cytoplasm, 
HIV-1 IN recognizes and binds to a specific, imperfect, and inverted sequence in the LTR of the 
Figure 3.2 Role of Divalent Metal Ions in 
Catalysis. This figure represents the catalytic 
pocket containing the pentacoordinated 
phosphate in the (hypothetical) transition state. 
One of the Mg2+ ions is proposed to act as a 
Lewis acid is shown to be coordinated with 
two aspartic acid residues and the oxyanion of 
the leaving group (R1 of nonbridging oxygen. 
The second Mg2+ is also shown to complex 
with the nonbridging oxygen and to act as a 
base for the deprotonization of the incoming 
nucleophile. The substrate is 3’R1-R25’, and 
the product is 3’R3-R25’. 
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reverse-transcribed DNA.
86, 267
 IN then catalyzes the removal of a GT dinucleotide immediately 
3’ to the conserved CA dinucleotide at the 3’ end of both strands of the viral cDNA (donor 
DNA) by a nucleophilic attack on the phosphodiester bond between deoxyguanosine and 
deoxyadenosine.
181, 268, 269
 This initial step is called 3’-P and the IN remains bound to the LTR, 
forming a preintegration complex (PIC). The PIC containing viral proteins is then transported to 
the nucleus, where second reaction called 3’-end joining or ST occurs. 
 The ST reaction consists of a direct nucleophilic attack on the host chromosome 
(acceptor DNA) by the 3’-hydroxy recessed viral DNA, which are kept in close proximity, 
integrate at the 5’-ends of the host chromosomal DNA with a 5-base pair stagger.86, 269-271 The 
two unpaired nucleotides at the 5’-ends of the viral DNA are removed, and the gaps at the 
integration site on both termini are 
likely filled by host cellular repair 
enzymes.
249, 272
 The ST reaction 
completes the viral DNA 
integration into the host genome. 
The intergrated viral DNA (proviral 
DNA becomes a template for virion 
synthesis, a process completed by 
host cellular machinery.
249
 
Figure 3.3 The Mechanism of the 3’Processing and ST Reactions269 
 
In general, IN inhibitors can be divided into dual inhibitors of 3’-P and ST (referred to as 
3’P inhibitors), and selective strand transfer inhibitors (INSTIs). Based on several structural 
activity relationship studies, it was established that IN inhibitors bind to distinct regions of the IN 
67 
enzyme following conformational change induced under donor DNA binding, and then impair 
IN enzyme function by interaction with the catalytic triad.
249
 The 3’-P inhibitors may contact 
both the donor and target DNA binding sites, whereas the ST inhibitors may bind selectivity to 
the target DNA binding site.
86, 273
 IN inhibitors on the market and in advanced clinical trials are 
members of the INSTI class of compounds. Chemically, they possess a β-hydroxy carbonyl, 
thought to bind the two metal ions coordinating the three catalytic residues D64, D116 and 
E152.
184, 225
 
 
3.2. PROPOSED MECHANISMS OF ST INHIBITION  
Interactions between HIV-1 IN and the HIV LTR are critical for IN-DNA binding, 3’-P, 
ST, and inhibitor interactions. Studies analyzing mutations in the IN amino acid or the LTR 
DNA base sequence provides insights into the structural requirements for IN 3’-P and ST.  
Collectively, understanding these IN-DNA interactions can provide useful information to aid in 
elucidating the interactions of IN inhibitors with IN. Although several synthetic and biological 
studies for DKA compounds have been reported, the mechanism by which they bind IN has not 
been well understood. 
In order to increase the understanding of IN interactions with DNA, IN catalysis with 
oligonucleotides containing DNA backbone, base, and groove modifications were placed at 
unique positions surrounding the 3’-P site. IN sequence specifically recognizes the conserved 5’-
CA in HIV LTR (Figure 3.4). Interactions between IN and the backbone of viral DNA have been  
68 
examined by substituting conformationally constrained sugars into the 3’-P cleavage site.274 The 
conformationally constrained sugar modifications prevented IN 3’-P, demonstrating that 
conformational restrictions at the 3’-P site block cleavage and suggesting DNA flexibility is 
required for 3’-P. From this study it was determined that IN has an open catalytic site that 
requires a flexible DNA backbone for 3’-P and ST.274, 275  Several oligonucleotides were 
synthesized containing benzo[a]pyrene 7,8-diol 9,10-epoxide (BaP DE) adducts were tested to 
probe the effects of DNA groove occupancy on IN catalysis.
274-276
 Only the adduct in the minor 
groove at the 3’-P site inhibited 3’-P, suggesting that the DNA minor groove surrounding the 3’-
P site is important for IN-DNA interactions are important during 3’P.274 The guanine/cytosine 
(GC) base-pair at the 3’-P site was replaced by the other 15 base-pair combinations to examine 
the importance of the base-pair sequence for IN reactions.
274
 From this exercise it was 
determined that the interaction between cytosine (L2 cytosine or 5’-C) and Gln148 is critical for 
IN ST and plausible partners for hydrogen bonding.
275
 From these studies several structural 
features of the viral cDNA that were found important for IN binding and reactions obtained from 
are summarized in Figure 3.5.
274-278
  
Figure 3.4 Role of Major and Minor Grooves in IN Reactions. (a) Sequences of U3 and U5 LTRs. Nucleotide positions 
are indicated by numbers above the U5 LTR sequence. The 3’-P cleavage sites are indicated by vertical arrows, the 
conserved 5’-CA dinucleotides are underlined and the AT stretches are boxed. (b) Diagram of IN 3’-P and ST reactions. 
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Several IN amino acids have been identified to interact with specific viral cDNA bases 
(Figure 3.6).
275
 The catalytic amino acids Glu152 and Asp64 interact with the U3 adenine and L3 
thymine, respectively.
279
 Lys159 interacts with the conserved U3 adenine
280
 and the scissile 
phosphate.
281
 The C-terminal domain residue Glu246 forms a disulfide cross-link with L7 
adenine, and the IN monomer containing the active-site residues.
282
 Gln148 interacts with the N-
3 group of the L2 cytosine,
277
 and Tyr143 forms a photo-cross-link with the terminal L1 
adenine.
280
 A specific viral LTR contact for the catalytic amino acid Asp116 has not been 
identified.
283
  
  Integrase strand transfer inhibitors define a 
functionally distinct mechanistic class of compounds 
that  selectively inhibit strand transfer in vitro and in 
infected cells.
175
 The opinions on the mechanism of IN 
inhibition by the β-DK class of compounds are divided. Previous studies have suggested that the 
binding of DKA inhibitors require that IN be assembled into a nucleoprotein complex competent 
to catalyze ST and that binding of the inhibitor and the target DNA are mutually exclusive.
252, 284
 
These studies suggest a biochemical basis for ST selectivity of these inhibitors. Alternative 
studies suggest a molecular basis of inhibition where there is interaction between IN inhibitor 
Figure 3.5 Important Components of IN/DNA 
Interactions. The components that are critical to 
IN reactions are noted. A base is required at U3 
adenine and U5 guanine positions. The L4 N2 
guanine is required for 3’-P; the L2 cytosine N-3 
group is required for ST. Interaction between IN 
and the cDNA minor groove is required for both 
3’-P and ST. 
Figure 3.6 IN amino acids interacting 
with viral cDNA bases. 
70 
and metal ion(s) in the IN active site, resulting in a functional sequestration of the critical 
cofactor(s).
86, 217, 218, 275
 
3.2.1. Biochemical Mechanisms  
In 1999, Goldgur et al. reported that the IN inhibitor, 5-CITEP (Figure 3.1, bound to the 
crystal structure of the CCD seems to mimic the DNA substrate/IN 
interaction.
211
  The stereo view of 5-CITEP bound at the active site 
represented in Figure 3.8, and a schematic of the contacting 
residues are shown in Figure 3.9.  These figures depict the 
inhibitor/active site interactions implicating several residues of importance for catalysis or DNA 
binding.
211
 Gln148 forms a hydrogen bond to the nitrogen of the indole ring; Glu152 is within 
hydrogen-bonding distance of the enol hydroxyl. All four nitrogen atoms of the tetrazole ring are 
hydrogen bonded to Asn155, Thr66, Lys159 and Lys156. Although no direct contacts  
Figure 3.8 Stereo Image of 5-CITEP Inhibitor/Protein Contacts. Contacting protein side chains are shown 
in cyan, with magnesium in purple and the catalytic residues Asp-64 and Asp-116 in pink.
211
 
 
with the two catalytically essential aspartates are observed, one of the four water molecules 
coordinating the magnesium ion is close enough to the plane of the indole ring to be regarded as 
van der Waals interaction. Based on electron density mapping 5-CITEP is bound in the middle of 
Figure 3.7 Structure 
of 5-CITEP 
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the active site between two aspartates, D64 and D116, and the glutamate E152, all three which 
are required for IN catalysis. This study also 
revealed that the inhibitor does not displace the 
bound magnesium ion, which remains  complexed 
to the two aspartic acid residues.
211
 
It was speculated that the interactions between 5-
CITEP and IN partially mimic the normal 
interactions with viral DNA substrate during the 
3’processing reaction. The distance between the 
indole and tetrazole ring systems on the inhibitor 
is approximately 8 Å, a distance that could easily 
be spanned by two nucleotides, with the sugar 
phosphate backbone containing the scissile bond passing between the active site carboxylates in 
close proximity to the bound magnesium ion. In this model the two bases adjacent to the scissile 
phosphate potentially would overlap the pockets in which the indole and tetrazole rings of the 
inhibitor are buried. It is postulated from this study that this DKA IN inhibitor, 5-CITEP, mimics 
the DNA substrate of the integration reaction and also interacts with unstacked DNA bases at the 
catalytic site.
211
 
In 2000, Espeseth et al. developed a scintillation proximity assay 
(SPA) that allows analysis of radiolabeled IN inhibitor binding and IN 
function.
284
 Investigations to aid in understanding the unique ability of 
DKA inhibitors to selectively inhibit the ST activity of IN in the 
absence of an effect on 3’end processing were investigated. 
Figure 3.10 Structure 
of L-731,988 
Figure 3.9 Schematic of 5-CITEP and Interacting 
Residues. The contacting distances corresponding to 
the potential hydrogen bonds are shown. Note that for 
this subunit the inhibitor makes two hydrogen bonds 
with its symmetry-related neighbor. Also, one of the 
oxygens of Glu-152 is within contact distance of both 
inhibitors. 
72 
Specifically, the mechanism of action of DKA, L-731,988 (Figure 3.10) and interactions of this 
inhibitor with IN were elucidated from this study. 175, 284 This study determined that L-731,988 
binds within the IN active site and inhibits ST by competing with target DNA substrate. High-
affinity binding of L-731,988 is shown to require the assembly of a specific complex on HIV-1 
LTR. The interaction of L-731,988 with the complex and the efficacy of L-731,988 in ST can be 
abolished by the interaction with target substrates, suggesting competition between the inhibitor 
and target DNA. Although distinct from that of the viral donor substrate, the binding site for the 
DKA inhibitors is within the active site.
284
 Given the results presented in this study it is 
surprising that 5-CITEP binds in the absence of donor substrate and that substantial 
conformational changes in the protein were not observed in the 5-CITEP complex.
211
 Although it 
is not known if the mechanism of inhibition for 5-CITEP and L-731,988 is analogous, it is 
possible that the 5-CITEP represents the less interesting weak micromolar binding mode 
observed for the DKAs in the absence of substrate. Whether this interaction is predictive of the 
high-affinity DKA inhibited complex is therefore unclear.
284
 
 
3.2.2. Molecular Mechanism 
 It is believed that the β-DKA 
pharmacophoric motif could be involved in 
a functional sequestration of one or both 
divalent metal ions (Figure 3.11) in the 
enzyme catalytic site
86, 217
 to form a ligand-
M
2+
-IN complex. This would subsequently 
block the transition state of the IN-DNA 
Figure 3.11 Complexing motifs for DKAs. (a) bidentate 
ligand (DKA-a and DKA-b), tridentate ligand (DKA-c), 
and (b) general scheme of two-metal-chelating state for 
DKA-type compounds. Dashed lines are the interactions 
with the metal ions (spheres). 
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complex by competing with the target DNA substrate.
86, 284, 285
  
 In 2002, Grobler et al. characterized the molecular basis of IN inhibition by using 
functional and binding assays to evaluate a series of DKA inhibitors.
217
 Binding and mechanistic 
studies suggest that the DKAs and 5-CITEP are structural homologs.
217, 250
 To explore the 
common functionalities in these compounds, carboxylate and tetrazole (isosteric replacement of 
carboxylate) containing compounds were synthesized and evaluated for binding and inhibition of 
IN. As shown in Table 3.1, both hybrid molecules were active; however, in the context of either 
template, the carboxylate (L-
731,988 and 3.2, respectively) 
was more potent. The choice of 
metal did not affect the affinity 
or potency of the carboxylate 
analogues. However, the 
tetrazole derivatives (3.1 and 5-
CITEP) exhibited reduced 
binding and inhibition in Mg
2+
 
relative to Mn
2+
. This 
observation can also in part explain the lack of antiviral activity in cellular system for the 
tetrazole containing DKAs, since Mg
2+ 
is the plausible metal in vivo.
250
 The acidic 
tetrazole/carboxylate moiety therefore is not required for binding but it is essential for inhibition. 
It was demonstrated from this study that binding to IN is in part mediated by the interaction of 
the acid functionality with metals in the active site.
217
 A model for the binding of the DKA 
analogs to IN that is consistent with the requirement for the acid functionality and observed  
Table 3.1 Binding and Inhibition by Hybrid Integrase Inhibitors 
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Figure 3.12 Model for the Binding of 
Two Divalent Metals by DKA Inhibitors 
metal dependence of these inhibitors was developed (Figure 3.12). In this model, the inhibitor 
coordinates two metals bound at the active site by the conserved DDE motif of IN.
217
 The bond 
lengths and angles for the acidic functional group used were based on the crystal structure of 5-
CITEP.
211
   Binding requires divalent metal and 
additionally, resistance is metal dependent with active 
site mutants displaying resistance only when the 
enzymes are evaluated in the context of Mg
2+
. The 
mechanism of action of these inhibitors is therefore 
likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active 
site, resulting in a functional sequestration of the critical metal cofactor(s).
217
 
 
3.2.3. Proposed Mechanisms and Inhibitor Development 
Even if the exact mechanism of action of IN inhibitors has not been completely 
elucidated, it is generally more widely accepted that INSTIs bind to the host chromosomal DNA 
site of the enzyme and act by sequestering the metal ion(s) bound in the IN active site to form a 
ligand-M
2+
-IN complex.
217, 286-288
 Furthermore, it has been believed that the inhibitors bind at the 
IN-DNA interface rather than to IN alone,
243, 284
 thus acting as interfacial inhibitors of protein-
nucleic acid interactions.
86, 289, 290
  Almost all of the authentic HIV-1 IN inhibitors developed 
share similar chemical structural features. All of these compounds possess at least two distinct 
regions: an aromatic hydrophobic region and a metal chelating region.
291
 Except for elvitegravir 
(GS-9137), the chelating region of all of these compounds is represented by a DKA motif or a 
bioisostere of DKA. In structural terms, these molecules have essentially three functional groups 
75 
in a coplanar conformation that are assumed to chelate two magnesium ions in the so-called two-
metal-ion mechianism.
217, 291
 
Research has focused on the molecular binding of INSTIs to IN complexes because of the 
increasing importance of selective INSTIs as ARV compounds and their unique mechanism of 
action.
86
 Unfortunately, a full understanding of the inhibitor binding mode remains unclear. 
Although the X-ray crystal structure of 5-CITEP bound to the HIV-1 CCD has been investigated, 
the ligand forms a dimer with another molecule of 5-CITEP at a crystallographic dimer 
interface.
211
 Therefore, the binding site of the inhibitor in the crystal is assumed rather unlikely 
to resemble the physiologically relevant binding configuration, especially considering that no 
DNA was observed in this structure.
290
 
 
3.3. DISCOVERY OF THE AMINOCARBOXYALTE SYSTEM 
 
3.3.1. Aromatic Substitutions of the DKAs 
One interesting trend noted with the 
β-DKA containing class of inhibitors is that 
several distinct compounds, while 
possessing various aromatic substitutions 
with the DKA scaffold (Figure 3.13), 
demonstrate potent ST inhibition and antiviral 
activity with remarkable fidelity.
273, 288, 292
 For 
example, the β-DKA (carboxylate or tetrazole) 
compounds containing the aromatic groups diphenylmethane (3.3),
293
 benzyl furan (S-1360),
294
 
Figure 3.13 Potent DKA ST inhibitors with 
Antiviral Activity. Aromatic substitutions 
highlighted in blue. 
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Table 3.2 SAR of Aromatic Substitution on β-DKA Scaffold 
 
benzyl pyrrole (L-731,988)
295
 or benzyl quinolone (3.4)
292, 296
 demonstrate potent IN inhibition 
(<50 nM) with antiviral activity. However, compounds lacking a bulky aromatic group (Table 
3.2) such as the indole derivative 5-CITEP and phenyl containing DKA 3.5 did not show 
antiviral activity in cells even though they demonstrated potent ST inhibition.  
In 2000, Wai et al. investigated 
the SAR of a series of DKAs 
using L-731,988 (Figure 3.13) as 
a lead molecule and replacing the 
central pyrrole ring with a series 
of aromatic systems.
212
 This SAR 
study provided a series of potent 
3-benzylphenyl DKA IN 
inhibitors (Table 3.2, compounds 
3.6-3.8) and revealed that by 
replacing the aromatic benzyl 
group with diphenylmethane or 
substituted diphenylmethane 
antiviral activity is significantly 
increased. For example, benzyl 
carboxylate 3.5 did not show any 
antiviral activity; however, when 
the aromatic group possesses an additional benzyl group (3.6) antiviral activity is observed. 
Furthermore, these compounds also show an increased selectivity for inhibition of ST reaction as 
77 
compared to 3’-P reaction and bind to IN only after viral DNA is bound.176, 284 Substitutions on 
the phenyl and benzyl ring of diphenylmethane (3.7-3.9) further increase the antiviral activity of 
compounds to nM activity (3.7-3.9).
212
 Compound 3.9 (2,4-difluoro-1-(4-
isopropoxybenzyl)benzene) was synthesized and tested previously by our collaborators, 
Panvirex, LLC (unpublished results), lending a potent ST IN inhibitor that has better antiviral 
potency compared to the previously studied aromatic substituted series.
212
 The mechanism of 
action of this series of compounds remains unknown but collectively, these studies suggest that 
the IN inhibitory potency is influenced by β-DKA motif of the molecule while the aryl 
substituents provide antiviral potency and ST specificity.  
 
3.3.2. Keto-Enol Tautomerism of DKA IN Inhibitors    
Several of the authentic IN inhibitors derived from the β-DKA class of compounds have 
multiple possible tautomers (Figure 3.14).
297
  It is generally accepted that the β-DKA compounds 
exist most favorably in the tautomer-B form (Figure 3.14), which was noted as the most 
favorable 
thermodynamic 
structure in the 
inhibitor bound crystal 
structure (PDB:1QS4).
211
  A lot of the early SAR work on the β-DKA compounds determined 
that the terminal carboxylate is involved in inhibitor binding and IN inhibition.
217
 To date, 
developmental strategies for alternative heterocyclic structures assume that the β-diketo 
functional groups are essential in IN inhibitor design and functional groups of tautomer-B are 
retained in an empirical manner. Previous studies investigated by our collaborators (Panvirex, 
78 
Table 3.3 SAR of β-Diketo Compounds Lacking the Terminal Carboxylate 
 
LLC.) investigated the significance of the tautomeric state of the β-diketo functional groups. The 
diol derivative (3.11) of 3-benzylphenyl DKA (3.6) was synthesized and evaluated for ST 
inhibition. In the diol derivative (3.11) the carboxylate functional group involved in IN inhibition 
was retained and the 
diketo groups were 
converted into diols. 
The diol derivative 
is similar to the β-diketo 
compound 3.6 in the 
sense that contains all of 
the functional groups as 
they would be present in 
the tautomeric state. It 
was anticipated that the 
derivative would either 
demonstrate potent or 
moderate IN inhibition. 
Surprisingly, diol (3.11) 
was a poor inhibitor (IC50 
>100 µM), although it 
contained all of the functional group requirements of the DKA 3.6 (Panvirex, unpublished data). 
The lack of ST inhibition of 3.11 in conjunction with data from previously studied compounds 
containing the β-diketo functional group devoid of a terminal carboxylate (Table 3.3)217 
79 
collectively indicate that potent IN inhibition is influenced by the tautomeric state of β-diketo 
groups together with the terminal functional group. One of the consequences in loss of the enolic 
configuration of the β-diketo functional group is that the intermolecular interaction between the 
keto groups is likely disrupted resulting in a non-planar configuration of the functional motif. 
From this study, it was assumed that the planar geometry of the functional motif is essential in a 
potent IN inhibitor. 
 
3.3.3. Aminocarboxylate: Alternative Surrogate for the β-DK scaffold 
Despite the success of selective ST inhibition, potency and antiviral activity of the β-
DKA class of IN inhibitors several serious limitations in regards to the development of drug 
candidates exist.  For example, the β-DKA class of compounds contains two reactive keto groups 
that react irreversibly with plasma proteins. The 
lead candidate S-1360 failed Phase II clinical 
trials due to lack of efficacy resulting from 99% 
of the drug being bound irreversibly to plasma 
proteins.
178
 Thus, compounds containing 
“druggable” characteristics while retaining the β-
DK motif functional groups were explored with 
heterocyclic systems using the geometry of the β-
DK motif. Using this approach, the β-DK characteristics were retained in the fused heterocyclic 
structures and evolution of the naphthyridine carboxamides (L-870, 810 and L-870,812) led to 
potent ST inhibition and good antiviral potency. However, development  of these compounds 
was suspended due to long-term cardiotoxicty in Phase II clinical trials.
251
  Alternative suitable 
Figure 3.16 Potent DKA IN Inhibitors 
 
80 
surrogates to the reactive β-DKA functional group may overcome the pharmacological 
limitations of these compounds. To date, there have been no reports of a functional domain that 
can serve as a surrogate for the β-DKA motif of IN inhibitors. 
 The work described in this dissertation project is focused on the development novel HIV-
1 IN inhibitors that contain an aminocarboxylate functional group to serve as a surrogate for the 
β-DKA functional motif.  In the design towards a lead molecule several key findings discussed in 
the preceding section were 
considered. The planar 
configuration of the functional 
domain was given high priority 
and less consideration was 
given to retaining the β-DK 
characteristics previously 
retained in the development of 
heterocyclic scaffolds (e.g., 
naphthyridine carboxamides, L-
870, 810 and L-870,812). 
Compound L-708,810 (3.6) was 
selected as the starting building 
block, since the aryl group, 3-
benzylphenyl, does not contain any additional substitutions. In this regard, it was anticipated that 
the ST inhibition response would rely solely on the role of the aminocarboxylate functional 
groups under evaluation. Several compounds containing the aminocarboxylate functional group 
Table 3.4 SAR of Aminocarboxylate Scaffolds 
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(28 total compounds) were evaluated in an all or non-response ST inhibition assay by our 
collaborators and the results of a few closely related compounds are summarized in Table 3.4 
(Panvirex, unpublished results). Among the various compounds analyzed, only 3.16 containing 
the oxalohydroxamate (OHA) motif showed potent ST inhibition, whereas all others were 
negative. From this SAR data, it was noted that 
the hydroxyl group of the terminal hydroxamic 
acid is critical to obtain potent ST inhibition. 
Interestingly, compounds containing a terminal 
carboxylate (3.17-3.20), previously considered 
to be essential for binding affinity and potent IN 
inhibition,
217
 did not show IN inhibition (Table 
3.4). In the serine amide derivative 3.18, the 
assumed α-keto group of the β-diketo motif 
hydroxyl (tautomer-B) is one carbon length 
away from its normal position. In the glycine amide 3.19 and oxalamic acid containing 
compound 3.20, all of the functional groups are present yet no IN inhibition was observed. It can 
be considered that the lack of IN inhibition shown from these compounds is a result of deviation 
of the functional motif from the planar configuration due to the free rotational bond (Table 3.4, 
highlighted with blue arrows). Such assumption is further supported by the observation that diol 
3.11 containing all of the groups of the functional motif also did not show inhibition of IN. 
However, the requirement of the planar geometry of the functional group is not absolute as it is 
previously assumed in the inhibitor.  The 3-benzylphenyl aryl group of 3.16 distorts the 
functional domain from the absolute planarity of the prototypical β-DKA inhibitor 3.6 or as in 
3.6 
3.16 
Figure 3.17 Overlapping 3D Geometry of 
Compounds 3.6 and 3.16. The compounds are 
overlaid on their 3-benzylphenyl aryl groups. 
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the naphthyridine carboxamides (L-870, 810 and L-870,812) as illustrated by the overlapping 
geometry in Figure 3.17. The moderate deviation appears to be tolerable without losing the 
potent IN inhibitor characteristics. Collectively, the structural observations of the OHA motif 
containing compounds suggests that the isosteric functional group of the β-diketo motif in 
moderate planar configuration (3.16) is sufficient for IN inhibition but significant deviation from 
planar or near planar configuration abolishes IN inhibitory potency (Table 3.4). 
 
3.3.4. Ligand Docking of Aminocarboxylate IN Inhibitors 
 Although the chelation model (Figure 3.12) of ST inhibition by the β-DKA class of 
compounds has been widely accepted as a plausible mechanism of IN inhibition several studies 
have surfaced, based largely on SAR and IN crystal structure studies, prompting investigators to 
revisit the proposed mechanisms of inhibition. In previous studies, the β-DKA 3.6 has 
demonstrated progressive drug resistant viral mutations beginning at T66I and it is followed with 
concomitant mutations of either amino residues S153Y, M154I or N155S.
175
  The T66I mutation 
alone is significant enough to render IN inhibitors less effective. Studies have also shown that the 
tetrazole β-diketo isoster, 5-CITEP (Figure 3.7), and carboxylate β-DKA, L-731,988 (Figure 
3.10), although having different aryl groups are ineffective to the same drug mutations 
(T66I/M154I) in IN.
211, 217
 These findings suggest that regardless of the aryl and terminal 
functional groups (tetrazole or carboxylate) present in the β-DKA molecule, the compounds 
appear to bind at the same site. Interestingly, the drug resistant mutations described above are in 
the vicinity of the tetrazole terminal functional group of 5-CITEP bound in the IN CCD and are 
located 180° opposite to the Mg
2+
 ion bound to the catalytic residues D64 and D116.
211
  In the 
chelation model, compound 5-CITEP should bind in an opposite orientation compared to the 
83 
orientation observed when bound in the IN CCD crystal structure (PDB: 1QS4). Also, the aryl 
group should contact the IN residues that undergo drug resistance mutations and the β-diketo 
functional groups should interact with the Mg
2+
 metal ions. It was suggested that the drug 
resistance mutations are capable of causing distortion of the molecule and result in loss of 
interaction with the Mg
2+
 ions. The inhibitor binding site has adequate room and compounds can 
be easily docked without steric hindrance in support of the chelation model and manual docking 
is sometimes utilized to demonstrate the likely scenario of metal ion chelation.
225
 Alternatively, 
since compounds containing both tetrazole and carboxylate terminal functional groups and are 
resistant to the same mutations, it is also possible that the binding orientation is the same. 
In collaboration with Panvirex, molecular docking studies were carried out to investigate the 
mechanism of IN inhibition.  Ultimately, clarity of the binding orientation of β-DKA class of 
compounds is essential to aid in the elucidation of the role of the terminal functional groups of 
the novel aminocarboxylate IN inhibitors and lead to the design of novel IN inhibitors. 
 The structural similarities between 5-CITEP and 3.5 (Table 3.2) and the availability of 5-
CITEP bound IN crystal structure provide an opportunity to understand the role of the terminal 
functional group interactions. In collaboration with Panvirex, molecular docking experiments 
were carried out in rigid ligand conformation since the planar or near planar configuration of the 
inhibitors was discovered essential in our previous SAR studies (Table 3.4 and diol derivative 
3.11).  In all of the docking experiments, the 5-CITEP bound region was chosen as the inhibitor 
binding site. The validity of the ligand docking was established by our collaborators by 
comparing the orientation and geometry of our docking of 5-CITEP to the previously reported 5-
CITEP bound IN crystal structure. From this comparison it was determined that the structural 
interactions are essentially the same as previously reported in the crystal structure.
211
 The major 
84 
Figure 3.18 Analysis of 5-CITEP 
bound in IN Crystal Structure 
(1QS4). 
 
focus of our docking studies is the hydrogen bonding interactions of the terminal functional 
group and the binding orientation of the inhibitors.  
In the initial analysis of 5-CITEP bound IN 
crystal structure all of the possible interactions of 5-
CITEP were mentioned. However, analysis of the 
crystal structure in Ligand Explorer
298
 within the 
hydrogen bonding threshold (3.3Å) with all of the 
residues including the water molecules that are present 
in the IN crystal structure suggest that the tetrazole 
functional  can only form two hydrogen bonds with 
T66 and K159. The enolic α-keto group provides 
hydrogen bond interactions with E-152 carbonyl and 
K156 side chain nitrogen (Figure 3.18).   The 
interaction of the α-keto group is not mentioned in the 
initial docking studies of 5-CITEP. The only possible 
interaction of the γ-keto group is with a water molecule which is about 5Å distance away. There 
Figure 3.19 Binding of the Carboxylate Derivative of 5-CITEP (3.5) (A) The flipped 
orientation binding of 3.5 in ligand docking (B) The hydrogen bonding interactions of 3.5. 
 
Carboxylate
3.5 
A B 
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were no hydrogen bond interactions noted with the nitrogen atoms of the tetrazole or indole 
although they can interact electrostatically with the nearby N155 and Q148 (Figure 3.18). In 
contrast, the carboxylate derivative of 5-CITEP (3.5) binds in a flipped orientation in the ligand 
docking but the carboxylate terminal functional group interacts with the same IN amino acid 
residues as that of the tetrazole (Figure 3.19A). The acid carbonyl oxygen of the carboxylate can 
form two bonds between the side chains of K159 and T66. The carbonyl oxygen of the 
carboxylate interacts with K156. In the flipped orientation the α-keto functional group of 3.5 
interacts with N155 (Figure3.19B). The interaction between E152 and the α-keto functional 
group of 3.5 is lost in the flipped configuration. However, the interaction of E152 is regained by 
the hydrogen atom or nitrogen atom of the indole ring. The γ-keto group is within hydrogen 
bonding distances with the D64 carbonyl but the carbonyl-carbonyl interactions are considered 
unlikely. The aryl group is flanked by the region occupied by E152, D64, D116 and Q148 and is 
within hydrogen bonding distances. In the ligand docking studies the compounds are in rigid 
conformation but the aryl group is expected to undergo some degree of rotation following 
enzyme binding as observed in the crystal structure bound 5-CITEP (Figure 3.20) and optimal 
interactions with any one of the residues is possible.  
The binding orientations of the tetrazole containing S-
1360 and the carboxylate containing compound L-731, 
988 having different aryl groups were also compared 
(Figure 3.21). These compounds bind essentially in the 
same orientation as observed with 5-CITEP and the 
interactions with the functional motifs were essentially 
identical. The tetrazole group of S-1360 interacts with T66, K156 and K159 (Figure 3.21B) as 
Figure 3.20 The Overlapping 
Geometry of Crystal Structure 
Bound 5-CITEP (C) and Energy 
Minimized Structure (E) 
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seen previously with 5-CITEP and L-731,988.  The terminal functional group interactions of L-
731,988 is essentially the same with coordination to K159 and T66 with the acid carbonyl of the 
carboxylate interacting with N155 
(Figure 3.21D).  
The potent ST inhibition 
exhibited with hydroxamate containing 
3.16 and complete loss of ST inhibition 
with closely related 3.17 (Table 3.4), 
lacking the hydroxamate terminal 
functional group, provides an 
opportunity to assess how the ST 
inhibition potential of an IN inhibitor is 
attained by docking the compounds in 
the crystal structure and comparing the    interactions. The compounds containing the OHA motif 
bind in the 5-CITEP binding direction but in a flipped orientation similar to the carboxylate 
derivative of 5-CITEP (3.5). In this configuration, the hydroxamate is centrally located between 
K156, K159 and T66 but only K159 and T66 residues can interact with the hydroxyl group 
(Figure 3.22B). The K156 is located 4.5Å from the nitrogen atom and 3.5Å from the hydrogen 
atom of the hydroxamate. The oxamate carbonyl in the trans position can interact with N155 as 
that of the carboxylate in the β-DK motif. The aryl group of 3.16 is in proximity of the D64, 
D116, E152 and Q148 residues (Figure 3.22B). 
Figure 3.21 The Binding Orientation and Interactions of     
S-1360 and L-731,988. 
 
A B 
C D 
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In this configuration it is easy to understand why 3.17, 
a compound lacking a hydroxamic acid group, did not 
show IN inhibition.  Compound 3.17 binds in the 
same configuration as that of 3.16 but the hydroxyl 
group of 3.17 did not have any interactions with K159 
or T66. Moreover,  the hydroxyl group of 
hydroxamate of 3.16 provides optimal hydrogen 
bonding interactions with K159 and T66. Thus, it is 
assumed that minimal terminal functional group 
interactions with T66 and K159 may be considered as 
the defining parameters of gain or loss of IN 
inhibition. This observation is supported by the 
consistent interactions of both the carboxylate and 
tetrazole terminal functional group with K159 and T66. The interactions with K156 and N155 
and all of the other interactions may be necessary for 
inhibitor binding. The binding orientation of 3.21 containing 
an aryl group with substitutions (2, 4-difluoro-1-(4-
isopropoxybenzyl) benzene, Figure 3.23) is comparable 
to the orientation observed in the core compound 3.16. 
The hydroxamate terminal group of 3.21 also interacts with K159 and T66 and the oxamate 
carbonyl interacts with N155. The benzyl functional group occupies the position between D64 
and D116 and the isopropoxy of the phenyl ring occupies the region surrounded by K156, E152 
and Q158 (Figure 3.24). 
Figure 3.22 Binding Orientation of 
Hydroxamate Containing Compound 3.16. 
 
B 
A 
Figure 3.23 Hydroxamate 3.21 with 
Substituted Aryl Group. 
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Figure 3.24 Binding Orientation of 3.21. 
E152, Q148 and D116 are not shown for 
clarity but locations are indicated. 
 
Ligand docking in the absence of DNA bound IN crystal structure has its limitations. However, it 
can provide insight towards the preferred orientation 
of compound binding.  Although, the binding 
configurations of various compounds are different, 
the terminal functional group interactions with K159 
and T66 are consistently noticed. Also, as previously 
mentioned, several of the β-DKA inhibitors are 
rendered ineffective when there is a mutation at T66I. 
The similarity of these compounds to interact with T66 suggests that the terminal functional 
group interaction with T66 together with K159 prevents ST reactions. The progressive N155S 
mutation encountered together with T66I as originally observed in the early carboxylate 
containing compounds
175
 and the interactions of the functional domains with these residues 
suggest selective evolutionary pressure to undergo drug resistance. Additional interactions 
contributed by the diketo or oxamate functional domain with K156 or N155 along with E152 and 
aryl group interactions with D64, D116 and Q148 can provide better binding affinity. These 
ligand docking studies are more aligned with the proposed biochemical mechanism
211
 of IN 
inhibition compared to the proposed chelation model
217
 of IN inhibition.  
 Studies indicate that the mutations of K156 or K159 impair DNA binding and mutation 
of either of these amino acid residues is lethal to HIV-1 virus.
280, 299
 In the IN crystal structure 
(PDB: 1K6Y) phosphate ion binding is observed between T66, H67 and C65 residues. The 
preferential interactions of these amino acids with a phosphate ion led to the assumption that 
these amino acid residues contact the phosphate backbone in DNA.
281
 The K156 and K159 bind 
equally to both viral LTR end and host DNA. However, photo-cross-linking with the viral DNA 
89 
Figure 3.25 Supimposed 5-CITEP inhibitor 
bound crystal structure (1QS4) and the 
phosphate ion bound IN structure (1K6Y). 
 
end shows specific interaction of K159 and K156 with viral adenine
280
 adjacent to the scissile 
phosphate of the CA dinucleotide at the 3’-end of the strand that undergoes 3’-processing 
reaction. Based on this observation it was proposed that the K156 and K159 are involved in viral 
DNA binding
280
 and the phosphate ion in the crystal structure (PDB: 1K6Y) could represent the 
viral DNA.
281
  In this context, 5-CITEP inhibitor bound crystal structure (PDB:1QS4) was 
superimposed with the phosphate ion bound IN structure (PDB: 1K6Y) to obtain a spatial 
configuration of inhibitor interactions. Superimposed structures indicate juxtaposed position of 
the inhibitor terminal residue with phosphate ion indicating that the site of viral DNA interaction 
and inhibitor terminal functional group is the same (Figure 3.25).  The superimposed crystal 
structures docked with the 5-LTR end double-stranded DNA (dsDNA) phosphate backbone on 
the phosphate ion of the phosphate ion bound IN structure (PDB: 1K6Y) suggests that the 
inhibitor binding site spans between the binding sites of the two strands. Interestingly, the 
terminal functional group of the inhibitor and the DNA phosphate backbone of 3’-P strand cross 
at T66 and K159. The scissile phosphate 5’-to the GT dinucleotide that undergoes 3’-P is exactly 
90 
on the catalytic site at the Mg
2+
 ion (Figure 3.26 arrow). It is observed in the docking study that 
the dsDNA confirmation is essential and it is consistent with the observation that single-stranded 
DNA (ssDNA) fail to bind to IN. The DNA sugar residue of the strand that undergoes 3’-P 
contact the K159 and its complementary strand sugar residues contact K156, E152, S157 and 
Q148. Studies have shown that the CA dinucleotide overhang of the complementary strand of the 
viral DNA that undergoes the 3’-P (T66 and K159 binding strand) forms a stable complex with 
Q148
204
 and mutation of Q148I abolishes viral DNA binding.
279
 From this study, it is indicated 
that the inhibitor terminal functional group interactions between T66, K156 and K159 and the 
aryl moiety is likely to interact with the Q148 and the viral DNA bridges the viral LTR end and 
prevents them from undergoing the ST reaction. Goldgur et al. proposed that the inhibitor may 
bind between the unstacked bases mimicking DNA substrate interactions.
211
 This view is 
consistent with the model (Figure 3.26) and the inhibitor functional motif is wedged between the 
bases of the two strands and the aryl group occupies the position in which the viral DNA bases 
undergo unstacking during the 3’-P reaction. It is apparent that the rigid conformation of the 
Figure 3.26 Superimposed DNA Phosphate Backbone of dsDNA 
(1K6Y) with 1QS4. The orientation of 3.16 docked in the 5-CITEP 
binding site is shown. P:phosphate ion of 1K6Y and DNA; S: Sugar 
Residue in DNA; Arrow: scissle phosphate; GT: nucleotides 
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inhibitors is essential for wedging between the bases. 
 It has been reported in the literature that the β-DK inhibitors should be considered as 
“interfacial inhibitors” because they interfere with host DNA binding.86 The structure based 
analysis of SAR functions of various compounds is in agreement with the view of interfacial 
inhibitors and provides a molecular mechanism of interaction. In comparing the interactions of 
the terminal functional groups, only the carboxylate containing compounds additionally interacts 
with N155 as compared to the tetrazole containing inhibitor (Table 3.5). In the OHA containing 
inhibitors, the oxamate is shown to interact with residue N155; however, there is not a noticeable 
interaction of the hydroxamate with K156.  The interaction of the oxamate carbonyl with N155 
suggests that the addition of a suitable terminal functional group can provide interaction with 
K156 which is likely missing from the hydroxamate functional group.  
 T66 E152 K156 K159 N155 # of bonds 
β-DK carboxylate + + + + + 5 
β-DK tetrazole + + + + - 4 
OHA + + - + + 4 
Table 3.5 Summary of Hydrogen Bond Interactions with β-BK and OHA Terminal Functional Groups 
 
3.3.5. Design of the Oxalamate IN inhibitors: Isosteric Replacement of the Hydroxamate 
Crystal structure based correlation of SAR studies indicate that the IN inhibitor 
interactions are essentially acid-base interactions. One of the major focuses of this project is to 
investigate the role of the terminal functional group interactions with the amino acid residues of 
IN.  The design of the target molecules is envisioned to contain three specific functional groups. 
Each molecule is designed to contain the core functional motif (α, β-diketoamide), optimal aryl 
groups (3-benzylphenyl or substituted 3-benzylphenyl) and a terminal group (proton donor or 
acceptor or amphoteric functional groups) in a planar or near planar configuration (Figure 3.27).  
92 
Figure 3.28 The interactions of β-DK class 
of IN inhibitors with IN aminoacids and their 
donor (D) and acceptor (A) functions. 
 
The molecular docking studies on the OHA motif completed in collaboration with Panvirex have 
led to the identification of an oxamate serving 
as a suitable surrogate for the β-DK functional 
group. The tetrazole and pyridine were 
identified as carboxylate isosters in the β-DK 
class of compounds and the OHA motif studies 
indicate that the hydroxamate can also serve as 
an isosteric replacement. It is likely that the 
tetrazole and pyridine can also function as a 
hydroxamate isoster in the oxamate scaffold. In addition, various terminal functional groups will 
be investigated for their potential to serve as isosteric replacements of the hydroxamate and the 
interactions with the IN amino acids can be determined. 
 
3.3.6. SAR of the Terminal Functional Groups of the Oxalamate Scaffolds 
The oxalamate derivitates to be investigated and synthesized can be classified in three 
groups (A-C) based upon the expected interactions of the terminal functional groups with the 
HIV-1 IN binding site (Figure 3.28). The group A terminal functional groups are expected to  
Figure 3.27 General SAR of Designed Oxalamate 
Scaffolds 
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have the same interactions as the hydroxamate (Figure 3.29). While the position of the terminal 
amine of A2 is similar to that of 
hydroxamate 3.16, the terminal 
amine of A3 is one carbon shorter. 
Compound A3 is expected to have 
potential electrostatic interactions 
with T66 and K159. The group B 
compounds B1 and B2 (Figure 
3.30) contain a phosphate or sulfate functional group and due to the position of the terminal 
functional group interaction is expected with the phosphate ion binding residue (Figure 3.25). 
The interactions of B1-B5 are expected to be similar to the carboxylate or tetrazole interactions 
with T66, K159 and K156. Additional interactions that are absent in the group A compounds are 
expected from the imidazole derivatives (B6 and B7) and the pyrimindine derivative (B8).  The 
group C compounds (Figure 3.31) are of interest because the terminal functional groups cytosine 
and uracil (C1-C3) of these compounds are expected to provide interactions. In biochemical 
studies of viral LTR interaction uracil was found to interact with K156 and K159.
280
 The 
carbonyl atom of the nucleotide and the phosphate or sulfate substituted in the pyrimidine (C4), 
pyridine (C5), pyrazine (C6), triazole (C8) and imidazole (C9 and C10) can coordinate 
additionally to the H67 and the amide nitrogen of the H67-T66 peptide bond. Ligand docking 
with phosphate substituted imidazole in the oxamate motif of  C9 containing the aryl group Ar-1 
(Figure 3.33) shows interactions with H67, T66, K156, K159, N155, and E152 (Figure 3.32). 
The phosphate of C9 interacts with backbone carbonyl of H67, the peptide bond nitrogen and 
hydroxyl group of T66. 
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The compounds from the three groups (A-C) will be synthesized in phases. For the initial 
evaluation of the various terminal functional groups, the compounds that will be synthesized  
will contain the Ar-1 aryl scaffold (Figure 3.33). The response of these compounds will be a 
direct reflection of the terminal functional group under evaluation. The compounds that 
demonstrate potent ST inhibition (<500 nM) will have the substituted aryl scaffold (Ar-2) 
incorportated in place of Ar-1, which was determined to be necessary for potent antiviral activity 
(Table 3.2, 3.9).  
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3.4 SYNTHETIC APPROACHES 
 
3.4.1. Heteroaromatic α-Oxoacetic Acids: Cyanohydrin Chemistry 
At the onset of this project we began to focus our attention on the synthesis of the several 
of the heteroaromatic α-oxoacetic acids. It was envisioned that several of these compounds could 
be obtained through cyanohydrin chemistry as proposed in Scheme 3.1. In general, commercially 
available heteroaromatic aldehydes (3.22) could be synthesized into corresponding cyanohydrins 
(3.23)
300, 301
 followed by hydrolysis of the cyanohydrin to obtain the α-hydroxy esters (3.24).302 
The α-hydroxy esters could then be oxidized303 to obtain the α,β-diketo derivatives (3.25) that 
could then undergo ester hydrolysis
304, 305
 to afford the desired α-oxoacetic acids (3.26). With 
Figure 3.32 The Ligand Docking Analysis of  C9 (Ar-1 Aryl Group) 
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access to the α-oxoacetic acids the final compounds (3.27) could easily be  made utilizing amide 
coupling conditions with desired aniline aryl scaffolds.
306
 
Of particular interest was the synthesis of the 2-, 3-, and 4-pyridine heterocyclic 
scaffolds. The availability of the pyridine carboxaldehydes and inexpensive reagents and 
solvents made this an attractive route for synthesizing the pyridine series of compounds (Scheme 
3.2). Sequential addition of potassium cyanide in water and acetic acid to the 2-, 3-, or 4- 
pyridine carboxaldehyde (3.28, 3.29 or 3.30) afforded the corresponding racemic cyanohydrin 
(3.31,  3.32 or 3.33).
300
 Cyanohydrins are well-documented as unstable and under basic 
conditions they can be converted back to the carbonyl compound or racemize through reversible 
loss of hydrogen cyanide (HCN).
307
 Therefore, it was necessary to proceed forward to the next 
reaction step, hydrolysis of the cyanohydrins, immediately following cyanohydrin isolation. The 
initial procedure (Scheme 3.2, method a) attempted for the hydrolysis of cyanohydrin derivatives 
97 
(3.31-3.33) was a method reported for the acid-catalyzed hydrolysis of mandelonitrile, the 
cyanohydrin of benzaldehyde, to obtain mandelic acid or the α-hydroxy ester (Scheme 3.3).302 
Although, hydrolysis of the cyanohydrins (3.31-3.33) did occur there were several issues with 
isolating the desired α-hydroxy acid and ester products (3.34-3.37) and yields were much lower 
than anticipated (9-38% yield). This was due primarily as a consequence of working with a 
heteroaromatic (pyridine) scaffold with acid/base properties and trying to adapt a procedure used 
for the synthesis of an aryl aromatic scaffold. In order to move the synthesis forward with 
optimal yields it was necessary to try and obtain a reaction procedure that included compounds 
possessing similar chemical properties as to the heteroaromatic scaffolds. Also, any examples 
found in the literature would allow us to gain an understanding on efficient work-up procedures 
and product isolation techniques for our heteroaromatic scaffolds, which had previously been our 
limiting factor. To our delight, a procedure from a 1986 patent was found for the synthesis of 
pyrid-3-yl-hydroxyacetic acid (3.35) from the corresponding pyrid-3-yl cyanohydrin (3.32) 
(Scheme 3.2, method b).
308
 The α-hydroxyacetic acids (3.34, 3.35 and 3.37) were obtained by 
refluxing the corresponding cyanohydrin in concentrated hydrochloric acid (HCl). Instead of 
isolating compounds using an acid/base work-up, as previously utilized,
302
 after reaction 
completion (monitored by mass spectrometry (MS)) the HCl was removed and products were 
simply obtained as pyridium chloride salts (3.34-3.37). Although, MS product peaks were 
identified for all three isomers (3.34, 
3.35 and 3.37) the NMR for the pyrid-
4-yl-hydroxyacetic acid (3.37) 
remains unclear, possibly due to 
impurities from the crude product, therefore, only the 2- and 3- derivatives (3.34 and 3.35) were 
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carried forward in the synthesis. In addition to obtaining the α-hydroxyacetic acids (3.34 and 
3.35), the procedure was easily modified by adding ethanol as a solvent and obtaining the ethyl 
ester products. Only ethyl pyrid-3-ylhydroxyacetate (3.36) was successfully obtained using this 
method. With the α-hydroxyacetic acids (3.34 and 3.35) or ester (3.37) in hand, the next logical 
step in our linear sequence was to oxidize the α-hydroxy to the α-keto acid or ester (3.25). 
Oxidative conditions using Collins reagent,
303
 Oxone,
309
 Fremy’s salt,310 and manganese 
dioxide
311
 proved unsuccessful for the conversion of the α-hydroxyacetic acids (3.34, 3.35 and 
3.36) to α, β-diketones.  The unsuccessful attempts for this conversion is assumed to be a result 
of reactivity issues with the pyridine series of compounds as well as solubility issues with the 
starting α-hydroxy compounds.  
An alternative route was required to obtain the desired oxoacetic acids. It was 
hypothesized that a reasonable step to proceed forward was to first complete the amide coupling 
reaction with α-hydroxyacetic 3.35 and aniline to obtain 3.43 (Scheme 3.3). Once 3.43 was 
synthesized attempts to oxidize the α-hydroxy to ketone and provide 3.44 could be easily 
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pursued. There were several advantages to using this route, the α-hydroxyacetic acids could be 
used as their pyridium chloride salts and the terminal carboxylic acid functional group would be 
removed and replaced by the amide bond and therefore solubility issues may be dealt with. Also, 
unlike the α-hydroxyacetic acids, compounds 3.41 and 3.43 could be easily purified by column 
chromatography. Initially, these reactions were rehearsed with aniline and once validated a 
practical approach to the reaction was then performed with 3-benzylaniline, primarily due to cost 
factors (3-benzylaniline 1g=$49.00; aniline 1g=$0.03). The reactions were conducted on both the 
2- and 3-pyridine series of compounds; however, the 2-pyridine oxamide was not successfully 
isolated from the reaction mixture.  The amide coupling of pyrid-3-yl-hydroxyacetic acid (3.35) 
and aniline or benzylaniline was completed with ease using standard amide coupling conditions 
to obtain 3.41 and 3.43, respectively.
306
 To our delight, a recent publication utilizing MnO2 as the 
oxidant for α-hydroxyacetic amides to oxamides was identified which led to the successful 
synthesis of 3.42 and 3.44 (Scheme 3.3).
312
 
Once this route was determined to be feasible to obtain the desired oxamide 3.44 for the 
pyridine series of compounds it was of interest to explore other heteroaromatic scaffolds using 
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the same methodology. Starting with 5-bromo-2-carbaldehyde we employed the same reaction 
conditions as previously noted in Scheme 3.5. The reactions proceeded forward smoothly until 
the amide bond formation between α-hydroxyacetic acid (3.47) and 3-benzylaniline.306  Although 
it had appeared as if product had formed by monitoring the reaction with MS analysis, column 
chromatography purification and isolation of all products from the reaction mixture 
demonstrated that the production of 3.48 was unsuccessful. The reaction was repeated several 
times with varying conditions but unfortunately, compound 3.48 was not isolated. 
 Similarly, the same cyanohydrin chemistries were employed with imidazole-2-
carboxaldehyde (3.50) and imidazole-4-carboxaldehyde (3.51) derivatives (Scheme 3.6). 
Unfortunately, using the previously noted procedure for the pyridine series the conversion of 
imidazole-2-carboxaldehyde 3.50 to desired imidazole-2-cyanohydrin 3.52 was not successful. 
However, success was demonstrated with the conversion of imidazole-4-carboxaldehyde 3.51 to 
imidazole-4-cyanohydrin 3.53 using this procedure.
300, 301
  The imidazole-4-cyanohydrin 3.53 
was successively hydrolyzed to the α-hydroxyacetic acid 3.56 and also as the ethyl ester 3.55.308 
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Analogous to problems faced with several of the other heteroaromatic derivatives previously 
noted at this stage, the amide coupling of α-hydroxyacetic acid 3.56 with 3-benzylaniline was 
unsuccessful and 3.58 was not isolated .
306
 
 The synthesis of the furan oxalamate derivative began with the coversion of furfural 
(3.61) to the cyanohydrin 3.62 (Scheme 3.7).
313, 314
  An attempt to convert the cyanohydrin 3.62 
to the methyl ester 3.63 via the corresponding imidate through a modified Pinner reaction
315
 was 
unsuccessful and alternative routes to obtain 3.63 were explored.
316
 However, due to the 
instability of the furan scaffold, especially under acidic conditions, this route was abandoned and 
more favorable routes were pursued (Scheme 3.13 and 3.19, compound 3.98). 
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3.4.2. Heteroaromatic α-Oxoacetic Acids: Activation of Pyridium Salts for Electrophilic 
Acylation 
 At the same time that the cyanohydrin chemistries were underway, alternative routes to 
obtain the pyridine derivatives were also being investigated. It is well-known that electrophilic 
aromatic substitution reactions of pyridines are extraordinarily challenging. Instead of C-
substitution at the pyridine ring, the electrophile typically forms an adduct with the pyridine 
nitrogen, which even further deactivates the already electron deficient pyridine ring toward 
electrophilic substitution. For example, the direct nitration of pyridine requires a reaction 
temperature of 330°C to provide only a 15% yield of 3-nitropyridine.
317
  
To overcome the lack of reactivity of pyridines, pyridines can be converted into a 
temporarily activated electron rich 1,4-dihydropyridine which features strongly enhanced 
reactivity towards electrophiles at the 3-position.
318-322
 Klapars et al. recently reported an indirect 
method for the 3-acylation 
of pyridines by converting 
recalcitrant pyridinium salts 
into Reissert-type 4-cyano-
1,4-dihydropyridines in a 
one-pot procedure. In 
general, this method works 
favorably if the equilibrium mixtures are treated with strong acylating agents such as ethyl oxalyl 
choride. However, treatment with weaker acylating agents does not provide the desired 
dihydropyridines. Instead, products resulting from the reaction of the cyanide ion, present in the 
equilibrium mixture, can be observed (Scheme 3.8). This method was a good alternative to the 
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cyanohydrin chemistry and was used to obtain ethyl 3-pyridineglyoxylate (3.67) which was used 
for the synthesis of the 3-pyridine oxalamate derivative (3.68).
323
  
The optimized procedure (Scheme 3.9) starting with pyridine (3.65) followed the 
sequence of N-alkylation with methyl chloromethyl ether (MOMCl) and addition of the soluble 
cyanide source benzyltrimethylammonium cyanide (BnMe3N
+
CN
-
) to generate the activated 
dihydropyridine 3.66, and C-acylation with ethyl oxalyl chloride in the presence of Hünig’s base.  
The aromatization of dihydropyridine 3.66 to the desired 3-acyl pyridine 3.67 was accomplished 
with the help of zinc chloride (ZnCl2) as a mild cyanophile. Upon addition of ZnCl2 to 3.66, a 
rapid decyanation to the pyridinium salt which activated the MOM group toward deprotection 
via nucleophilic displacement. This was accomplished by refluxing the crude pyridinium salt 
mixture in ethanol, resulting in the formation of ethyl 3-pyridineglyoxylate 3.67 in moderate 
yields. 
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 Initial attempts of amide formation by heating ethyl ester 3.67 in the presence of 3-
benzylaniline in a CEM microwave synthesizer for 10 min at 65 °C and an initial power of 65 W 
or refluxing the reaction mixture overnight did not give corresponding oxamide (3.44) and only 
starting material (3.67) remained.
324
 The ethyl 3-pyridineglyoxylate 3.67 was then subjected to 
amide coupling conditions using sodium hexamethyldisilazide (NaHMDS) to deprotect the 
aniline and then to react with the ethyl ester to give the required amide 3.44. Although, the 
desired amide was obtained, the product was contaminated with an undesired Schiff-base 
product 3.68. The thin-layer chromatography (TLC) profile of the isolated product from the 
reaction mixture appeared as one spot; however, NMR and HPLC analysis revealed both 
products 3.44 and 3.68 (50:50 ratio). 
 
3.4.3. Heteroaromatic α-Oxoacetic Acids: Heterocyclic α-Iminonitriles 
 There are several synthetic procedures for the preparation of α-Iminonitriles (Schiff-
bases), however, most of them are multistep processes and have a limited application scope.
325-
337
 Jursic et al. reported this procedure as for the conversion of heterocyclic aldehydes (3.28-
3.30) into heterocyclic methylidene-p-hydroxyanilines , heterocyclic α-iminonitriles (3.75-3.77), 
and finally into heterocyclic α-oxoacetic acids (3.38, 3.39 and 3.78).338 Initially, this route was 
anticipated as an efficient three-step route for the synthesis of heteroaromatic α-oxoacetic acids 
(Scheme 3.10).
338
  A simple reaction of 2-, 3- and 4-pyridine carboxaldehydes (3.28-3.30) with 
p-aminophenol in methanol resulted in the corresponding heterocyclic imines (3.69-3.71) in high 
purity and yields. The heterocyclic imines were then treated with sodium cyanide and dimethyl 
sulfoxide (DMSO) and subjected to air oxidation to yield the α-iminonitriles (3.75-3.77). 
Following the reported procedure, preparation of 3.77 was straight-forward and product was 
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identified with ease in high yield. Interestingly, it was extremely difficult to identify and purify 
both of the 2- and 3- pyridine α-iminonitrile derivatives (3.75 and 3.76) following the reported 
procedure. However, after carefully modifying the purification method both of the desired α-
iminonitriles (3.75 and 3.76) were identified successfully. With all three α-iminonitriles available 
the next step invoked hydrolysis to the desired heterocyclic-α-oxoacetic acids (3.38, 3.39 and 
3.78). The α-iminonitriles represent a class of compounds that should hydrolyze rather easily to 
the desired heterocyclic-α-oxoacetic acids.338, 339 However, following the reported approach of 
stirring an aqueous hydrochloric acid suspension of heterocyclic α-iminonitrile followed by 
separation of the heterocyclic-α-oxoacetic acid (3.38, 3.39 and 3.78) from p-aminophenol (3.79) 
106 
failed. Hydrolysis was attempted several times with varying reaction conditions, times and 
temperatures.
339-342
 Collectively, the hydrolysis methods tested did not yield the desired 
heterocyclic-α-oxoacetic acids (3.38, 3.39 and 3.78), and the products identified from the 
hydrolysis reactions were nicotinic acid (3.80-3.82) and p-aminophenol (3.79) co-eluting as a 
mixture (Scheme 3.10).  After reviewing the literature it became apparent that mechanistically, 
the hydrolysis of the α-imino functional group happens at a faster reaction rate compared to the 
nitrile functional group and therefore lending to the formation of nicotinic acid instead to α-
oxoacetic acids (3.11).
339-342
 Although the published method reports the synthesis of α-oxoacetic 
acids there is skeptism due to the lack of reproducibility. It is worth mentioning that since the 
publication of this preliminary report there have been no other reports using this method to 
obtain α-oxoacetic acids in the literature. Also, comparing the reported NMR values for 3.39 in 
this paper
338
 to known and estimated values of 3.39 shows discrepancy (Figure 3.35).  
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In order to elucidate a reason for this and potentially come to a more reliable reaction 
protocol, we chose to investigate alternative reaction conditions. Additionally, when aniline 3.85 
was used as an alternative to the p-aminophenol 3.79, containing an electron donating hydroxyl 
group, the same reaction products were obtained (Scheme 3.10).We decided to use the lessons 
learned from this chemistry to explore an alternative route to obtain the α-oxoacetic acids 
(Scheme 3.12).  It was evident that the major hurdle to overcome was the competing hydrolysis 
reaction rate of the α-imino group compared to that of the nitrile functional group. We 
envisioned that a more robust route would invoke an α-amino group in place of the α-imino 
group.  Therefore, a simple and efficient one-pot, three component method was used for the 
synthesis of α-aminonitrile 3.88.343 The α-aminonitrile 3.88 was subjected to Pinner synthesis to 
hydrolyze the nitrile and afford the amino ester 3.89.
344
 The next step towards the synthesis of 
the α-oxoacetic acid 3.39 was to oxidize the α-amino to an α-imino functional group with 2, 3-
dichloro-5, 6-dicyano-1, 4-benzoquinone (DDQ)
345, 346
 to furnish 3.90, in preparation of 
hydrolysis of both the ester and α-imino functional group to provide α-oxoacetic acid 3.39.338  
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3.4.4. Aryl α-Keto Esters and Acids 
In the past several decades, much attention focused on the synthesis of α-keto esters. 
Several routes were reported including the oxidation of α-hydroxy esters with either  pyridinium 
chlorochromate (PCC) or Dess-Martin periodinane (DMP),
347, 348
 Friedel-Crafts acylation, 
349
 
oxidative cleavage of cyano keto phosphoranes,
350
 hydrolysis and esterification of acyl 
cyanides,
351
 the reaction of organometallic species with oxalic ester derivatives,
352
 and acylation 
or alkylation of mono-substituted 1,3-dithianes.
353
 The most common route for the synthesis of 
α-keto esters is the reaction of Grignard reagents with oxalyl chloride.354 However, all of these 
methods involve either strict reaction conditions, complicated procedures, or in some instances 
low yields. Collectively, all of the drawbacks associated with these procedures have limited the 
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synthetic application of these methods to obtain α-keto esters. Recently, Zhaung et al.  reported 
an efficient one-pot synthesis of α-keto acids and α-keto esters by using selenium dioxide to 
oxidize aryl ketones (Scheme 3.13).
355
  Although there are several routes for the synthesis of aryl 
α-keto esters as noted above, this method provided a convenient and efficient route for the 
synthesis of our aryl α-keto acids (Figure 3.34). With the synthesis outlined in Scheme 3.14, 
numerous compounds could be effortlessly synthesized starting with readily available aryl 
ketones 3.91 to obtain the α-ketoacids 3.92. The α-ketoacids produced could then be used in 
subsequent amide coupling reactions
306
 with aniline or 3-benzylaniline to obtain target 
compounds 3.93-3.105 (Figure 3.34).   
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The brominated aryl 
oxalamate compounds 3.95 and 3.96 
were of particular interest because 
they are viable precursors for the 
palladium-catalyzed cross-coupling reaction with dialkyl phosphites (Scheme 3.15).
356
 
Traditional synthetic methods for aryl- and vinylphosphonic acid class of compounds include 
Friedel-Crafts reactions,
357
 Cu-catalyzed reactions of diazonium salts with PCl3,
324, 358
 
nucleophilic substitution reactions of activated aryl halides and sodium dialkylphosphites,
359
 Ni- 
or Cu-mediated couplings between aryl halides and trialkyl phosphites,
360-364
 and reaction of 
arylmetal derivatives and trialkyl phosphites.
365-367
 However, due to the aggressive and harsh 
reaction conditions required, these transformations tend to be incompatible with sensitive 
functionalities.
356
 A potentially more general access to dialkyl arylphosphonates based on 
palladium-catalyzed reaction of aryl halides with dialkyl phosphite has been previously reported 
by Hirao et al. (Scheme 3.15).
368-372
  Unfortunately, when Gooβen et al. employed these 
previously published procedures for the preparation of various functionalized aryl phosphonates 
the reactions provided unsatisfactory yields.
356
  Therefore it was necessary to explore alternative 
111 
reaction conditions to develop an efficient and broadly applicable approach for the cross-
coupling of aryl bromides with dialkyl phosphites. The best results were obtained using 
Pd(OAc)2 as the Pd-source, triphenylphosphine as the phosphine source, a sterically demanding 
tertiary amine as the base, and use of the protic solvent ethanol. Remarkably clean reactions were 
observed even with functionalized molecules bearing keto, nitro, ester, thioether, nitrile and even 
hydroxyl functional groups.
356
 Therefore, this method seemed reasonable to follow with the α, β-
diketo containing oxoamide starting materials 3.95 or 3.96 (Scheme 3.16). After reaction 
completion and subsequent purification by column chromatography, two products were isolated. 
Unfortunately, neither product was the desired aryl phosphonate (3.111 or 3.112), as determined 
by spectroscopic methods of analysis. The products isolated from both the 3- and 4-substituted 
derivatives were 3.113 and 3.115 or 3.114 and 3.116, respectively (Scheme 3.16). It appears 
from the reaction mechanism that products 3.113 and 3.114 are a result of nucleophilic addition 
to the reactive α-keto carbonyl with diethyl phosphite, happening at a faster reaction rate than the 
phosphorus-carbon bond coupling reaction. Products 3.115 and 3.116 are a result from the 
diethyl phosphite acting as a hydride source and reducing the α-keto carbonyl group. Therefore, 
it can be concluded that both products are a result from the reactivity of the α-carbonyl ketone. A 
solution for this problem was to install the phosphonate ester first (3.119 or 3.120, Scheme 3.17) 
and then oxidize the aryl ketone to obtain the α-hydroxyacetic acid (3.121 or 3.122).306, 355 Once 
the phosphonate α-hydroxyacetic acid derivatives were available, amide bond formation with 3-
benzylamine (3.111 or 3.112) and deprotection of the phosphonates under mild conditions to 
afford the phosphoric acid oxalamate derivatives 3.123 or 3.124.
306, 373
 Unexpectedly, the 
reaction yielded a mixture of multiple products of mono-dealkylated, di-dealkylated instead of 
the phosphonate ester α-keto acids (3.121 and 3.122). It was quickly apparent from the two 
112 
methods employed that an alternative route was warranted for the synthesis of the phosphoric 
acid oxalamate derivatives. 
 
 
3.4.5. Negishi and Suzuki Cross-Coupling Reactions with Acid Chlorides 
In 2011, Kim et al. published a procedure for a Ni-catalyzed cross-coupling reaction of 
organozinc reagents with acid chlorides.
374
 From the series of compounds derived from this 
study, of particular interest was the Negishi cross-coupling reaction between ethyl 2-oxalyl 
chloride and an aryl zinc bromide (Scheme 3.18). This was of interest because the reaction 
conditions reported were well-tolerated by the acid chloride which contained two ester 
functionalities. This procedure seemed to be feasible method for the synthesis of the furan 
oxalamate scaffold 3.107 
(Scheme 3.19). The furan 
zinc bromide 3.126 was 
113 
synthesized
375
 and subjected to Ni-catalyzed cross-coupling conditions to afford 3.127 in 
moderate yield. During the time that this synthetic route was being pursued an alternative route 
to synthesize the furan oxalamate 3.107 (Scheme 3.14) was discovered and this route was 
abandoned.  However, the use of acid chlorides, specifically diketo acid chloride prompted us to 
pursue alternative interesting and less exploited cross-coupling reactions (Scheme 3.21).  
 
 Currently, there is no procedure reported for the Suzuki cross-coupling of diketo acid 
chlorides with arylboronic acids.  In 1999, a procedure by Haddach et al. for the Pd-catalyzed 
cross-coupling of acid chlorides with arylboronic acids was reported (Scheme 3.20).
376
  This 
method provided a convenient route to ketones, since boronic acids and acid chlorides are 
inexpensive commercially available starting reagents. The Suzuki coupling reaction is generally  
carried out as a two-phase Pd-catalyzed reaction in ethanol, toluene and water.
377
 These 
conditions are not suitable for the coupling of acid chlorides with boronic acids. However, this 
procedure synthesis ketones from acid chlorides and boronic acids under anhydrous Suzuki 
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cross-coupling reaction conditions with Pd-catalyst and cesium carbonate in toluene (Scheme 
3.20).
376
 
It was projected that Suzuki cross-coupling with diketo acid chlorides and boronic acids, 
derived from this seminal paper,
376
 would offer the ability to synthesize a library of oxalamate 
derivative scaffolds for this project. Several boronic acids with ethyl oxalyl chloride (Scheme 
3.21, Table 3.6 ) were subjected to Pd-catalyzed cross-coupling conditions using similar reaction 
conditions as reported in the literature. Both NMR and mass spectral analysis of the products 
isolated from the performed reactions determined that although in several instances the desired 
diketo ester product had formed it was in undesirable yields (0-28% yield). The anticipated 
products in the crude reaction mixture were among several byproducts. One of the most 
commonly observed byproducts formed from these reactions was the homocoupling of the 
boronic acid to itself rather than boronic acid coupling to the acid chloride. An interesting 
observation was noted when Tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) was used as 
the catalyst for these Suzuki-cross coupling reactions. The (Pd2(dba)3) catalyzed reactions 
provided some of the higher yields 
compared to the reactions using 
alternative palladium catalysts. However, 
when the desired products were isolated 
they were co-eluted as inseparable 
mixtures with dibenzalacetone (dba) that 
had been dissociated from the (Pd2(dba)3) 
catalyst (Figure 3.35). Due to the 
115 
undesirable yields and complicated reaction mixtures these chemistries were not continued as a 
method for obtaining the oxalamate scaffolds.  
 
 
 
 
 
 
Reference Boronic Acid Boronic 
Acid Eq 
 
Cs2CO3 Catalyst Catalyst 
Eq 
Results 
NB11P53 
 
1 2 2.5 Pd(PPh3)4 2.57 mol% Several products 
(homocoupling) 
NB11P57 
 
1 3 2.5 Pd(PPh3)4 1.61 mol% Isolated major product 
(byproduct) 
NB11P60 
 
1 3 2.5 Pd(PPh3)4 1.04 mol% Several products 
NB11P66 
 
1 2 2.5 Pd(PPh3)4 4 mol% Several products 
NB11P83 
 
1 2 5 Pd(PPh3)4 5 mol% homocoupling 
NB11P86 
 
1 2 5 Pd(PPh3)4 5 mol% Several products 
(could not isolate prod) 
 
NB11P87 
 
1 2 5 Pd(PPh3)4 5 mol% Several products 
(could not isolate prod) 
 
NB11P93 
 
1 2 2.62 Pd(PPh3)4 5 mol% Several products 
Mass spec shows 
product 
 
NB11P97 
 
1 3 3 Pd(PPh3)4 5 mol% homocoupling 
 
NB12P03 
 
1 3 3 Pd2(dba)3 5 mol% TLC  matches  Negishi 
NMR-shows but  w/dba 
NB12P05 
 
1 3 3 Pd(OAc)2 5 mol% homocoupling 
NB12P07 
 
1 3 3 Pd2(dba)3 5 mol% TLC-one bright spot 
NMR-mixture  w/dba 
NB12P15 
 
1 3 3 Pd2(dba)3 5 mol% TLC-one bright spot 
NMR-mixture  w/dba 
NB12P17 
 
1 3 3 Pd2(dba)3 5 mol% TLC-one bright spot 
NMR-mixture  w/dba 
 
 
Table 3.6 Suzuki Methodology Summary of Coupling with Acid Chlorides and Aryl Boronic Acids  
Figure 3.36 TLC of Desired Product B co-eluting with dba A 
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3.4.6. Friedel-Crafts Acylation  
In the early 2000s, with the emergence of resistance from the commonly prescribed 
marketed HIV therapeutics, Bristol-Myers Squibb (BMS) implemented a screening program to 
identify new classes of HIV-1 inhibitors that acted against novel drug targets without bias for a 
particular mechanism of action.
378
 This initiative produced a number of compounds that 
interfered with HIV-1 replication in cell culture without overt cytotoxicity. Most of the 
compounds discovered were characterized as NNRTIs. However, one compound, the simple 
indole glyoxamide (A, Figure 3.36), emerged as a molecule with a unique mechanistic profile.
379, 
380
 Time-of-addition experiments eventually elucidated that the indole glyoxamides (Figure 3.36) 
inhibited an early event in HIV infection that was subsequently determined to be interference 
with the binding of HIV-1 gp120 to the host-cell receptor CD4.
380
   
 
The ease of the synthesis for the indole glyoxamide class of compounds using Friedel-
Crafts acylation chemistry, their advent as HIV-1 entry inhibitors with similar structural features 
to our proposed molecules made these scaffolds interesting molecules to pursue and test as HIV-
1 IN inhibitors. Moreover, considering the analogous structural features of the library of 
synthesized molecules from this dissertation project it may be worthwhile to also evaluate our 
compounds as HIV-1 entry inhibitors. 
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As shown in Scheme 3.22 and 3.23, Friedel-Crafts acylation of substituted indoles led to 
the synthesis of several indole glyoxamides. Due to the high nucleophilic character at the 3-
position of indole, the treatment with oxalyl chloride of appropriate indoles 3.138 produced the 
corresponding 2-(1H-indol-3-yl)-2-oxoacetyl chloride intermediates 3.139 which were then 
coupled with aniline or 3-benzylaniline in alkaline medium in a one-pot procedure to give the 
desired indole oxalamate derivatives 3.140-3.144 (Scheme 3.22).
381, 382
 The synthesis of 
azaindole (3.148) is depicted in Scheme 3.23 and is initiated by acylating 7-azaindole (3.145) 
with ethyl chlorooxoacetate in the presence of AlCl3 to afford 3.146.
383
 Hydrolysis of the 
resulting ester, using K2CO3 in aqueous MeOH,
305
 followed by coupling with 3-benzylaniline 
afforded the azaindole glyoxamide 3.148.
306
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3.5. BIOLOGICAL EVALUATION 
 
The compounds designed and synthesized from this dissertation project were completed 
with an agreement between the University of Mississippi and Panvirex, LLC. In summary, 
several of the compounds (3.41-3.44, 3.95-3.107, 3.113-3.115, 3.140-3.144 and 3.148) that were 
synthesized during the course of this project have been submitted to our collaborators at 
Panvirex, LLC. and the biological data is currently pending at the time of writing this 
dissertation. The synthetic analogues will undergo biological screening to determine the IN 
inhibitory activity, the sensitivity to known IN inhibitor mutations and analyzed for their 
antiviral efficacy.  
 
3.5.1. Determination of IN inhibition 
 The selectivity of β-DKA class of IN inhibitors towards the inhibition of the ST-reaction 
provides specificity to the viral enzyme mediated reaction. Several types of assays to determine 
IN inhibition have been previously described in the literature.
203, 384-389
 The high-throughput 
electrochemiluminescent (ECL) based determination of the ST inhibition reaction and the solid 
phase ELISA assay (Biomek® robotic system) will be used for the evaluation of the synthesized 
chemical scaffolds (Figure 3.37). The principles of the ECL and ELISA assays are essentially the 
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same, however, in the solid-phase ELISA assay either biotin or fluorescent FTC (fluorescein-5-
thiosemicarbazide) labeled DNA is used and in the ECL assay the DNA label is a 
chemiluminescence molecule. The high-throughput ECL assay (BioVeris Inc., Gaithersburg, 
MD) is commercially available and will be used in routine analysis of IC50 potency of the 
synthesized compounds.  
 Both the solid-phas ELISA assay and high-throughput ECL can only determine the 
inhibition of the ST reaction, which is important from a drug development perspective. However, 
it is important to also determine the inhibitor selectivity of the ST-reaction over the 3’-P reaction. 
The traditional gel-based assay containing the labeled 21-mer duplex oligonucleotide 
corresponding to the U5 end of the HIV LTR sequence can determine both ST-inhibition and 3’-
P inhibition. Although this assay is cumbersome and tedious, it will be of great importance from 
a mechanistic perspective.  The evaluated compounds that show ST inhibition from the high-
throughput ECL assay will be evaluated using this gel-based assay to determine if any inhibition 
of the 3’-P 
reaction is 
also seen.  
 
  
 
 
 
     Figure 3.37 Standard ELISA ST IN Assay
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3.5.2. Determination of Sensitivity to Known IN Inhibitor Mutations 
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 It has been previously reported that the β-DKA class of compounds induce progressive 
drug resistance mutations of T66I/S153Y, T66I/M154I or T66I/SI53Y/N155S. These mutations 
in the enzyme do not alter the enzyme efficiency as observed with the emergence of drug 
resistant viruses and also established by in vitro studies. In this regard, compounds synthesized 
will be evaluated against the IN enzyme containing either an individual mutation or a 
combination of mutations. Analysis of ST inhibition in IN mutations of K156 and K159 or Q148 
are not meaningful because these residues are involved in host and viral DNA binding and ST 
inhibition is lost if these residues are mutated. Similarly, mutations of the residues in the 
catalytic triad, E152, D64 and D116, are not possible. The histidine (His) Tag-recombinant 
cDNA clones of the IN enzyme containing T66I, S153Y and M154I are readily available at 
Panvirex, LLC and the combination of mutants were obtained as a gift from Dr. Vinay Pathak, at 
the National Cancer Institute (NCI). 
 
3.5.3 Determination of Antiviral Efficacy  
 The antiviral activity of the compounds determined to have IC50 values of <500 nM will 
be determined in multiple rounds of replication inhibition assays comparable to a Phase I clinical 
study. The cytotoxicity of the newly synthesized molecules will also be evaluated prior to being 
subjected to the antiviral inhibition assay. Briefly, cells infected with HXB-2 or CEM-TART 
cells infected with HIV-1 MC99IIIB∆Tat-Rev viral strains390 will be added to uninfected cells 
and the extent of viral replication will be determined using commercially available ELISA kits . 
The EC50 will be determined by comparing the viral replication of cells exposed to synthesized 
inhibitors to no inhibitor control.  
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3.6 CONCLUSIONS AND FUTURE DIRECTIONS 
 The identification and characterization of HIV-1 as the causative pathogen of AIDS in 
1984 triggered an enthusiastic effort to identify antiviral drugs capable of interrupting replication 
of the virus that in absence of therapeutic intervention represents a death sentence.
391, 392
  
HIV-1 encodes three enzymes that are required for viral replication: reverse transcriptase (RT), 
protease (PR) and integrase (IN). To date, there are 25 ARV drugs approved for the treatment of 
HIV-1 infection and AIDS. FDA-approved therapies target three steps of the HIV life cycle: 
reverse transcription, proteolytic maturation and fusion. Triple therapy, commonly referred to as 
highly active antiretroviral therapy (HAART) is the standard treatment for HIV. HAART 
consists of a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) 
in combination with two nucleoside reverse transcriptase inhibitors (NRTI.)
86
 HAART, however, 
is often not well tolerated by patients, requires discipline, is expensive and leads to multidrug 
resistance and cross-resistance.
86, 165, 393
 Despite the quantity of marketed antiretroviral HIV-1 
drugs, there are only a limited number of mechanistic drug classes to build combinations from. 
HIV-1 exhibits poor fidelity of replication which eventually leads to the emergence of resistance 
viruses and treatment failure making the development of new inhibitors essential for continued 
therapy.  
The third viral enzyme, IN,  has emerged as an attractive target because it is necessary for 
stable infection and has no cellular human equivalent.
86
 Substantial progress has been achieved 
since IN was first recognized as an important antiretroviral drug target. In October 2007, the 
FDA approved raltegravir, the first example of a drug active against IN, validated the enzyme as 
a new target in the field of anti-HIV drug research.
227, 228, 394
 Over the last decade, a number of 
IN inhibitors have been discovered but many of these compounds are toxic, do not show antiviral 
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activity or display decreased potency. Therefore, new classes of potent IN inhibitors are 
desperately needed. The β-diketo (β-DK) class of compounds has emerged as one of the most 
successful classes of IN inhibitors. Although several β-DK inhibitors with potent antiviral 
activity are known, compounds containing β-DK motifs have limitations in drug development.  
 The overall objective of this dissertation was to design and synthesize a novel series of 
IN inhibitors that retain the favorable characteristics of the β-DK scaffolds but are devoid the 
“undruggable” properties. Several analogs proposed from crystal structure-based correlation and 
structure-activity relationship studies were synthesized during the course of this dissertation 
project. Many of the originally projected synthetic pathways to obtain these inhibitors, although 
initially appearing as reasonable routes, failed in the practical setting. These challenges led to the 
exploration of alternative chemistries and allowed us to gain new insight into alternative 
chemistries as a mechanism to synthesize several of the oxalamate scaffolds.  
 
3.6.1. Alternative Strategy for the Synthesis of α, β-diketo Amides 
A common strategy employed for the synthesis of the majority of desired α, β-diketo 
amide desired compounds was to establish the α-hydroxy or α-carbonyl in the early stages of 
compound synthesis (Scheme 3.24). Although these routes seemed feasible originally, and 
several compounds were obtained through these methods, there were also several problems 
encountered when exploiting these synthetic routes. For example, the initial attempts to oxidize 
the α-hydroxy functional group of α-hydroxy acetic acids were not straightforward (Scheme 3.2), 
the anticipated Pd-catalyzed coupling of aryl bromides with diethyl phosphite failed due to the 
reactivity of the electrophilic α-carbonyl functional group (Scheme 3.16), and hydrolysis of the 
α-iminonitriles to provide diketo acids was unsuccessful because the hydrolysis reaction rate of 
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the α-imino functional group was faster than that of the nitrile functional group (Scheme 3.11). A 
common theme observed with these unexpected difficulties was the involvement of the α-
hydroxy or α-carbonyl functional group. In terms of optimizing and planning a more efficient 
synthetic route to obtain α, β-diketo amide derivatives the reactivity of the α-functional groups 
was considered. An alternative synthetic route the observed byproduct (compounds 3.115 and 
3.116) isolated from the phosphonate coupling reaction and the challenges associated with the 
chemistries described above was to begin the synthesis without the α-hydroxy or α-carbonyl 
functional group in place and then oxidize to the α-keto amides at a later step in the linear 
synthesis (Scheme 3.25 and 3.26). 
  
After reviewing the literature for chemistries that are concurrent with the new synthetic 
approach a few appealing synthetic opportunities were discovered.  One option for the new 
synthetic route is to do a direct α-oxidation of amides or esters using SeO2 as a metal oxidant.
395-
399
  This oxidation of the methylene group adjacent to the carbonyl using SeO2 is generally 
referred to as a Riley oxidation and this method has been reported previously with a variety of 
aromatic and heterocyclic scaffolds.
395-399
 It would be beneficial to employ this reaction using 
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commercially available or easily synthesized aryl- or heteroarylacetamides or esters (Scheme 
3.25).  
 
In 2012, Shao et al.
400
 reported a simple synthetic route using a sodium bicarbonate 
promoted aerobic oxidation reaction to prepare α-keto amides from easily available aryl- or 
heteroarylacetamides (Scheme 3.26). This method was explored on a variety of functionalized 
molecules that were tolerated and readily to give the corresponding α-keto amides in good yields. 
The oxidation reaction was not limited to simple benzene-containing aromatics, substrates 
containing the substructure of naphthalene, pyrimidine, pyridine, and aliphatic chains also gave 
good yields. This route would potentially offer the ability to synthesize several structurally 
diverse compounds conviently without the use of toxic reagents and harsh conditions.  
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3.6.2. Synthetic Strategies for Alternative Aryl Scaffolds 
The main focus of the compounds synthesized to date was to determine the SAR and role 
of the terminal functional group in regards to IN inhibition. Almost all of the compounds 
developed contained either an aniline or diphenylmethane as the aromatic functional group. One 
of the long term goals of this project is to develop analogues with “decorated” aromatic 
substituted scaffolds in place of the diphenylmethane scaffold (Figure 3.33). Preliminary data 
showed that substitutions on the phenyl and benzyl ring of diphenylmethane further increase the 
antiviral activity of compounds to nM activity (3.7-3.9, Table 3.2).  
It was originally proposed that (2,4-difluoro-1-(4-isopropoxybenzyl)benzene) could be 
synthesized using a three-step protocol (Scheme 3.27). Initially, a Kumada coupling of 1-chloro-
2,4-difluorobenzene (3.155) and the appropriate Grignard reagent using Ni/C catalyst to afford 
diaryl methane (3.156).
401, 402
 Electrophilic nitration of 3.156 with ammonium nitrate/TFAA 
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utilizing the ionic liquid 3-methylimidazolium (emim) to produce the nitration product, and 
subsequent catalytic hydrogenation will afford aniline 3.157.
403
 However, initial attempts by the 
Rimoldi research group to synthesize 3.157 using this method were unsuccessful. Therefore, 
alternative routes to obtain substituted aryl scaffolds were considered.  
 
In 2010, Fan et al.
404
 published an efficient and practical method to a wide range of 
perfluorinated unsymmetrical diarylmethanes with good to excellent yields and high 
regioselectivity using a direct Pd-catalyzed benzylation (Scheme 3.28). The most widely used 
approaches to this functional group array rely on cross-couplings of a stoichiometric amount of 
organometallic aryl with electrophiles.
405
 However, this “prefunctionalization” process suffers 
from the requirement of additional steps for the preparation of organometallic reagents and the 
incompatibility of functional groups.
404
 In this regard, direct benzylation of arenes and 
heteroarenes has been successfully discovered recently and this current method provides a 
method for the direct benzylation of highly electron-deficient perfluorenes with various 
functional groups.
404, 406-408
 Collectively, these methods may provide access to a variety of 
substituted aromatic scaffolds. 
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3.6.3. Opportunities for Alternative Biological Targets  
3.6.3.1 p38α Mitogen-Activated Protein Kinase Inhibitors 
The p38α mitogen-activated protein kinase (MAPK) is a serine-theonine protein kinase 
and is recognized as a highly attractive target for therapeutic intervention. It is well established 
the proinflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-β), play 
an important role in the pathogenesis of various inflammatory diseases and that the stress-
activated signal transduction pathway leading to these cytokines is in part regulated by p38α 
MAPK.  
Recent publications like that of Mavunkel 
et al. 
409
 report the design and synthesis of MAPK 
inhibitors based on 4-fluorobenzylpiperdine 
heterocyclic oxalyl amides (Figure 3.38). In 2008, 
Montalban et al.
410
 identified a novel series of p38α 
MAPK inhibitors through structure-based design and 
interestingly the α-ketoamide series of compounds were 
examined for p38α MAPK inhibition. Although, the 
representative molecule (Figure 3.39) only showed 
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moderate TNF-α inhibition it may eventually be used as a lead molecule towards the 
development of more potent p38α MAPK inhibitors.  Although the synthesized α-ketoamides 
from this dissertation project were designed as HIV-1 IN inhibitors it would be interesting to 
examine the activity of the molecules as MAPK inhibitors, considering the similar structural 
features of the compound. Additionally, numerous studies have shown that the MAPK signal 
pathway can regulate the replication of HIV-1, but exactly how each MAPK pathway affects 
HIV-1 infection and replication is not fully understood.
411
   
3.6.3.2 Inhibitors of HIV-1 Attachment 
 The interaction of HIV-1 surface glycoprotein gp120 with CD4, a glycoprotein receptor 
expressed in mammalian cells, is the critical first step of a series of several events that allows 
virus access to the host cells.
71
 As mentioned previously in this dissertation with the synthesis of 
the indole glyoxamide derivatives, several structurally similar indole glyoxamides (A, Figure 
3.36) were determined previously to inhibit an early event in HIV infection. These inhibitors 
were subsequently shown to be interfering with the binding of HIV-1 gp120 to the host-cell 
receptor CD4. 
379, 380
 With the apparent similarities of the indole glyoxamide HIV-1 attachment 
inhibitors and the α, β-diketo amides class of compounds, it is likely that the synthetic analogs of 
this dissertation project may possess inhibitory activity against HIV-1 attachment.  
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IV. EXPERIMENTAL 
 
General Methods: 
 Moisture and oxygen sensitive reactions were carried out in flame-dried glassware under 
an inert argon atmosphere. Anhydrous tetrahydrofuran (THF), diethyl ether (Et2O), and 1,4-
dioxane were distilled over sodium metal in the presence of benzophenone indicator. Anhydrous 
dichloromethane (DCM, CH2Cl2), acetonitrile (AcN) and toluene were distilled over calcium 
hydride (CaH2). All commercially available starting materials and reagents were purchased at the 
highest commercial quality and used without further purification, unless otherwise noted. 
Reactions were monitored by thin-layer chromatography (TLC) carried out on 225 µm aluminum 
backed TLC sheets coated with silica gel 60 F254 (EMD Chemicals Inc. Gibbstown, NJ, USA). 
TLCs were visualized under UV (254 nm) and by staining with either p-anisaldehyde, 
phosphomolybdic acid (PMA), iodine, or Dragendorff’s reagent. NMR spectra were recorded at 
room temperature on Bruker Avance DRX 400 (400 MHz) and DRX 500 (400 MHz) 
spectrometers. The following abbreviations were used to explain the multiplicities: s = singlet, d 
= doublet, t = triplet, q = quartet and m = multiplet. Infrared (IR) spectra were recorded on 
Bruker Vector 33 FT-IR spectrometer. Electrospray ionization (ESI) mass spectrometry (MS) 
experiments were performed on a Waters Micromass ZQ single quadrupole mass spectrometer. 
High-resolution mass spectra (HR-MS) were recorded using a Waters Micromass quadrupole 
time of flight (Q-TOF) micro mass spectrometer. High-performance liquid chromatography 
liquid chromatography (HPLC) analysis was conducted using a Waters Delta Prep 4000 System 
with a 77725I Rheodyne injector, a Waters 2487 Dual Wavelength Absorbance Detector, and an 
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XTerraTM MS C18 5 µm 4.6 x 100 mm column. Elemental Analysis was obtained using a 
PerkinElmer 2400 Series II CHNS/O Analyzer. 
 
General Procedure for the Synthesis of 2-, 3- and 4-pyridineacetonitriles (S2): 
Using an adapted procedure from Sauerberg et al.,
300
 to 
a solution of potassium cyanide (KCN) (1.33 g, 0.0205 
mol, 1.10 eq) in water (8.39 mL) was added 
pyridinecarboxaldehyde S1 (2.0 g, 0.0187 mol, 1.0 eq ) 
over 30 minutes at 5-10 °C. To the reaction mixture was added AcOH (1.17 mL, 0.0205 mol, 
1.10 eq) over 30 minutes at 5-10 °C. The reaction mixture was stirred at room temperature for 16 
hours and then cooled to 0 °C. The precipitate was filtered using a Buchner funnel and the 2-, 3- 
and 4-pyridineacetonitriles (S2) solid products were collected, washed with cold water and used 
immediately. CAUTION: potassium cyanide is highly toxic. Care should be taken when 
handling this reagent.
412
 
 
2-Pyridineacetonitrile, α-hydroxy- (3.31) 
Synthesized using the general procedure described for S2. Light yellow solid 
(41% crude yield); Rf = 0.30 (50:50 EtOAc: hexanes); 
1
H NMR (400 MHz, 
DMSO) δ 8.59 (d, J = 3.2 Hz, 1H), 7.90 (t, J = 7.7 Hz, 1H), 7.58 (d, J = 7.8 Hz, 
1H), 7.45 – 7.39 (m, 1H), 5.81 (s, 1H); 13C NMR (101 MHz, DMSO) δ 156.39, 149.35, 137.60, 
123.93, 120.72, 120.38, 63.74; DEPT-135 101 MHz, DMSO) δ 149.54, 138.09, 124.39, 121.02, 
64.12; ESI+ MS: m/z 134 [MH]
+
. 
 
131 
3-Pyridineacetonitrile, α-hydroxy- (3.32) 
Synthesized using the general procedure described for S2. Pale yellow 
crystalline solid (67 % crude yield);  Rf = 0.30 (50:50 EtOAc: hexanes); 
1
H 
NMR (400 MHz, DMSO) δ 8.72 (s, 1H), 8.63 (s, 1H), 7.93 (d, J = 5.2 Hz, 
1H), 7.51 (s, 1H), 7.30 (s, 1H), 5.90 (s, 1H); 
13
C NMR (101 MHz, DMSO) δ 150.54, 148.12, 
134.77, 133.42, 124.33, 120.41, 60.45; DEPT-135 (101 MHz, DMSO) δ 150.55, 148.13, 134.79, 
124.34, 60.45; ESI+ MS: m/z 134 [MH]
+
. 
 
4-Pyridineacetonitrile, α-hydroxy- (3.33) 
Synthesized using the general procedure described for S2. Light orange-pink 
clay-like solid (81% crude yield); Rf = 0.30 (50:50 EtOAc: hexanes); 
1
H NMR 
(400 MHz, DMSO) δ 8.65 (d, J = 4.9 Hz, 2H), 8.53 (d, J = 4.9 Hz, 1H), 7.53 (d, 
J = 5.0 Hz, 2H), 7.39 (d, J = 4.9 Hz, 2H), 5.48 (s, 1H), 4.79 (s, 1H); 
13
C NMR (101 MHz, 
DMSO) δ 150.92, 150.62, 150.04, 149.19, 148.45, 123.68, 123.25, 121.72, 121.37, 119.75, 
76.92, 76.66; DEPT-135 (101 MHz, DMSO) δ 150.91, 150.60, 150.03, 149.54, 149.18, 149.01, 
123.67, 123.24, 123.17, 122.47, 121.76, 121.71, 121.36, 76.66, 76.30; ESI+ MS: m/z 135 
[MH]
+
. 
 
2-Pyridineacetic acid, α-hydroxy-, hydrochloride (3.34) 
Using an adapted procedure from Ward et al.,
308
 a suspension of crude 
cyanohydrin 3.31 (500 mg, 3.73 mmol)  in 5 mL of concentrated HCl was 
refluxed for 15 hours. The concentrated HCl was removed under reduced pressure (0.03 mmHg) 
with slight heating (60 °C). The residue was washed with water and the water was removed 
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under reduced pressure (0.03 mmHg) with slight heating (60 °C) to yield 3.34 as an orange-
brown solid powder (96% crude yield). No further purification was used; ESI+ MS: m/z 153 
[MH]
+
; ESI- MS: m/z 151 [M-H]
-
. 
 
3-Pyridineacetic acid, α-hydroxy-, hydrochloride (3.35) 
Using an adapted procedure from Ward et al.,
308
 a suspension of crude 
cyanohydrin 3.32 (500 mg, 3.73 mmol)  in 5 mL of concentrated HCl was 
refluxed for 15 hours. The concentrated HCl was removed under reduced 
pressure (0.03 mmHg) with slight heating (60 °C). The residue was washed with water and the 
water was removed under reduced pressure (0.03 mmHg) with slight heating (60 °C) to yield 
3.35 as a pale yellow solid (63% crude yield). No further purification was used.; 
1
H NMR (400 
MHz, D2O) δ 8.94 (s, 1H), 8.79 (d, J = 5.6 Hz, 1H), 8.74 (d, J = 8.2 Hz, 1H), 8.12 (dd, J = 7.9, 
6.1 Hz, 1H), 5.65 (s, 1H); 
13
C NMR (101 MHz, D2O) δ 173.46, 145.03, 140.83, 139.43, 139.07, 
127.34, 69.33; DEPT-135 (101 MHz, D2O) δ 145.03, 140.84, 139.43, 127.34, 69.33. ESI+ MS: 
m/z 154[MH]
+
; ESI- MS: m/z 151 [M-H]
-
. 
 
3-Pyridineacetic acid, α-hydroxy-, ethyl ester, hydrochloride (3.36) 
Using an adapted procedure from Ward et al.,
308
 and Baeza et al.,
302
 to a 
solution of crude cyanohydrin 3.32 (500 mg, 3.73 mmol) in ethanol (11 mL) 
and water (11 mL) was slowly added concentrated HCl (22 mL). The reaction 
flask was fitted with a reflux condenser and refluxed for 15 hours. The solvents 
were removed under reduced pressure (0.03 mmHg) with slight heating (50-60 °C) to yield 3.36 
as a white solid (91% crude yield). No further purification was used; ESI+ MS: m/z 181 [MH]
+
. 
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2-hydroxy-N-phenyl-2-(pyridin-3-yl) acetamide (3.41) 
Using a modified procedure from Martyn et al.,
306
 to a mixture of 
crude 3.35 (250 mg, 1.33 mmol, 1.0 eq) and freshly distilled aniline 
(0.134 mL, 1.47 mmol, 1.1 eq) in anhydrous DCM (14 mL) was added 
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (331.80 mg, 1.73 mmol, 1.3eq) 
and 1-hydroxybenzotriazole hydrate (HOBT) (269.6 mg, 1.96 mmol, 1.5 eq) at room 
temperature. The reaction mixture was yellow and cloudy in appearance. N, N-
Diisopropylethylamine (0.256 mL, 1.47 mmol, 1.1 eq) was added dropwise and the reaction 
mixture stirred at room temperature for 18 hours. The reaction was quenched with H2O (5 mL) 
and stirred for 30 minutes at room temperature. The solution was diluted with DCM (10 mL), 
washed with 1N HCl (3 x 10 mL), water (3 x 10 mL), and the combined aqueous washings were 
back-extracted with fresh DCM (3 x10 mL). The combined organic fractions were dried over 
Na2SO4 and the solvent was removed in vacuo to afford crude product. Flash-column 
chromatography on silica using a gradient of 10:90 EtOAc:Hexanes to 100% EtOAc followed by 
10:90 MeOH:EtOAc afforded 3.41 as a brown “caramel-color” sticky oil (110.3 mg, 36%); Rf = 
0.34 (10:90 MeOH:EtOAc; stains white with anisaldehyde/orange spot with Dragendorf 
reagent);
1
H NMR (400 MHz, CDCl3); 
13
C NMR (101 MHz, CDCl3); DEPT-135 (101 MHz, 
CDCl3); ESI+ MS: m/z 229 [MH]
+
; ESI- MS: m/z 227 [M-H]
-
. 
 
2-oxo-N-phenyl-2-(pyridin-3-yl) acetamide (3.42) 
Using a modified procedure from Bou-Hamdan et al.,
312
 to a solution 
of 3.41 (24.3 mg, 0.107 mmol, 1.0 eq) in anhydrous DCM (1 mL) was 
added MnO2 (93.03 mg, 1.07 mmol, 10 eq) and the mixture was stirred 
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at room temperature for 1 hour. The mixture was filtered through a short pad of silica gel and the 
silica layer was washed with fresh DCM (20 mL). Concentration of the filtrate afforded 24 mg 
(quant. yield) of 3.42 as a solid; ESI+ MS: m/z 227 [MH]
+
. 
 
N-(3-benzylphenyl)-2-hydroxy-2-(pyridin-3-yl) acetamide (3.43) 
Using a modified procedure from Martyn et al.,
306
 to a 
mixture of crude 3.35 (132.9 mg, 0.703 mmol, 1.0 eq) and 3-
benzylaniline (141.66 mg, 0.773, 1.1 eq) in anhydrous DCM 
(9.52 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (175.29 
mg, 0.914 mmol, 1.3eq) and 1-hydroxybenzotriazole hydrate (HOBT) (142.43 mg, 1.054 mmol, 
1.5 eq) at room temperature. The reaction mixture was an orange-pink color. N, N-
Diisopropylethylamine (0.202 mL, 1.15 mmol, 1.65 eq) was added dropwise (reaction mixture 
became yellow in color) and the reaction mixture stirred at room temperature for 24 hours. The 
reaction was quenched with H2O (5 mL) and stirred for 30 minutes at room temperature. The 
solution was diluted with DCM (10 mL), washed with 1N HCl (3 x 10 mL), water (3 x 10 mL), 
and the combined aqueous washings were back-extracted with fresh DCM (3 x 10 mL). The 
combined organic fractions were dried over Na2SO4 and the solvent was removed in vacuo to 
afford crude product. Flash-column chromatography on silica using a gradient of 10:90 
EtOAc:Hexanes to 100% EtOAc afforded 3.43 as a pale yellow sticky oil (54 mg, 24%); Rf = 
0.53 (100% EtOAc; stains white with anisaldehyde/orange spot with Dragendorf reagent); 
1
H 
NMR (400 MHz, CDCl3) δ 8.92 (s, 1H), 8.49 (s, 1H), 8.33 (d, J = 3.6 Hz, 1H), 7.87 (d, J = 7.8 
Hz, 1H), 7.47 – 7.35 (m, 3H), 7.30 – 7.13 (m, 5H), 6.95 (d, J = 7.4 Hz, 1H), 5.15 (s, 1H), 3.92 (s, 
2H); 
13
C NMR (101 MHz, CDCl3) δ 169.64, 148.23, 147.15, 142.29, 140.72, 137.16, 136.37, 
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135.56, 129.19, 128.91, 128.53, 126.22, 125.44, 124.00, 120.25, 117.62, 71.76, 41.86; DEPT-
135 (101 MHz, CDCl3) δ 148.23, 147.15, 135.56, 129.19, 128.91, 128.53, 126.22, 125.44, 
123.99, 120.25, 117.62, 71.76, 41.86; ESI- MS: m/z 317 [M-H]
-
. 
 
N-(3-benzylphenyl)-2-oxo-2-(pyridin-3-yl) acetamide (3.44) 
Using a modified procedure from Bou-Hamdan et al.,
312
 to a 
solution of 3.43 (17.5 mg, 1.0 eq, 0.0550) in anhydrous DCM 
(1 mL) was added freshly prepared MnO2 (119 mg, 25 eq, 
1.375 mmol) and the mixture was stirred at room temperature for 16 hours. The mixture was 
filtered through a short pad of silica gel and the silica layer was washed with fresh DCM. 
Concentration of the filtrate afforded 17 mg ( quant yield) of 3.42 as a yellow solid residue; Rf = 
0.75 (100% EtOAc);
 1
H NMR (400 MHz, DMSO) δ 10.90 (s, 1H), 9.22 (s, 1H), 8.88 (s, 1H), 
8.43 (d, J = 7.2 Hz, 1H), 7.38 – 7.14 (m, 10H), 3.97 (s, J = 22.7 Hz, 2H).;ESI- MS: m/z 315 [M-
H]
-
. 
 
2-(5-bromopyridin-2-yl)-2-hydroxyacetonitrile (3.46) 
Using an adapted procedure from Sauerberg et al.,
300
 to a solution of KCN 
(192.34 mg, 2.959 mmol, 1.10 eq) in water (2.08 mL) was added 5-
bromopyridine-2-carboxaldehyde (500 mg, 2.69 mmol, 1.0 eq) over 30 
minutes at 5-10 °C. To the reaction mixture was added AcOH (0.169 mL, 2.959 mmol, 1.10 eq) 
over 30 minutes at 5-10 °C. The reaction mixture was stirred at room temperature for 16 hours. 
After 16 hours, the reaction mixture was cooled to 0°C and the solids were collected via vacuum 
filtration in a Buchner funnel to afford 3.46 as a yellow-brown golden solid (575 mg, 
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quantitative crude yield) Compound 3.46 was used immediately without any additional 
purification. ESI- MS: m/z 124 [M-H]
-
.  
 
2-Pyridineacetic acid, 5-bromo-α-hydroxy-, hydrochloride (3.47) 
Using a modified procedure from Baeza et al.,
302
 compound 3.46 (515 mg, 
2.417 mmol) was dissolved in a 1.5:1 mixture of EtOH:H20 (5 mL) at 
room temperature. To this mixture was slowly added concentrated HCl (5 
mL). The reaction flask was fitted with a reflux condenser and refluxed for 24 hours. The 
reaction was cooled to room temperature and neutralized with saturated NaHCO3 (pH ~6). The 
aqueous mixture was extracted with EtOAc (3 x 20 mL) and the organic layers were combined, 
dried over Na2SO4 and concentrated in vacuo to afford crude 3.47 as a red-brown solid (253.1 
mg, 45% crude yield). No further purification was used. ESI+ MS: m/z 253, 252 [MH]
+
. 
 
1H-Imidazole-4-acetonitrile, α-hydroxy- (3.53)  
Using an adapted procedure from Sauerberg et al.,
300
 to a solution of KCN 
(372.74 mg, 5.724 mmol, 1.10 eq) in water (2.094 mL) was added imidazole-
4-carboxaldehyde (500 mg, 5.203 mmol, 1.0 eq ) over 30 minutes at 5-10 °C. 
To the reaction mixture was added AcOH (0.327 mL, 5.724 mmol, 1.10 eq) over 30 minutes at 
5-10 °C. The reaction mixture was stirred at 0 °C for 18 hours. After 18 hours, the solvents were 
removed under reduced pressure (0.03 mmHg) with slight heating (45 °C) to afford 3.53 as 
orange-yellow solid (598 mg, 85% crude yield). Compound 3.53 was used immediately without 
any additional purification. ESI- MS: m/z 124 [M-H]
-
.  
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1H-Imidazole-4-acetic acid, α-hydroxy-(3.56) 
Using an adapted procedure from Ward et al.,
308
 to a suspension of crude 
cyanohydrin 3.53 (540 mg, 4.38 mmol)  in 10 mL of EtOH: H2O 
(5mL:5mL) was slowly added 10 mL of concentrated HCl. The reaction 
flask was fitted with a reflux condenser and refluxed for 16 hours. The concentrated HCl was 
removed under reduced pressure (0.03 mmHg) with slight heating (50 °C). The residue was 
washed with water and the water was removed under reduced pressure (0.03 mmHg) with slight 
heating (50 °C) to yield 3.56 as a pale yellow solid (600.4 mg, 79% crude yield). No further 
purification was used. 
1
H NMR (400 MHz, MeOD) δ 8.91 (d, J = 1.4 Hz, 1H), 7.55 (s, 2H), 5.42 
(d, J = 0.8 Hz, 2H); 
1
H NMR (400 MHz, DMSO) δ 9.12 (s, 1H), 7.64 (s, 1H), 5.32 (s, 1H); 13C 
NMR (101 MHz, DMSO) δ 171.80, 134.60, 132.42, 116.93, 64.76; DEPT-135 (101 MHz, 
DMSO) δ 134.59, 116.92, 64.75; ESI- MS: m/z 140 [M-H]-. 
 
2-Furanacetonitrile, α-hydroxy-(3.62) 
Using an adapted procedure from Felfer et al.,
314
 trimethylsilyl cyanide 
(TMSCN) (0.333 mL, 2.496 mmol, 1.2 eq) was added to freshly distilled 
furfural (0.172 mL, 2.08 mmol, 1.0 eq) in anhydrous DCM at 0 °C. After the 
addition of a few crystals of ZnBr the reaction was stirred at 0 °C for 15 minutes before it was 
allowed to warm to room temperature. The reaction stirred for 45 minutes at room temperature. 
The TMS protected cyanohydrin was subjected to acid-hydrolysis by the addition of 3N HCl 
(3.75 g) at 0 °C. The mixture was stirred for 1 hour at room temperature. The crude reaction 
mixture was extracted with ether (3 x 20 mL), combined, dried over Na2SO4 and concentrated in 
vacuo to afford crude product as an orange yellow oil (307.1 mg, quantitative crude yield); Rf = 
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0.71 (50:50 EtOAc: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.59 – 7.39 (m, 1H), 6.59 (d, J = 
3.3 Hz, 1H), 6.42 (dd, J = 3.3, 1.9 Hz, 1H), 5.55 (s, 1H), 3.80 (s, 1H). 
 
Ethyl 4-cyano-1-methoxymethyl-1, 4-dihydro-3-pyridineglyoxylate (3.66) 
Preparation of Benzyltrimethylammonium Cyanide (BnMe3N
+
CN
-
): 
was prepared according to a procedure by Vedejs and Monahan
413
 with 
modification. Benzyltrimethylammonium chloride (1.33 grams, 7.18 mmol) 
was dried at 0.5 mmHg vacuum and dissolved in anhydrous MeOH (1.67 
mL). The resulting solution was transferred via syringe into a stirring 
solution of NaCN (525 mg, 10.71 mmol) in 10 mL of anhydrous MeOH. After stirring for 30 
minutes at room temperature, the white suspension was carefully concentrated by rotary 
evaporation with minimal exposure to atmospheric moisture. The white residue was treated with 
10 mL of hot anhydrous AcN and the resulting suspension was filtered hot through a fritted glass 
filter under argon. The filtrate was carefully concentrated by rotary evaporation at room 
temperature to dryness and collected and dried under reduced pressure (0.03 mmHg) to yield 
white hygroscopic crystals (373.10 mg, 29%). 
Using an adapted procedure from Klapars and Vedejs, 
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 to a solution of anhydrous pyridine 
(0.33 mL, 4.08 mmol) in 10 mL of anhydrous CHCl3 at room temperature was added 
methoxymethyl chloride (0.34 mL, 4.48 mmol). After stirring at room temperature for 1 hour, 
the colorless solution was transferred via syringe into a 50 mL flame-dried round bottom flask 
charged with BnMe3N
+
CN
- 
(660 mg, 3.74 mmol). The resulting clear solution was cooled in an 
ice-bath to 0 °C, and diisopropylethylamine (0.80 mL, 4.59 mmol) was added followed by ethyl 
oxalyl chloride (0.48 mL, 4.30 mmol). After stirring at 0 °C for 1 hour, the orange solution was 
139 
poured into 50 mL of ether and washed with 2 x 20 mL of H2O. The bright yellow organic layer 
was dried over Na2SO4 and concentrated by rotary evaporation to give crude dihydropyridine 
3.66, which was used immediately in the next step without further purification. Yellow-orange 
oil; Rf = 0.47 (50:50 acetone:hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 6.26 (d, J = 
7.9 Hz, 1H), 5.20 (dd, J = 7.9, 4.5 Hz, 1H), 4.64 (s, 2H), 4.60 (d, J = 4.5 Hz, 1H), 4.35 (d, J = 7.1 
Hz, 2H), 3.36 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H); ESI+ MS: m/z 251 [MH]
+
. 
 
3-Pyridineacetic acid, α-oxo-, ethyl ester (3.67) 
The crude dihydropyridine 3.66 was dissolved in anhydrous AcN (5 mL, 
including syringe washings), and the solution was transferred via syringe 
into a 25 mL round bottom flask charged with ZnCl2 (1.05g, 7.70 mmol). 
After stirring at room temperature for 5 hours, the yellow suspension was filtered through Celite 
eluting 2 x 2 mL of anhydrous AcN. Anhydrous EtOH (10 mL) was added to the filtrate, the 
resulting tan solution was refluxed for 15 hours, cooled to room temperature, and poured into 
10% aqueous solution of NaHCO3 (20 mL) at 0°C (ice-bath). The resulting suspension was 
filtered through Celite eluting with 2 x 10 mL of EtOH. The tan filtrate was extracted with DCM 
(3 x 30 mL). The combined organic phase was dried over Na2SO4, concentrated by rotary 
evaporation, and the orange-red residue was purified by flash chromatography on silica gel using 
4:1 hexanes:acetone to yield 3.67 yellow solid (147.2 mg, 82%); 
1
H NMR (400 MHz, CDCl3) δ 
9.26 (d, J = 1.7 Hz, 1H), 8.86 (dd, J = 4.8, 1.6 Hz, 1H), 8.37 (d, J = 8.0 Hz, 1H), 7.61 – 7.37 (m, 
1H), 4.48 (q, J = 7.1 Hz, 2H), 1.43 (dd, J = 23.4, 16.3 Hz, 3H);  ESI+ MS: m/z 359 [M+MH]
+
. 
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Phenol, 4-[(2-pyridinylmethylene) amino] - (3.69) 
Using an adapted procedure from Jursic et al.,
338
 a mixture of 2-
pyridine-carboxaldehyde (0.446 mL, 500 mg, 4.66 mmol) and 4-
aminophenol (509 mg, 4.66 mmol) in methanol (93 mL) was refluxed 
for 2 hours.  The solvent was reduced to 1/10 of its original volume (~10 
mL). The resulting suspension was cooled in an ice-water bath. The bright yellow crystalline 
solid was separated by filtration, washed with cold methanol (3x10 mL) and dried under high-
vacuum to afford 3.69 (687.2 mg, 74 %). No further purification was needed for the next step. Rf 
= 0.30 (50:50 EtOAc: hexanes); 
1
H NMR (400 MHz, DMSO) δ 9.67 (s, 1H), 8.70 (d, J = 4.6 Hz, 
1H), 8.62 (s, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.92 (dd, J = 11.0, 4.2 Hz, 1H), 7.49 (dd, J = 6.8, 5.4 
Hz, 1H), 7.32 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H); 
13
C NMR (101 MHz, DMSO) δ 
157.53, 157.40, 155.02, 149.99, 141.97, 137.32, 125.50, 123.40, 121.14, 116.29; DEPT-135 
(101 MHz, DMSO) δ 157.40, 149.99, 137.32, 125.51, 123.40, 121.14, 116.29; ESI+ MS: m/z 
199 [MH]
+
. 
 
Phenol, 4-[(3-pyridinylmethylene) amino] - (3.70) 
Prepared by the procedure described for 3.69. Pale yellow fluffy solid 
(8.55 g, 92 %) Rf = 0.37 (70:30 EtOAc: hexanes); 
1
H NMR (400 MHz, 
DMSO) δ 9.59 (s, 1H), 9.03 (d, J = 1.5 Hz, 1H), 8.70 (s, 1H), 8.67 (dd, J 
= 4.7, 1.5 Hz, 1H), 8.27 (dd, J = 7.9, 1.7 Hz, 1H), 7.52 (dd, J = 7.8, 4.8 Hz, 1H), 7.26 (d, J = 8.7 
Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H); 
13
C NMR (101 MHz, DMSO) δ 157.14, 155.14, 151.79, 
150.48, 142.64, 134.95, 132.41, 124.42, 123.14, 116.18; DEPT-135 (101 MHz, DMSO) δ 
155.15, 151.80, 150.50, 134.96, 124.43, 123.16, 116.20; ESI+ MS: m/z 199 [MH]
+
. 
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Phenol, 4-[(4-pyridinylmethylene) amino] - (3.71) 
Prepared by the procedure described for 3.69.Gold-yellow solid (7.11 g, 
76%) Rf = 0.28 (70:30 EtOAc: Hexanes); 
1
H NMR (400 MHz, DMSO) 
δ 9.69 (s, 1H), 8.72 (d, J = 5.7 Hz, 2H), 8.68 (s, 1H), 7.81 (d, J = 5.8 Hz, 
2H), 7.31 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H); 
13
C NMR (101 
MHz, DMSO) δ 157.68, 155.55, 150.80, 143.45, 142.04, 123.53, 122.32, 116.26; DEPT-135 
(101 MHz, DMSO) δ 155.55, 150.80, 123.53, 122.32, 116.26; ; ESI+ MS: m/z 199 [MH]+. 
 
4-Pyridineacetonitrile, α-[(4-hydroxyphenyl) imino] - (3.77) 
Using an adapted procedure from Jursic et al.,
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 a DMSO (20 mL) 
solution of 3.71 (600 mg, 3.02 mmol) and sodium cyanide (162.8 mg, 
3.32 mmol) stirred at room temperature for 24 hours. In the first 5 
minutes, the solution went from yellow to orange then to deep red. After 24 hours at room 
temperature, the DMSO was evaporated at reduced pressure (0.03 mmHg) with slight heating 
(60 °C). A dark burgundy residue remained which was then dissolved in THF (slight heating 40-
50 °C was needed). The solution was immediately filtered through a pad of silica gel in a fritted 
Buchner funnel and washed with fresh THF (6 x 50 mL). Immediately it was noted that a bright 
orange solid was crashing out of the THF solution.  The combined THF filtrates were evaporated 
to a solid. The solid residue was slurred in MeOH (50 mL) and the resulting suspension was 
heated at 50 °C for 10 minutes, cooled down in an ice-water bath and the fluorescent-orange 
solid was collected by vacuum filtration and washed with ice-cold MeOH (3x20 mL) and dried 
under high-vacuum to afford 3.77 (381 mg, 56 %). No further purification was needed for the 
next step.; Rf = 0.60 (70:30 EtOAc: hexanes; stains bright yellow with p-anisaldehyde); 
1
H 
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NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 8.94 – 8.68 (m, 2H), 8.12 – 7.69 (m, 2H), 7.43 (d, J = 
8.8 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H); 
13
C NMR (101 MHz, DMSO) δ 159.37, 151.18, 141.20, 
139.68, 133.65, 124.75, 121.21, 116.41, 112.10; DEPT-135 (101 MHz, DMSO) δ 151.18, 
124.75, 121.21, 116.42. ESI+ MS: m/z 224 [MH]
+
. 
 
2-Pyridineacetonitrile, α-[(4-hydroxyphenyl) imino] - (3.75) 
Prepared by the procedure described for 3.77, with modification of the 
purification method. Unlike previously reported, no solid residue formed 
to be filtered and collected as product. Therefore, the MeOH solution 
was concentrated in vacuo to afford crude product. Purification was 
achievable via flash-column chromatography (20:80 to 50:50 EtOAc: Hexanes) to yield bright 
yellow solid “saw dust” (95.4 mg, 42 %) Rf = 0.77 (70:30 EtOAc: hexanes; stains bright yellow 
with p-anisaldehyde); 
1
H NMR (400 MHz, DMSO) δ 10.08 (s, 1H), 8.79 (d, J = 4.3 Hz, 1H), 
8.20 (d, J = 7.9 Hz, 1H), 8.02 (t, J = 7.7 Hz, 1H), 7.71 – 7.56 (m, 1H), 7.42 (d, J = 8.7 Hz, 2H), 
6.94 (d, J = 8.7 Hz, 2H). 
13
C NMR (101 MHz, DMSO) δ 158.96, 152.50, 149.95, 139.52, 
138.03, 136.53, 126.83, 124.52, 121.63, 116.33, 112.49; DEPT-135 (101 MHz, DMSO) δ 
149.95, 138.03, 126.82, 124.52, 121.63, 116.33; ESI+ MS: m/z 224 [MH]
+
.  
 
3-Pyridineacetonitrile, α-[(4-hydroxyphenyl) imino] - (3.76) 
Prepared by same procedure described for 3.75. Burnt orange solid 
(88.9 mg, 13%); Rf = 0.71 (70:30 EtOAc: hexanes; stains bright yellow 
with p-anisaldehyde);
1
H NMR (400 MHz, DMSO) δ 10.07 (s, 1H), 
9.16 (s, 1H), 8.80 (d, J = 3.8 Hz, 1H), 8.36 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 7.9, 4.8 Hz, 1H), 
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7.37 (d, J = 8.6 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H); 
13
C NMR (101 MHz, DMSO) δ 158.70, 
152.96, 148.75, 140.15, 135.25, 133.87, 130.27, 124.57, 124.20, 116.31, 111.97; DEPT-135 
(101 MHz, DMSO) δ 152.96, 148.75, 135.25, 124.57, 124.21, 116.31; ESI+ MS: m/z 224 
[MH]
+
. 
 
Benzenamine, N-(3-pyridinylmethylene) - (3.83) 
Using an adapted procedure from Dickson et al.,
414
 freshly distilled aniline 
(0.294 mL, 300 mg, 3.22 mmol) and freshly distilled 3-pyridine 
carboxaldehyde (0.324 mL, 369.7 mg, 3.38 mmol) were dissolved in 
anhydrous 1, 2-dichloroethane (38.34 mL), and magnesium sulfate (461.4 
mg, 3.83 mmol) was added. The reaction flask was fitted with a reflux condenser and refluxed 
for 18 hours. The solution was filtered to remove the magnesium sulfate and the solvents were 
concentrated under reduced pressure to yield crude product as a viscous dark orange oil. Flash-
column chromatography on silica using a gradient of 20:80 EtOAc:hexanes to 30:70 
EtOAc:hexanes  afforded 3.83 as a bright orange oil (498 mg, 84%); ( Rf = 0.38 (50:50 EtOAc: 
Hexanes; stains bright yellow with p-anisaldehyde) 
1
H NMR (400 MHz, CDCl3) δ 9.01 (d, J = 
1.2 Hz, 1H), 8.70 (d, J = 3.5 Hz, 1H), 8.49 (s, 1H), 8.29 (d, J = 7.9 Hz, 1H), 7.47 – 7.36 (m, 3H), 
7.30 – 7.19 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 157.18, 151.99, 151.43, 150.94, 134.89, 
131.82, 129.25, 126.55, 123.80, 120.85; DEPT-135 (101 MHz, CDCl3) δ 157.18, 151.99, 
151.43, 150.94, 134.89, 131.82, 129.25, 126.55, 123.80, 120.85; ESI+ MS: m/z 183 [MH]
+
. 
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3-Pyridineacetonitrile, α-(phenylimino) - (3.84) 
Using an adapted procedure from Surya K. De.,
415
 a mixture of freshly 
distilled 3-pyridinecarboxaldehye (0.103 mL, 1.073 mmol, 1.0 eq), freshly 
distilled aniline (1.022 mL, 1.073 mmol, 1.0 eq), KCN (104.9 mg, 1.609 
mmol, 1.5 eq) and CoCl2 (14.36 mg, 10 mol%) in anhydrous AcN (20 mL) was stirred at room 
temperature for 3 hours. After reaction completion, the reaction mixture was extracted with 
EtOAc (2 x 20 mL). The organic layers were washed with water (20 mL), brine (20 mL), dried 
over Na2SO4, and concentrated by rotary evaporation to yield crude yellow-orange oil. The 
residue was purified by flash-column chromatography on silica using a gradient of 10:90 
EtOAc:hexanes to 100% EtOAc to afford 3.84 as an orange-yellow waxy residue (36.4 mg, 16 
%); Rf = 0.58 (50:50 EtOAc: hexanes; stains light yellow with p-anisaldehyde); 
1
H NMR (400 
MHz, CDCl3) δ 9.36 (s, 1H), 8.82 (d, J = 3.7 Hz, 1H), 8.41 (dd, J = 6.2, 1.9 Hz, 1H), 7.55 – 7.44 
(m, 3H), 7.36 (t, J = 7.4 Hz, 1H), 7.29 – 7.21 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 153.19, 
149.53, 148.47, 137.09, 135.22, 129.53, 129.41, 128.09, 123.71, 120.59, 110.32; DEPT-135 
(101 MHz, CDCl3) δ 153.20, 149.53, 135.22, 129.41, 128.09, 123.71, 120.59. ESI+ MS: m/z 210 
[MH]
+
; ESI- MS: m/z 208 [MH]
-
. 
 
3-Pyridineacetonitrile, α-(phenylamino) - (3.88) 
Using a modified procedure from Jarusiewicz et al.,
343, 414
 to a mixture of 
PdCl2 (14.89 mg, 3 mol%), freshly distilled 3-pyridinecarboxaldehyde 
(0.268 mL, 2.80 mmol, 1.0 eq), freshly distilled aniline (0.255 mL, 2.80 
mmol, 1.0 eq), and Na2SO4 (1.39 g, 9.80 mmol, 3.5 eq) in anhydrous DCM 
(4 mL) was added dropwise TMSCN (0.700 mL, 5.60 mmol, 2.0 eq). The reaction was stirred at 
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room temperature for 24 hours. After completion the mixture was filtered and the filtrate was 
concentrated under reduced pressure to yield a pale yellow solid (712.8 mg, 60%). Product was 
used in the subsequent reaction without further purification; Rf = 0.35 (50:50 EtOAc: hexanes; 
stains bright yellow with p-anisaldehyde); 
1
H NMR (400 MHz, CDCl3) δ 8.82 (d, J = 1.7 Hz, 
1H), 8.66 (d, J = 4.6 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.38 (dd, J = 7.9, 4.9 Hz, 1H), 7.28 (t, J = 
7.9 Hz, 2H), 6.93 (t, J = 7.4 Hz, 1H), 6.82 – 6.76 (m, 2H), 5.49 (s, 1H), 4.34 (s, 1H); 13C NMR 
(400 MHz, CDCl3) δ 150.63 , 148.58, 144.26, 135.03, 130.08, 129.67, 123.97, 120.78, 117.32, 
114.46, 48.19; DEPT-135 
13
C NMR (101 MHz, CDCl3) δ 150.63, 148.58, 135.03, 129.67, 
123.97, 120.78, 114.46, 48.19; ESI+ MS: m/z 210 [MH]
+
; ESI- MS: m/z 209 [M-H]
-
. 
 
3-Pyridineacetic acid, α-(phenylamino)-, methyl ester (3.89) 
Using a modified procedure from Burkhart et al.,
344
 the α-amino nitrile 3.88 
(199.5 mg, 0.953 mmol) was dissolved in anhydrous MeOH (5 mL) and 
cooled to 0°C with an ice-bath. Anhydrous HCl gas was bubbled into the 
solution for 30 minutes until the solution was completely saturated. The reaction was warmed to 
room temperature and stirred for 12 hours. After completion the reaction was neutralized with 
saturated NaHCO3 and the extracted with EtOAc (3 x 20 mL). The organic layers were collected, 
dried over Na2SO4 and evaporated under reduced pressure. The caramel-colored crude residue 
was purified by flash-column chromatography on silica using a gradient of 10:90 EtOAc:hexanes 
to 100% EtOAc to yield 3.89 as a yellow-orange oil (65.0 mg, 54%); Rf = 0.54 (70:30 EtOAc: 
hexanes, stains pink with p-anisaldehyde); 
1
H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H), 8.58 (d, J 
= 3.9 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.31 (dd, J = 7.8, 4.9 Hz, 1H), 7.12 (t, J = 7.9 Hz, 2H), 
6.72 (t, J = 7.3 Hz, 1H), 6.54 (d, J = 7.7 Hz, 2H), 5.14 (s, 1H), 3.75 (s, 3H); 
13
C NMR (101 
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MHz, CDCl3) δ 171.29, 148.85, 148.60, 145.31, 135.21, 134.00, 129.36, 124.07, 118.64, 113.51, 
58.47, 53.18; DEPT-135 (101 MHz, CDCl3) δ 148.85, 148.60, 135.21, 129.36, 124.08, 118.64, 
113.51, 58.47, 53.18; ESI+ MS: m/z 243 [MH]
+
. 
 
3-Pyridineacetic acid, α-(phenylimino)-, methyl ester (3.90) 
Using a modified procedure from Vu et al.,
416
 a mixture of 3.89 (25.0 mg, 
0.103 mmol, 1.0 eq) and DDQ (25.71mg, 0.113 mmol, 1.1 eq) in anhydrous 
benzene (3 mL) was stirred at room temperature for 24 hours. Initially, the 
reaction mixture was yellow then went to green followed by a dark maroon 
color. After reaction completion the solvent was removed by rotary evaporation and immediately 
purified using flash-column chromatography on basic alumina using a gradient of 100% hexanes 
to 10:90 EtOAc:hexanes to yield 3.90 as a yellow oil (2.0 mg, 8%); 
 
Rf = 0.62 (50:50 EtOAc: 
hexanes; stains yellow with p-anisaldehyde); 
1
H NMR (400 MHz, CDCl3) δ 9.09 (s, 1H), 8.79 (s, 
1H), 8.25 (d, J = 8.0 Hz, 1H), 7.56 – 7.42 (m, 1H), 7.36 (t, J = 7.9 Hz, 2H), 7.19 (dd, J = 14.0, 
6.6 Hz, 1H), 6.99 – 6.94 (m, 2H), 3.67 (s, 3H).; ESI+ MS: m/z 241 [MH]+. 
 
General Procedure A for the Synthesis of Aryl α-Keto Acids (S4-S13): 
Using an adapted procedure from Zhuang et al.,
355
 in a 
15 mL oven-dried pressure tube was added aryl ketone 
S3 (1.0 eq), selenium dioxide (2.0 eq) and anhydrous 
pyridine (6.25 eq) under argon. The reaction was heated between 110°C-120°C for 15 hours. The 
reaction was cooled and filtered through a pad of Celite eluting 2 x 2 mL of EtOAc and the 
filtrate was concentrated by rotary evaporation. The crude residue was dissolved in EtOAc, 
transferred into a separatory funnel and washed with 2 M NaOH (3 x 10 mL). The aqueous 
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layers were combined, cooled to 0°C and acidified with concentrated HCl (pH 1-2) and back-
extracted with fresh EtOAc (3 x 20 mL). The organic layers were combined dried over Na2SO4 
and concentrated in vacuo to afford crude product S4-S13 which were used without any 
additional purification. 
 
General Procedure B for the Synthesis of Aryl Oxalamate Scaffolds (3.95-3.107) 
Using an adapted procedure from Martyn 
et al.,
306
 to a mixture of crude S14 (1.0 eq) 
and 3-benzylaniline or aniline(1.1 eq) in 
anhydrous DCM (213 eq) was added 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.3eq) and 1-hydroxybenzotriazole 
hydrate (HOBT) (1.5 eq) at room temperature. N, N-Diisopropylethylamine (1.1 eq) was added 
dropwise and the reaction mixture stirred at room temperature for 24 hours. The reaction was 
quenched with H2O (5 mL) and stirred for 30 minutes at room temperature. The solution was 
diluted with DCM (10 mL), washed with 1N HCl (3 x 10 mL), water (3 x 10 mL), and the 
combined aqueous washings were back-extracted with fresh DCM (3 x 10 mL). The combined 
organic fractions were dried over Na2SO4 and the solvent was removed in vacuo to afford crude 
product. Flash-column chromatography on silica using a gradient of 10:90 EtOAc:hexanes to 
100% EtOAc afforded 3.95-3.107 as pure oxalamates. 
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2-(4-bromophenyl)-2-oxoacetic acid (S4) 
Synthesized using the general procedure A described for aryl α-keto acids. Salmon-pink solid  
(1.48 g, quantitative crude yield ); 
 
Rf = 0.17 (20:80 EtOAc: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 9.81 (s, 1H), 8.17 (d, J = 8.6 Hz, 2H), 
7.66 (dd, J = 17.9, 8.5 Hz, 2H); 
13
C NMR (101 MHz, CDCl3) δ 
183.56, 162.35, 132.47, 132.44, 131.63, 130.47; DEPT-135 (101 MHz, CDCl3) δ 132.47, 
132.44; ESI- MS: m/z 227, 229[M-H]
-
; ESI+ MS: m/z 456, 458 [MNa]
+
. 
 
N-(3-benzylphenyl)-2-(4-bromophenyl)-2-oxoacetamide (3.95) 
Synthesized using the general procedure B described for 
aryl oxalamate scaffolds with modification. Flash-
column chromatography on silica using a gradient of 
50:50 CHCl3:hexanes to 100% CHCl3 afforded 3.95 as a pale yellow solid (192 mg, 54%); Rf = 
0.50 (50:50 CHCl3: hexanes, stains yellow with p-anisaldehyde);
1
H NMR (400 MHz, CDCl3) δ 
8.88 (s, 1H), 8.30 (d, J = 8.6 Hz, 2H), 7.64 (d, J = 8.6 Hz, 2H), 7.56 (d, J = 8.0 Hz, 1H), 7.48 (s, 
1H), 7.30 (td, J = 7.4, 3.9 Hz, 3H), 7.21 (t, J = 7.1 Hz, 3H), 7.03 (d, J = 7.5 Hz, 1H), 4.00 (s, 
2H); 
13
C NMR (101 MHz, CDCl3) δ 186.29, 158.46, 142.56, 140.54, 136.60, 132.97, 131.96, 
131.82, 130.45, 129.36, 128.94, 128.58, 126.30, 126.11, 120.40, 117.78, 41.87; DEPT-135 (101 
MHz, CDCl3) δ 132.97, 131.96, 129.36, 128.93, 128.58, 126.30, 126.11, 120.40, 117.78, 41.87; 
ESI- MS: m/z 392, 394 [M-H]
-
; Elemental Analysis: Calc. for C21H16BrNO2: C, 63.97; H, 4.09; 
N, 3.55. Found: C, 63.75; H, 3.91; N, 3.49; melting point: 110-112 °C. 
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2-(3-bromophenyl)-2-oxoacetic acid (S5) 
Synthesized using the general procedure A described for aryl α-keto 
acids. Yellow solid (844.8 mg, 64% crude yield); Rf = 0.17 (20:80 
EtOAc: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 9.30 (s, 1H), 8.51 – 
8.31 (m, 1H), 8.22 (d, J = 7.9 Hz, 1H), 7.82 (dd, J = 8.0, 0.9 Hz, 1H), 7.52 – 7.37 (m, 1H). 13C 
NMR (101 MHz, CDCl3) δ 183.63, 162.59, 138.30, 133.57, 130.50, 129.64, 123.20; DEPT-135 
(101 MHz, CDCl3) δ 138.30, 133.57, 130.50, 129.64; ESI- MS: m/z 226, 228 [M-H]
-
. 
 
N-(3-benzylphenyl)-2-(3-bromophenyl)-2-oxoacetamide (3.96) 
Synthesized using the general procedure B described for 
aryl oxalamate scaffolds with modification. Flash-
column chromatography on silica using a gradient of 
50:50 CHCl3:hexanes to 100% CHCl3 afforded 3.96 as a pale yellow crystalline solid (302.2 mg, 
71%); Rf = 0.50 (50:50 CHCl3: hexanes; stains yellow with p-anisaldehyde);
1
H NMR (400 
MHz, CDCl3) δ 8.89 (s, 1H), 8.56 (s, 1H), 8.39 (d, J = 7.9 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.60 
(d, J = 7.9 Hz, 1H), 7.51 (s, 1H), 7.42 – 7.20 (m, 8H), 4.02 (s, 2H); 13C NMR (101 MHz, CDCl3) 
δ 186.01, 158.20, 142.56, 140.52, 137.41, 136.54, 134.73, 134.15, 130.09, 129.36, 128.93, 
128.58, 126.30, 126.15, 122.71, 120.41, 117.80, 41.87; DEPT-135 (101 MHz, CDCl3) δ 137.42, 
134.16, 130.11, 129.37, 128.94, 128.59, 126.31, 126.16, 120.42, 117.81, 41.87. ESI- MS: m/z 
391, 393 [M-H]
-
; Elemental Analysis: Calc. for C21H16BrNO2: C, 63.97; H, 4.09; N, 3.55. 
Found: C, 63.27; H, 3.86; N, 3.46; melting point: 103-105°C. 
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2-oxo-2-(2,3,4-trimethoxyphenyl)acetic acid (S6) 
Synthesized using the general procedure A described for aryl α-keto 
acids. Yellow solid (240.2 mg, quantitative crude yield);
 
Rf = 0.10 
(50:50 EtOAc: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 10.97 (s, 3H), 7.73 (d, J = 8.9 Hz, 1H), 
6.80 (d, J = 8.9 Hz, 1H), 3.99 (s, 3H), 3.96 (s, 2H), 3.87 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
184.50, 169.85, 160.22, 155.48, 141.18, 126.44, 119.66, 107.84, 61.52, 60.85, 56.35; DEPT-135 
(101 MHz, CDCl3) δ 126.43, 107.83, 61.51, 60.85, 56.34; ESI- MS: m/z 239 [M-H]
-
. 
 
2-oxo-N-phenyl-2-(2,3,4-trimethoxyphenyl)acetamide (3.97) 
Synthesized using the general procedure B described for aryl 
oxalamate scaffolds. Orange-brown oil (45 mg, 34%); Rf = 0.68 
(50:50 EtOAc: hexanes);
1
H NMR (400 MHz, CDCl3) δ 8.46 (s, 
1H), 7.70 – 7.66 (m, 2H), 7.58 (d, J = 8.8 Hz, 1H), 7.38 (t, J = 7.9 Hz, 2H), 7.17 (t, J = 7.4 Hz, 
1H), 6.75 (d, J = 8.8 Hz, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.85 (s, 3H); 
13
C NMR (101 MHz, 
CDCl3) δ 189.78, 161.00, 158.79, 154.68, 141.67, 137.02, 129.17, 127.05, 124.95, 121.55, 
119.80, 106.99, 61.79, 60.76, 56.24; DEPT-135 (101 MHz, CDCl3) δ 129.17, 127.06, 124.95, 
120.16, 119.80, 106.99, 61.78, 60.76, 56.24. ESI+ MS: m/z 316 [MH]
+
; Elemental Analysis: 
Calc. for C17H17NO5: C, 64.75; H, 5.43; N, 4.44. Found: C, 64.22; H, 5.81; N, 4.06. 
 
2-(3,4-dimethoxyphenyl)-2-oxoacetic acid (S7) 
Synthesized using the general procedure A described for aryl α-keto 
acids. Off-white powder (466.5 mg, quantitative crude yield); Rf = 0.11 
(50:50 EtOAc: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 9.15 (s, 1H), 8.19 (dd, J = 8.5, 1.9 Hz, 
1H), 7.79 (d, J = 1.8 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 3.98 (d, J = 15.7 Hz, 6H); 
13
C NMR (101 
151 
MHz, CDCl3) δ 182.32, 162.12, 155.82, 149.29, 128.08, 124.80, 112.11, 110.48, 99.99, 56.30, 
56.07; DEPT-135 (101 MHz, CDCl3) δ 128.08, 112.10, 110.48, 56.30, 56.07; ESI+ MS: ESI- 
MS: m/z 209 [M-H]
-
. 
 
N-(3-benzylphenyl)-2-(3,4-dimethoxyphenyl)-2-oxoacetamide (3.98) 
Synthesized using the general procedure B described for 
aryl oxalamate scaffolds. Brown-orange sticky residue 
(42.5 mg, 79%); Rf = 0.603 (50:50 EtOAc: hexanes; 
stains orange-yellow with p-anisaldehyde); 
1
H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H), 8.33 (dd, 
J = 8.6, 1.9 Hz, 1H), 7.92 (d, J = 1.8 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.35 – 7.26 
(m, 3H), 7.21 (t, J = 5.5 Hz, 3H), 7.02 (d, J = 7.5 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 4.00 (s, 2H), 
3.97 (s, 3H), 3.95 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 185.07, 159.48, 154.92, 148.88, 
142.44, 140.62, 136.89, 129.30, 128.93, 128.56, 127.72, 126.26, 126.16, 125.87, 120.44, 117.82, 
112.92, 110.25, 56.18, 56.03, 41.87; DEPT-135 (101 MHz, CDCl3) δ 129.28, 128.92, 128.54, 
127.71, 126.24, 125.86, 120.43, 117.80, 112.91, 110.24, 56.17, 56.03, 41.86; Elemental 
Analysis: Calc. for C23H21NO4: C, 73.58; H, 5.64; N, 3.73. Found: C, 71.86 H, 6.37 N, 3.15. 
 
2-(3-chlorophenyl)-2-oxoacetic acid (S8) 
Synthesized using the general procedure A described for aryl α-keto 
acids. Light tan solid (240.1 mg, quantitative crude yield); 
 
Rf = 0.10 
(30:70 EtOAc: hexanes);
1
H NMR (400 MHz, CDCl3) δ 10.57 (s, 1H), 
8.32 – 7.98 (m, 2H), 7.63 (dd, J = 21.0, 7.7 Hz, 1H), 7.56 – 7.38 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 183.42, 163.33, 135.40, 135.32, 133.29, 130.52, 130.30, 129.04; DEPT-135  (101 
152 
MHz, CDCl3) δ 135.40, 134.22, 130.52, 130.31, 129.93, 129.04, 128.41 ESI- MS: m/z 182, 184 
[M-H]
-
. 
 
N-(3-benzylphenyl)-2-(3-chlorophenyl)-2-oxoacetamide (3.99) 
Using an adapted procedure from Kumar et al.,
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carbonyldiimidazole (CDI) (66.32 mg, 0.409 mmol, 1.5 
eq) was dissolved in anhydrous THF (3 mL) and stirred 
at room temperature. To this mixture was slowly added S8 (75.54 mg, 0.409 mmol, 1.5 eq). The 
reaction mixture was further stirred for 10 minutes at room temperature and then after the 
evolution of CO2 ceased, 3-benzylaniline (50 mg, 0.273 mmol, 1.0 eq) was added. The stirring 
was continued for an additional 10 minutes at room temperature and then refluxed for 16 hours. 
After completion of the reaction, monitored by TLC, reaction mixture was concentrated in vacuo 
to obtain crude product as orange-brown oil. The crude product was immediately purified by 
flash-column chromatography using a gradient of 10:90 EtOAc: hexanes to 30:70 
EtOAc:hexanes to afford 3.99 (54.6 mg, 38%) as a yellow oil. Rf = 0.89 (30:70 EtOAc: hexanes; 
stains yellow eith p-anisaldehyde); 
1
H NMR (400 MHz, CDCl3) δ 8.87 (s, 1H), 8.39 (d, J = 1.6 
Hz, 1H), 8.32 (d, J = 7.8 Hz, 1H), 7.65 – 7.54 (m, 2H), 7.49 (s, 1H), 7.43 (t, J = 7.9 Hz, 1H), 
7.30 (dd, J = 12.8, 7.4 Hz, 3H), 7.21 (t, J = 6.8 Hz, 3H), 7.04 (d, J = 7.5 Hz, 1H), 4.00 (s, 2H); 
13
C NMR (101 MHz, CDCl3) δ 186.12, 158.24, 142.56, 140.52, 136.54, 134.80, 134.51, 131.27, 
129.86, 129.63, 129.36, 128.93, 128.57, 126.29, 126.15, 120.41, 117.80, 41.86; DEPT-135 (101 
MHz, CDCl3) δ 134.51, 131.27, 129.86, 129.64, 129.36, 128.93, 128.57, 126.29, 126.15, 120.41, 
117.80, 41.86; ESI- MS: m/z 209 [M-H]. 
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2-(3,4-dimethoxyphenyl)-2-oxo-N-phenylacetamide (3.100) 
Synthesized using the general procedure B described for aryl 
oxalamate scaffolds. Yellow crystalline solid
  
(51 mg, 53%); Rf = 
0.72 (50:50 EtOAc: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 9.05 
(s, 1H), 8.33 (dd, J = 8.6, 1.9 Hz, 1H), 7.93 (d, J = 1.8 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.39 (t, 
J = 7.9 Hz, 2H), 7.18 (t, J = 7.4 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 3.97 (s, 3H), 3.95 (s, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 185.09, 159.56, 154.91, 148.86, 136.76, 129.19, 127.70, 126.15, 
125.19, 120.00, 112.91, 110.26, 56.16, 56.00; DEPT-135 (101 MHz, CDCl3) δ 129.19, 127.70, 
125.19, 120.00, 112.91, 110.26, 56.16, 56.00; Elemental Analysis: Calc. for C16H15NO4: C, 
67.36; H, 5.30; N, 4.91. Found: C, 66.85; H, 5.0; N, 4.90. 
 
N-(3-benzylphenyl)-2-oxo-2-(2,3,4-trimethoxyphenyl)acetamide (3.101) 
Synthesized using the general procedure B described for 
aryl oxalamate scaffolds. Pale yellow oil (15.3 mg, 18 
%); 
 
Rf = 0.85 (50:50EtOAc: hexanes);
1
H NMR (400 
MHz, CDCl3) δ 8.37 (s, 1H), 7.57 (t, J = 7.1 Hz, 2H), 7.45 (s, 1H), 7.25 (dt, J = 24.6, 7.7 Hz, 
5H), 7.01 (d, J = 7.5 Hz, 1H), 6.73 (d, J = 8.8 Hz, 1H), 3.99 (s, 2H), 3.93 (d, J = 4.4 Hz, 6H), 
3.84 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 189.71, 160.84, 158.76, 142.44, 140.60, 137.14, 
129.27, 128.96, 128.54, 127.03, 126.24, 125.58, 121.61, 120.25, 117.62, 106.99, 61.77, 60.76, 
56.23, 41.85; DEPT-135 (101 MHz, CDCl3) δ 129.26, 128.95, 128.53, 127.02, 126.23, 125.57, 
120.24, 117.61, 106.98, 61.76, 60.75, 56.23, 41.85; Elemental Analysis: Calc. for C24H23NO5: 
C, 71.10; H, 5.72; N, 3.45. Found: C, 70.38 H, 5.87 N, 3.30. 
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2-(4-methoxyphenyl)-2-oxoacetic acid (S9) 
Synthesized using the general procedure A described for aryl α-keto 
acids. Pale pink-orange oil (479 mg, quantitative crude yield); Rf = 0.106 
(50:50 EtOAc: hexanes);
1
H NMR (400 MHz, CDCl3) δ 12.56 (s, 1H), 
8.07 (d, J = 8.9 Hz, 2H), 6.93 (d, J = 8.9 Hz, 2H), 3.86 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
188.68, 168.43, 164.57, 132.70, 114.01, 55.54; DEPT-135 (101 MHz, CDCl3) δ 132.70, 114.01, 
55.54; ESI- MS: m/z 179 [M-H]
-
. 
 
N-(3-benzylphenyl)-2-(4-methoxyphenyl)-2-oxoacetamide (3.102) 
Synthesized using the general procedure B described for 
aryl oxalamate scaffolds. Pale yellow oil (18 mg, 24 %);
 
Rf = 0.80 (50:50 EtOAc: hexanes; stains red/pink with p-
anisaldehyde);
1
H NMR (400 MHz, CDCl3) δ 8.98 (s, 3H), 8.48 (d, J = 9.0 Hz, 2H), 7.58 (d, J = 
8.3 Hz, 1H), 7.51 (s, 1H), 7.30 (t, J = 8.2 Hz, 3H), 7.20 (d, J = 7.8 Hz, 3H), 7.02 (d, J = 7.5 Hz, 
1H), 6.96 (d, J = 9.0 Hz, 2H), 4.00 (s, 2H), 3.89 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 185.18, 
164.89, 159.43, 142.44, 140.62, 136.89, 134.27, 129.30, 128.94, 128.57, 126.26, 126.07, 125.81, 
120.33, 117.70, 113.92, 55.62, 41.88; DEPT -135 (101 MHz, CDCl3) δ 134.27, 129.30, 128.94, 
128.57, 126.26, 125.81, 120.33, 117.70, 113.95, 113.92, 55.63, 55.62, 41.89, 41.88. 
 
2-oxo-2-(p-tolyl) acetic acid (S10) 
Synthesized using the general procedure A described for aryl α-keto acids. 
Golden yellow solid (402.8 mg, quantitative crude yield); Rf = 0.17 (50:50 
EtOAc: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 9.23 (s, 1H), 8.12 (d, J = 
155 
8.1 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 2.44 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 184.88, 
164.23, 147.05, 131.06, 129.72, 129.38, 21.96; DEPT-135 (101 MHz, CDCl3) δ 131.05, 129.70, 
21.96; ESI- MS: m/z 163 [M-H]
-
. 
 
2-oxo-N-phenyl-2-(p-tolyl) acetamide (3.103) 
Synthesized using the general procedure B described for aryl 
oxalamate scaffolds. Bright yellow solid (42 mg, 41%);
 
 
 
Rf = 0.86 
(30:70 EtOAc: hexanes) 
1
H NMR (400 MHz, CDCl3) δ 8.99 (s, 1H), 
8.34 (d, J = 8.3 Hz, 2H), 7.81 – 7.58 (m, 2H), 7.40 (dd, J = 10.8, 5.2 Hz, 2H), 7.31 (d, J = 8.0 
Hz, 2H), 7.19 (dd, J = 10.6, 4.2 Hz, 1H), 2.44 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 186.83, 
159.13, 146.00, 136.69, 131.67, 130.54, 129.35, 129.22, 125.23, 119.89, 21.98; DEPT-135 
13
C 
NMR (400 MHz, CDCl3) δ 197.38, 196.79, 196.76, 195.76, 194.42, 169.78; melting point: 119-
122 °C. 
 
N-(3-benzylphenyl)-2-oxo-2-(p-tolyl) acetamide (3.104) 
Synthesized using the general procedure B described for 
aryl oxalamate scaffolds. Bright yellow crystalline solid 
(43.8 mg, 72%); Rf = 0.75 (30:70 EtOAc: hexanes); 
1
H 
NMR (400 MHz, CDCl3) δ 8.91 (s, 1H), 8.32 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 7.8 Hz, 1H), 7.50 
(s, 1H), 7.28 (d, J = 8.1 Hz, 5H), 7.20 (d, J = 7.5 Hz, 2H), 7.01 (d, J = 7.5 Hz, 1H), 3.99 (s, 2H), 
2.43 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 186.80, 159.11, 145.92, 142.45, 140.60, 136.86, 
131.65, 130.60, 129.31, 128.93, 128.56, 126.26, 125.86, 120.37, 117.74, 41.88, 21.93; DEPT-
135 (101 MHz, CDCl3) δ 131.66, 129.31, 128.93, 128.56, 126.26, 125.86, 120.37, 117.74, 41.88, 
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21.93; ESI+ MS: m/z 352 [MNa]
+
; ESI- MS: m/z 328 [MH]
+
;  Elemental Analysis: Calc. for 
C22H19NO2: C, 80.22; H, 5.81; N, 4.25. Found: C, 80.0; H, 5.65; N, 4.25. 
 
2-oxo-2-(1H-pyrrol-2-yl) acetic acid (S11) 
Synthesized using the general procedure A described for aryl α-keto acids. 
Dark red-orange solid (318 mg, quantitative crude yield); Rf = 0.075 (90:10 
DCM: MeOH; stains dark brown with p-anisaldehyde); 
1
H NMR (400 MHz, 
DMSO) δ 12.22 (s, 1H), 7.28 (s, 1H), 7.12 (s, 1H), 6.27 (s, 1H); 13C NMR (101 MHz, DMSO) δ 
175.39, 172.49, 165.35, 129.35, 128.88, 121.89, 111.62; DEPT-135 (101 MHz, DMSO) δ 
129.34, 121.87, 111.61; ESI- MS: m/z 137 [MH]
+
. 
 
N-(3-benzylphenyl)-2-oxo-2-(1H-pyrrol-2-yl) acetamide (3.105) 
Synthesized using the general procedure B described for aryl 
oxalamate scaffolds. Light yellow solid powder  (45.5 mg, 
22%); Rf = 0.59 (30:70 EtOAc: hexanes; stains dark orange-
brown with p-anisaldehyde); 
1
H NMR (500 MHz, DMSO) δ 12.24 (s, 1H), 10.57 (s, 1H), 7.71 
(s, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.38 – 7.15 (m, 8H), 7.02 (d, J = 7.5 Hz, 1H), 6.35 – 6.27 (m, 
1H), 3.94 (s, 2H); 
13
C NMR (126 MHz, DMSO) δ 162.37, 142.34, 141.50, 138.46, 129.26, 
129.17, 128.97, 128.91, 126.49, 125.29, 121.05, 118.54, 111.69, 41.68; DEPT-135
 
(126 MHz, 
DMSO) δ 129.26, 129.17, 128.91, 126.49, 125.29, 122.34, 121.05, 118.54, 111.70, 41.68; 
Elemental Analysis: Calc. for C19H16N2O2: C, 74.98; H, 5.30; N, 9.20. Found: C, 74.66; H, 
5.31 N, 8.64; melting point: 148-150 °C. 
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2-oxo-2-phenylacetic acid (S12) 
Synthesized using the general procedure A described for aryl α-keto acids. 
Pale yellow oil (312 mg, quantitative crude yield); Rf = 0.57 (20:80 EtOAc: 
Hexanes);
 1
H NMR (400 MHz, CDCl3) δ 10.00 (s, 1H), 8.22 (d, J = 7.7 Hz, 
2H), 7.77 – 7.64 (m, 1H), 7.58 – 7.43 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 185.20, 163.99, 
135.55, 131.79, 130.90, 130.35, 128.99, 128.61; DEPT-135 (101 MHz, CDCl3) δ 135.55, 
130.90, 130.35, 128.99, 128.61; ESI- MS: m/z 148 [M-H]. 
 
N-(3-benzylphenyl)-2-oxo-2-phenylacetamide (3.106) 
Synthesized using the general procedure B described for aryl 
oxalamate scaffolds. Light yellow solid (46 mg, 44%); Rf = 
0.57 (20:80 EtOAc: hexanes); 
1
H NMR (400 MHz, ) δ 8.91 (s, 1H), 8.54 – 8.23 (m, 2H), 7.62 
(dd, J = 15.7, 8.5 Hz, 2H), 7.53 – 7.44 (m, 3H), 7.34 – 7.25 (m, 3H), 7.21 (dd, J = 11.1, 6.7 Hz, 
3H), 7.02 (d, J = 7.6 Hz, 1H), 3.99 (s, 2H); 
13
C NMR (101 MHz, CDCl3) δ 187.45, 158.93, 
142.51, 140.63, 136.84, 134.62, 133.13, 131.48, 129.34, 128.97, 128.60, 128.57, 126.31, 125.97, 
120.44, 117.82, 41.91.DEPT-135 (101 MHz, CDCl3) δ 134.61, 131.47, 129.33, 128.96, 128.59, 
128.56, 126.29, 125.96, 120.43, 117.80, 41.90; ESI-MS: m/z 313 [M-H]. 
 
2-(furan-2-yl)-2-oxoacetic acid (S13) 
Synthesized using the general procedure A described for aryl α-keto acids. 
Yellow solid (313 mg, quantitative crude yield); Rf = 0.15 (50:50 EtOAc: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H), 8.15 (s, 1H), 7.86 (s, 
1H), 6.70 (s, 1H); 
13
C NMR (101 MHz, CDCl3) δ 169.76, 159.54, 150.67, 128.07, 120.12, 
113.39; DEPT-135 (101 MHz, CDCl3) δ 150.68, 127.76, 113.09; ESI- MS: m/z 138[M-H]. 
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N-(3-benzylphenyl)-2-(furan-2-yl)-2-oxoacetamide (3.107) 
Synthesized using the general procedure B described for aryl 
oxalamate scaffolds. Bright yellow solid (15.3 mg, 14%) Rf = 
0.55 (30:70 EtOAc: hexanes; stains purple with p-
anisaldehyde); 
1
H NMR (400 MHz, CDCl3) δ 9.04 (s, 1H), 8.25 (d, J = 3.6 Hz, 1H), 7.76 (s, 
1H), 7.58 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.30 (dd, J = 11.4, 5.5 Hz, 3H), 7.20 (t, J = 6.6 Hz, 
3H), 7.02 (d, J = 7.6 Hz, 1H), 6.63 (dd, J = 3.5, 1.4 Hz, 1H), 3.99 (s, 2H); 
13
C NMR (101 MHz, 
CDCl3) δ 173.50, 157.53, 149.73, 149.30, 142.51, 140.57, 136.56, 129.34, 128.94, 128.58, 
127.39, 126.29, 126.05, 120.42, 117.79, 113.36, 41.86; DEPT-135 (101 MHz, CDCl3) δ 149.73, 
129.34, 128.94, 128.58, 127.39, 126.29, 126.05, 120.42, 117.79, 113.36, 41.86; ESI+MS: m/z 
328 [MNa]
+
. Elemental Analysis: Calc. for C15H13NO2: C, 75.30; H, 5.48; N, 5.85. Found: C, 
73.68; H, 4.91; N, 4.52. 
 
Diethyl (2-((3-benzylphenyl) amino)-1-(3-bromophenyl)-1-hydroxy-2-oxoethyl) 
phosphonate (3.113) 
Using an adapted procedure from Gooβen and Dezfuli,356 
in a flame-dried round  flask was added 
Tetrakis(triphenylphosphine)palladium(0) (2 mol%) and 
PPh3 (3.99 mg, 6 mol%). The reaction vessel was fitted 
with a reflux condenser and purged with argon. Subsequently, anhydrous EtOH (3 mL), 3.96 
(100 mg, 0.254 mmol, 1.0 eq), N, N-Diisopropylethylamine (49.5 mg, 66.7 µL, 0.381 mmol, 1.5 
eq) and diethylphosphite (42.1 mg, 39.2 µL, 0.305mmol, 1.2 eq) were added. The reaction 
mixture was heated to 80°C overnight (16 hours). After the disappearance of the starting 
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material, the reaction was quenched with 1 N HCl (5 mL) and EtOAc was added (5 mL). The 
mixture was transferred into a separatory funnel and the organic layer was washed with water (3 
x 10 mL) and brine (2 x 10 mL). The organic layers were dried over Na2SO4 and concentrated by 
rotary evaporation. The crude residue was purified by flash-column chromatography using a 
gradient of 10:90 EtOAc:hexanes to 70:30 EtOAc:hexanes to yield 3.113 (80.8 mg, 70%) and 
3.115 (10.9 mg, 11 %). 3.113: White crystalline solid Rf = 0.13 (30:70 EtOAc: Hexanes); 
1
H 
NMR (500 MHz, CDCl3) δ 9.09 (s, 1H), 7.74 (s, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.48 – 7.38 (m, 
7H), 7.28 – 7.11 (m, 7H), 6.91 (d, J = 7.5 Hz, 1H), 5.89 (d, J = 8.5 Hz, 1H), 4.10 (dddd, J = 24.8, 
21.7, 11.0, 4.8 Hz, 4H), 3.90 (s, 2H), 1.43 – 1.11 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 
165.88, 165.83, 142.09, 140.77, 138.04, 138.00, 137.49, 132.24, 130.25, 130.05, 129.03, 128.88, 
128.49, 126.16, 125.79, 125.38, 122.69, 120.50, 117.83, 77.82, 77.78, 64.90, 64.85, 64.73, 64.69, 
41.92, 16.07, 16.04, 16.02, 15.99; DEPT-135 (126 MHz, CDCl3) δ 132.26, 132.24, 130.28, 
130.25, 130.05, 129.08, 129.03, 128.90, 128.88, 128.50, 126.16, 125.79, 125.37, 120.50, 117.83, 
77.82, 77.78, 77.75, 64.86, 64.74, 64.68, 41.93, 41.92; Elemental Analysis: Calc. for 
C25H27BrNO5P: C, 56.40; H, 5.11; N, 2.63. Found: C, 56.37; H, 4.93 N, 2.52; melting point: 
93-95 °C. 
 
N-(3-benzylphenyl)-2-(3-bromophenyl) acetamide (3.115) 
Prepared by procedure described for 3.113. White fluffy 
powder (10.9 mg, 11 %).; Rf = 0.52 (30:70 EtOAc: 
hexanes); 
1
H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 
7.52 (s, 1H), 7.44 (dd, J = 8.4, 2.6 Hz, 3H), 7.29 (dt, J = 14.1, 7.1 Hz, 4H), 7.24 – 7.13 (m, 4H), 
6.92 (d, J = 7.5 Hz, 1H), 3.89 (s, 2H), 3.62 (s, 2H); 
13
C NMR (101 MHz, DMSO) δ 168.91, 
160 
142.30, 141.52, 139.63, 139.11, 132.37, 130.85, 129.86, 129.22, 129.14, 128.88, 128.75, 126.45, 
121.89, 119.84, 117.35, 43.04, 41.62, 40.61, 40.40, 40.19, 39.99, 39.78, 39.57, 39.36; DEPT-
135 (101 MHz, DMSO) δ 132.36, 130.85, 129.85, 129.22, 129.14, 129.11, 128.87, 128.85, 
128.74, 128.70, 126.44, 124.26, 124.23, 119.83, 119.81, 117.35, 117.31, 43.05, 43.02, 41.63, 
41.61; ESI- MS: m/z 378, 380 [M-H]
-
. 
 
Diethyl (2-((3-benzylphenyl) amino)-1-(4-bromophenyl)-1-hydroxy-2-oxoethyl) 
phosphonate (3.114) 
Using an adapted procedure from Gooβen and Dezfuli,356 
in a flame-dried round  flask was added Pd(OAc2)  (2 
mol%) and PPh3 (2.75 mg, 6 mol%). The reaction vessel 
was fitted with a reflux condenser and purged with argon. Subsequently, anhydrous EtOH (4 
mL), 3.95 (68.9 mg, 0.175 mmol, 1.0 eq), N, N-Diisopropylethylamine (33.93 mg, 45.7 µL, 
0.263 mmol, 1.5 eq) and diethylphosphite (29 mg, 27.1 µL, 0.210mmol, 1.2 eq) were added. The 
reaction mixture was heated to 80°C overnight (16 hours). After the disappearance of the starting 
material, the reaction was quenched with 1 N HCl (5 mL) and EtOAc was added (5 mL). The 
mixture was transferred into a separatory funnel and the organic layer was washed with water (3 
x 10 mL) and brine (2 x 10 mL). The organic layers were dried over Na2SO4 and concentrated by 
rotary evaporation. The crude residue was purified by flash-column chromatography using a 
gradient of 10:90 EtOAc:hexanes to 70:30 EtOAc:hexanes to yield 3.114 (24.6 mg, 26%) and 
3.116 (17.2 mg, 25%). 3.114: white crystalline solid;  Rf = 0.13 (30:70 EtOAc: hexanes); 
1
H 
NMR (500 MHz, CDCl3) δ 9.04 (s, 1H), 7.43 (dt, J = 24.3, 7.9 Hz, 6H), 7.24 (t, J = 7.4 Hz, 2H), 
7.21 – 7.10 (m, 4H), 6.91 (d, J = 7.4 Hz, 1H), 5.87 (d, J = 8.5 Hz, 1H), 4.22 – 3.97 (m, 4H), 3.89 
(s, 2H), 1.24 (dt, J = 14.4, 7.0 Hz, 6H); 
13
C NMR (126 MHz, CDCl3) δ 166.03, 165.98, 142.11, 
161 
140.78, 137.48, 134.94, 134.90, 131.86, 129.06, 128.89, 128.81, 128.51, 126.18, 125.41, 123.41, 
120.48, 117.82, 78.00, 77.96, 64.86, 64.81, 64.68, 64.63, 41.92, 16.09, 16.05, 16.03, 16.00; 
DEPT-135 (126 MHz, CDCl3) δ 131.87, 129.06, 128.89, 128.81, 128.51, 126.18, 125.41, 
120.48, 117.82, 78.00, 77.95, 64.86, 64.81, 64.68, 64.64, 41.92. Elemental Analysis: Calc. for 
C25H27BrNO5P: C, 56.40; H, 5.11; N, 2.63. Found: C, 56.45; H, 5.02 N, 2.54; melting point: 
97-100 °C. 
 
N-(3-benzylphenyl)-2-(4-bromophenyl) acetamide (3.116) 
Prepared by procedure described for 3.114. White fluffy 
powder (17.2 mg, 25%); Rf = 0.52 (30:70 EtOAc: 
hexanes); 
1
H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 
7.57 – 7.39 (m, 4H), 7.32 – 7.23 (m, 4H), 7.24 – 7.13 (m, 4H), 6.92 (d, J = 7.4 Hz, 1H), 3.88 (s, 
2H), 3.60 (s, 2H); 
13
C NMR (101 MHz, DMSO) δ 169.03, 142.29, 141.52, 139.67, 135.83, 
131.87, 131.57, 129.22, 129.14, 128.88, 126.44, 124.23, 120.20, 119.78, 117.31, 42.94, 41.63; 
DEPT-135 (101 MHz, DMSO) δ 131.87, 131.57, 129.22, 129.14, 128.87, 126.44, 124.22, 
119.78, 117.31, 42.94, 41.63; ESI- MS: m/z 378, 380 [M-H]
-
. 
 
Diethyl (3-acetylphenyl) phosphonate (3.119) 
Using an adapted procedure from Gooβen and Dezfuli,356  a flame-dried round bottom flask 
fitted with a reflux condenser  charged with Pd(OAc)2 (13.5 mg, 2 mol%) and PPh3 (47.48 mg, 6 
mol%) was evacuated and purged with argon.  Subsequently, anhydrous EtOH (15 mL), 3’-
bromoacetophenone (600 mg, 3.014 mmol, 1.0 eq), N, N-Diisopropylethylamine (587 mg, 792 
µL, 4.52 mmol, 1.5 eq) and diethylphosphite (500 mg, 466 µL, 3.62 mmol, 1.2 eq) were added. 
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The reaction mixture was heated to 80°C overnight (16 hours). After the 
disappearance of the starting material, the reaction was quenched with 1 N 
HCl (5 mL) and EtOAc was added (5 mL). The mixture was transferred 
into a separatory funnel and the organic layer was washed with water (3 x 10 mL) and brine (2 x 
10 mL). The organic layers were dried over Na2SO4 and concentrated by rotary evaporation. The 
crude residue was purified by flash-column chromatography using 75:25 EtOAc:hexanes to yield 
3.119 as a colorless oil (563 mg, 73%); Rf = 0.30 (70:30 EtOAc: hexanes); 
1
H NMR (400 MHz, 
CDCl3) δ 8.39 (d, J = 13.8 Hz, 1H), 8.16 (d, J = 7.8 Hz, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.61 (dd, J 
= 7.6, 4.0 Hz, 1H), 4.17 (dddd, J = 24.2, 10.1, 7.3, 2.6 Hz, 4H), 2.65 (s, 3H), 1.35 (t, J = 7.0 Hz, 
6H); 
13
C NMR (101 MHz, CDCl3) δ 197.08, 137.18, 137.04, 136.02, 135.92, 131.99, 131.84, 
131.81, 131.68, 131.58, 130.29, 128.99, 128.84, 128.41, 62.44, 62.38, 26.63, 16.31, 16.25; 
DEPT-135 (101 MHz, CDCl3) δ 136.02, 135.92, 131.99, 131.84, 131.81, 131.68, 131.58, 
128.99, 128.84, 62.44, 62.38, 26.63, 16.31, 16.25; ESI+MS: m/z 257 [MH]
+
, m/z 279 [MNa]
+
. 
 
Diethyl (4-acetylphenyl)phosphonate (3.120) 
Same procedure for was used as described for 3.119 except using 4’-
bromoacetophenone as the starting material. Colorless oil (601 mg, 78%);  
Rf = 0.32 (70:30 EtOAc: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.08 – 
7.99 (m, 2H), 7.92 (dd, J = 12.8, 8.4 Hz, 2H), 4.20 – 4.06 (m, 4H), 2.64 (s, 3H), 1.34 (t, J = 7.1 
Hz, 6H); 
13
C NMR (101 MHz, CDCl3) δ 197.49, 139.82, 134.20, 132.34, 132.10, 132.00, 
128.57, 128.45, 128.10, 127.95, 62.48, 62.43, 26.77, 16.32, 16.26; DEPT-135 (101 MHz, 
CDCl3) δ 132.08, 132.01, 131.98, 128.56, 128.44, 128.09, 127.94, 62.47, 62.42, 26.77, 16.33, 
16.32, 16.25; ESI+MS: m/z 257 [MH]
+
, m/z 279 [MNa]
+
. 
163 
Ethyl 2-(furan-2-yl)-2-oxoacetate (3.127) 
Using an adapted procedure from Cheng et al.
1
 and Kim et al., 
374
 to a 
solution of furan (0.191 mL, 3.00 mmol, 1.0 eq) in anhydrous THF (4 
mL) was added slowly n-butyl lithium (2.373 mL, 3.15 mmol, 1.05 eq) 
at -78°C. The reaction mixture was stirred at -78°C for 30 minutes.  After 30 minutes, a solution 
(cooled to -78°C) of ZnBr2 (532.0 mg, 3.6 mmol, 1.20 eq) in anhydrous THF (2 mL) was added 
to the reaction flask slowly and stirred for 30 minutes.  To a separate reaction flask containing 
Ni(acac) (11.3 mg, 2 mol%) was added 6.9 mL of the ZnBr2 reagent mixture (6.9 mL, 2.197 
mmol, 1.2 eq) at -78°C. This reaction stirred for 15 minutes and then a solution of ethyl oxalyl 
chloride (0.205 mL, 1.831 mmol, 1.0 eq) in anhydrous THF (2 mL) was added and stirred for 30 
minutes. After 30 minutes, the reaction was quenched with a saturated NH4Cl solution (10 mL) 
and extracted with EtOAc. The combined organic layers were washed with a saturated Na2S2O3 
solution (2 x 10 mL), brine (2 x 10 mL), dried over Na2SO4 and concentrated by rotary 
evaporation to afford crude orange yellow oil. The crude oil was purified by flash-column 
chromatography using a gradient of 10:90 EtOAc:hexanes to 50:50 EtOAc:hexanes to afford 
3.129 as a dark yellow oil (21.4 mg, 4 %); Rf = 0.32 (10:90 EtOAc: hexanes; stains white with p-
anisaldehyde); 
1
H NMR (400 MHz, CDCl3) δ 7.79 (dd, J = 1.6, 0.7 Hz, 1H), 7.74 (dd, J = 3.7, 
0.6 Hz, 1H), 6.65 (dd, J = 3.7, 1.7 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 1.45 (td, J = 7.1, 2.8 Hz, 
3H); 
13
C NMR (101 MHz, CDCl3) δ 171.12, 161.01, 149.75, 149.50, 149.49, 124.68, 112.99, 
62.69, 13.98; ESI+ MS: m/z 169 [MH]
+
, m/z 191 [MNa]
+
. 
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N-(3-benzylphenyl)-2-(5-methoxy-1H-indol-3-yl)-2-
oxoacetamide (3.143) 
Using an adapted procedure from Lee et al.
418
 and 
Marchand et al,
419
 a mixture of 5-methoxyindole (30 
mg, 21.4 µL 0.204 mmol, 1.0 eq) and anhydrous ether 
(1 mL) was cooled to 0°C and stirred for 30 minutes. After 30 minutes, oxalyl chloride (31.09 
mg, 21 µL, 0.245 mmol, 1.2 eq) was added slowly dropwise at 0°C. Solution went from light 
orange in color to an intense orange-red color. The mixture was stirred for 2 hours at 0°C. After 
2 hours, the solvent was carefully removed by rotary evaporation and to the crude residue was 
added anhydrous THF (1 mL) and 3-benzylaniline (37.38 mg, 0.204 mmol, 1.0 eq) and 1 drop 
(catalytic amount) of triethylamine. The reaction mixture became golden yellow and cloudy and 
was stirred at room temperature for 2 hours. The mixture was quenched with saturated NaHCO3 
(10 mL) then extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried over 
Na2SO4 and concentrated via rotary evaporation. The crude solid was then recrystallized from 
EtOAc:hexanes to yield pure 3.121 as a golden yellow solid (27.6 mg, 35%);  
1
H NMR (400 
MHz, CDCl3) δ 8.98 (s, 3H), 8.48 (d, J = 9.0 Hz, 2H), 7.58 (d, J = 8.3 Hz, 1H), 7.51 (s, 1H), 7.30 
(t, J = 8.2 Hz, 3H), 7.20 (d, J = 7.8 Hz, 3H), 7.02 (d, J = 7.5 Hz, 1H), 6.96 (d, J = 9.0 Hz, 2H), 
4.00 (s, 2H), 3.89 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 185.18, 164.89, 159.43, 142.44, 
140.62, 136.89, 134.27, 129.30, 128.94, 128.57, 126.26, 126.07, 125.81, 120.33, 117.70, 113.92, 
55.62, 41.88; DEPT-135 (101 MHz, CDCl3) δ 134.27, 129.30, 128.94, 128.57, 126.26, 125.81, 
120.33, 117.70, 113.95, 113.92, 55.63, 55.62, 41.89, 41.88; ESI+MS: m/z 383 [MH]
+
; 
Elemental Analysis: Calc. for C24H20N2O3: C, 74.98; H, 5.24; N, 7.29. Found: C, 73.49; H, 
4.98 N, 7.08. 
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N-(3-benzylphenyl)-2-(5-methoxy-1H-indol-3-yl)-2-oxoacetamide (3.144) 
Using an adapted procedure from Lee et al.
418
 and Marchand et 
al,
419
 a mixture of 5-methoxyindole (50 mg, 35.7 µL 0.339 
mmol) and anhydrous ether (1 mL) was cooled to 0°C and 
stirred for 30 minutes. After 30 minutes, oxalyl chloride (51.75 
mg, 35 µL, 0.408 mmol) was added slowly dropwise at 0°C. Solution went from light orange in 
color to an intense orange-red color. The mixture was stirred for 2 hours at 0°C. After 2 hours, 
the solvent was carefully removed by rotary evaporation and to the crude residue was added 
anhydrous THF (2 mL) and aniline (31.59 mg, 30.9 µL, 0.339 mmol, 1.0 eq) and 1 drop 
(catalytic amount) of triethylamine. The reaction mixture became golden yellow and cloudy and 
was stirred at room temperature for 2 hours. The mixture was quenched with saturated NaHCO3 
then extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried over Na2SO4 
and concentrated via rotary evaporation. The crude orange yellow solid was then recrystallized 
from EtOAc:hexanes to yield pure 3.122 as a light tan powder (53.5 mg, 53%); Rf = 0.333 (20:80 
EtOAc: hexanes);
1
H NMR (400 MHz, DMSO) δ 12.26 (s, 1H), 10.66 (s, 1H), 8.72 (s, 1H), 7.86 
(dd, J = 17.6, 5.0 Hz, 3H), 7.48 (d, J = 8.8 Hz, 1H), 7.39 (t, J = 7.8 Hz, 2H), 7.15 (t, J = 7.3 Hz, 
1H), 6.94 (dd, J = 8.7, 2.3 Hz, 1H), 3.83 (s, 3H); 
13
C NMR (101 MHz, DMSO) δ 182.22, 
162.87, 156.56, 138.97, 138.53, 131.60, 129.19, 127.64, 124.67, 120.65, 113.89, 113.43, 112.30, 
103.83, 55.71; DEPT-135 (101 MHz, DMSO) δ 138.97, 129.19, 124.67, 120.65, 113.89, 113.43, 
103.83, 55.71; Elemental Analysis: Calc. for C23H18N2O2: C, 77.95; H, 5.12; N, 7.90. Found: C, 
77.47; H, 4.92 N, 7.78; melting point: 243-245 °C (decomp). 
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N-(3-benzylphenyl)-2-(1H-indol-3-yl)-2-oxoacetamide (3.140) 
Using an adapted procedure from Lee et al.
418
 and Marchand 
et al,
419
 a mixture of indole (50 mg, 0.427 mmol, 1.0 eq) and 
anhydrous ether (1.14 mL) was cooled to 0°C and stirred for 
30 minutes. After 30 minutes, oxalyl chloride (65 mg, 43.9 
µL, 0.512 mmol, 1.2 eq) was added slowly dropwise at 0°C. Solution was bright yellow in color. 
The mixture was stirred for 2 hours at 0°C. After 2 hours, the solvent was carefully removed by 
rotary evaporation and to the crude residue was added anhydrous THF (2 mL) and 3-
benzylaniline (78.2 mg, 0.427 mmol, 1.0 eq) and 1 drop (catalytic amount) of triethylamine. The 
reaction mixture became an orange brown color and was stirred at room temperature for 2 hours. 
The mixture was quenched with saturated NaHCO3 (10 mL) then extracted with EtOAc (3 x 10 
mL). The organic layers were combined, dried over Na2SO4 and concentrated via rotary 
evaporation to yield 3.140 as a light tan powder (155.1 mg, quantitative yield); Rf = 0.333 (20:80 
EtOAc: hexanes; stains light brown with p-anisaldehyde); 
1
H NMR (400 MHz, DMSO) δ 12.34 
(s, 1H), 10.61 (s, 1H), 8.76 (s, 1H), 8.29 (dd, J = 6.2, 2.6 Hz, 1H), 7.79 (s, 1H), 7.69 (d, J = 8.1 
Hz, 1H), 7.61 – 7.51 (m, 1H), 7.37 – 7.14 (m, 9H), 7.02 (d, J = 7.5 Hz, 1H), 3.95 (s, 2H); 13C 
NMR (101 MHz, DMSO) δ 182.42, 162.80, 142.29, 141.52, 139.04, 138.62, 136.85, 129.23, 
129.15, 128.89, 126.64, 126.47, 125.17, 124.02, 123.16, 121.69, 121.04, 118.53, 113.12, 112.41; 
DEPT-135 101 MHz, DMSO) δ 139.04, 129.23, 129.15, 128.89, 126.47, 125.17, 124.02, 123.16, 
121.69, 121.04, 118.53, 113.12; Elemental Analysis: Calc. for C23H18N2O2: C, 77.95; H, 5.12; 
N, 7.90. Found: C, 77.47; H, 4.92 N, 7.78. 
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N-(3-benzylphenyl)-2-(7-methyl-1H-indol-3-yl)-2-oxoacetamide (3.142) 
Using an adapted procedure from Lee et al.
418
 and Marchand et 
al,
419
 a mixture of 7-methylindole (30 mg, 0.229 mmol, 1.0 eq) 
and anhydrous ether (1 mL) was cooled to 0°C and stirred for 
30 minutes. After 30 minutes, oxalyl chloride (34.84 mg, 23.6 
µL, 0.274 mmol, 1.2 eq) was added slowly dropwise at 0°C. The mixture was stirred for 2 hours 
at 0°C. After 2 hours, the solvent was carefully removed by rotary evaporation and to the crude 
residue was added anhydrous THF (2 mL) and 3-benzylaniline (41.9 mg, 0.229 mmol, 1.0 eq) 
and 1 drop (catalytic amount) of triethylamine. The reaction mixture was stirred at room 
temperature for 2 hours. The mixture was quenched with saturated NaHCO3 (10 mL) then 
extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried over Na2SO4 and 
concentrated via rotary evaporation to yield 3.142 as a brown tan solid (155.1 mg, quantitative 
yield); Rf = 0.333 (20:80 EtOAc: hexanes; stains light brown with p-anisaldehyde); 
1
H NMR 
(400 MHz, DMSO) δ 12.39 (s, 1H), 10.74 (s, 1H), 10.60 (s, 1H), 8.71 (s, 1H), 8.12 (d, J = 7.8 
Hz, 1H), 7.78 (d, J = 6.1 Hz, 2H), 7.67 (t, J = 8.9 Hz, 2H), 7.32 – 7.19 (m, 5H), 7.09 (d, J = 7.1 
Hz, 1H), 7.06 – 6.98 (m, 1H), 3.94 (d, J = 6.1 Hz, 2H), 2.53 (s, 2H); 13C NMR (101 MHz, 
DMSO) δ 182.41, 162.80, 158.98, 142.35, 142.27, 141.53, 141.43, 138.62, 138.18, 136.28, 
129.17, 128.90, 126.48, 125.47, 124.67, 123.37, 122.49, 121.17, 119.25, 118.64, 112.75, 41.70, 
17.09; DEPT-135 (101 MHz, DMSO) δ 138.55, 129.21, 129.17, 128.90, 126.48, 125.47, 125.17, 
124.67, 123.37, 121.17, 121.04, 119.25, 118.64, 118.53, 41.70, 17.09; ESI- MS: m/z 367 [MH]
-
; 
Elemental Analysis: Calc. for C24H20N2O2: C, 78.24; H, 5.47; N, 7.60. Found: C, 77.98; H, 
5.46 N, 7.02. 
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2-(1H-indol-3-yl)-2-oxo-N-phenylacetamide (3.141) 
Using an adapted procedure from Lee et al.
418
 and Marchand et al,
419
 
a mixture of indole (200 mg, 1.71 mmol, 1.0 eq) and anhydrous ether 
(4.57 mL) was cooled to 0°C and stirred for 30 minutes. After 30 
minutes, oxalyl chloride (260.46 mg, 175 mL, 0.512 mmol, 1.2 eq) was added slowly dropwise 
at 0°C. Solution was bright yellow in color. The mixture was stirred for 2 hours at 0°C. After 2 
hours, the solvent was carefully removed by rotary evaporation and to the crude residue was 
added anhydrous THF (4 mL) and freshly distilled aniline (54.5 mg, 53.4 µL, 0.1.71 mmol, 1.0 
eq) and 1 drop (catalytic amount) of triethylamine. The reaction mixture became an orange 
yellow color and was stirred at room temperature for 2 hours. The mixture was quenched with 
saturated NaHCO3 (20 mL) then extracted with EtOAc (3 x 20 mL). The organic layers were 
combined, dried over Na2SO4 and concentrated via rotary evaporation to yield 3.141 as a golden-
yellow solid (335.9 mg, 94% yield);  Rf = 0.77 (50:50 EtOAc: hexanes; stains purple/pink with 
p-anisaldehyde); 
1
H NMR (400 MHz, DMSO) δ 12.37 (s, 1H), 10.69 (s, 1H), 8.80 (d, J = 2.3 
Hz, 1H), 8.33 (dd, J = 5.8, 2.3 Hz, 1H), 7.90 (d, J = 8.0 Hz, 2H), 7.66 – 7.56 (m, 1H), 7.41 (t, J = 
7.9 Hz, 2H), 7.37 – 7.30 (m, 2H), 7.17 (t, J = 7.3 Hz, 1H); 13C NMR (101 MHz, DMSO) δ 
182.45, 162.82, 139.05, 138.52, 136.86, 129.19, 126.64, 124.69, 124.04, 123.18, 121.69, 120.72, 
113.13, 112.43; DEPT-135 (101 MHz, DMSO) δ 139.05, 129.19, 124.69, 124.04, 123.18, 
121.69, 120.73, 113.13.3; Elemental Analysis: Calc. for C16H12N2O2: C, 72.72; H, 4.58; N, 
10.60. Found: C, 72.19; H, 4.30 N, 10.45; melting point: 240-242 °C (decomp). 
 
  
 
169 
Ethyl 2-oxo-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)acetate (3.146) 
Using an adapted procedure from Zhang et al.,
383
 azaindole (250 mg, 2.12 
mmol, 1 eq) was added to a stirred suspension of AlCl3 (1.413 g, 10.6 
mmol, 5 eq) in anhydrous DCM (50 mL). After the mixture stirred at 
room temperature for 1 hour, ethyl oxalyl chloride (1.18 mL, 10.6 mmol, 5 
eq) was added dropwise. It was noted that as the ethyl oxalyl chloride was added the solution 
went from yellow color to an orange color. After 12 hours of stirring at room temperature the 
reaction flask was placed in an ice-water and MeOH was slowly added dropwise to quench the 
reaction. The color of the solution went from an orange yellow cloudy color to a light brownish 
orange clear color. DCM was added and the organic layer was separated, washed with saturated 
NaHCO3 (3 x 20 mL), H20 (2 x 20 mL) and brine (2 x 20 mL). The organic layers were 
combined, dried over Na2SO4 and concentrated by rotary evaporation to afford an orange-yellow 
solid. The solid was washed with ice-cold ether to obtain 3.146 as an off-white powder (186.9 
mg, 40%); Rf = 0.77 (10:1 EtOAc: MeOH; stains white with p-anisaldehyde); 
1
H NMR (400 
MHz, CDCl3) δ 13.51 (s, 1H), 8.76 (dd, J = 7.9, 1.4 Hz, 1H), 8.72 (s, 1H), 7.34 (dd, J = 7.9, 4.9 
Hz, 1H), 4.45 (q, J = 7.1 Hz, 2H), 4.36 (q, J = 7.1 Hz, 1H), 1.46 (t, J = 7.1 Hz, 3H), 1.38 (t, J = 
7.1 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 178.03, 162.31, 149.13, 144.00, 137.57, 131.99, 
119.82, 119.12, 112.68, 63.16, 62.31, 14.09, 13.91; DEPT-135 (101 MHz, CDCl3) δ 143.99, 
137.56, 131.98, 119.11, 63.15, 62.30, 14.09, 13.90; ESI+MS: m/z 219 [MH]
+
; 
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Potassium 2-oxo-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)acetate (3.147) 
Using an adapted procedure from Wang et al.,
305
 K2CO3 (151.36 mg, 0.916 
mmol, 2.0 eq) was added to a solution of 3.126 (100 mg, 0.458 mmol, 1 
eq) in 1:1 mixture of MeOH:H2O (2 mL), and the mixture stirred at room 
temperature for 8 hours. The white precipitate was collected and washed 
with cold H2O (5 mL) to afford 3.147 as an off-white crystalline powder (68.2 mg, 78%), which 
was used in the next step without further purification; 
1
H NMR (400 MHz, DMSO) δ 8.35 (s, 
1H), 8.18 (s, 1H), 7.07 (s, 1H); ESI- MS: m/z 189 [M-H]
-
; 
 
N-(3-benzylphenyl)-2-oxo-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)acetamide (3.148) 
Using an adapted procedure from Martyn et al.,
306
 to a 
mixture of  3.148 (43.9 mg, 0.193 mmol, 1.0 eq) and 3-
benzylaniline (38.85 mg, 0.212 mmol, 1.1 eq) in anhydrous 
DMF (2 mL) was added 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (48.12, 0.251 mmol, 1.3eq) and 1-hydroxybenzotriazole 
hydrate (HOBT) (39.12, 0.289, 1.5 eq) at room temperature. N, N-Diisopropylethylamine (37.0 
µL, 27.40 mg, 0.212 mmol, 1.1 eq) was added dropwise and the reaction mixture stirred at room 
temperature for 16 hours. The reaction was quenched with H2O (5 mL) and stirred for 30 
minutes at room temperature. The solution was diluted with EtOAc (10 mL) and the organic 
layer was washed with H2O (5 x 100 mL), saturated NaHCO3 and brine. The organic layers were 
combined, dried over Na3SO4 and concentrated to afford an orange-yellow crude solid product 
3.128 (66 mg, 96% crude yield); ESI- MS: m/z 354 [M-H]
-
. 
 
 
171 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
 
 
 
 
 
172 
1. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; 
Salzberg, A. C.; Huang, E. S., Structure-based maximal affinity model predicts small-molecule 
druggability. Nature Biotechnology 2007, 25, (1), 71-75. 
2. CDC HIV/AIDS Surveillance Report: Diagnoses of HIV Infection and AIDS in the 
United States and Dependent Areas, 2009. 
http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/index.htm (March 1, 2012),  
3. United States Census Bureau 2008 American Community Survery. 
http://factfinder2.census.gov/faces/nav/jsf/pages/index.xhtml (March 1, 2012),  
4. AVERT HIV and AIDS in America. www.avert.org/america.htm (March 1, 2012),  
5. UNAIDS Fast Facts about HIV. 
http://www.unaids.org/en/resources/presscentre/factsheets/ (February 28, 2012),  
6. Osmond, D. H. Epidemiology of Disease Progression in HIV. 
http://hivinsite.ucsf.edu/InSite?page=kb-03-01-04 (February 28, 2012),  
7. Keele, B. F.; Van Heuverswyn, F.; Li, Y.; Bailes, E.; Takehisa, J.; Santiago, M. L.; 
Bibollet-Ruche, F.; Chen, Y.; Wain, L. V.; Liegeois, F.; Loul, S.; Ngole, E. M.; Bienvenue, Y.; 
Delaporte, E.; Brookfield, J. F. Y.; Sharp, P. M.; Shaw, G. M.; Peeters, M.; Hahn, B. H., 
Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1. Science 2006, 313, (5786), 523-
526. 
8. Volberding, P. A.; Deeks, S. G., Antiretroviral therapy and management of HIV 
infection. The Lancet 2010, 376, (9734), 49-62. 
9. History of AIDS Up to 1986. http://www.avert.org/aids-history-86.htm (February 25, 
2012),  
10. CDC Pneumocystis Pneumonia --- Los Angeles, MMWR; 1981; pp 250-252. 
11. Altman, L. K., Rare Cancer Seen in 41 Homosexuals The New York Times 1981. 
12. CDC Kaposi's Sarcoma and Pneumocystis Pneumonia among Homosexual Men- New 
York City and California, MMWR; 1981; pp 305-308. 
13. Altman, L. K., New Homosexual Disorder Worries Health Officials The New York Times 
1982. 
14. du Bois, R.; Branthwaite, M.; Mikhail, J.; Batten, J., Primary Pneumocystis carinii and 
cytomegalovirus infections. Lancet 1981, 2, 1339. 
15. Masur, H.; Michelis, M. A.; Greene, J. B.; Onorato, I.; Stouwe, R. A.; Holzman, R. S.; 
Wormser, G.; Brettman, L.; Lange, M.; Murray, H. W.; Cunnigham-Rundles, S., An Outbreak of 
community acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune 
dysfunction. The New England Journal Of Medicine 1981, 305, (24), 1431-1438. 
173 
16. CDC Kaposi's sarcoma (KS), Pneumocytis pneumonia (PCP), and other opportunistic 
infections (01): case reported to CDC as of July 8th 1982, MMWR 31; 1982; pp 507-508, 513-
514. 
17. WHO Acquired Immune Deficiency Syndrome Emergencies, Report of a WHO Meeting; 
Geneva, 1983. 
18. CDC Current  trends prevention of Aquired Immune Deficiency Syndrome (AIDS): report 
of interagency recommendations, MMWR; 1983; pp 101-103. 
19. Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; 
Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L., 
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency 
syndrome (AIDS). Science 1983, 220, (4599), 868-871. 
20. Marx, J. L., Strong new candidate for AIDS agent. Science 1984, 224, (4648), 475-477. 
21. Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C., Detection, isolation, and 
continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-
AIDS. Science 1984, 224, (4648), 497-500. 
22. Coffin, J.; Haase, A.; Levy, J. A.; Montagnier, L., Oroszlan, S.; Teich, N.; Temin, H.; 
Toyoshima, K.; Varmus, H.; Vogt, P., et al., What to call the AIDS virus? Nature 1986, 321. 
23. Hardy, A. M.; Allen, J. R.; Morgan, W. M.; Curran, J. W., The incidence rate of acquired 
immunodeficiency syndrome in selected populations JAMA : the journal of the American 
Medical Association 1985, 253, (2), 215-220. 
24. Cameron, D. W.; D'Costa, L.; Maitha, G.; Cheang, M.; Piot, P.; Simonsen, J. N.; Ronald, 
A.; Gakinya, M.; Ndinya-Achola, J. O.; Brunham, R.; Plummer, F., Female to Male 
Transmission of Human Immunodeficiency Virus Type 1: Risk Factors for Seroconversion in 
Men. . The Lancet 1989, 334, (8660), 403-407. 
25. Kingsley, L.; Kaslow, R.; Rinaldo, C.; Detre, K.; Odaka, N.; Vanraden, M.; Detels, R.; 
Polk, B. F.; Chmiel, J.; Kelsey, S.; Ostrow, D.; Visscher, B., Risk Factors for Seroconversion to 
Human Immunodeficiency Virus Among Male Homosexuals. The Lancet 1987, 329, (8529), 
345-349. 
26. CDC HIV/AIDS. http://www.cdc.gov/hiv/default.htm  
27. What is Aids? http://www.aids.org/topics/aids-factsheets/aids-background-
information/what-is-aids/ (February 27, 2012),  
28. Schacker, T.; Collier, A. C.; Hughes, J.; Shea, T.; Corey, L., Clinical and epidemiologic 
features of primary HIV infection. Annals of Internal Medicine 1996, 125, 257-264. 
174 
29. Weintrob, A.; Giner, J.; Menezes, P.; Patrick, E.; Benjamin, D. J.; J, L.; CD, P.; JJ, E.; 
CB, H., Infrequent diagnosis of primary human immunodeficiency virus infection: missed 
opportunities in acute care settings. Archives of Internal Medicine 2003, 163, 2097-3100. 
30. CDC, 1993 revised classification system for HIV infection and expanded surveillance 
case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992, 18, (44(RR-
17)), 1-19. 
31. CDC, Guidelines for national human immunodeficiency virus case surveillance, 
including monitoring for human immunodeficiency virus infection and acquired 
immunodeficiency syndrome. . MMWR Recomm Rep 1999, 10, (48(RR-13)), 1-27, 29-31. 
32. WHO WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and 
Immunological Classification of HIV-Related Disease in Adults and Children. 
http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf (February 28, 2012),  
33. UNAIDS Joint United Nations Programme on HIV/AIDS (UNAIDS) Global report: 
UNAIDS report on the global AIDS epidemic Switzerland, 2010. 
34. Schader, S. M.; Wainberg, M. A., Insights into HIV-1 pathogenesis through drug 
discovery: 30 years of basic research and concerns for the future. HIV & AIDS Review 2011, 10, 
(4), 91-98. 
35. The Henry J. Kaiser Family Foundation U.S. Global Health Policy: The Global 
HIV/AIDS Epidemic Fact Sheet. http://www.kff.org/hivaids/upload/3030-16.pdf (March 1, 
2012),  
36. The Henry J. Kaiser Family Foundation HIV/AIDS Policy Fact Sheet: The Global 
HIV/AIDS Epidemic. http://www.kff.org/hivaids/upload/3030-07.pdf (March 1, 2012),  
37. UNAIDS World AIDS Day Report. 
http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216
_WorldAIDSday_report_2011_en.pdf (March 1, 2012),  
38. WHO Tuberculosis and HIV. http://www.who.int/hiv/topics/tb/en/index.html (March 1, 
2012),  
39. UNAIDS Core Slides: Global Summary of the AIDS Epidemic. 
http://www.unaids.org/en/dataanalysis/epidemiology/epidemiologyslides/ (March 1, 2012),  
40. UNAIDS Policy Brief: HIV and Sex Between Men. 
http://www.unaids.org/en/media/unaids/contentassets/dataimport/publications/irc-pub07/jc1269-
policybrief-msm_en.pdf (February 29, 2012),  
41. AVERT HIV, AIDS and Men Who Have Sex with Med. http://www.avert.org/men-sex-
men.htm (March 1, 2012),  
175 
42. UNAIDS New Same Sex and Transgender Action Framework. 
http://www.unaids.org/en/Resources/PressCentre/Featurestories/2009/May/20090515ActionFra
mework/ (March 1, 2012),  
43. MSMGF Top Ten Key Global Policy Developments in 2010: Reflections from the Global 
Forum on MSM & HIV http://www.msmgf.org/index.cfm/id/11/aid/3027/langID/1/ (March 1, 
2012),  
44. WHO Women and health: today's evidence tomorrow's agenda. 
http://www.who.int/gender/documents/9789241563857/en/index.html (March 2, 2012),  
45. UNAIDS AIDS SCORECARD Overview: UNAIDS Report on the Global AIDS 
Epidemic 2010. http://www.unaids.org/documents/20101123_AIDS_scorecards_em.pdf 
(February 27, 2012),  
46. CDC HIV/AIDS among men who have sex with men. 
http://www.cdc.gov/nchhstp/newsroom/docs/fastfacts-msm-final508comp.pdf (February 29, 
2012),  
47. Purcell, D. W.; Johnson, C.; Lansky, A.; Prejean, J.; Stein, R.; Denning, Z.; Weinstock, 
G. H.; Su, J.; Crepaz, N. In Calculating HIV and Syphilis Rates for Risk Groups: Estimating the 
National Population Size of Men Who Have Sex with Men, National STD Prevention Conference, 
Atlanta, 2010; Atlanta, 2010. 
48. CDC HIV among Gay, Bisexual and Other Men Who Have Sex with Men (MSM). 
http://www.cdc.gov/hiv/topics/msm/index.htm (February 29, 2012),  
49. CDC CDC Fact Sheet: Estimates of New HIV Infections in the United States, 2006-2009. 
http://www.cdc.gov/nchhstp/newsroom/docs/HIV-Infections-2006-2009.pdf (February 29, 
2012),  
50. Hall, H. I.; Song, R.; Rhodes, P.; Prejean, J.; An, Q.; Lee, L. M.; Karon, J.; Brookmeyer, 
R.; Kaplan, E. H.; McKenna, M. T.; Janssen, R. S., Estimation of HIV Incidence in the United 
States. JAMA: The Journal of the American Medical Association 2008, 300, (5), 520-529. 
51. CDC Estimated Lifetime Risk for Diagnosis of HIV Infection Among Hispanics/Latinos 
--- 37 States and Puerto Rico, 2007. 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5940a2.htm (March 1, 2012),  
52. CDC HIV among Latinos. http://www.cdc.gov/hiv/latinos/index.htm (March 1, 2012),  
53. CDC HIV in the United States: An Overview. 
http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/incidence-overview.htm (March 
2, 2012),  
54. The Henry J. Kaiser Family Foundation. HIV/AIDS Policy: The HIV/AIDS Epidemic in 
the United States. http://www.kff.org/hivaids/upload/3029-12.pdf (March 2, 2012),  
176 
55. McEnery, R. Why is HIV Ravaging D.C.? 
http://www.iavireport.org/archives/2010/Pages/IAVI-Report-14%286%29-HIV-In-DC.aspx 
(March 1, 2012),  
56. The Henry J. Kaiser Family Foundation. Estimated Numbers of AIDS Diagnoses, All 
Ages, 2009. 
http://www.statehealthfacts.org/comparemaptable.jsp?ind=508&cat=11&sub=119&yr=92&typ=
1&sort=a (March 2, 2012),  
57. Prejean, J.; Song, R.; Hernandez, A.; Ziebell, R.; Green, T.; Walker, F.; Lin, L. S.; An, 
Q.; Mermin, J.; Lansky, A.; Hall, H. I., Estimated HIV Incidence in the United States, 2006-
2009. PLoS ONE 2011, 6, (8), e17502. 
58. Monterroso, E. R.; Hamburger M E ; Vlahov, D.; Des Jarlais, D. C.; Ouellet, L. J.; Altice, 
F. L.; Byers, R. H.; Kerndt, P. R.; Watters, J. K.; Bowser, B. P.; Fernando, M. D.; Holmberg, S. 
D., Prevention of HIV infection in street-recruited injection drug users. The Collaborative 
Injection Drug User Study (CIDUS). Journal of Acquired Immune Deficiency Syndromes 2000, 
25, (1), 63-70. 
59. Des Jarlais, D. C.; Perlis, T.; Arasteh, K.; Torian, L. V.; Beatrice, S.; Milliken, J.; 
Mildvan, D.; Yancovitz, S.; Friedman, S. R., HIV Incidence Among Injection Drug Users in 
New York City, 1990 to 2002: Use of Serologic Test Algorithm to Assess Expansion of HIV 
Prevention Services. American Journal of Public Health 2005, 95, (8), 1439-1444. 
60. Barr, S. Kaiser Health News: Needle-Exchange Programs Face New Federal Funding 
Ban http://www.kaiserhealthnews.org/Stories/2011/December/21/needle-exchange-federal-
funding.aspx (March 2, 2012),  
61. NIAID HIV/AIDS: Structure of HIV. 
http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/Pages/structure.aspx (March 
7, 2012),  
62. NIAID HIV/AIDS. 
http://www.niaid.nih.gov/TOPICS/HIVAIDS/UNDERSTANDING/HOWHIVCAUSESAIDS/Pa
ges/howhiv.aspx (March 3, 2012),  
63. Jonathan, K., Tackling Tat. Journal of Molecular Biology 1999, 293, (2), 235-254. 
64. Freed, E. O., HIV-1 and the host cell: an intimate association. Trends in Microbiology 
2004, 12, (4), 170-177. 
65. Vives, R. R.; Imberty, A.; Sattentau, Q. J.; Lortat-Jacob, H., Heparan Sulfate Targets the 
HIV-1 Envelope Glycoprotein gp120 Coreceptor Binding Site. The Journal of Biological 
Chemistry 2005, 280, (22), 21353-21357. 
66. Shukla, D.; Liu, J.; Blaiklock, P.; Shworak, N. W.; Bai, X.; Esko, J. D.; Cohen, G. H.; 
Eisenberg, R. J.; Rosenberg, R. D.; Spear, P. G., A Novel Role for 3-O-Sulfated Heparan Sulfate 
in Herpes Simplex Virus 1 Entry. Cell 1999, 99, (1), 13-22. 
177 
67. Chen, Y.; Maguire, T.; Hileman, R. E.; Fromm, J. R.; Esko, J. D.; Linhardt, R. J.; Marks, 
R. M., Dengue virus infectivity depends on envelope protein binding to target cell heparan 
sulfate. Nature Medicine 1997, 3, (8), 866-871. 
68. Kaiser, G. E. IV. Viruses: Animal Virus Life Cycles-The Life Cycle of HIV. 
http://faculty.ccbcmd.edu/courses/bio141/lecguide/unit3/viruses/hivlc.html (March 4, 2012),  
69. Geijtenbeek, T. B. H.; Kwon, D. S.; Torensma, R.; van Vliet, S. J.; van Duijnhoven, G. 
C. F.; Middel, J.; Cornelissen, I. L. M. H. A.; Nottet, H. S. L. M.; KewalRamani, V. N.; Littman, 
D. R.; Figdor, C. G.; van Kooyk, Y., DC-SIGN, a Dendritic Cell-Specific HIV-1-Binding Protein 
that Enhances trans-Infection of T Cells. Cell 2000, 100, (5), 587-597. 
70. Mondor, I.; Ugolini, S.; Sattentau, Q. J., Human Immunodeficiency Virus Type 1 
Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell 
Surface Heparans. Journal of Virology 1998, 72, (5), 3623-3634. 
71. Doms, R. W., Beyond Receptor Expression: The Influence of Receptor Conformation, 
Density, and Affinity in HIV-1 Infection. Virology 2000, 276, (2), 229-237. 
72. De Clercq, E., HIV Life Cycle: Targets for Anti-HIV Agents. In HIV-1 Integrase: 
Mechanism and Inhibitor Design, 1 ed.; Neamati, N., Ed. John Wiley & Sons: 2011; pp 1-14. 
73. Connor, R. I.; Sheridan, K. E.; Ceradini, D.; Choe, S.; Landau, N. R., Change in 
Coreceptor Use Correlates with Disease Progression in HIV-1-Infected Individuals. The Journal 
of Experimental Medicine 1997, 185, (4), 621-628. 
74. Scarlatti, G. T., Eleonora; Bjorndal, Asa; Fredriksson, Robert; Colognesi, Claudia; Deng, 
Hong Kui; Malnati, Mauro S.; Plebani, Anna; Siccardi, Antonio G.; Littman, Dan R.; Fenyo, Eva 
Maria; Lusso, Paolo In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-
mediated suppression. Nature Medicine 1997, 3, (11), 1259-1265. 
75. De Clercq, E., Strategies in the Design of Antiviral Drugs Nature Reviews Drug 
Discovery 2002, 1, 13-25. 
76. Greene, W. C.; Peterlin, B. M., Charting HIV's remarkable voyage through the cell: Basic 
science as a passport to future therapy. Nature Medicine 2002, 8, (7), 673. 
77. Adamson, C. S.; Freed, E. O., Advances in Pharmacology, HIV-1: Molecular Biology 
and Pathogenesis: Viral Mechanims. In [Online] Jeang, K.-T., Ed. Elsevier: 2007. 
78. Ganser-Pornillos, B. K.; Yeager, M.; Sundquist, W. I., The structural biology of HIV 
assembly. Current Opinion in Structural Biology 2008, 18, (2), 203-217. 
79. Cartier, C.; Sivard, P.; Tranchat, C.; Decimo, D.; Desgranges, C.; Boyer, V. r., 
Identification of Three Major Phosphorylation Sites within HIV-1 Capsid. Journal of Biological 
Chemistry 1999, 274, (27), 19434-19440. 
178 
80. Franke, E. K.; Yuan, H. E. H.; Luban, J., Specific incorporation of cyclophilin A into 
HIV-1 virions. Nature (London) 1994, 372, (6504), 359-362. 
81. Schaeffer, E.; Geleziunas, R.; Greene, W. C., Human Immunodeficiency Virus Type 1 
Nef Functions at the Level of Virus Entry by Enhancing Cytoplasmic Delivery of Virions. 
Journal of Virology 2001, 75, (6), 2993-3000. 
82. Ohagen, A.; Gabuzda, D., Role of Vif in Stability of the Human Immunodeficiency Virus 
Type 1 Core. Journal of Virology 2000, 74, (23), 11055-11066. 
83. Karageorgos, L. L., Peng; Burrell, Chris, Characterization of HIV replication complexes 
early after cell-to-cell infection. AIDS Research and Human Retroviruses 1993, 9, (9), 817-823. 
84. Bukrinskaya, A.; Brichacek, B.; Mann, A.; Stevenson, M., Establishment of a Functional 
Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcription Complex Involves the 
Cytoskeleton. The Journal of Experimental Medicine 1998, 188, (11), 2113-2125. 
85. Duyk, G.; Leis, J.; Longiaru, M.; Skalka, A. M., Selective cleavage in the avian retroviral 
long terminal repeat sequence by the endonuclease associated with the alpha beta form of avian 
reverse transcriptase. Proceedings of the National Academy of Sciences 1983, 80, (22), 6745-
6749. 
86. Pommier, Y.; Johnson, A. A.; Marchand, C., Integrase inhibitors to treat HIV/Aids. 
Nature Reviews Drug Discovery 2005, 4, (3), 236-248. 
87. Kalpana, G. V.; Marmon, S.; Wang, W.; Crabtree, G. R.; Goff, S. P., Binding and 
stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 
1994, 266, (5193), 2002-2006. 
88. Cherepanov, P.; Maertens, G.; Proost, P.; Devreese, B.; Van Beeumen, J.; Engelborghs, 
Y.; De Clercq, E.; Debyser, Z., HIV-1 Integrase Forms Stable Tetramers and Associates with 
LEDGF/p75 Protein in Human Cells. Journal of Biological Chemistry 2003, 278, (1), 372-381. 
89. Violot, S. b.; Hong, S. S.; Rakotobe, D.; Petit, C.; Gay, B.; Moreau, K.; Billaud, G. v.; 
Priet, S. p.; Sire, J. p.; Schwartz, O.; Mouscadet, J.-F. o.; Boulanger, P., The Human Polycomb 
Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1. 
Journal of Virology 2003, 77, (23), 12507-12522. 
90. Parissi, V.; Calmels, C.; De Soultrait, V. R.; Caumont, A.; Fournier, M.; Chaignepain, S. 
p.; Litvak, S., Functional Interactions of Human Immunodeficiency Virus Type 1 Integrase with 
Human and Yeast HSP60. Journal of Virology 2001, 75, (23), 11344-11353. 
91. Turlure, F. D., Eric; Silver, Pamela A.; Engelman, Alan Human cell proteins and human 
immunodeficiency virus DNA integration. Frontiers in bioscience 2004, 9, (suppl.), 3187-3208. 
92. Jordan, A.; Defechereux, P.; Verdin, E., The site of HIV-1 integration in the human 
genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 
2001, 20, (7), 1726-1738. 
179 
93. Stevens, M.; De Clercq, E.; Balzarini, J., The regulation of HIV-1 transcription: 
Molecular targets for chemotherapeutic intervention. Medicinal Research Reviews 2006, 26, (5), 
595-625. 
94. Taube, R.; Fujinaga, K.; Wimmer, J.; Barboric, M.; Peterlin, B. M., Tat Transactivation: 
A Model for the Regulation of Eukaryotic Transcriptional Elongation. Virology 1999, 264, (2), 
245-253. 
95. Yamaguchi, Y.; Takagi, T.; Wada, T.; Yano, K.; Furuya, A.; Sugimoto, S.; Hasegawa, J.; 
Handa, H., NELF, a Multisubunit Complex Containing RD, Cooperates with DSIF to Repress 
RNA Polymerase II Elongation. Cell 1999, 97, (1), 41-51. 
96. Yamaguchi, Y.; Filipovska, J.; Yano, K.; Furuya, A.; Inukai, N.; Narita, T.; Wada, T.; 
Sugimoto, S.; Konarska, M. M.; Handa, H., Stimulation of RNA Polymerase II Elongation by 
Hepatitis Delta Antigen. Science 2001, 293, (5527), 124-127. 
97. Yamaguchi, Y., HIV-1 Transcription: Activation Mediated by Acetylation of Tat. 
Structure 2002, 10, 443-446. 
98. Garber, M. E.; Jones, K. A., HIV-1 Tat: coping with negative elongation factors. Current 
Opinion in Immunology 1999, 11, 460-465. 
99. Wong, K.; Sharma, A.; Awasthi, S.; Matlock, E. F.; Rogers, L.; Van Lint, C.; Skiest, D. 
J.; Burns, D. K.; Harrod, R., HIV-1 Tat Interactions with p300 and PCAF Transcriptional 
Coactivators Inhibit Histone Acetylation and Neurotrophin Signaling through CREB. Journal of 
Biological Chemistry 2005, 280, (10), 9390-9399. 
100. Adamson, C. S.; Freed, E. O., Novel approaches to inhibiting HIV-1 replication. Antiviral 
Research 2010, 85, (1), 119-141. 
101. Cihlar, T.; Ray, A. S., Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 
years after zidovudine. Antiviral Research 2011, 85, (1), 39-58. 
102. Wensing, A. M. J. v. M., Noortje M; Nijhuis, Monique Fifteen years of HIV Protease 
Inhibitors: raising the barrier to resistance. Antiviral research 2010, 85, (1), 59-74. 
103. de Bethune, M.-P., Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their 
discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 
years (1989-2009). Antiviral Research 2010, 85, (1), 75-90. 
104. McColl, D. J.; Chen, X., Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new 
era of antiretroviral therapy. Antiviral Research 2010, 85, (1), 101-118. 
105. Tilton, J. C.; Doms, R. W., Entry inhibitors in the treatment of HIV-1 infection. Antiviral 
Research 2010, 85, (1), 91-100. 
106. Tantillo, C. D., Jianping; Jacobo-Molina, Alfredo; Nanni, Raymond G.; Boyer, Paul L.; 
Hughes, Stephen H.; Pauwels, Rudi; Andries, Koen; Janssen, Paul A. J.; Arnold, Edward 
180 
Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional 
Structure of HIV-1 Reverse Transcriptase Implications for Mechanisms of Drug Inhibition and 
Resistance. Journal of Molecular Biology 1994, 243, (3), 369-387. 
107. Rudi, P., New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development 
for the treatment of HIV infections. Current Opinion in Pharmacology 2004, 4, (5), 437-446. 
108. Furman, P. A.; Fyfe, J. A.; St Clair, M. H.; Weinhold, K.; Rideout, J. L.; Freeman, G. A.; 
Lehrman, S. N.; Bolognesi, D. P.; Broder, S.; Mitsuya, H., Phosphorylation of 3'-azido-3'-
deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency 
virus reverse transcriptase. Proceedings of the National Academy of Sciences 1986, 83, (21), 
8333-8337. 
109. Cheng, Y. C.; Dutschman, G. E.; Bastow, K. F.; Sarngadharan, M. G.; Ting, R. Y., 
Human immunodeficiency virus reverse transcriptase. General properties and its interactions 
with nucleoside triphosphate analogs. Journal of Biological Chemistry 1987, 262, (5), 2187-
2189. 
110. St Clair, M. H.; Richards, C. A.; Spector, T.; Weinhold, K.; Miller, W. H.; Langlois, A. 
J.; Furman, P. A., 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of 
purified human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 
1987, 31, (12), 1972-1977. 
111. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and 
Adolescents. http://aidsinfo.nih.gov/contentfiles/AA_Tables.pdf (March 8, 2012),  
112. Ray, A. S., Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse 
transcriptase. AIDS Reviews 2005, 7, 113-125. 
113. Roberts, J. D.; Bebenek, K.; Kunkel, T. A., The accuracy of reverse transcriptase from 
HIV-1. Science 1988, 242, 1171-1173. 
114. Coffin, J. M., HIV population dynamics in vivo: implications for genetic variation, 
pathogenesis, and therapy. Science 1995, 267, 483-489. 
115. Lewis, W.; Day, B. J.; Copeland, W. C., Mitochondrial Toxicity of NRTI Antiviral 
Drugs: An Integrated Cellular Perspective. Nature Reviews Drug Discovery 2003, 2, 812-822. 
116. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A.; 
Scolnick, E. M.; Sigal, I. S., Active human immunodeficiency virus protease is required for viral 
infectivity. Proceedings of the National Academy of Sciences 1988, 85, (13), 4686-4690. 
117. Jacks, T. P., Michael D.; Masiarz, Frank R.; Luciw, Paul A.; Barr, Philip J.; Varmus, 
Harold E. , Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 
1988, 331, (6153), 280-283. 
181 
118. Karacostas, V.; Nagashima, K.; Gonda, M. A.; Moss, B., Human immunodeficiency 
virus-like particles produced by a vaccinia virus expression vector. Proceedings of the National 
Academy of Sciences 1989, 86, 8964-8967. 
119. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. 
B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Kröhn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; 
Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J., 
Rational Design of Peptide-Based HIV Proteinase Inhibitors. Science 1990, 248, (4953), 358-
361. 
120. Craig, J. C. D., I. B.; Hockley, D.; Grief, C.; Roberts, N. A.; Mills, J. S. , Antiviral 
properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. 
Antiviral Research 1991, 16, (4), 295-305. 
121. Kempf, D. J. M., Kennan C.; Denissen, Jon F.; McDonald, Edith; Vasavanonda, 
Sudthida; Flentge, Charles A.; Green, Brian E.; Fino, Lynnmarie; Park, Chang H.; Kong, Xiang-
Peng; Wideburg, Norman E.; Saldivar, Ayda; Ruiz, Lisa; Kati, Warren M.; Sham, Hing L; 
Robins, Terry; Stewart, Kent D.; Hsu, Ann; Plattner, Jacob J.; Leonard, John M.; Norbeck, 
Daniel W., ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has 
High Oral Bioavailability in Humans. PNAS : Proceedings of the National Academy of Sciences 
1995, 92, (7), 2484-2488. 
122. Koh, Y. N., Hirotomo; Maeda, Kenji; Ogata, Hiromi; Bilcer, Geoffrey; Devasamudram, 
Thippeswamy; Kincaid, John F.; Boross, Peter; Wang, Yuan-Fang; Tie, Yunfeng; Volarath, 
Patra; Gaddis, Laquasha; Harrison, Robert W.; Weber, Irene T.; Ghosh, Arun K.; Mitsuya, 
Hiroaki Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) 
UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human 
Immunodeficiency Virus In Vitro. Antimicrobial Agents and Chemotherapy 2003, 47, (10), 
3123-3129. 
123. Partaledis, J. A. Y., Koushi; Tisdale, Margaret; Blair, Edward E.; Falcione, Cristina; 
Maschera, Barbara; Myers, Richard E.; Pazhanisamy, S.; Futer, Olga; Cullinan, Aine B.; Stuver, 
Cameron M.; Byrn, Randal A.; Livingston, David J., In vitro selection and characterization of 
human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to 
hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. Journal of Virology 1995, 
69, (9), 5228. 
124. Patick, A. K.; Mo, H.; Markowitz, M.; Appelt, K.; Wu, B.; Musick, L.; Kalish, V.; 
Kaldor, S.; Reich, S.; Ho, D.; Webber, S., Antiviral and resistance studies of AG1343, an orally 
bioavailable inhibitor of human immunodeficiency virus protease. Antimicrobial Agents and 
Chemotherapy 1996, 40, (2), 292-7. 
125. Robinson, B. S.; Riccardi, K. A.; Gong, Y.-f.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, 
B. J.; Deminie, C. A.; Djang, F.; Colonno, R. J.; Lin, P.-f., BMS-232632, a Highly Potent 
Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with 
Other Available Antiretroviral Agents. Antimicrobial Agents and Chemotherapy 2000, 44, (8), 
2093-2099. 
182 
126. Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. N.; Chen, C.-M.; Kati, 
W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, 
E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; 
Granneman, G. R.; Sun, E.; Japour, A. J.; Leonard, J. M.; Plattner, J. J.; Norbeck, D. W., ABT-
378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease. Antimicrobial 
Agents and Chemotherapy 1998, 42, (12), 3218-3224. 
127. Vacca, J. P. D., B.D.; Schleif, W.A.; Levin, R.B.; McDaniel, S.L.; Darke, P.L.; Zugay, J.; 
Quintero, J.C.; Blahly, O.M.; Roth, E., L-735,524: An Orally Bioavailable Human 
Immunodeficiency Virus Type 1 Protease Inhibitor. Proceedings of the National Academy of 
Sciences 1994, 91, (9), 4096-4100. 
128. Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Aristoff, P. A.; Johnson, P. D.; 
Skulnick, H. I.; Dolak, L. A.; Seest, E. P.; Tomich, P. K.; Bohanon, M. J.; Horng, M.-M.; Lynn, 
J. C.; Chong, K.-T.; Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thaisrivongs, S., 
Tipranavir (PNU140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 
5,6-dihydro-4hydroxy-2-pyrone sulfonamide class. Journal of Medicinal Chemistry 1998, 41, 
(18), 3467-3476. 
129. Gulnik, S. V., HIV-1 Protease Inhibitors as Antiretroviral Agents. In Enzyme Inhibition 
in Drug Discovery and Development, Lu, C.; Li, A. P. L., Eds. John Wiley & Sons, Inc.: 
Hoboken, NJ, 2010; pp 749-810. 
130. Furfine, E. S.; Baker, C. T.; Hale, M. R.; Reynolds, D. J.; Salisbury, J. A.; Searle, A. D.; 
Studenberg, S. D.; Todd, D.; Tung, R. D.; Spaltenstein, A., Preclinical Pharmacology and 
Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency 
Virus Protease Inhibitor Amprenavir. Antimicrobial Agents and Chemotherapy 2004, 48, (3), 
791-798. 
131. King, J. R.; Acosta, E. P., Tipranavir: a novel peptidic protease inhibitor of HIV. Clinical 
Pharmacokinetics 2006, 45, 665-682. 
132. Sluis-Cremer, N.; Temiz, N. A.; Bahar, I., Conformational changes in HIV-1 reverse 
transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Current HIV 
Research 2004, 2, 323-332. 
133. Blas-Garcia, A.; Esplugues, J. V.; Apostolova, N., Twenty Years of HIV-1 Non-
Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity. Current 
Medicinal Chemistry 2011, 18, 2186-2195. 
134. Podzamczer, D.; Fumero, E., The role of nevirapine in the treatment of HIV-1 disease. 
Expert Opinion in Pharmacotherapy 2001, 2, 2065-2078. 
135. Best, B. M.; Goicoechea, M., Efavirenz-still first-line king? Expert Opinion in Drug 
Metabolism & Toxicology 2008, 4, 965-972. 
183 
136. Kitchen, C. M.; Kitchen, S. G.; Dubin, J. A.; Gottlieb, M. S., Initial Virological and 
Immunologic Response to Highly Active Antiretroviral Therapy Predicts Long-Term Clinical 
Outcome. Clinical Infectious Diseases 2001, 33, (4), 466-472. 
137. Hammer, S. M.; Eron, J. J.; Reiss, P.; Schooley, R. T.; Thompson, M. A.; Walmsley, S.; 
Cahn, P.; Fischl, M. A.; Gatell, J. M.; Hirsch, M. S.; Jacobsen, D. M.; Montaner, J. S. G.; 
Richman, D. D.; Yeni, P. G.; Volberding, P. A., Antiretroviral Treatment of Adult HIV 
Infection. JAMA: The Journal of the American Medical Association 2008, 300, (5), 555-570. 
138. Clercq, E. D., From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™. Future 
Virology 2006, 1, (6), 709-715. 
139. Poveda, E.; Briz, V.; Soriano, V., Enfuvirtide, the First Fusion Entry Inhibitor to Treat 
HIV Infection. AIDS Reviews 2005, 7, 139-147. 
140. Wild, C.; Oas, T.; McDanal, C.; Bolognesi, D.; Matthews, T., A synthetic peptide 
inhibitor of human immunodeficiency virus replication: correlation between solution structure 
and viral inhibition. Proceedings of the National Academy of Sciences 1992, 89, (21), 10537-
10541. 
141. Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. B.; Matthews, T. J., Peptides 
corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 
gp41 are potent inhibitors of virus infection. Proceedings of the National Academy of Sciences 
1994, 91, (21), 9770-9774. 
142. Jiang, S.; Li, K.; Strik, N.; Neurath, A., HIV-1 inhibition by a peptide. Nature 1993, 365, 
(6442), 113-113. 
143. Dietrich, U., HIV-1 Entry Inhibitors. AIDS Reviews 2001, 3, 89-97. 
144. Weiss, C., HIV-1 gp41: Mediator of Fusion and Target for Inhibition. AIDS Reviews 
2003, 5, 214-221. 
145. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D., 
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev 
Drug Discov 2004, 3, (3), 215-225. 
146. Greenberg, M. L.; Cammack, N., Resistance to enfuvirtide, the first HIV fusion inhibitor. 
Journal of Antimicrobial Chemotherapy 2004, 54, (2), 333-340. 
147. De Clercq, E.; Yamamoto, N.; Pauwels, R.; Balzarini, J.; Witvrouw, M.; De Vreese, K.; 
Debyser, Z.; Rosenwirth, B.; Peichl, B.; Datema, R.; Thorton, D.; Skerlj, R.; Gaul, F.; 
Padmanabhan, S.; Bridger, G.; Henson, G.; Abrams, M., Highly potent and selective inhibition 
of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrobial Agents and 
Chemotherapy 1994, 38, 668-674. 
184 
148. Schols, D.; Struyf, S.; J., V. D.; Esté, J. A.; Henson, G.; De Clercq, E., Inhibition of T-
trophic HIV strains by selective antagonization of the chemokine receptor CXCR4. Journal of 
Experimental Medicine 1997, 186, 1383-1388. 
149. Perros, M., CCR5 antagonists for the treatment of HIV infection and AIDS. In Advances 
in Antiviral Drug Design, Elsevier: Amsterdam, 2007; Vol. 5, pp 185-212. 
150. Levy, J. A., HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 
2009, 23, (2), 147-160. 
151. Biswas, P.; Tambussi, G.; Lazzarin, A., Access denied? The status of co-receptor 
inhibition to counter HIV entry. Expert Opinion in Pharmacotherapy 2007, 8, (7), 923-933. 
152. Emmelkamp, J.; Rockstroh, J., CCR5 antagonists: comparison of efficacy, side effects, 
pharmacokinetics and interactions--review of the literature. European Journal of Medical 
Research 2007, 12, (9), 409-417. 
153. Westby, M.; Lewis, M.; Whitcomb, J.; Youle, M.; Pozniak, A. L.; James, I. T.; Jenkins, 
T. M.; Perros, M.; van der Ryst, E., Emergence of CXCR4-Using Human Immunodeficiency 
Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment 
with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir. 
Journal of Virology 2006, 80, (10), 4909-4920. 
154. Westby, M.; Smith-Burchnell, C.; Mori, J.; Lewis, M.; Mosley, M.; Stockdale, M.; Dorr, 
P.; Ciaramella, G.; Perros, M., Reduced Maximal Inhibition in Phenotypic Susceptibility Assays 
Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound 
Receptor for Entry. Journal of Virology 2007, 81, (5), 2359-2371. 
155. Daelemans, D.; Lu, R.; De Clercq, E.; Engelman, A., Characterization of a Replication-
Competent, Integrase-Defective Human Immunodeficiency Virus (HIV)/Simian Virus 40 
Chimera as a Powerful Tool for the Discovery and Validation of HIV Integrase Inhibitors. 
Journal of Virology 2007, 81, (8), 4381-4385. 
156. Grinsztejn, B.; Nguyen, B.-Y.; Katlama, C.; Gatell, J. M.; Lazzarin, A.; Vittecoq, D.; 
Gonzalez, C. J.; Chen, J.; Harvey, C. M.; Isaacs, R. D., Safety and efficacy of the HIV-1 
integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-
resistant virus: a phase II randomised controlled trial. The Lancet 2007, 369, (9569), 1261-1269. 
157. Ross, A. L.; Brave, A.; Scarlatti, G.; Manrique, A.; Buonaguro, L., Progress towards 
development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infectious 
Diseases 2010, 10, (5), 305-316. 
158. Jesil, A. M.; Palanimuthu Vasanth Raj, A. M.; Rao, J. V., HIV Vaccines: Present 
Scenario and Future Prospects. Pharmacologyonline 2011, 2, 90-103. 
159. Mocroft, A.; Phillips, A. N.; Gatell, J.; Ledergerber, B.; Fisher, M.; Clumeck, N.; Losso, 
M.; Lazzarin, A.; Fatkenheuer, G.; Lundgren, J. D., Normalisation of CD4 counts in patients 
185 
with HIV-1 infection and maximum virological suppression who are taking combination 
antiretroviral therapy: an observational cohort study. The Lancet 2007, 370, (9585), 407-413. 
160. Rodriguez, B.; Sethi, A. K.; Cheruvu, V. K.; Mackay, W.; Bosch, R. J.; Kitahata, M.; 
Boswell, S. L.; Mathews, W. C.; Bangsberg, D. R.; Martin, J.; Whalen, C. C.; Sieg, S.; 
Yadavalli, S.; Deeks, S. G.; Lederman, M. M., Predictive Value of Plasma HIV RNA Level on 
Rate of CD4 T-Cell Decline in Untreated HIV Infection. JAMA: The Journal of the American 
Medical Association 2006, 296, (12), 1498-1506. 
161. Mellors, J. W.; Margolick, J. B.; Phair, J. P.; Rinaldo, C. R.; Detels, R.; Jacobson, L. P.; 
Munoz, A., Prognostic Value of HIV-1 RNA, CD4 Cell Count, and CD4 Cell Count Slope for 
Progression to AIDS and Death in Untreated HIV-1 Infection. JAMA: The Journal of the 
American Medical Association 2007, 297, (21), 2349-2350. 
162. Johnson, V.; Brun-Vezinet, F.; Clotet, B.; Gunthard, H.; Kuritzkes, D.; Pillay, D.; 
Schapiro, J.; Richman, D., Update of the drug resistance mutations in HIV-1: December 2009. 
Top HIV Med 2009, 17, (5), 138-145. 
163. Moore, J. P.; Kitchen, S. G.; Pugach, P.; Zack, J. A., The CCR5 and CXCR4 
Coreceptors—Central to Understanding the Transmission and Pathogenesis of Human 
Immunodeficiency Virus Type 1 Infection AIDS Research and Human Retroviruses 2004, 20, 
(1), 111-126. 
164. Hirsch, M. S.; Gunthard, H. F.; Schapiro, J. M.; Vezinet, F. B.; Clotet, B.; Hammer, S. 
M.; Johnson, V. A.; Kuritzkes, D. R.; Mellors, J. W.; Pillay, D.; Yeni, P. G.; Jacobsen, D. M.; 
Richman, D. D., Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 
Recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases 
2008, 47, (2), 266-285. 
165. Cohen, J., Confronting the Limits of Success. Science 2002, 296, (5577), 2320-2324. 
166. Freedberg, K. A.; Losina, E.; Weinstein, M. C.; Paltiel, A. D.; Cohen, C. J.; Seage, G. R.; 
Craven, D. E.; Zhang, H.; Kimmel, A. D.; Goldie, S. J., The Cost Effectiveness of Combination 
Antiretroviral Therapy for HIV Disease. New England Journal of Medicine 2001, 344, (11), 824-
831. 
167. Asante-Appiah, E.; Skalka, A. M., Molecular mechanisms in retrovirus DNA integration. 
Antiviral Research 1997, 36, (3), 139-156. 
168. Liao, C.; Marchand, C.; Burke, T. R.; Pommier, Y.; Nicklaus, M. C., Authentic HIV-1 
integrase inhibitors. Future Medicinal Chemistry 2010, 2, (7), 1107-1122. 
169. Halgren, T. A., Identifying and Characterizing Binding Sites and Assessing Druggability. 
Journal of Chemical Information and Modeling 2009, 49, (2), 377-389. 
170. Schmidtke, P.; Barril, X., Understanding and Predicting Druggability. A High-
Throughput Method for Detection of Drug Binding Sites. Journal of Medicinal Chemistry 2010, 
53, (15), 5858-5867. 
186 
171. Miller, M. D.; Farnet, C. M.; Bushman, F. D., Human immunodeficiency virus type 1 
preintegration complexes: studies of organization and composition. Journal of Virology 1997, 
71, (7), 5382-8390. 
172. Chiu, P.; Craigie, R.; Davies, D. R., Structure and Function of HIV-1 integrase. Current 
Topics in Medicinal Chemistry 2004, 4, 965-977. 
173. Engelman, A.; Mizuuchi, K.; Craigie, R., HIV-1 DNA integration: Mechanism of viral 
DNA cleavage and DNA strand transfer. Cell 1991, 67, (6), 1211-1221. 
174. Schroder, A. R. W.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J. R.; Bushman, F., HIV-1 
Integration in the Human Genome Favors Active Genes and Local Hotspots. Cell 2002, 110, (4), 
521-529. 
175. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, 
A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D., Inhibitors of Strand Transfer That 
Prevent Integration and Inhibit HIV-1 Replication in Cells. Science 2000, 287, (5453), 646-650. 
176. Asante-Appiah, E.; Skalka, A. M.; Karl Rlaramorosch, F. A. M.; Aaron, J. S., HIV-1 
Integrase: Structural Organization, Conformational Changes, and Catalysis. In Advances in Virus 
Research, Academic Press: 1999; Vol. Volume 52, pp 351-369. 
177. Bushman, F. D.; Craigie, R., Activities of human immunodeficiency virus (HIV) 
integration protein in vitro: specific cleavage and integration of HIV DNA. Proceedings of the 
National Academy of Sciences 1991, 88, (4), 1339-1343. 
178. Neamati, N., Structure-based HIV-1 integrase inhibitor design: a future perspective. 
Expert opinion on investigational drugs 2001, 10, (2), 281-296. 
179. Deng, J.; Kelley, J. A.; Barchi, J. J.; Sanchez, T.; Dayam, R.; Pommier, Y.; Neamati, N., 
Mining the NCI antiviral compounds for HIV-1 integrase inhibitors. Bioorganic &amp; 
Medicinal Chemistry 2006, 14, (11), 3785-3792. 
180. Bushman, F. D.; Fujiwara, T.; Craigie, R., Retroviral DNA integration directed by HIV 
integration protein in vitro. Science 1990, 249, (4976), 1555-1558. 
181. Sherman, P. A.; Fyfe, J. A., Human immunodeficiency virus integration protein 
expressed in Escherichia coli possesses selective DNA cleaving activity. Proceedings of the 
National Academy of Sciences 1990, 87, (13), 5119-5123. 
182. Farnet, C. M.; Haseltine, W. A., Integration of human immunodeficiency virus type 1 
DNA in vitro. Proceedings of the National Academy of Sciences 1990, 87, (11), 4164-4168. 
183. Fesen, M. R.; Kohn, K. W.; Leteurtre, F.; Pommier, Y., Inhibitors of human 
immunodeficiency virus integrase. Proceedings of the National Academy of Sciences 1993, 90, 
(6), 2399-2403. 
187 
184. Savarino, A., A Historical Sketch of the Discovery and Development of HIV-1 Integrase 
Inhibitors. Expert opinion on Investigational Drugs 2006, 15, (12), 1507-1522. 
185. Craigie, R.; Bushman, F.; Mizuchi, K. Retroviral in vitro integration assay for screening 
for inhibitors of integration factors. WO 9203578, March 5, 1992. 
186. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. W., 
Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related 
compounds. Biochemical Pharmacology 1994, 48, (3), 595-608. 
187. Kim, H. J.; Woo, E.-R.; Shin, C.-G.; Park, H., A New Flavonol Glycoside Gallate Ester 
from Acer okamotoanum and Its Inhibitory Activity against Human Immunodeficiency Virus-1 
(HIV-1) Integrase. Journal of Natural Products 1998, 61, (1), 145-148. 
188. LaFemina, R. L.; Graham, P. L.; LeGrow, K.; Hastings, J. C.; Wolfe, A.; Young, S. D.; 
Emini, E. A.; Hazuda, D. J., Inhibition of human immunodeficiency virus integrase by bis-
catechols. . Antimicrobial agents and chemotherapy 1995, 39, (2), 320-324. 
189. Mazumder, A.; Wang, S.; Neamati, N.; Nicklaus, M.; Sunder, S.; Chen, J.; Milne, G. W. 
A.; Rice, W. G.; Burke, T. R.; Pommier, Y., Antiretroviral Agents as Inhibitors of both Human 
Immunodeficiency Virus Type 1 Integrase and Protease. Journal of Medicinal Chemistry 1996, 
39, (13), 2472-2481. 
190. Eich, E.; Pertz, H.; Kaloga, M.; Schulz, J.; Fesen, M. R.; Mazumder, A.; Pommier, Y., (-
)-Arctigenin as a Lead Structure for Inhibitors of Human Immunodeficiency Virus Type-1 
Integrase. Journal of Medicinal Chemistry 1996, 39, (1), 86-95. 
191. Mazumder, A.; Gazit, A.; Levitzki, A.; Nicklaus, M.; Yung, J.; Kohlhagen, G.; Pommier, 
Y., Effects of Tyrphostins, Protein Kinase Inhibitors, on Human Immunodeficiency Virus Type 1 
Integrase. Biochemistry 1995, 34, (46), 15111-15122. 
192. Robinson, W. E.; Cordeiro, M.; Abdel-Malek, S.; Jia, Q.; Chow, S. A.; Reinecke, M. G.; 
Mitchell, W. M., Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: 
inhibition of the core catalytic domain of human immunodeficiency virus integrase. Molecular 
Pharmacology 1996, 50, (4), 846-855. 
193. Robinson, W. E.; Reinecke, M. G.; Abdel-Malek, S.; Jia, Q.; Chow, S. A., Inhibitors of 
HIV-1 replication that inhibit HIV integrase. Proceedings of the National Academy of Sciences 
1996, 93, (13), 6326-6331. 
194. Neamati, N.; Sunder, S.; Pommier, Y., Design and discovery of HIV-1 integrase 
inhibitors. Drug Discovery Today 1997, 2, (11), 487-498. 
195. Stanwell, C.; Ye, B.; Yuspa, S. H.; Burke, T. R., Cell Protein Cross-linking by Erbstatin 
and Related Compounds. Biochemical Pharmacology 1996, 52, 475-480. 
188 
196. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. 
W. A.; Pommier, Y., HIV-1 Integrase Pharmacophore: Discovery of Inhibitors through Three-
Dimensional Database Searching. Journal of Medicinal Chemistry 1997, 40, (6), 920-929. 
197. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G. W.; Pommier, Y.; 
Burke, T. R., Hydrazide-containing inhibitors of HIV-1 integrase. Journal of Medicinal 
Chemistry 1997, 40, 937-941. 
198. Neamati, N.; Hong, H.; Owen, J. M.; Sunder, S.; Winslow, H. E.; Christensen, J. L.; 
Zhao, H.; Burke, T. R.; Milne, G. W.; Pommier, Y., Salicylhydrazine-containing inhibitors of 
HIV-1 integrase: Implication for a selective chelation in the integrase active site. Journal of 
Medicinal Chemistry 1998, 41, 3202-3209. 
199. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A.; Zhao, H.; Burke, T. 
R.; Pommier, Y.; Milne, G. W., Discovery of HIV-1 integrase inhibitors by pharmacophore 
searching. Journal of Medicinal Chemistry 1997, 40, (6), 930-936. 
200. Zhao, X. Z.; Semenova, E. A.; Vu, B. C.; Maddali, K.; Marchand, C.; Hughes, S. H.; 
Pommier, Y.; Burke, T. R., 2,3-Dihydro-6,7-dihydroxy-1H-isoindol-1-one-Based HIV-1 
Integrase Inhibitors. Journal of Medicinal Chemistry 2008, 51, (2), 251-259. 
201. Dayam, R.; Neamati, N., Small-Molecule HIV-1 Integrase Inhibitors: the 2001-2002 
Update. Current Pharmaceutical Design 2003, 9, (22), 1789. 
202. Pommier, Y.; Neamati, N., Inhibitors of human immunodeficiency virus integrase. 
Advances in Virus Research 1999, 52, 427-458. 
203. Hazuda, D. J.; Felock, P. J.; Hastings, J. C.; Pramanik, B.; Wolfe, A. L., Differential 
Divalent Cation Requirements Uncouple the Assembly and Catalytic Reactions of Human 
Immunodeficiency Virus Type 1 Integrase. Journal of Virology 1997, 71, (9), 7005-7011. 
204. Ellison, V.; Brown, P. O., A stable complex between integrase and viral DNA ends 
mediates human immunodeficiency virus integration in vitro. Proceedings of the National 
Academy of Sciences 1994, 91, (15), 7316-7320. 
205. Parrill, A. L., HIV-1 Integrase Inhibition: Binding Sites, Structure Activity Relationships 
and Future Perspectives. Current Medicinal Chemistry 2003, 10, (18), 1811. 
206. Asante-Appiah, E.; Skalka, A. M., A Metal-induced Conformational Change and 
Activation of HIV-1 Integrase. Journal of Biological Chemistry 1997, 272, (26), 16196-16205. 
207. Wolfe, A. L.; Felock, P. J.; Hastings, J. C.; Blau, C. U.; Hazuda, D. J., The role of 
manganese in promoting multimerization and assembly of human immunodeficiency virus type 1 
integrase as a catalytically active complex on immobilized long terminal repeat substrates. 
Journal of Virology 1996, 70, (3), 1424-1432. 
208. Hazuda, D. J.; Hastings, J. C.; Wolfe, A. L.; Emini, E. A., A novel assay for the DNA 
strand-transfer reaction of HIV-1 integrase. Nucleic Acids Research 1994, 22, (6), 1121-1122. 
189 
209. Singh, S. B.; Pelaez, F.; Hazuda, D. J.; Lingham, R. B., Discovery of natural product 
inhibitors of HIV-1 integrase at Merck. Drugs of the Future 2005, 30, (3), 277-299. 
210. Selnick, H. G.; Hazuda, D. J.; Egbertson, M.; Guare, J. P., Jr.; Wai, J. S.; Young, S. D.; 
Clark, D. L.; Medina, J. C. Preparation of nitrogen-containing 4-heteroaryl-2,4-dioxobutyric 
acids useful as HIV integrase inhibitors. WO 9962513 A1, 1999. 
211. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; 
Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R., Structure of the HIV-1 integrase catalytic 
domain complexed with an inhibitor: A platform for antiviral drug design. Proceedings of the 
National Academy of Sciences 1999, 96, (23), 13040-13043. 
212. Wai, J. S.; Egbertson, M. S.; Payne, L. S.; Fisher, T. E.; Embrey, M. W.; Tran, L. O.; 
Melamed, J. Y.; Langford, H. M.; Guare, J. P.; Zhuang, L.; Grey, V. E.; Vacca, J. P.; Holloway, 
M. K.; Naylor-Olsen, A. M.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Schleif, 
W. A.; Gabryelski, L. J.; Young, S. D., 4-Aryl-2,4-dioxobutanoic Acid Inhibitors of HIV-1 
Integrase and Viral Replication in Cells. Journal of Medicinal Chemistry 2000, 43, (26), 4923-
4926. 
213. Pais, G. C. G.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E. 
S.; Pathak, V. K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T. R., Jr. , Structure Activity of 
3-Aryl-1,3-diketo-Containing Compounds as HIV-1 Integrase Inhibitors. Journal of Medicinal 
Chemistry 2002, 45, (15), 3184-3194. 
214. Neamati, N., Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. 
Expert Opinion on Therapeutic Patents 2002, 15, (5), 709-724. 
215. Marchand, C.; Maddali, K.; Métifiot, M.; Pommier, Y., HIV-1 IN Inhibitors: 2010 
Update and Perspectives. Current Topics in Medicinal Chemistry 2009, 9, (11), 1016-1037. 
216. Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craige, R.; Davies, D. R., Crystal Structure of 
the Catalytic Domain of HIV-1 Integrase: Similarity of Other Polynucleotide Transferases. 
Science 1994, 266, 1981-1986. 
217. Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A. S.; Wolfe, A.; 
Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J. S.; Young, S.; Vacca, J.; Hazuda, D. J., 
Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the 
active site of phosphotransferase enzymes. Proceedings of the National Academy of Sciences 
2002, 99, (10), 6661-6666. 
218. Marchand, C.; Johnson, A. A.; Karki, R. G.; Pais, G. C. G.; Zhang, X.; Cowansage, K.; 
Patel, T. A.; Nicklaus, M. C.; Burke, T. R.; Pommier, Y., Metal-Dependent Inhibition of HIV-1 
Integrase by Î²-Diketo Acids and Resistance of the Soluble Double-Mutant (F185K/C280S). 
Molecular Pharmacology 2003, 64, (3), 600-609. 
219. Egbertson, M. S.; Anthony, N. J.; Summa, V., HIV-Integrase Inhibitor Design: From 
Diketo Acids to Heterocyclic Templates: History of HIV Integrase Medicinal Chemistry at 
Merck West Point and Merck Rome (IRBM) Leading to Discovery of Raltegravir. In HIV-1 
190 
Integrase: Mechanism and Inhibitor Design, Neamati, N., Ed. John Wiley & Sons, Inc.: 2011; pp 
197-229. 
220. Young, S. D.; Egbertson, M.; Payne, L. S.; Wai, J. S.; Fisher, T. E.; Guare, J. P., Jr.; 
Embrey, M. W.; Tran, L.; Zhuang, L.; Vacca, J. P.; Langford, M.; Melamed, J.; Clark, D. L.; 
Medina, J. C.; Jaen, J. Preparation of aromatic and heteroaromatic 4-aryl-2,4-dioxobutyric acid 
derivatives useful as HIV integrase inhibitors. WO 9962520, Dec 9, 1999. 
221. Uenaka, M.; Kawata, K.; Nagai, M.; Endoh, T. Novel processes for the preparation of 
substituted propenone derivatives. . WO 2000075122, Dec 14, 2000. 
222. Billich, A., S-1360(Shionogi-GlaxoSmithKline). Current Opinion in Investigational 
Drugs (Thomson Current Drugs) 2003, 4, (2), 206-209. 
223. Ramkumar, K.; Serrao, E.; Odde, S.; Neamati, N., HIV-1 integrase inhibitors: 2007–2008 
update. Medicinal Research Reviews 2010, 30, (6), 890-954. 
224. Embrey, M. W.; Wai, J. S.; Funk, T. W.; Homnick, C. F.; Perlow, D. S.; Young, S. D.; 
Vacca, J. P.; Hazuda, D. J.; Felock, P. J.; Stillmock, K. A.; Witmer, M. V.; Moyer, G.; Schleif, 
W. A.; Gabryelski, L. J.; Jin, L.; Chen, I. W.; Ellis, J. D.; Wong, B. K.; Lin, J. H.; Leonard, Y. 
M.; Tsou, N. N.; Zhuang, L., A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-
[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and 
viral replication in cells. Bioorganic &amp; Medicinal Chemistry Letters 2005, 15, (20), 4550-
4554. 
225. Hazuda, D. J.; Anthony, N. J.; Gomez, R. P.; Jolly, S. M.; Wai, J. S.; Zhuang, L.; Fisher, 
T. E.; Embrey, M.; Guare, J. P.; Egbertson, M. S.; Vacca, J. P.; Huff, J. R.; Felock, P. J.; Witmer, 
M. V.; Stillmock, K. A.; Danovich, R.; Grobler, J.; Miller, M. D.; Espeseth, A. S.; Jin, L.; Chen, 
I. W.; Lin, J. H.; Kassahun, K.; Ellis, J. D.; Wong, B. K.; Xu, W.; Pearson, P. G.; Schleif, W. A.; 
Cortese, R.; Emini, E.; Summa, V.; Holloway, M. K.; Young, S. D., A naphthyridine 
carboxamide provides evidence for discordant resistance between mechanistically identical 
inhibitors of HIV-1 integrase. Proceedings of the National Academy of Sciences of the United 
States of America 2004, 101, (31), 11233-11238. 
226. Hazuda, D. J.; Young, S. D.; Guare, J. P.; Anthony, N. J.; Gomez, R. P.; Wai, J. S.; 
Vacca, J. P.; Handt, L.; Motzel, S. L.; Klein, H. J.; Dornadula, G.; Danovich, R. M.; Witmer, M. 
V.; Wilson, K. A. A.; Tussey, L.; Schleif, W. A.; Gabryelski, L. S.; Jin, L.; Miller, M. D.; 
Casimiro, D. R.; Emini, E. A.; Shiver, J. W., Integrase Inhibitors and Cellular Immunity 
Suppress Retroviral Replication in Rhesus Macaques. Science 2004, 305, (5683), 528-532. 
227. Dayam, R.; Gundla, R.; Al-Mawsawi, L. Q.; Neamati, N., HIV-1 integrase inhibitors: 
2005–2006 update. Medicinal Research Reviews 2008, 28, (1), 118-154. 
228. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; 
Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; 
Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, 
M. V.; Rowley, M., Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-
191 
Integrase Inhibitor for the Treatment of HIV-AIDS Infection. Journal of Medicinal Chemistry 
2008, 51, (18), 5843-5855. 
229. Pace, P., Integrase inhibitors for the treatment of HIV infection. Current opinion in drug 
discovery & development 2008, 11, (4), 471-479. 
230. Kazmierski, W. M., Antiviral Drugs: From Basic Discovery through Clinical Trials. 1 
ed.; John Wiley & Sons, Inc.: 2011. 
231. Summa, V.; Petrocchi, A.; Matassa, V. G.; Gardelli, C.; Muraglia, E.; Rowley, M.; Paz, 
O. G.; Laufer, R.; Monteagudo, E.; Pace, P., 4,5-Dihydroxypyrimidine Carboxamides and N-
Alkyl-5-hydroxypyrimidinone Carboxamides Are Potent, Selective HIV Integrase Inhibitors 
with Good Pharmacokinetic Profiles in Preclinical Species. Journal of Medicinal Chemistry 
2006, 49, (23), 6646-6649. 
232. Summa, V.; Petrocchi, A.; Matassa, V. G.; Taliani, M.; Laufer, R.; De Francesco, R.; 
Altamura, S.; Pace, P., HCV NS5b RNA-dependent RNA polymerase inhibitors: from 
alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-
hydroxypyrimidinonecarboxylic acids. Design and synthesis. Journal of Medicinal Chemistry 
2004, 47, (22), 5336-5339. 
233. Pace, P.; Nizi, E.; Pacini, B.; Pesci, S.; Matassa, V.; De Francesco, R.; Altamura, S.; 
Summa, V., The monoethyl ester of meconic acid is an active site inhibitor of HCV NS5B RNA-
dependent RNA polymerase. Bioorganic & Medicinal Chemistry Letters 2004, 14, (12), 3257-
3261. 
234. Koch, U.; Attenni, B.; Malancona, S.; Colarusso, S.; Conte, I.; Di Filippo, M.; Harper, S.; 
Pacini, B.; Giomini, C.; Thomas, S.; Incitti, I.; Tomei, L.; De Francesco, R.; Altamura, S.; 
Matassa, V. G.; Narjes, F., 2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as Inhibitors of 
the Hepatitis C Virus NS5B Polymerase:â€‰ Discovery, SAR, Modeling, and Mutagenesis. 
Journal of Medicinal Chemistry 2006, 49, (5), 1693-1705. 
235. Shimura, K.; Kodama, E. N., Elvitegravir: a new HIV integrase inhibitor. Antiviral 
Chemistry & Chemotherapy 2009, 20, (2), 79-85. 
236. Ramanathan, S., Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV 
Integrase Inhibitor Elvitegravir. Clinical Pharmacokinetics 2011, 50, (4), 229-244. 
237. Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Kawakami, 
H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, 
H., Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics. Journal of Medicinal 
Chemistry 2006, 49, (5), 1506-1508. 
238. Serrao, E.; Odde, S.; Ramkumar, K.; Neamati, N., Raltegravir, Elvitegravir, and 
Metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6, 1-14. 
239. Reddy, Y. S.; Min, S. S.; Borland, J.; Song, I.; Lin, J.; Palleja, S.; Symonds, W. T., Safety 
and Pharmacokinetics of GSK364735, a Human Immunodeficiency Virus Type 1 Integrase 
192 
Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects. Antimicrob. 
Agents Chemother. 2007, 51, (12), 4284-4289. 
240. Garvey, E. P.; Johns, B. A.; Gartland, M. J.; Foster, S. A.; Miller, W. H.; Ferris, R. G.; 
Hazen, R. J.; Underwood, M. R.; Boros, E. E.; Thompson, J. B.; Weatherhead, J. G.; Koble, C. 
S.; Allen, S. H.; Schaller, L. T.; Sherrill, R. G.; Yoshinaga, T.; Kobayashi, M.; Wakasa-
Morimoto, C.; Miki, S.; Nakahara, K.; Noshi, T.; Sato, A.; Fujiwara, T., The Naphthyridinone 
GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and 
Antiretroviral. Antimicrobial Agents and Chemotherapy 2008, 52, (3), 901-908. 
241. Shimura, K.; Kodama, E.; Sakagami, Y.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; 
Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M.; Kano, M.; Ikeda, S.; Matsuoka, M., Broad 
Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus 
Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). Journal of Virology 2008, 82, (2), 764-774. 
242. Kobayashi, M.; Nakahara, K.; Seki, T.; Miki, S.; Kawauchi, S.; Suyama, A.; Wakasa-
Morimoto, C.; Kodama, M.; Endoh, T.; Oosugi, E.; Matsushita, Y.; Murai, H.; Fujishita, T.; 
Yoshinaga, T.; Garvey, E.; Foster, S.; Underwood, M.; Johns, B.; Sato, A.; Fujiwara, T., 
Selection of diverse and clinically relevant integrase inhibitor-resistant human 
immunodeficiency virus type 1 mutants. Antiviral Research 2008, 80, (2), 213-222. 
243. Marinello, J.; Marchand, C.; Mott, B. T.; Bain, A.; Thomas, C. J.; Pommier, Y., 
Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a 
Series of Drug-Resistant Integrase Mutants Biochemistry 2008, 47, (36), 9345-9354. 
244. Delelis, O.; Malet, I.; Na, L.; Tchertanov, L.; Calvez, V.; Marcelin, A.-G.; Subra, F.; 
Deprez, E.; Mouscadet, J.-F. o., The G140S mutation in HIV integrases from raltegravir-resistant 
patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Research 
2009, 37, (4), 1193-1201. 
245. Malet, I.; Delelis, O.; Valantin, M.-A.; Montes, B.; Soulie, C.; Wirden, M.; Tchertanov, 
L.; Peytavin, G.; Reynes, J.; Mouscadet, J.-F. o.; Katlama, C.; Calvez, V.; Marcelin, A.-G. v., 
Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the 
Inhibitor In Vitro. Antimicrobial Agents and Chemotherapy 2008, 52, (4), 1351-1358. 
246. Delelis, O.; Thierry, S.; Subra, F.; Simon, F.; Malet, I.; Alloui, C.; Sayon, S.; Calvez, V.; 
Deprez, E.; Marcelin, A.-G.; Tchertanov, L.; Mouscadet, J.-F., Impact of Y143 HIV-1 Integrase 
Mutations on Resistance to Raltegravir In Vitro and In Vivo. Antimicrobial Agents and 
Chemotherapy 2009, 54, (1), 491-501. 
247. Sichtig, N.; Sierra, S.; Kaiser, R.; Däumer, M.; Reuter, S.; Schülter, E.; Altmann, A.; 
Fätkenheuer, G.; Dittmer, U.; Pfister, H.; Esser, S., Evolution of raltegravir resistance during 
therapy. Journal of Antimicrobial Chemotherapy 2009, 64, (1), 25-32. 
248. Malet, I.; Delelis, O.; Soulie, C.; Wirden, M.; Tchertanov, L.; Mottaz, P.; Peytavin, G.; 
Katlama, C.; Mouscadet, J.-F.; Calvez, V.; Marcelin, A.-G., Quasispecies variant dynamics 
during emergence of resistance to raltegravir in HIV-1-infected patients. Journal of 
Antimicrobial Chemotherapy 2009, 63, (4), 795-804. 
193 
249. Jegede, O.; Babu, J.; Di Santo, R.; McColl, D. J.; Weber, J.; Quiñones-Mateu, M., HIV 
type 1 integrase inhibitors: from basic research to clinical implications. AIDS Reviews 2008, 10, 
(3), 172-189. 
250. Sechi, M.; Carcelli, M.; Rogolino, D.; Neamati, N., Role of Metals in HIV-1 Integrase 
Inhibitor Design. In HIV-1 Integrase: Mechanism and Inhibitor Design, 1 ed.; Neamati, N., Ed. 
John Wiley & Sons, Inc.: 2011; pp 287-307. 
251. Neamati, N., HIV-1 Integrase: Mechanism and Inhibitor Design. 1 ed.; Wiley: 2011; p 
528. 
252. Savarino, A., In-Silico Docking of HIV-1 Integrase Inhibitors Reveals a Novel Drug 
Type Acting on an Enzyme/DNA Reaction Intermediate. Retrovirology 2007, 4, (21), 1-15. 
253. Sharkey, M.; Triques, K.; Kuritzkes, D. R.; Stevenson, M., In Vivo Evidence for 
Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA. Journal of Virology 
2005, 79, (8), 5203-5210. 
254. Ellison, V.; Gerton, J.; Vincent, K. A.; Brown, P. O., An Essential Interaction between 
Distinct Domains of HIV-1 Integrase Mediates Assembly of the Active Multimer. Journal of 
Biological Chemistry 1995, 270, (7), 3320-3326. 
255. Engelman, A.; Bushman, F. D.; Craigie, R., Identification of discrete functional domains 
of HIV-1 integrase and their organization within an active multimeric complex. EMBO J 1993, 
12, (8), 3269–3275. 
256. Burke, C. J.; Sanyal, G.; Bruner, M. W.; Ryan, J. A.; LaFemina, R. L.; Robbins, H. L.; 
Zeft, A. S.; Middaugh, C. R.; Cordingley, M. G., Structural implications of spectroscopic 
characterization of a putative zinc finger peptide from HIV-1 integrase. Journal of Biological 
Chemistry 1992, 267, (14), 9639-9644. 
257. Cai, M. Z., Ronglan; Caffrey, Michael; Craigie, Robert; Clore, G. Marius; Gronenborn, 
Angela M. , Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nature 
structural biology 1997, 4, (7), 567-577. 
258. Zheng, R.; Jenkins, T. M.; Craigie, R., Zinc folds the N-terminal domain of HIV-1 
integrase, promotes multimerization and enhances catalytic activity. Proceedings of the National 
Academy of Sciences 1996, 93, 13659-13664. 
259. Engelman, A.; Craigie, R., Identification of conserved amino acid residues critical for 
human immunodeficiency virus type 1 integrase function in vitro. Journal of Virology 1992, 66, 
(11), 6361-6369. 
260. Chen, J. C. H.; Krucinski, J.; Miercke, L. J. W.; Finer-Moore, J. S.; Tang, A. H.; Leavitt, 
A. D.; Stroud, R. M., Crystal structure of the HIV-1 integrase catalytic core and C-terminal 
domains: A model for viral DNA binding. Proceedings of the National Academy of Sciences 
2000, 97, (15), 8233-8238. 
194 
261. Lubkowski, J.; Yang, F.; Alexandratos, J.; Wlodawer, A.; Zhao, H.; Burke, T. R.; 
Neamati, N.; Pommier, Y.; Merkel, G.; Skalka, A. M., Structure of the catalytic domain of avian 
sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proceedings of the 
National Academy of Sciences 1998, 95, (9), 4831-4836. 
262. Vink, C.; Plasterk, R. H. A., The human immunodeficiency virus integrase protein. 
Trends in Genetics 1993, 9, (12), 433-437. 
263. Bushman, F. D.; Engelman, A.; Palmer, I.; Wingfield, P.; Craigie, R., Domains of the 
integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl 
transfer and zinc binding. Proceedings of the National Academy of Sciences 1993, 90, (8), 3428-
3432. 
264. Chow, S. A.; Vincent, K. A.; Ellison, V.; Brown, P. O., Reversal of integration and DNA 
splicing mediated by integrase of human immunodeficiency virus. Science 1992, 255, (5045), 
723-726. 
265. Craigie, R., Integrase Mechanism and Function. In HIV-1 Integrase: Mechanism and 
Inhibitor Design, 1 ed.; Neamati, N., Ed. John Wiley & Sons: 2011; pp 23-34. 
266. Pluymers, W.; De Clercq, E.; Debyser, Z., HIV-1 Integration as a Target for 
Antiretroviral Therapy: A Review. Current Drug Targets - Infectious Disorders 2001, 1, 133-
149. 
267. Colicelli, J.; Goff, S., Sequence and spacing requirements of a retrovirus integration site. 
Journal of Molecular Biology 1988, 199, (1), 47-59. 
268. LaFemina, R. L.; Callahan, P.; Cordingley, M. G., Substrate specificity of recombinant 
HIV integrase protein. Journal of Virology 1991, 65, 5624-5630. 
269. Haren, L.; Ton-Hoang, B., Integrating DNA: Transposases and retroviral integrases. 
Annual Review of Microbiology 1999, 53, (1), 245. 
270. Johnson, A.; Marchand, C.; Pommier, Y., HIV-1 integrase inhibitors: a decade of 
reserach and two drugs in cliniclal trial. Current Topics in Medicinal Chemistry 2004, 4, 1059-
1077. 
271. Leavitt, A. D.; Rose, R. B.; Varmus, H. E., Both substrate and target oligonucleotide 
sequences affect in vitro integration mediated by human immunodeficiency virus type 1 
integrase protein produced in Saccharomyces cerevisiae. Journal of Virology 1992, 66, (4), 
2359-2368. 
272. Yoder, K.; Bushman, F., Repair of gaps in the retroviral DNA integration intermediates. 
Journal of Virology 2000, 74, 11191-11200. 
273. Marchand, C.; Zhang, X.; Pais, G. C. G.; Cowansage, K.; Neamati, N.; Burke, T. R.; 
Pommier, Y., Structural Determinants for HIV-1 Integrase Inhibition by β-Diketo Acids. Journal 
of Biological Chemistry 2002, 277, (15), 12596-12603. 
195 
274. Johnson, A. A.; Sayer, J. M.; Yagi, H.; Patil, S. S.; Debart, F. o.; Maier, M. A.; Corey, D. 
R.; Vasseur, J.-J.; Burke, T. R.; Marquez, V. E.; Jerina, D. M.; Pommier, Y., Effect of DNA 
Modifications on DNA Processing by HIV-1 Integrase and Inhibitor Binding. Journal of 
Biological Chemistry 2006, 281, (43), 32428-32438. 
275. Johnson, A.; Marchand, C.; Pommier, Y., Insights into HIV-1 Integrase-DNA 
Interactions. In HIV-1 Integrase: Mechanism and Inhibitor Design, 1 ed.; Neamati, N., Ed. John 
Wiley & Sons: 2011; pp 83-94. 
276. Johnson, A. A.; Sayer, J. M.; Yagi, H.; Kalena, G. P.; Amin, R.; Jerina, D. M.; Pommier, 
Y., Position-specific Suppression and Enhancement of HIV-1 Integrase Reactions by Minor 
Groove Benzo[a]pyrene Diol Epoxide Deoxyguanine Adducts. Journal of Biological Chemistry 
2004, 279, (9), 7947-7955. 
277. Johnson, A. A.; Santos, W.; Pais, G. C. G.; Marchand, C.; Amin, R.; Burke, T. R.; 
Verdine, G.; Pommier, Y., Integration requires a specific interaction of the donor DNA terminal 
5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. Journal of Biological 
Chemistry 2006, 281, (1), 461-467. 
278. Mazumder, A.; Pommier, Y., Processing of deoxyuridine mismatches and abasic sites by 
human immunodeficiency virus type- integrase. Nucleic Acids Research 1995, 23, (15), 2865-
2871. 
279. Gerton, J. L.; Ohgi, S.; Olsen, M.; DeRisi, J.; Brown, P. O., Effects of Mutations in 
Residues near the Active Site of Human Immunodeficiency Virus Type 1 Integrase on Specific 
Enzyme-Substrate Interactions. Journal of Virology 1998, 72, (6), 5046-5055. 
280. Jenkins, T. M.; Esposito, D.; Engelman, A.; Craigie, R., Critical contacts between HIV-1 
integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J 
1997, 16, 6849-6859. 
281. Wang, J.-Y.; Ling, H.; Yang, W.; Craigie, R., Structure of a two-domain fragment of 
HIV-1 integrase: implications for domain organization in the intact protein. EMBO J 2001, 20, 
(24), 7333-7343. 
282. Gao, K.; Butler, S. L.; Bushman, F., Human immunodeficiency virus type 1 integrase: 
arrangement of protein domains in active cDNA complexes. EMBO J 2001, 20, (13), 3565-3576. 
283. Johnson, T. W.; Tanis, S. P.; Butler, S. L.; Dalvie, D.; DeLisle, D. M.; Dress, K. R.; 
Flahive, E. J.; Hu, Q.; Kuehler, J. E.; Kuki, A.; Liu, W.; McClellan, G. A.; Peng, Q.; Plewe, M. 
B.; Richardson, P. F.; Smith, G. L.; Solowiej, J.; Tran, K. T.; Wang, H.; Yu, X.; Zhang, J.; Zhu, 
H., Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally 
Bioavailable HIV-1 Integrase Inhibitors. Journal of Medicinal Chemistry 2011, 54, (9), 3393-
3417. 
284. Espeseth, A. S.; Felock, P.; Wolfe, A.; Witmer, M.; Grobler, J.; Anthony, N.; Egbertson, 
M.; Melamed, J. Y.; Young, S.; Hamill, T.; Cole, J. L.; Hazuda, D. J., HIV-1 integrase inhibitors 
196 
that compete with the target DNA substrate define a unique strand transfer conformation for 
integrase. Proceedings of the National Academy of Sciences 2000, 97, (21), 11244-11249. 
285. Pais, G. C. G.; Burke, T. R., Novel aryl diketo-containing inhibitors of HIV-1 integrase. 
Drugs of the Future 2002, 27, 1101-1111. 
286. Johns, B. A.; Svolto, A. C., Advances in two-metal chelation inhibitors of HIV integrase. 
Expert Opinion on Therapeutic Patents 2008, 18, (11), 1225-1237. 
287. Kawasuji, T.; Fuji, M.; Yoshinaga, T.; Sato, A.; Fujiwara, T.; Kiyama, R., A platform for 
designing HIV integrase inhibitors. Part 2: A two-metal binding model as a potential mechanism 
of HIV integrase inhibitors. Bioorganic & Medicinal Chemistry 2006, 14, (24), 8420-8429. 
288. Marchand, C.; Johnson, A. A.; Karki, R. G.; Pais, G. C. G.; Zhang, X.; Cowansage, K.; 
Patel, T. A.; Nicklaus, M. C.; Burke, T. R.; Pommier, Y., Metal-Dependent Inhibition of HIV-1 
Integrase by β-Diketo Acids and Resistance of the Soluble Double-Mutant (F185K/C280S) 
Molecular Pharmacology 2003, 64, (3), 600-609. 
289. Pommier, Y.; Cherfils, J., Interfacial inhibition of macromolecular interactions: nature's 
paradigm for drug discovery. Trends in Pharmacological Sciences 2005, 26, (3), 138-145. 
290. Barreca, M. L.; Iraci, N.; De Luca, L.; Chimirri, A., Induced-Fit Docking Approach 
Provides Insight into the Binding Mode and Mechanism of Action of HIV-1 Integrase Inhibitors. 
ChemMedChem 2009, 4, (9), 1446-1456. 
291. Liao, C.; Nicklaus, M. C., Tautomerism and Magnesium Chelation of HIV-1 Integrase 
Inhibitors: A Theoretical Study. ChemMedChem 2010, 5, (7), 1053-1066. 
292. Di Santo, R.; Costi, R.; Roux, A.; Miele, G.; Crucitti, G. C.; Iacovo, A.; Rosi, F.; 
Lavecchia, A.; Marinelli, L.; Di Giovanni, C.; Novellino, E.; Palmisano, L.; Andreotti, M.; 
Amici, R.; Galluzzo, C. M.; Nencioni, L.; Palamara, A. T.; Pommier, Y.; Marchand, C., Novel 
Quinolinonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, and 
Biological Activities. Journal of Medicinal Chemistry 2008, 51, (15), 4744-4750. 
293. Sato, M.; Kawakami, H.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, 
Y.; Matsuzaki, Y.; Yamataka, K.; Ikeda, S.; Shinkai, H., Quinolone Carboxylic Acids as a Novel 
Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors. Journal 
of Medicinal Chemistry 2009, 52, (15), 4869-4882. 
294. Fujishita, T.; Yoshinaga, T.; Sato, A. Preparation of aromatic heterocycle compounds 
having HIV integrase inhibiting activities. WO 2000039086, 2000. 
295. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; 
Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E., L-735,524: an orally bioavailable human 
immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of 
Sciences 1994, 91, (9), 4096-4100. 
197 
296. Di Santo, R. P., Yves; Marchand, Christophe; Artico, Marino; Costi, Roberta Preparation 
of quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and aids 
related complex (ARC). WO 2005087759, 2005. 
297. Pospisil, P.; Ballmer, P.; Scapozza, L.; Folkers, G., Tautomerism in Computer-Aided 
Drug Design. Journal of Receptors and Signal Transduction 2003, 23, (4), 361-371. 
298. Moreland, J.; Gramada, A.; Buzko, O.; Zhang, Q.; Bourne, P., The Molecular Biology 
Toolkit (MBT): a modular platform for developing molecular visualization applications. BMC 
Bioinformatics 2005, 6, (1), 21. 
299. Wiskerchen, M.; Muesing, M. A., Human immunodeficiency virus type 1 integrase: 
effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated 
viral DNA templates, and sustain viral propagation in primary cells. Journal of Virology 1995, 
69, (1), 376-86. 
300. Sauerberg, P.; Olesen, P. H.; Nielsen, S.; Treppendahl, S.; Sheardown, M. J.; Honor, T.; 
Mitch, C. H.; Ward, J. S.; Pike, A. J.; Bymaster, F. P.; Sawyer, B. D.; Shannon, H. E., Novel 
functional M1 selective muscarinic agonists.  Synthesis and structure-activity relationships of 3-
(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. Journal of Medicinal Chemistry 1992, 
35, (12), 2274-2283. 
301. Kane, B. E.; Grant, M. K. O.; El-Fakahany, E. E.; Ferguson, D. M., Synthesis and 
evaluation of xanomeline analogs—Probing the wash-resistant phenomenon at the M1 
muscarinic acetylcholine receptor. Bioorganic & Medicinal Chemistry 2008, 16, (3), 1376-1392. 
302. Baeza, A.; Casas, J.; Nájera, C.; Sansano, J. M.; Saá, J. M., Enantioselective Synthesis of 
O-Methoxycarbonyl Cyanohydrins: Chiral Building Blocks Generated by Bifunctional Catalysis 
with BINOLAM-AlCl. European Journal of Organic Chemistry 2006, 2006, (8), 1949-1958. 
303. Subramanyam, C.; Noguchi, M.; Weinreb, S. M., An approach to amphimedine and 
related marine alkaloids utilizing an intramolecular Kondrat'eva pyridine synthesis Journal of 
Organic Chemistry 1989, 54, (23), 5580-5585. 
304. Yeung, K.-S.; Farkas, M. E.; Kadow, J. F.; Meanwell, N. A.; Taylor, M.; Johnston, D.; 
Coulter, T. S.; Wright; Kim, J. J. Indole, azaindole and related heterocyclic N-substituted 
piperazine derivatives and their preparation and use for the treatment of HIV infection. US 
8039486, 2011. 
305. Wang, T.; Yin, Z.; Zhang, Z.; Bender, J. A.; Yang, Z.; Johnson, G.; Yang, Z.; Zadjura, L. 
M.; D'Arienzo, C. J.; DiGiugno Parker, D.; Gesenberg, C.; Yamanaka, G. A.; Gong, Y.-F.; Ho, 
H.-T.; Fang, H.; Zhou, N.; McAuliffe, B. V.; Eggers, B. J.; Fan, L.; Nowicka-Sans, B.; Dicker, I. 
B.; Gao, Q.; Colonno, R. J.; Lin, P.-F.; Meanwell, N. A.; Kadow, J. F., Inhibitors of human 
immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles 
leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-
c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral 
activity in HIV-1-infected subjects. Journal of Medicinal Chemistry 2009, 52, (23), 7778-7787. 
198 
306. Martyn, D.; Abell, A., N-[5-(3-Phenylpropionyl)-1H-pyrrole-2-carbonyl]-L-proline 
Methyl Ester. Molbank 2003, (3), M338. 
307. DeSantis, G.; Zhu, Z.; Greenberg, W. A.; Wong, K.; Chaplin, J.; Hanson, S. R.; Farwell, 
B.; Nicholson, L. W.; Rand, C. L.; Weiner, D. P.; Robertson, D. E.; Burk, M. J., An Enzyme 
Library Approach to Biocatalysis: Development of Nitrilases for Enantioselective Production of 
Carboxylic Acid Derivatives. Journal of the American Chemical Society 2002, 124, (31), 9024-
9025. 
308. Ward, C. E. Herbicidal 2-(Nitrogen Heterocycle)5-Amino-3-Oxo-4-(Substituted-Phenyl)-
2,3-Dihydrofurans. 1986. 
309. Travis, B. R.; Sivakumar, M.; Hollist, G. O.; Borhan, B., Facile Oxidation of Aldehydes 
to Acids and Esters with Oxone. Organic Letters 2003, 5, (7), 1031-1034. 
310. Garcia-Raso, A.; Deya, P. M.; Saa, J. M., Oxidation of α-amino acids and α-hydroxy 
acids by Fremy's salt. A model for oxidases? The Journal of Organic Chemistry 1986, 51, (22), 
4285-4287. 
311. Zhou, Y.; Bourque, E.; Zhu, Y.; McEachern, E. J.; Harwig, C.; Skerlj, R. T.; Bridger, G. 
J.; Li, T.-S.; Metz, M. Substituted imidazolidinones and related compounds as chemokine 
receptor binding compounds and their preparation, pharmaceutical compositions and use in the 
treatment of infection of target cells by human immunodeficiency virus. WO 2007022371, 2007. 
312. Bou-Hamdan, F. R.; Leighton, J. L., Highly Enantioselective Pictet–Spengler Reactions 
with α-Ketoamide-Derived Ketimines: Access to an Unusual Class of Quaternary α-Amino 
Amides. Angewandte Chemie International Edition 2009, 48, (13), 2403-2406. 
313. Montalban, A. G.; Boman, E.; Chang, C.-D.; Ceide, S. C.; Dahl, R.; Dalesandro, D.; 
Delaet, N. G. J.; Erb, E.; Gibbs, A.; Kahl, J.; Kessler, L.; Lundström, J.; Miller, S.; Nakanishi, 
H.; Roberts, E.; Saiah, E.; Sullivan, R.; Wang, Z.; Larson, C. J., 'Reverse' [alpha]-ketoamide-
based p38 MAP kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 2008, 18, (20), 
5456-5459. 
314. Felfer, U.; Strauss, U. T.; Kroutil, W.; Fabian, W. M. F.; Faber, K., Substrate spectrum of 
mandelate racemase: Part 2. (Hetero)-aryl-substituted mandelate derivatives and modulation of 
activity. Journal of Molecular Catalysis B: Enzymatic 2001, 15, (4-6), 213-222. 
315. Brussee, J.; Loos, W. T.; Kruse, C. G.; Van Der Gen, A., Synthesis of optically active 
silyl protected cyanohydrins. Tetrahedron 1990, 46, (3), 979-986. 
316. Bull, J. A.; Balskus, E. P.; Horan, R. A. J.; Langner, M.; Ley, S. V., Total Synthesis of 
Potent Antifungal Marine Bisoxazole Natural Products Bengazoles A and B. Chemistry – A 
European Journal 2007, 13, (19), 5515-5538. 
317. Friedl, F., Preparation of Nitropyridine. Berichte der Deutschen Chemischen Gesellschaft 
1912, 45, 428-430. 
199 
318. Acheson, R. M.; Wright, N. D.; Tasker, P. A., Addition reactions of heterocyclic 
compounds. LI. Cyclobuta[b]pyridines from reactions of dimethyl acetylenedicarboxylate with 
1-alkyl-1,4-dihydropyridines and the cycloelimination of amide and carboxy groups. Perkin 
transactions. 1 1972, (23), 2918. 
319. Comins, D. L.; Mantlo, N. B., Synthesis of 3-acylpyridines utilizing a friedel-crafts 
reaction. Tetrahedron Letters 1983, 24, (35), 3683-3686. 
320. Tsuge, O.; Kanemasa, S.; Naritomi, T.; Tanaka, J., Regioselective alkyl group 
introduction at the 3-position of pyridine via 1,4-bis(trimethylsilyl)-1,4-dihydropyridine. 
Chemistry letters 1984, (7), 1255-1258. 
321. Haase, M.; Goerls, H.; Anders, E., Synthesis of PO(OR)2- and PR3 -disubstituted 
pyridines via N-(trifluoromethylsulfonyl)pyridinium triflates. Synthesis (Stuttgart) 1998, (2), 
195-200. 
322. Bennasar, M. L. s.; Juan, C. l.; Bosch, J., Synthesis of 3,5-diacyl-4-phenyl-1,4-
dihydropyridines. Tetrahedron Letters 1998, 39, (50), 9275-9278. 
323. Klapars, A.; Vedejs, E., Activation of pyridinium salts for electrophilic acylation: A 
method for conversion of pyridines into 3-acylpyridines Chemistry of Heterocyclic Compounds 
2004, 40, (6), 759-766. 
324. Jones, I. L.; Schofield, D. J.; Strevens, R. R.; Horton, P. N.; Hursthouse, M. B.; 
Tomkinson, N. C. O., Novel steroid mimics: synthesis of tri- and tetra-substituted oxamides and 
oxoamides. Tetrahedron Letters 2007, 48, (4), 521-525. 
325. De Corte, B.; Denis, J. M.; De Kimpe, N., A convenient synthesis of C-unsubstituted and 
C-monoalkylated ketene imines by dehydrocyanation of imidoyl cyanides using vacuum gas-
solid reactions. The Journal of Organic Chemistry 1987, 52, (6), 1147-1149. 
326. Maruoka, K.; Miyazaki, T.; Ando, M.; Matsumura, Y.; Sakane, S.; Hattori, K.; 
Yamamoto, H., Organoaluminum-promoted Beckmann rearrangement of oxime sulfonates. 
Journal of the American Chemical Society 1983, 105, (9), 2831-2843. 
327. Takahashi, K.; Kimura, S.; Ogawa, Y.; Yamada, K.; Iida, H., A convenient synthesis of 
α,β-disubstituted cinnamonitriles (1-anilino-2-cyano-1,2-diphenylethenes). Synthesis (Stuttgart) 
1978, (12), 892. 
328. Boyer, J. H.; Dabek, H., Iminoacetonitriles, a new family of compounds. N-t-
butyliminoacetonitrile. Journal of the Chemical Society D: Chemical Communications 1970, 
(18), 1204. 
329. De Kimpe, N.; Verhe, R.; De Buyck, L.; Chys, J.; Schamp, N., Synthesis of α-
iminonitriles (imidoyl cyanides). Synthesis (Stuttgart) 1978, (12), 895-897. 
200 
330. Drenkard, S.; Ferris, J.; Eschenmoser, A., Chemistry of α-aminonitriles. 2. Aziridine-2-
carbonitrile: photochemical formation from 2-aminopropenenitrile. Helvetica chimica acta 1990, 
73, (5), 1373-1390. 
331. Smith, J. G.; Irwin, D. C., α-Iminonitriles (imidoyl cyanides); their preparation using 
phase-transfer catalysis and their reductive dimerization. Synthesis (Stuttgart) 1978, (12), 894-
895. 
332. Dutta, D. K.; Prajapati, D.; Sandhu, J. S.; Baruah, J. N., A new facile method for the 
preparation of α-iminonitriles from aldonitrones and cyanotrimethylsilane. Synthetic 
communications 1985, 15, (4), 335-339. 
333. Konwar, D.; Goswami, B. N.; Borthakur, N., Organic synthesis with anion exchange 
resins: synthesis of α-imino nitriles from nitrones. Journal of chemical research. Synopses 1999, 
(3), 242-243. 
334. Pochat, F., A new method for the preparation of α-iminonitriles from aromatic aldehydes. 
Tetrahedron Letters 1981, 22, (10), 955-956. 
335. Saegusa, T.; Takaishi, N.; Ito, Y., Cationic isomerization and oligomerization of 
isocyanide. The Journal of Organic Chemistry 1969, 34, (12), 4040-4046. 
336. Pellissier, H.; Gil, G., Reaction of isocyanides. III. Synthesis of β-alkoxy imidoyl 
cyanides from acetals. Tetrahedron Letters 1989, 30, (2), 171-172. 
337. Tobisu, M.; Kitajima, A.; Yoshioka, S.; Hyodo, I.; Oshita, M.; Chatani, N., Bronsted 
Acid Catalyzed Formal Insertion of Isocyanides into a C-O Bond of Acetals. Journal of the 
American Chemical Society 2007, 129, (37), 11431-11437. 
338. Jursic, B. S.; Douelle, F.; Bowdy, K.; Stevens, E. D., A new facile method for preparation 
of heterocyclic α-iminonitriles and α-oxoacetic acid from heterocyclic aldehydes, p-
aminophenol, and sodium cyanide. Tetrahedron Letters 2002, 43, (30), 5361-5365. 
339. Masui, M.; Ohmori, H.; Ueda, C.; Yamauchi, M., Hydrolysis of α-
cyanobenzylideneanilines.  I.  Kinetic studies in acidic media. Perkin transactions. 2 1974, (12), 
1448-1453. 
340. Okuyama, T.; Pletcher, T. C.; Sahn, D. J.; Schmir, G. L., Hydrolysis of imidate esters 
derived from weakly basic amines. Influences of structure and pH on the partitioning of 
tetrahedral intermediates. Journal of the American Chemical Society 1973, 95, (4), 1253-1265. 
341. Okuyama, T.; Sahn, D. J.; Schmir, G. L., Hydrolysis of imidate esters derived from 
weakly basic amines. II. Influence of general acid-base catalysis on the partitioning of tetrahedral 
intermediates. Journal of the American Chemical Society 1973, 95, (7), 2345-2352. 
342. Culbertson, J. B., Factors Affecting the Rate of Hydrolysis of Ketimines. Journal of the 
American Chemical Society 1951, 73, (10), 4818-4823. 
201 
343. Jarusiewicz, J.; Choe, Y.; Yoo, K. S.; Park, C. P.; Jung, K. W., Efficient Three-
Component Strecker Reaction of Aldehydes/Ketones via NHC-Amidate Palladium(II) Complex 
Catalysis. The Journal of Organic Chemistry 2009, 74, (7), 2873-2876. 
344. Burkhart, D. J.; McKenzie, A. R.; Nelson, J. K.; Myers, K. I.; Zhao, X.; Magnusson, K. 
R.; Natale, N. R., Catalytic Asymmetric Synthesis of Glutamate Analogues. Organic Letters 
2004, 6, (8), 1285-1288. 
345. Vu, C. B. C., Rebecca L. Preparation of 8-substituted quinolines and related analogs as 
sirtuin modulators. WO 2010101949, 2010. 
346. Vu, C. B. D., Jeremy S.; Springer, Stephanie K.; Blum, Charles A.; Perni, Robert B. 
Quinolines and related analogs as sirtuin modulators and their preparation, pharmaceutical 
compositions and use in the treatment of diseases. WO 2009134973, 2009. 
347. Yamada, K.; Kato, M.; Iyoda, M.; Hirata, Y., Total synthesis of (+-)-4-isoavenaciolide, a 
metabolite of Aspergillus avenaceus. Journal of the Chemical Society. Chemical communications 
1973, (14), 499-500. 
348. Burkhart, J. P.; Peet, N. P.; Bey, P., Oxidation of α-hydroxy esters to α-keto esters using 
the dess-martin periodinane reagent. Tetrahedron Letters 1988, 29, (28), 3433-3436. 
349. Micetich, R. G., Arylglyoxylic esters.  Friedel-Crafts reaction. Organic preparations and 
procedures 1970, 2, (4), 249-252. 
350. Wasserman, H. H.; Ho, W.-B., (Cyanomethylene)phosphoranes as Novel Carbonyl 1,1-
Dipole Synthons: An Efficient Synthesis of .alpha.-Keto Acids, Esters, and Amides. The Journal 
of Organic Chemistry 1994, 59, (16), 4364-4366. 
351. Photis, J. M. M., Halide-directed nitrile hydrolysis. Tetrahedron Letters 1980, 21, (37), 
3539-3540. 
352. Singh, J.; Kissick, T. P.; Mueller, R. H., Improved procedure for the one-step synthesis of 
α-keto esters. Organic Preparations and Procedures International 1989, 21, (4), 501-504. 
353. Corey, E. J.; Erickson, B. W., Oxidative hydrolysis of 1,3-dithiane derivatives to 
carbonyl compounds using N-halosuccinimide reagents. The Journal of Organic Chemistry 
1971, 36, (23), 3553-3560. 
354. Babudri, F.; Fiandanese, V.; Marchese, G.; Punzi, A., A general and straightforward 
approach to α,ω-ketoesters. Tetrahedron 1996, 52, (42), 13513-13520. 
355. Zhuang, J.; Wang, C.; Xie, F.; Zhang, W., One-pot efficient synthesis of aryl α-keto 
esters from aryl-ketones. Tetrahedron 2009, 65, (47), 9797-9800. 
356. GooBen, L. J.; Dezfuli, M. K., Practical Protocol for Palladium-Catalyzed Synthesis of 
Arylphosphonates from Bromoarenes and Diethyl Phosphite. Synlett 2005, 3, 0445-0448. 
202 
357. Kosolapoff, G. M., The Chemistry of Phosphonic Acids with Aromatic Nuclei. I. 
Orientation of Phosphorus in Friedelâ€”Crafts Synthesis. Journal of the American Chemical 
Society 1952, 74, (16), 4119-4120. 
358. Freedman, L. D.; Doak, G. O., The Preparation of the Isomeric Ethylphenylphosphonic 
Acids1. Journal of the American Chemical Society 1955, 77, (1), 173-174. 
359. Boumekouez, A.; About-Jaudet, E.; Collignon, N.; Savignac, P., A remarkable 
accelerating effect of iodide ions in the photostimulated phosphonylation of bromoaromatic 
compounds. Journal of organometallic chemistry 1992, 440, (3), 297-301. 
360. Yuan, C.; Feng, H., Studies on organophosphorus compounds. XL. A one-pot procedure 
for the mono-O-alkylation of phosphonic acid: a facile synthesis of alkyl hydrogen p-substituted 
phenylphosphonates. Synthesis (Stuttgart) 1990, (2), 140-141. 
361. Tavs, P., Reaction of aryl halides with trialkyl phosphites or dialkyl phenylphosphonites 
to aromatic phosphonates or phosphinates by nickel salt catalyzed arylation. Chemische Berichte 
1970, 103, (8), 2428-2436. 
362. Tavs, P., Preparation of aromatic phosphonic acid esters from aryl halides and trialkyl 
phosphites. Tetrahedron 1967, 23, (12), 4677-4679. 
363. Gelman, D.; Jiang, L.; Buchwald, S. L., Copper-Catalyzed C−P Bond Construction via 
Direct Coupling of Secondary Phosphines and Phosphites with Aryl and Vinyl Halides. Organic 
Letters 2003, 5, (13), 2315-2318. 
364. Osuka, A.; Ohmasa, N.; Yoshida, Y.; Suzuki, H., Synthesis of arenephosphonates by 
copper(I) iodide-promoted arylation of phosphite anions. Synthesis (Stuttgart) 1983, (1), 69-71. 
365. Burger, A.; Dawson, N. D., The Reaction of Dialkyl Chlorophosphates with 
Arylmagnesium Halides. The Journal of Organic Chemistry 1951, 16, (8), 1250-1254. 
366. Edmundson, R. S.; Wrigley, J. O. L., Cyclic organophosphorus compounds.  IV.  
Cleavage of 1,3,2-dioxaphospholane and 1,3,2-dioxaphosphorinane rings by Grignard reagents. 
Tetrahedron 1967, 23, (1), 283-290. 
367. Freeman, S.; Harger, M. J. P., Influence of ortho methyl and isopropyl substituents on the 
reactivity of N-tert-butyl P-arylphosphonamidic chlorides with isopropylamine and tert-
butylamine. Steric acceleration of metaphosphonimidate formation by an elimination-addition 
mechanism. Contrasting behavior of N,N-dimethyl-P-arylphosphonamidic chlorides. Perkin 
transactions. 1 1987, (6), 1399-1406. 
368. Hirao, T.; Masunaga, T.; Ohshiro, Y.; Agawa, T., A novel synthesis of dialkyl 
arenephosphonates. Synthesis (Stuttgart) 1981, (1), 56. 
369. Hirao, T.; Masunaga, T.; Yamada, N.; Ohshiro, Y.; Agawa, T., Palladium-catalyzed new 
carbon-phosphorus bond formation. Bulletin of the Chemical Society of Japan 1982, 55, (3), 909-
913. 
203 
370. Petrakis, K. S.; Nagabhushan, T. L., Palladium-catalyzed substitutions of triflates derived 
from tyrosine-containing peptides and simpler hydroxyarenes forming 4-
(diethoxyphosphinyl)phenylalanines and diethyl arylphosphonates. Journal of the American 
Chemical Society 1987, 109, (9), 2831-2833. 
371. Ngo, H. L.; Lin, W., Chiral Crown Ether Pillared Lamellar Lanthanide Phosphonates. 
Journal of the American Chemical Society 2002, 124, (48), 14298-14299. 
372. Beletskaya, I. P. P., Palladium catalyzed C-C and C-heteroatom bond formation 
reactions. Pure and applied chemistry 1997, 69, (3), 471-476. 
373. Sabitha, G.; Reddy, B. V. S.; Abraham, S.; Yadav, J. S., Deprotection of sulfonamides 
using iodotrimethylsilane. Tetrahedron Letters 1999, 40, (8), 1569-1570. 
374. Kim, S.-H.; Rieke, R. D., Preparation of aryl ketones via Ni-catalyzed Negishi-coupling 
reactions with acid chlorides. Tetrahedron Letters 2011, 52, (13), 1523-1526. 
375. Cheng, G.; Fan, R.; Hernandez-Torres, J. M.; Boulineau, F. P.; Wei, A., syn Additions to 
4α-Epoxypyranosides:  Synthesis of l-Idopyranosides. Organic Letters 2007, 9, (23), 4849-4852. 
376. Haddach, M.; McCarthy, J. R., A new method for the synthesis of ketones: The 
palladium-catalyzed cross-coupling of acid chlorides with arylboronic acids. Tetrahedron Letters 
1999, 40, (16), 3109-3112. 
377. Ohe, T.; Miyaura, N.; Suzuki, A., Palladium-catalyzed cross-coupling reaction of 
organoboron compounds with organic triflates. The Journal of Organic Chemistry 1993, 58, (8), 
2201-2208. 
378. Blair, W. S.; Spicer, T. P. HIV-1 reporter viruses and their use in assaying anti-viral 
compounds. WO 2001096610, 2001. 
379. Blair, W. S.; Deshpande, M.; Fang, H.; Lin, P.-f.; Spicer, T. P.; Wallace, O. B.; Wang, 
H.; Wang, T.; Zhang, Z.; Yeung, K.-s. Preparation of antiviral indoleoxoacetyl piperazine 
derivatives. WO 2000076521, 2000. 
380. Wang, T.; Zhang, Z.; Wallace, O. B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L. M.; 
Tweedie, D. L.; Huang, S.; Zhao, F.; Ranadive, S.; Robinson, B. S.; Gong, Y.-F.; Ricarrdi, K.; 
Spicer, T. P.; Deminie, C.; Rose, R.; Wang, H.-G. H.; Blair, W. S.; Shi, P.-Y.; Lin, P.-f.; 
Colonno, R. J.; Meanwell, N. A., Discovery of 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-
b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment 
Inhibitor That Interferes with CD4-gp120 Interactions Journal of Medicinal Chemistry 2003, 46, 
(20), 4236-4239. 
381. Gitto, R.; Luca, L. D.; Ferro, S.; Citraro, R.; Sarro, G. D.; Costa, L.; Ciranna, L.; 
Chimirri, A., Development of 3-substituted-1H-indole derivatives as NR2B/NMDA receptor 
antagonists. Bioorganic & Medicinal Chemistry 2009, 17, (4), 1640-1647. 
204 
382. Vermeulen, E. S.; van Smeden, M.; Schmidt, A. W.; Sprouse, J. S.; Wikstroem, H. V.; 
Grol, C. J., Novel 5-HT7 Receptor Inverse Agonists. Synthesis and Molecular Modeling of 
Arylpiperazine- and 1,2,3,4-Tetrahydroisoquinoline-Based Arylsulfonamides. Journal of 
Medicinal Chemistry 2004, 47, (22), 5451-5466. 
383. Zhang, Z.; Yang, Z.; Wong, H.; Zhu, J.; Meanwell, N. A.; Kadow, J. F.; Wang, T., An 
Effective Procedure for the Acylation of Azaindoles at C-3. The Journal of Organic Chemistry 
2002, 67, (17), 6226-6227. 
384. Carteau, S.; Mouscadet, J. F.; Goulaouic, H.; Subra, F.; Auclair, C., Quantitative in Vitro 
Assay for Human Immunodeficiency Virus Deoxyribonucleic Acid Integration. Archives of 
biochemistry and biophysics 1993, 300, (2), 756-760. 
385. Chow, S. A., In VitroAssays for Activities of Retroviral Integrase. Methods 1997, 12, (4), 
306-317. 
386. Debyser, Z., Assays for the evaluation of HIV-1 integrase inhibitors. Methods in 
molecular biology (Clifton, N.J.) 2001, 160, (nuclease methods and protocols), 139. 
387. Zhimin, G.; Hongshan, C., [HIV-1 integrase enzyme linked immunosorbent assay and 
inhibitors]. Zhonghua shi yan he lin chuang bing du xue za ji 2002, 16, (2), 119-23. 
388. Hwang, Y.; Rhodes, D.; Bushman, F., Rapid microtiter assays for poxvirus 
topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: application to inhibitor 
isolation. Nucleic Acids Research 2000, 28, (24), 4884-4892. 
389. Chang, Y.-C.; Ching, T.-T.; Syu, W., Jr., Assaying the activity of HIV-1 integrase with 
DNA-coated plates. Journal of Virological Methods 1996, 59, (1-2), 135-140. 
390. Chen, H.; Boyle, T. J.; Malim, M. H.; Cullen, B. R.; Lyerly, H. K., Derivation of a 
Biologically Contained Replication System for Human Immunodeficiency Virus Type 1. 
Proceedings of the National Academy of Sciences of the United States of America 1992, 89, (16), 
7678-7682. 
391. Gallo, R. C.; Montagnier, L., The Discovery of HIV as the Cause of AIDS. New England 
Journal of Medicine 2003, 349, (24), 2283-2285. 
392. Pomerantz, R. J.; Horn, D. L., Twenty years of therapy for HIV-1 infection. Nat Med 
2003, 9, (7), 867-873. 
393. Moyle, G.; Gatell, J.; Perno, C.-F.; Ratanasuwan, W.; Schechter, M.; Tsoukas, C., 
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. 
AIDS patient care and STDs 2008, 22, (6), 459-471. 
394. Markowitz, M.; Evering, T. H., Raltegravir (MK-0518): An integrase inhibitor for the 
treatment of HIV-1. Drugs Today 2007, 43, (12), 1699-3993. 
205 
395. Buu-Hoi, N. P.; Saint-Ruf, G.; Bourgeade, J. C., Phthalonimides (1,3,4-trioxo-1,2,3,4-
tetrahydroisoquinolines) of potential biological interest. Journal of heterocyclic chemistry 1968, 
5, (4), 545-547. 
396. Chen, Y.-H.; Zhang, Y.-H.; Zhang, H.-J.; Liu, D.-Z.; Gu, M.; Li, J.-Y.; Wu, F.; Zhu, X.-
Z.; Li, J.; Nan, F.-J., Design, Synthesis, and Biological Evaluation of Isoquinoline-1,3,4-trione 
Derivatives as Potent Caspase-3 Inhibitors. Journal of Medicinal Chemistry 2006, 49, (5), 1613-
1623. 
397. Zaitsu, K.; Nakazono, M.; Tani, K. Preparation of of fluorescent compound with 
bis(benzofuranyl)maleimide structure. JP 2011162546, 2011. 
398. Kozikowski, A. P.; Gaysina, I. Benzofuran-3-yl(indol-3-yl)maleimides as potent GSK3 
inhibitors and their preparation, and use in the treatment of diseases. US 20100004308, 2010. 
399. Wang, L.; Hubert, J. A.; Lee, S. J.; Pan, J.; Qian, S.; Reitman, M. L.; Strack, A. M.; 
Weingarth, D. T.; MacNeil, D. J.; Weber, A. E.; Edmondson, S. D., Discovery of pyrimidine 
carboxamides as potent and selective CCK1 receptor agonists. Bioorganic & Medicinal 
Chemistry Letters 2011, 21, (10), 2911-2915. 
400. Shao, J.; Huang, X.; Wang, S.; Liu, B.; Xu, B., A straightforward synthesis of N-
monosubstituted α-keto amides via aerobic benzylic oxidation of amides. Tetrahedron 2012, 68, 
(2), 573-579. 
401. Park, S. Y.; Kang, M.; Yie, J. E.; Kim, J. M.; Lee, I.-M., A novel and efficient route to 
diarylmethanes catalyzed by nickel(II) ion on nanoporous carbon. Tetrahedron Letters 2005, 46, 
(16), 2849-2852. 
402. Tasler, S.; Lipshutz, B. H., Nickel-on-Charcoal-Catalyzed Aromatic Aminations and 
Kumada Couplings: Mechanistic and Synthetic Aspects. The Journal of Organic Chemistry 
2002, 68, (4), 1190-1199. 
403. Laali, K. K.; Gettwert, V. J., Electrophilic Nitration of Aromatics in Ionic Liquid 
Solvents. The Journal of Organic Chemistry 2000, 66, (1), 35-40. 
404. Fan, S.; He, C.-Y.; Zhang, X., Direct Pd-catalyzed benzylation of highly electron-
deficient perfluoroarenes. Chemical Communications 2010, 46, (27), 4926-4928. 
405. Liegault, B.; Renaud, J.-L.; Bruneau, C., Activation and functionalization of benzylic 
derivatives by palladium catalysts. Chemical Society Reviews 2008, 37, (2), 290-299. 
406. Martins, A.; Lautens, M., Aromatic ortho-Benzylation Reveals an Unexpected Reductant. 
Organic Letters 2008, 10, (21), 5095-5097. 
407. Verrier, C.; Hoarau, C.; Marsais, F., Direct palladium-catalyzed alkenylation, benzylation 
and alkylation of ethyl oxazole-4-carboxylate with alkenyl-, benzyl- and alkyl halides. Organic 
& Biomolecular Chemistry 2009, 7, (4), 647-650. 
206 
408. Mukai, T.; Hirano, K.; Satoh, T.; Miura, M., Palladium-Catalyzed Direct Benzylation of 
Azoles with Benzyl Carbonates. Organic Letters 2010, 12, (6), 1360-1363. 
409. Mavunkel, B. J.; Perumattam, J. J.; Tan, X.; Luedtke, G. R.; Lu, Q.; Lim, D.; Kizer, D.; 
Dugar, S.; Chakravarty, S.; Xu, Y.-j.; Jung, J.; Liclican, A.; Levy, D. E.; Tabora, J., Piperidine-
based heterocyclic oxalyl amides as potent p38α MAP kinase inhibitors. Bioorganic &amp; 
Medicinal Chemistry Letters 2009, 20, (3), 1059-1062. 
410. Montalban, A. G.; Boman, E.; Chang, C.-D.; Ceide, S. C.; Dahl, R.; Dalesandro, D.; 
Delaet, N. G. J.; Erb, E.; Ernst, J. T.; Gibbs, A.; Kahl, J.; Kessler, L.; LundstrÃ¶m, J.; Miller, S.; 
Nakanishi, H.; Roberts, E.; Saiah, E.; Sullivan, R.; Wang, Z.; Larson, C. J., The design and 
synthesis of novel Î±-ketoamide-based p38 MAP kinase inhibitors. Bioorganic &amp; Medicinal 
Chemistry Letters 2008, 18, (6), 1772-1777. 
411. Gong, J.; Shen, X.-h.; Chen, C.; Qiu, H.; Yang, R.-g., Down-regulation of HIV-1 
infection by inhibition of the MAPK signaling pathway. Virologica Sinica 2012, 26, (2), 114-
122. 
412. National Research Council (US) Committee on Prudent Practices in the Laboratory. 
National Prudent Practices in the Laboratory: Handling and Management of Chemical Hazards: 
Updated Version. National Academies Press (US): Washington (DC), 2011. 
413. Vedejs, E.; Monahan, S. D., Competing Pathways in the Azomethine Ylide Route to 
Indoloquinones:  An Improved Procedure for the Generation of a Transient 4-Oxazoline from the 
Oxazolium Salt. The Journal of Organic Chemistry 1997, 62, (14), 4763-4769. 
414. Dickson, S. J.; Biagini, S. C. G.; Steed, J. W., Anion binding in (arene)ruthenium(ii)-
based hosts. Chemical Communications 2007, (46), 4955-4957. 
415. De, S. K., Cobalt(II) chloride catalyzed one-pot synthesis of α-aminonitriles. Beilstein J. 
Org. Chem. 2005, 1, (8), 1-3. 
416. Chi B. Vu, J. S. D., Stephanic K. Springer, Charles A. Blum, Robert B. Perni Quinolines 
and related analogs as sirtuin modulators and their preparation, pharmaceutical compositions and 
use in the treatment of diseases. WO 2009134973, 2011. 
417. Kumar, A.; Narasimhan, B.; Kumar, D., Synthesis, antimicrobial, and QSAR studies of 
substituted benzamides. Bioorganic & Medicinal Chemistry 2007, 15, (12), 4113-4124. 
418. Lee, Y.-J.; Han, Y.-R.; Park, W.; Nam, S.-H.; Oh, K.-B.; Lee, H.-S., Synthetic analogs of 
indole-containing natural products as inhibitors of sortase A and isocitrate lyase. Bioorganic 
&amp; Medicinal Chemistry Letters 2010, 20, (23), 6882-6885. 
419. Marchand, P.; Antoine, M.; Baut, G. L.; Czech, M.; Baasner, S.; Guenther, E., Synthesis 
and structure-activity relationships of N-aryl(indol-3-yl)glyoxamides as antitumor agents. 
Bioorganic & Medicinal Chemistry 2009, 17, (18), 6715-6727. 
 
207 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Appendices 
 
 
 
 
 
 
 
 
 
 
 
208 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix: A 
Spectral Data 
 
 
 
 
 
 
 
 
 
 
209 
 
210 
 
211 
 
212 
 
213 
 
214 
 
215 
 
216 
 
217 
 
218 
 
219 
 
220 
 
221 
 
222 
 
223 
 
224 
 
225 
 
226 
 
227 
 
228 
 
229 
 
230 
 
231 
 
232 
 
233 
 
234 
 
235 
 
236 
 
237 
 
238 
 
239 
 
240 
 
241 
 
242 
 
243 
 
244 
 
245 
 
246 
 
247 
 
248 
 
249 
 
250 
 
251 
 
252 
 
253 
 
254 
 
255 
 
256 
 
257 
 
258 
 
259 
 
260 
 
261 
 
262 
 
263 
 
264 
 
265 
 
266 
 
267 
 
268 
 
269 
 
270 
 
271 
 
272 
 
273 
 
274 
 
275 
 
276 
 
277 
 
278 
 
279 
 
280 
 
281 
 
282 
 
283 
 
284 
 
285 
 
286 
 
287 
 
288 
 
289 
 
290 
 
291 
 
292 
 
293 
 
294 
 
295 
 
296 
 
297 
 
298 
 
299 
 
300 
 
301 
 
302 
 
303 
 
304 
 
305 
 
306 
 
307 
 
308 
 
309 
 
310 
 
311 
 
312 
 
313 
 
314 
 
315 
 
316 
 
317 
 
318 
 
319 
 
320 
 
321 
 
322 
 
323 
 
324 
 
325 
 
326 
 
327 
 
328 
 
329 
 
330 
 
331 
 
332 
 
333 
 
334 
 
335 
 
336 
 
337 
 
338 
 
339 
 
340 
 
341 
 
342 
 
343 
 
344 
 
345 
 
346 
 
347 
 
348 
 
349 
 
350 
 
351 
 
352 
 
353 
 
354 
 
355 
 
356 
 
357 
 
358 
 
359 
 
360 
 
361 
 
362 
 
363 
 
364 
 
365 
 
366 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix: B 
Copyright Permissions 
 
 
 
 
 
 
 
 
 
 
 
367 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012021_1329760716388[5/3/2012 4:53:05 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2853160924388 
License date Feb 20, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Biotechnology 
Licensed content title Structure-based maximal affinity model predicts small-molecule 
druggability 
Licensed content author Alan C Cheng, Ryan G Coleman, Kathleen T Smyth, Qing Cao, 
Patricia Soulard 
Licensed content date Jan 1, 2007 
Volume number 25 
Issue number 1 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures The figure that I am requesting to use is (Figure 2. Calculated 
druggability for a set of 27 target binding sites, Page 72 of the 
publication). 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
 
 
 
 
 
 
 
 
 
 
368 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012021_1329760716388[5/3/2012 4:57:09 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2853160924388 
License date Feb 20, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Biotechnology 
Licensed content title Structure-based maximal affinity model predicts small-molecule 
druggability 
Licensed content author Alan C Cheng, Ryan G Coleman, Kathleen T Smyth, Qing Cao, 
Patricia Soulard 
Licensed content date Jan 1, 2007 
Volume number 25 
Issue number 1 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures The figure that I am requesting to use is (Figure 2. Calculated 
druggability for a set of 27 target binding sites, Page 72 of the 
publication). 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
 
 
 
 
 
 
 
 
 
 
 
369 
 
 
From: Sarah Marie Scarry 
To: JOHN M RIMOLDI 
Subject: FW: 87551 Form to request permission to reproduce or reprint WHO copyrighted material 
Date: Thursday, May 03, 2012 4:55:51 PM 
From: CAMPANARIO, Dolores [mailto:campanariod@who.int] 
Sent: Monday, February 27, 2012 5:51 AM 
To: schajkow@olemiss.edu 
Subject: ID: 87551 Form to request permission to reproduce or reprint WHO copyrighted material 
Dear MS Scarry, 
Thank you for your enquiry. On behalf of the World Health Organization, we are pleased to grant you 
permission to reproduce the following WHO item/s, as indicated in your message below: 
The Global Summary of the AIDS epidemic, 2009. 
(http://www.searo.who.int/linkfiles/facts_and_figures_hiv_globalsituationpdf (page 5: Adults and Children 
estimated to be living with HIV, 2009)) 
Please note that this permission is granted under the following terms: 
This is a non-exclusive permission to reproduce the material detailed below. 
WHO material should not be reproduced for use in association with commercial nor promotional activities 
There should be no suggestion that WHO endorses any specific company nor products in the (article, book 
etc.) nor in the manner of distribution of the article, book etc.). 
The material will be reproduced as it was published by WHO and no changes should be made to the 
content or meaning. Publishers may reformat the material in the style of the publication. 
The WHO Logo/Emblem should not be reproduced, unless it appears on an original WHO publication or 
unless a specific permission is given by WHO for it's use. 
Please ensure that the original WHO source is appropriately acknowledged with either (i) the appropriate 
bibliographical reference (including publication title, author, publisher, volume/edition number, page numbers, 
copyright notice year) or (ii) in the case of materials published on the WHO web site, the URL reference and the 
date accessed. 
WHO will not charge any fee for the above permission, however we would like you to please provide me 
with 1 original hard copy or 2 of your final publication for our records, specifically showing where/how WHO 
material appears and how it is referenced on your product . Also indicate the attached Permission ID…. 
Number and please send directly to this address: 
Ms Dolores Campanario 
World Health Organization Press 
WHP (Permissions Management and Reprint Rights) 
20 Avenue Appia, Office 4152 
CH-1211 Genève 27, Switzerland 
Please also send as well a copy by e-mail to: permissions@who.int If available on CD/DVD please send me copies or if 
web page (send the direct link to where WHO is indicated on your site as well). 
We thank you for your interest in WHO Information products. We wish you all the best with your project. 
With kind regards. 
Ms Dolores Campanario 
WHO Press - (Permissions Management, Licensing and Reprint Rights) 
Department of Knowledge Management and Sharing 
Innovation, Information, Evidence and Research Cluster 
World Health Organization Press 
20 Avenue Appia, CH-1211 Genève 27, Switzerland 
Tel: +41 22 791 24 83 - Fax: +41 22 791 4857 - Office: 4152 - E-mail: campanariod@who.int 
Direct Links: 
To request for permission to reproduce parts or complete reprints of WHO copyrighted materials, complete this form - 
http://www.who.int/about/licensing/copyright_form/en/index.html 
Information on Permissions and Licensing - http://www.who.int/about/licensing/en/ 
370 
To order WHO publications on sale - http://apps.who.int/bookorders/ 
"Please note that if the requested item was jointly produced with other organization/s outside WHO or if not originally produced by WHO 
source, then please, also make every effort to obtain permissions from the appropriate external sources as mentioned on the original 
product details." 
-----Original Message----- 
From: internet@who.int [mailto:internet@who.int] 
Sent: lundi 20 février 2012 19:49 
To: permissions; schajkow@olemiss.edu 
Subject: [DataCol Web] Form to request permission to reproduce or reprint WHO copyrighted material 
DataCol Web: Form to request permission to reproduce or reprint WHO copyrighted material 
=================================================== 
ID: 87551 
Section: Contact details 
--------------------------------------------------- 
* Title 
* Ms 
------------------------- 
* First name 
* Sarah 
------------------------- 
* Family name 
* Scarry 
------------------------- 
* Organization/affiliation 
* The University of Mississippi 
------------------------- 
* Web site address 
* www.olemiss.edu 
------------------------- 
* Type of organization/affiliation 
* Academic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
371 
From: Sarah Marie Scarry 
To: JOHN M RIMOLDI 
Subject: FW: C-Query: Permission Requests 
Date: Thursday, May 03, 2012 4:55:31 PM 
From: AMBREEN IRSHAD - BSP [mailto:ambreenirshad@benthamscience.org] 
Sent: Tuesday, February 21, 2012 4:28 AM 
To: schajkow@olemiss.edu 
Cc: m.ahmed@benthamscience.org 
Subject: RE: C-Query: Permission Requests 
Grant of Permission 
Dear Dr. Scarry: 
Thank you for your interest in our copyrighted material, and for requesting permission for its use. 
Permission is granted for the following subject to the conditions outlined below: 
Figure 2 : Marchand, C.; Maddali, K.; Métifiot, M.; Pommier, Y., HIV-1 IN Inhibitors: 2010 Update and 
Perspectives. Current Topics in Medicinal Chemistry 2009, 9, (11), 1016-1037 
To be used in the following manner: 
1. Bentham Science Publishers grants you the right to reproduce the material indicated above on a 
one-time, non-exclusive basis, solely for the purpose described. Permission must be requested 
separately for any future or additional use. 
2. For an article, the copyright notice must be printed on the first page of article or book chapter. 
For figures, photographs, covers, or tables, the notice may appear with the material, in a 
footnote, or in the reference list. 
Thank you for your patience while your request was being processed. If you wish to contact us further, 
please use the address below. 
Sincerely, 
AMBREEN IRSHAD 
Permissions & Rights Manager 
Bentham Science Publishers Ltd 
Email: permission@benthamscience.org 
URL: www.benthamscience.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
372 
-----Original Message----- 
From: schajkow@olemiss.edu [mailto:schajkow@olemiss.edu] 
Sent: Monday, February 20, 2012 10:51 PM 
To: permission@benthamscience.org 
Subject: C-Query: Permission Requests 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012021_1330398492210[5/3/2012 5:03:54 PM] 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Elsevier 
("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists 
of your order details, the terms and conditions provided by Elsevier, and the 
payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Sarah C. Scarry 
Customer address 4749 Sardis Lake Drive 
Batesville, MS 38606 
License number 2857380636210 
License date Feb 27, 2012 
Licensed content publisher Elsevier 
Licensed content publication Trends in Microbiology 
Licensed content title HIV-1 and the host cell: an intimate association 
Licensed content author Eric O Freed 
Licensed content date April 2004 
Licensed content volume 
number 
12 
Licensed content issue 
number 
4 
Number of pages 8 
Start Page 170 
End Page 177 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new 
work 
other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format both print and electronic 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Order reference number 
Title of your 
thesis/dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Rightslink Printable License 
373 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012021_1330398492210[5/3/2012 5:03:54 PM] 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the Billing and Payment 
terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at 
the time that you opened your Rightslink account and that are available at any 
time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material 
subject to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) 
has appeared in our publication with credit or acknowledgement to another source, 
permission must also be sought from that source. If such permission is not 
obtained then that material may not be included in your publication/copies. 
Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / 
title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR 
APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - 
“Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., 
Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may 
be altered/adapted minimally to serve your work. Any other abbreviations, 
additions, deletions and/or any other alterations shall be made only with prior 
written authorization of Elsevier Ltd. (Please contact Elsevier at 
permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this 
instance, please be advised that your future requests for Elsevier materials may 
attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed 
immediately upon issuance of the license at the end of the licensing process for the 
374 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012021_1330398492210[5/3/2012 5:10:05 PM] 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Elsevier 
("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists 
of your order details, the terms and conditions provided by Elsevier, and the 
payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Sarah C. Scarry 
Customer address 4749 Sardis Lake Drive 
Batesville, MS 38606 
License number 2857380636210 
License date Feb 27, 2012 
Licensed content publisher Elsevier 
Licensed content publication Trends in Microbiology 
Licensed content title HIV-1 and the host cell: an intimate association 
Licensed content author Eric O Freed 
Licensed content date April 2004 
Licensed content volume 
number 
12 
Licensed content issue 
number 
4 
Number of pages 8 
Start Page 170 
End Page 177 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new 
work 
other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format both print and electronic 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Order reference number 
Title of your 
thesis/dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012021_1330398492210[5/3/2012 5:10:05 PM] 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
375 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the Billing and Payment 
terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at 
the time that you opened your Rightslink account and that are available at any 
time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material 
subject to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) 
has appeared in our publication with credit or acknowledgement to another source, 
permission must also be sought from that source. If such permission is not 
obtained then that material may not be included in your publication/copies. 
Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / 
title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR 
APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - 
“Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., 
Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may 
be altered/adapted minimally to serve your work. Any other abbreviations, 
additions, deletions and/or any other alterations shall be made only with prior 
written authorization of Elsevier Ltd. (Please contact Elsevier at 
permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this 
instance, please be advised that your future requests for Elsevier materials may 
attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed 
immediately upon issuance of the license at the end of the licensing process for the 
 
 
 
 
 
376 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826741877[5/3/2012 5:11:37 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2861640773877 
License date Mar 03, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Reviews Drug Discovery 
Licensed content title The design of drugs for HIV and HCV 
Licensed content author Erik De Clercq 
Licensed content date Dec 1, 2007 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 1(a). Simplified flow charts of the life cycle of human 
immunodeficiency virus (HIV) 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826741877[5/3/2012 5:11:37 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
377 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
378 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826902330[5/3/2012 5:17:21 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2861640934330 
License date Mar 03, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Reviews Drug Discovery 
Licensed content title The design of drugs for HIV and HCV 
Licensed content author Erik De Clercq 
Licensed content date Dec 1, 2007 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 3 (a). Nucleoside and non-nucleoside reverse 
transcriptase inhibitors/Mechanism of action of NRTIs 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826902330[5/3/2012 5:17:21 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
379 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
380 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826902330[5/3/2012 5:30:41 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2861640934330 
License date Mar 03, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Reviews Drug Discovery 
Licensed content title The design of drugs for HIV and HCV 
Licensed content author Erik De Clercq 
Licensed content date Dec 1, 2007 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 3 (a). Nucleoside and non-nucleoside reverse 
transcriptase inhibitors/Mechanism of action of NRTIs 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826902330[5/3/2012 5:30:41 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
381 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
382 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826741877[5/3/2012 5:32:14 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2861640773877 
License date Mar 03, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Reviews Drug Discovery 
Licensed content title The design of drugs for HIV and HCV 
Licensed content author Erik De Clercq 
Licensed content date Dec 1, 2007 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 1(a). Simplified flow charts of the life cycle of human 
immunodeficiency virus (HIV) 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826741877[5/3/2012 5:32:14 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
383 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
384 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826902330[5/3/2012 5:39:27 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2861640934330 
License date Mar 03, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Reviews Drug Discovery 
Licensed content title The design of drugs for HIV and HCV 
Licensed content author Erik De Clercq 
Licensed content date Dec 1, 2007 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 3 (a). Nucleoside and non-nucleoside reverse 
transcriptase inhibitors/Mechanism of action of NRTIs 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330826902330[5/3/2012 5:39:27 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
385 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
386 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330974521001[5/3/2012 5:48:11 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2862620377001 
License date Mar 05, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Reviews Drug Discovery 
Licensed content title Integrase inhibitors to treat HIV/Aids 
Licensed content author Yves Pommier, Allison A. Johnson, Christophe Marchand 
Licensed content date Feb 24, 2005 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 2. The two integrase catalytic reactions (3'-processing and 
strand transfer) 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330974521001[5/3/2012 5:48:11 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
387 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
388 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330974521001[5/3/2012 5:50:19 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2862620377001 
License date Mar 05, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Reviews Drug Discovery 
Licensed content title Integrase inhibitors to treat HIV/Aids 
Licensed content author Yves Pommier, Allison A. Johnson, Christophe Marchand 
Licensed content date Feb 24, 2005 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 2. The two integrase catalytic reactions (3'-processing and 
strand transfer) 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1330974521001[5/3/2012 5:50:19 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
389 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
390 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331076497751[5/3/2012 5:51:11 PM] 
OXFORD UNIVERSITY PRESS LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Oxford 
University Press ("Oxford University Press") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Oxford University Press, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2863291049751 
License date Mar 06, 2012 
Licensed content publisher Oxford University Press 
Licensed content publication Journal of Antimicrobial Chemotherapy 
Licensed content title Resistance to enfuvirtide, the first HIV fusion inhibitor: 
Licensed content author Michael L. Greenberg, Nick Cammack 
Licensed content date 08/01/2004 
Type of Use Thesis/Dissertation 
Institution name 
Title of your work The Synthesis of HIV-1 IN Inhibitors 
Publisher of your work n/a 
Expected publication date May 2012 
Permissions cost 0.00 USD 
Value added tax 0.00 USD 
Total 0.00 USD 
Total 0.00 USD 
Terms and Conditions 
STANDARD TERMS AND CONDITIONS FOR REPRODUCTION OF 
MATERIAL FROM AN OXFORD UNIVERSITY PRESS JOURNAL 
1. Use of the material is restricted to the type of use specified in your order 
details. 
2. This permission covers the use of the material in the English language in the 
following territory: world. If you have requested additional permission to translate 
this material, the terms and conditions of this reuse will be set out in clause 12. 
3. This permission is limited to the particular use authorized in (1) above and does 
not allow you to sanction its use elsewhere in any other format other than 
specified above, nor does it apply to quotations, images, artistic works etc that 
have been reproduced from other sources which may be part of the material to be 
used. 
4. No alteration, omission or addition is made to the material without our written 
consent. Permission must be re-cleared with Oxford University Press if/when you 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331076497751[5/3/2012 5:51:11 PM] 
decide to reprint. 
5. The following credit line appears wherever the material is used: author, title, 
journal, year, volume, issue number, pagination, by permission of Oxford University 
Press or the sponsoring society if the journal is a society journal. Where a journal is 
being published on behalf of a learned society, the details of that society must be 
included in the credit line. 
6. For the reproduction of a full article from an Oxford University Press journal for 
391 
whatever purpose, the corresponding author of the material concerned should be 
informed of the proposed use. Contact details for the corresponding authors of all 
Oxford University Press journal contact can be found alongside either the abstract 
or full text of the article concerned, accessible from www.oxfordjournals.org Should 
there be a problem clearing these rights, please contact 
journals.permissions@oxfordjournals.org 
7. If the credit line or acknowledgement in our publication indicates that any of the 
figures, images or photos was reproduced, drawn or modified from an earlier 
source it will be necessary for you to clear this permission with the original 
publisher as well. If this permission has not been obtained, please note that this 
material cannot be included in your publication/photocopies. 
8. While you may exercise the rights licensed immediately upon issuance of the 
license at the end of the licensing process for the transaction, provided that you 
have disclosed complete and accurate details of your proposed use, no license is 
finally effective unless and until full payment is received from you (either by Oxford 
University Press or by Copyright Clearance Center (CCC)) as provided in CCC's 
Billing and Payment terms and conditions. If full payment is not received on a 
timely basis, then any license preliminarily granted shall be deemed automatically 
revoked and shall be void as if never granted. Further, in the event that you 
breach any of these terms and conditions or any of CCC's Billing and Payment 
terms and conditions, the license is automatically revoked and shall be void as if 
never granted. Use of materials as described in a revoked license, as well as any 
use of the materials beyond the scope of an unrevoked license, may constitute 
copyright infringement and Oxford University Press reserves the right to take any 
and all action to protect its copyright in the materials. 
9. This license is personal to you and may not be sublicensed, assigned or 
transferred by you to any other person without Oxford University Press’s written 
permission. 
10. Oxford University Press reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions and (iii) CCC’s Billing and 
Payment terms and conditions. 
11. You hereby indemnify and agree to hold harmless Oxford University Press and 
CCC, and their respective officers, directors, employs and agents, from and against 
any and all claims arising out of your use of the licensed material other than as 
specifically authorized pursuant to this license. 
12. Other Terms and Conditions: 
v1.4 
If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be 
invoiced within 48 hours of the license date. Payment should be in the form of a check 
 
 
 
 
 
 
392 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331138797497[5/3/2012 5:55:01 PM] 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Elsevier 
("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists 
of your order details, the terms and conditions provided by Elsevier, and the 
payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company 
Number 
1982084 
Customer name Sarah C. Scarry 
Customer address 4749 Sardis Lake Drive 
Batesville, MS 38606 
License number 2863701357497 
License date Mar 07, 2012 
Licensed content publisher Elsevier 
Licensed content publication Structure 
Licensed content title HIV-1 Transcription: Activation Mediated by Acetylation of Tat 
Licensed content author Yoshihiro Nakatani 
Licensed content date April 2002 
Licensed content volume 
number 
10 
Licensed content issue 
number 
4 
Number of pages 2 
Start Page 443 
End Page 444 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new 
work 
other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format both print and electronic 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Order reference number 
Title of your The Synthesis of HIV-1 IN Inhibitors 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331138797497[5/3/2012 5:55:01 PM] 
thesis/dissertation 
Expected completion date May 2012 
Estimated size (number of 
pages) 
393 
350 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the Billing and Payment 
terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at 
the time that you opened your Rightslink account and that are available at any 
time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material 
subject to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) 
has appeared in our publication with credit or acknowledgement to another source, 
permission must also be sought from that source. If such permission is not 
obtained then that material may not be included in your publication/copies. 
Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / 
title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR 
APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - 
“Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., 
Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may 
be altered/adapted minimally to serve your work. Any other abbreviations, 
additions, deletions and/or any other alterations shall be made only with prior 
written authorization of Elsevier Ltd. (Please contact Elsevier at 
permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this 
instance, please be advised that your future requests for Elsevier materials may 
attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed 
 
 
 
 
 
394 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331138797497[5/3/2012 5:57:30 PM] 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Elsevier 
("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists 
of your order details, the terms and conditions provided by Elsevier, and the 
payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company 
Number 
1982084 
Customer name Sarah C. Scarry 
Customer address 4749 Sardis Lake Drive 
Batesville, MS 38606 
License number 2863701357497 
License date Mar 07, 2012 
Licensed content publisher Elsevier 
Licensed content publication Structure 
Licensed content title HIV-1 Transcription: Activation Mediated by Acetylation of Tat 
Licensed content author Yoshihiro Nakatani 
Licensed content date April 2002 
Licensed content volume 
number 
10 
Licensed content issue 
number 
4 
Number of pages 2 
Start Page 443 
End Page 444 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new 
work 
other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format both print and electronic 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Order reference number 
Title of your The Synthesis of HIV-1 IN Inhibitors 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331138797497[5/3/2012 5:57:30 PM] 
thesis/dissertation 
Expected completion date May 2012 
Estimated size (number of 
pages) 
395 
350 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the Billing and Payment 
terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at 
the time that you opened your Rightslink account and that are available at any 
time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material 
subject to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) 
has appeared in our publication with credit or acknowledgement to another source, 
permission must also be sought from that source. If such permission is not 
obtained then that material may not be included in your publication/copies. 
Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / 
title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR 
APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - 
“Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., 
Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may 
be altered/adapted minimally to serve your work. Any other abbreviations, 
additions, deletions and/or any other alterations shall be made only with prior 
written authorization of Elsevier Ltd. (Please contact Elsevier at 
permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this 
instance, please be advised that your future requests for Elsevier materials may 
attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed 
 
 
 
 
 
396 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331151394117[5/3/2012 6:02:08 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2863790346117 
License date Mar 07, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Medicine 
Licensed content title Charting HIV's remarkable voyage through the cell: Basic science 
as a passport to future therapy 
Licensed content author Warner C. Greene, B. Matija Peterlin 
Licensed content date Jul 1, 2002 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 2. Schematic of Early Events Occurring after HIV infection. 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331151394117[5/3/2012 6:02:08 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
397 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
398 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331151394117[5/3/2012 6:03:48 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2863790346117 
License date Mar 07, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Medicine 
Licensed content title Charting HIV's remarkable voyage through the cell: Basic science 
as a passport to future therapy 
Licensed content author Warner C. Greene, B. Matija Peterlin 
Licensed content date Jul 1, 2002 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 2. Schematic of Early Events Occurring after HIV infection. 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331151394117[5/3/2012 6:03:48 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
399 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
400 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331151768427[5/3/2012 6:09:30 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2863790720427 
License date Mar 07, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Medicine 
Licensed content title Charting HIV's remarkable voyage through the cell: Basic science 
as a passport to future therapy 
Licensed content author Warner C. Greene, B. Matija Peterlin 
Licensed content date Jul 1, 2002 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures An overview of the organization of the ~9-kilobase genome of the 
HIV provirus and summary of its nine genes encoding 15 proteins. 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331151768427[5/3/2012 6:09:30 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
401 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
402 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331151768427[5/3/2012 6:11:11 PM] 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Nature 
Publishing Group ("Nature Publishing Group") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions 
provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2863790720427 
License date Mar 07, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Medicine 
Licensed content title Charting HIV's remarkable voyage through the cell: Basic science 
as a passport to future therapy 
Licensed content author Warner C. Greene, B. Matija Peterlin 
Licensed content date Jul 1, 2002 
Type of Use reuse in a thesis/dissertation 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures An overview of the organization of the ~9-kilobase genome of the 
HIV provirus and summary of its nine genes encoding 15 proteins. 
Author of this NPG article no 
Your reference number 
Title of your thesis / 
dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
Estimated size (number of 
pages) 
350 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use, subject to the conditions 
below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to Nature Publishing Group and does not carry the 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331151768427[5/3/2012 6:11:11 PM] 
copyright of another entity (as credited in the published version). If the credit 
line on any part of the material you have requested indicates that it was 
reprinted or adapted by NPG with permission from another source, then you 
should also seek permission from that source to reuse the material. 
2. Permission granted free of charge for material in print is also usually granted 
403 
for any electronic version of that work, provided that the material is 
incidental to the work as a whole and that the electronic version is essentially 
equivalent to, or substitutes for, the print version. Where print permission has 
been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has 
already been accounted for during your initial request in the calculation of a 
print run). NB: In all cases, web-based use of full-text articles must be 
authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and 
subsequent editions and for editions in other languages (except for 
signatories to the STM Permissions Guidelines, or where the first edition 
permission was granted for free). 
4. Nature Publishing Group's permission must be acknowledged next to the 
figure, table or abstract in print. In electronic form, this acknowledgement 
must be visible at the same time as the figure/table/abstract, and must be 
hyperlinked to the journal's homepage. 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
Note: For republication from the British Journal of Cancer, the 
following credit lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
6. Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
Note: For adaptation from the British Journal of Cancer, the 
following credit line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
7. Translations of 401 words up to a whole article require NPG approval. Please 
 
 
 
404 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331599255927[5/3/2012 6:13:04 PM] 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Elsevier 
("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists 
of your order details, the terms and conditions provided by Elsevier, and the 
payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company 
Number 
1982084 
Customer name Sarah C. Scarry 
Customer address 4749 Sardis Lake Drive 
Batesville, MS 38606 
License number 2866750655927 
License date Mar 12, 2012 
Licensed content publisher Elsevier 
Licensed content publication Antiviral Research 
Licensed content title Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era 
of antiretroviral therapy 
Licensed content author Damian J. McColl,Xiaowu Chen 
Licensed content date January 2010 
Licensed content volume 
number 
85 
Licensed content issue 
number 
1 
Number of pages 18 
Start Page 101 
End Page 118 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new 
work 
other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format both print and electronic 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Order reference number 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331599255927[5/3/2012 6:13:04 PM] 
Title of your 
thesis/dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
405 
Estimated size (number of 
pages) 
350 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the Billing and Payment 
terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at 
the time that you opened your Rightslink account and that are available at any 
time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material 
subject to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) 
has appeared in our publication with credit or acknowledgement to another source, 
permission must also be sought from that source. If such permission is not 
obtained then that material may not be included in your publication/copies. 
Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / 
title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR 
APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - 
“Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., 
Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may 
be altered/adapted minimally to serve your work. Any other abbreviations, 
additions, deletions and/or any other alterations shall be made only with prior 
written authorization of Elsevier Ltd. (Please contact Elsevier at 
permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this 
instance, please be advised that your future requests for Elsevier materials may 
attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms and conditions. 
 
 
 
 
 
406 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331599255927[5/3/2012 6:14:35 PM] 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Elsevier 
("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists 
of your order details, the terms and conditions provided by Elsevier, and the 
payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company 
Number 
1982084 
Customer name Sarah C. Scarry 
Customer address 4749 Sardis Lake Drive 
Batesville, MS 38606 
License number 2866750655927 
License date Mar 12, 2012 
Licensed content publisher Elsevier 
Licensed content publication Antiviral Research 
Licensed content title Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era 
of antiretroviral therapy 
Licensed content author Damian J. McColl,Xiaowu Chen 
Licensed content date January 2010 
Licensed content volume 
number 
85 
Licensed content issue 
number 
1 
Number of pages 18 
Start Page 101 
End Page 118 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new 
work 
other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format both print and electronic 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Order reference number 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331599255927[5/3/2012 6:14:35 PM] 
Title of your 
thesis/dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
407 
Estimated size (number of 
pages) 
350 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the Billing and Payment 
terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at 
the time that you opened your Rightslink account and that are available at any 
time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material 
subject to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) 
has appeared in our publication with credit or acknowledgement to another source, 
permission must also be sought from that source. If such permission is not 
obtained then that material may not be included in your publication/copies. 
Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / 
title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR 
APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - 
“Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., 
Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may 
be altered/adapted minimally to serve your work. Any other abbreviations, 
additions, deletions and/or any other alterations shall be made only with prior 
written authorization of Elsevier Ltd. (Please contact Elsevier at 
permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this 
instance, please be advised that your future requests for Elsevier materials may 
attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms and conditions. 
 
 
 
 
 
408 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331599560382[5/3/2012 6:17:29 PM] 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Elsevier 
("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists 
of your order details, the terms and conditions provided by Elsevier, and the 
payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company 
Number 
1982084 
Customer name Sarah C. Scarry 
Customer address 4749 Sardis Lake Drive 
Batesville, MS 38606 
License number 2866750960382 
License date Mar 12, 2012 
Licensed content publisher Elsevier 
Licensed content publication Antiviral Research 
Licensed content title Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era 
of antiretroviral therapy 
Licensed content author Damian J. McColl,Xiaowu Chen 
Licensed content date January 2010 
Licensed content volume 
number 
85 
Licensed content issue 
number 
1 
Number of pages 18 
Start Page 101 
End Page 118 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new 
work 
other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format both print and electronic 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Order reference number 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331599560382[5/3/2012 6:17:29 PM] 
Title of your 
thesis/dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
409 
Estimated size (number of 
pages) 
350 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the Billing and Payment 
terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at 
the time that you opened your Rightslink account and that are available at any 
time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material 
subject to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) 
has appeared in our publication with credit or acknowledgement to another source, 
permission must also be sought from that source. If such permission is not 
obtained then that material may not be included in your publication/copies. 
Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / 
title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR 
APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - 
“Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., 
Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may 
be altered/adapted minimally to serve your work. Any other abbreviations, 
additions, deletions and/or any other alterations shall be made only with prior 
written authorization of Elsevier Ltd. (Please contact Elsevier at 
permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this 
instance, please be advised that your future requests for Elsevier materials may 
attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms and conditions. 
 
 
 
 
 
410 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331599560382[5/3/2012 6:19:25 PM] 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
May 03, 2012 
This is a License Agreement between Sarah C. Scarry ("You") and Elsevier 
("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists 
of your order details, the terms and conditions provided by Elsevier, and the 
payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company 
Number 
1982084 
Customer name Sarah C. Scarry 
Customer address 4749 Sardis Lake Drive 
Batesville, MS 38606 
License number 2866750960382 
License date Mar 12, 2012 
Licensed content publisher Elsevier 
Licensed content publication Antiviral Research 
Licensed content title Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era 
of antiretroviral therapy 
Licensed content author Damian J. McColl,Xiaowu Chen 
Licensed content date January 2010 
Licensed content volume 
number 
85 
Licensed content issue 
number 
1 
Number of pages 18 
Start Page 101 
End Page 118 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new 
work 
other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format both print and electronic 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Order reference number 
Rightslink Printable License 
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2012030_1331599560382[5/3/2012 6:19:25 PM] 
Title of your 
thesis/dissertation 
The Synthesis of HIV-1 IN Inhibitors 
Expected completion date May 2012 
411 
Estimated size (number of 
pages) 
350 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the Billing and Payment 
terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at 
the time that you opened your Rightslink account and that are available at any 
time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material 
subject to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) 
has appeared in our publication with credit or acknowledgement to another source, 
permission must also be sought from that source. If such permission is not 
obtained then that material may not be included in your publication/copies. 
Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / 
title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR 
APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - 
“Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., 
Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may 
be altered/adapted minimally to serve your work. Any other abbreviations, 
additions, deletions and/or any other alterations shall be made only with prior 
written authorization of Elsevier Ltd. (Please contact Elsevier at 
permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this 
instance, please be advised that your future requests for Elsevier materials may 
attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms and conditions. 
 
 
 
 
 
412 
From: Sarah Marie Scarry 
To: JOHN M RIMOLDI 
Subject: FW: Kaiser Family Foundation permissions 
Date: Thursday, May 03, 2012 5:11:30 PM 
From: Kanani Kauka [mailto:KananiK@kff.org] 
Sent: Tuesday, March 13, 2012 5:16 PM 
To: 'schajkow@olemiss.edu' 
Subject: Kaiser Family Foundation permissions 
Thank you for your copyright permission request. This is to grant permission to you and your 
organization for one-time use of the material cited in your e-mail below. Permission is granted with the 
understanding that the material is not to be altered or presented out of context. 
Please source the material as follows: 
"Fact Sheet: The HIV/AIDS Epidemic in the United States”, (#3029-12), The Henry J. Kaiser Family 
Foundation, February 2012 
Our permission statement is: 
This information was reprinted with permission from the Henry J. Kaiser Family Foundation. The Kaiser 
Family Foundation, a leader in health policy analysis, health journalism and communication, is 
dedicated to filling the need for trusted, independent information on the major health issues facing our 
nation and its people. The Foundation is a non-profit private operating foundation, based in Menlo 
Park, California. 
Please let me know if you have questions. 
Thanks, 
Kanani 
__________________________ 
Kanani Kauka 
production assistant 
Kaiser Family Foundation 
2400 Sand Hill Road | Menlo Park, CA 94025 
kkauka@kff.org | 650.854.9400 
www.kff.org | www.kaiserhealthnews.org | www.statehealthfacts.org | www.kaiserEDU.org 
SIGN UP FOR E-MAIL ALERTS AT: www.kff.org/email 
Requester's Name*: Sarah Scarry 
Name of Organization*: The University of Mississippi 
Email Address*: schajkow@olemiss.edu 
Phone*: 662-915-8865 
Fax: 
Organization Web site: www.olemiss.edu 
Kaiser Publication Title*: HIV/AIDS Policy Fact Sheet: The HIV/AIDS Epidemic in the United States 
Kaiser Publication URL*: http://www.kff.org/hivaids/upload/3029-12.pdf 
Kaiser Publication Number: http://www.kff.org/hivaids/upload/3029-12.pdf 
Intended Use*: This figure (Top Ten States by Cumulative AIDS Diagnoses and by AIDS Diagnosis 
Rate Per 100,000) will be used in a dissertation. 
Distribution*: Electronic and print. May 2012 
Intent to Sell*: No. Not for profit. 
Comments: 
From: Sarah Marie Scarry 
To: JOHN M RIMOLDI 
Subject: FW: Kaiser Family Foundation permissions 
Date: Thursday, May 03, 2012 5:11:49 PM 
From: Kanani Kauka [mailto:KananiK@kff.org] 
Sent: Tuesday, March 13, 2012 5:19 PM 
To: 'schajkow@olemiss.edu' 
Subject: Kaiser Family Foundation permissions 
Thank you for your copyright permission request. This is to grant permission to you and your 
organization for one-time use of the material cited in your e-mail below. Permission is granted with the 
413 
understanding that the material is not to be altered or presented out of context. 
Please source the material as follows: 
"Estimated Numbers of AIDS Diagnoses, All Ages, 2009”, statehealthfacts.org, The Henry J. Kaiser 
Family Foundation, February 2011 
Our permission statement is: 
This information was reprinted with permission from the Henry J. Kaiser Family Foundation. The Kaiser 
Family Foundation, a leader in health policy analysis, health journalism and communication, is 
dedicated to filling the need for trusted, independent information on the major health issues facing our 
nation and its people. The Foundation is a non-profit private operating foundation, based in Menlo 
Park, California. 
Please let me know if you have questions. 
Thanks, 
Kanani 
__________________________ 
Kanani Kauka 
production assistant 
Kaiser Family Foundation 
2400 Sand Hill Road | Menlo Park, CA 94025 
kkauka@kff.org | 650.854.9400 
www.kff.org | www.kaiserhealthnews.org | www.statehealthfacts.org | www.kaiserEDU.org 
SIGN UP FOR E-MAIL ALERTS AT: www.kff.org/email 
Requester's Name*: Sarah Scarry 
Name of Organization*: The University of Mississippi 
Email Address*: schajkow@olemiss.edu 
Phone*: 662-915-8865 
Fax: 
Organization Web site: www.olemiss.edu 
Kaiser Publication Title*: Statehealthfacts.org Estimated Numbers of AIDS Diagnoses, All Ages, 2009 
Kaiser Publication URL*: http://www.statehealthfacts.org/savemap.jsp? 
ind=508&cat=11&sub=119&yr=92&typ=1&sort=a 
Kaiser Publication Number: http://www.statehealthfacts.org/comparemaptable.jsp? 
ind=508&cat=11&sub=119&yr=92&typ=1&sort=a 
Intended Use*: This figure will be used in a dissertation. 
Distribution*: Electronic and print. 
Intent to Sell*: No. Not for profit. 
Comments: 
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